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SYNOPSIS 
 
THIS THESIS SYSTEMATICALLY REVIEWED THE LITERATURE 
ON TESTS AND TREATMENTS FOR FETAL GROWTH 
RESTRICTION AND COMPROMISE AND INCORPORATED THIS 
INFORMATION IN A DECISION-ANALYTIC MODEL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ii 
 
Abstract 
 
Restriction of fetal growth and compromise of its wellbeing remain significant causes of 
perinatal death and childhood disability. There is a lack of scientific consensus about the 
best strategies for predicting these conditions before birth and thus there is uncertainty 
about the best management of pregnant women who might have a growth-restricted 
baby. This health technology assessment thesis used state of the art methods to review 
337 studies including 472,544 women. It determined : 1. The accuracy of available tests 
for predicting small for gestational age infants (SGA) and 2. Compromise of fetal 
wellbeing and 3. Summarised the effectiveness of available treatments for these 
conditions. To allow translation of these results into patient care, the diagnostic and 
therapeutic information was integrated in a model based economic evaluation. This 
thesis has demonstrated that the tests reviewed have a limited use in screening/diagnosis 
for SGA/compromise of fetal and neonatal wellbeing when used in isolation. The 
quality of primary research was variable with recommendations being made particularly 
for the use of standardised and relevant outcome measures. The decision model and 
economic analysis identified that an effective, affordable and safe intervention applied 
to all mothers without prior testing is likely to be the most cost-effective strategy in the 
prevention of these conditions. 
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Executive Summary 
 
Background 
Restriction of fetal growth and compromise of its wellbeing remain significant causes of 
perinatal death and childhood disability. At present, there is a lack of scientific 
consensus about the best strategies for predicting these conditions before birth. 
Therefore, there is uncertainty about the best management of pregnant women who 
might have a growth-restricted baby. This is likely to be due to a dearth of clear, 
collated information from individual research studies drawn from different sources on 
this subject. This thesis contains health technology assessment of test treatment 
strategies for prevention of fetal growth restriction and compromise of fetal wellbeing to 
guide clinical practice and future research in this area. 
 
Objectives 
This thesis undertook health technology assessment for a range of tests and 
interventions for SGA and compromise of fetal/neonatal wellbeing. The objectives were 
to a) obtain summary estimates of effects of available tests and treatments for restriction 
of fetal growth and compromise of its wellbeing; b) To evaluate the effect of study 
reporting and methodological quality on test accuracy; c) to integrate the summarised 
diagnostic and therapeutic information using decision-analytic modelling.  
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Methods 
A health technology assessment was performed based on prospective protocols using 
contemporary methods. The following methods were employed: systematic review and 
meta-analyses of test accuracy, reviews of effectiveness of interventions and economic 
evaluation using a decision tree model.  
 
For the test accuracy reviews, literature was identified from electronic sources, contact 
with experts and checking of reference lists. Inclusion criteria were studies performed in 
pregnant women at any gestation using an appropriate test and reference standard where 
2x2 data could be calculated. Methodological quality was assessed using the Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS) criteria. Meta-analyses were 
performed with the bivariate approach. Assessment of study reporting and 
methodological quality of included accuracy studies and assessment of their impact on 
accuracy was also performed. 
 
The effectiveness review was a review of systematic reviews of effectiveness. Literature 
was identified from electronic sources, reference lists and contact with experts. Included 
reviews had to be systematic reviews of randomised controlled trials comparing an 
intervention for prevention of fetal growth restriction or compromise of fetal wellbeing 
to placebo, no intervention or usual care. Quality was assessed using a checklist based 
on the Critical appraisal skills programme (CASP) checklist. Data were presented as 
relative risk with 95% confidence intervals.  
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The economic evaluation employed a decision tree model. The perspective was that of 
the National Health Service (NHS) with inputs to the model derived from the systematic 
reviews performed and published literature. Deterministic and probabilistic sensitivity 
analyses were performed. The main outcome measure was cost-effectiveness per case of 
fetal growth restriction avoided. 
 
  
Results 
Main findings of test accuracy reviews 
There were 10,107 citations identified as being potentially relevant for this work. Of 
these, 1,157 papers were read in full with 337 included in the reviews including 472,544 
women tested. The following tests were reviewed; five Down‟s syndrome screening 
markers (alpha feto-protein, human chorionic gonadotrophin, estriol, inhibin A, 
pregnancy associated plasma protein A) and four Doppler measurements (uterine artery, 
umbilical artery, middle cerebral artery and ductus venosus). The median number of 
women included was 33,292 (interquartile range 13,273-40,637). The median number of 
studies per test was 60 (interquartile range 31-86). The tests overall for prediction of 
small gestational age infants and adverse perinatal outcome demonstrated low predictive 
accuracy with no tests having a positive likelihood ratio LR>5 and a negative LR<0.5. 
 
Main findings of effects of study quality on test accuracy  
A total of 195 studies were included in this work. The overall reporting quality of 
included studies was poor (adequate reporting >50% of the time for 62.1% (18/29) of 
the items).  The overall methodological quality was poor (>50% compliance with 57.1% 
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of quality items). There was a positive correlation (p<0.0001) between study sample 
size and reporting quality but not with methodological quality. No correlation with 
geographical area of publication and compliance with quality criteria could be 
demonstrated. Meta-regression analysis showed that no individual quality item had a 
significant impact on accuracy. There was an association between reporting and 
methodological quality (r=0.51 p<0.0001). This work demonstrated that the reporting 
and methodological quality of papers in Obstetrics is improving but that there is still 
considerable scope for improvement.  
 
Main findings of review of systematic reviews of effectiveness of interventions  
This work included 71 systematic reviews with a total of 733 randomised controlled 
trials reporting on 42 different interventions. After considering the results and the 
quality of evidence, antiplatelets and multiple micronutrient supplements were the 
interventions that were found to be effective in preventing the small for gestational age 
fetus and suitable for use in all pregnant women. For high risk pregnant women the 
following were found to be effective: antiplatelets, multiple micronutrient supplements, 
smoking cessation interventions and progesterone therapy. For prevention/reduction of 
perinatal mortality antiplatelets and antenatal corticosteroids were the interventions 
shown to be effective. 
 
Main findings from health economic evaluation and decision analytic modelling  
The model used an outcome of cost per case of fetal growth restriction avoided and 
incorporated first and second trimester tests from the test accuracy reviews and all 
relevant interventions identified from the effectiveness reviews. Costs of tests and 
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treatments and outcomes were identified from local data and the literature. Testing prior 
to intervention was not shown to be the most cost-effective strategy in the analyses for 
all pregnant women. Anti-platelet therapy, without prior testing, was highlighted as 
potentially cost-effective in preventing fetal growth restriction in this population. In 
high risk women, testing with serum human chorionic gonadotrophin followed by anti-
platelet therapy in those that test positive was a potentially cost-effective strategy. 
Threshold analysis revealed that for a test to be considered as an option prior to 
treatment in unselected pregnant women it would have to have high levels of accuracy 
and be relatively cheap (£5). This is likely to be due to the fact that the majority of 
treatments available are themselves relatively cheap (£2.60 for aspirin) and thus from a 
cost point of view it will always be preferential to apply treatment to all rather than to 
test first. This has to be interpreted in light of the limitations of the model, importantly 
the lack of inclusion of adverse effects of treatment. 
 
Conclusions 
This thesis has demonstrated that the tests reviewed have limited use in 
screening/diagnosis for SGA baby/compromise of fetal and neonatal wellbeing when 
used in isolation. The main implications of this work are thus not for recommendations 
for practice but for future research. Further research in this area needs to consider the 
use of tests in combination and the role that other diagnostic tools, such as risk factor 
assessment and clinical features, add to the clinical decision making process. This 
research needs to be robustly designed, include primary test evaluation strategies with 
reference to relevant quality criteria and include a sample size calculation to ensure that 
results have sufficient power. There is a particular need for researchers in the area of 
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fetal growth restriction to determine the most appropriate reference standards/outcome 
measures to be used that truly identify the growth restricted baby. This will ensure that 
primary research is not only directed at the fetuses/pregnancies at risk but will facilitate 
future systematic reviews and meta-analysis. 
 
To ensure that the results of any future economic analysis and decision model analysis 
can be translated into recommendations for practice there will be a need for models, and 
the primary research that informs them, to be able to compare both directly and 
indirectly all combinations of tests and treatments with consideration of side effects. 
There will also need to be further primary research to determine accurate costs of the 
outcomes. This research will also need to be directed to look at the impact of these 
clinical management strategies on multiple outcomes e.g. pre-eclampsia, pre-term birth 
and fetal growth restriction to ensure that a truly comprehensive clinical management 
pathway that is applicable to a general pregnant population within the NHS can be 
devised.
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CHAPTER 1: INTRODUCTION 
 
1.1 Aim and objectives of thesis 
The aim of this thesis was to perform an health technology assessment (HTA) in 
Obstetrics through evaluation of a range of tests and interventions for small for 
gestational age (SGA) fetuses and compromise of fetal/neonatal wellbeing. The main 
objectives were as follows: 
1. To obtain summary estimates of accuracy of available tests for SGA fetuses and 
compromise of fetal wellbeing. 
2. To evaluate the effect of study reporting and methodological quality on test 
accuracy.  
3. To obtain summary estimates of effects of available treatments for SGA fetuses 
and compromise of fetal wellbeing. 
4. To integrate summarised diagnostic and therapeutic information using decision-
analytic modelling. 
 
1.2 Outline of thesis 
The work performed has been divided into two volumes:  
Volume I 
PART A: SYSTEMATIC REVIEWS OF TEST ACCURACY 
Systematic reviews of the existing evidence on the accuracy of tests to predict small for 
gestational age fetuses and compromise of fetal/neonatal wellbeing (chapters 4-10).  
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PART B: METHODOLOGICAL RESEARCH INTO THE EFFECTS OF REPORTING 
AND METHODOLOGICAL QUALITY OF SYSTEMATIC REVIEWS OF TEST 
ACCURACY  
The quality of reporting of primary test accuracy studies in Obstetrics reviewed in this 
thesis: application of the STARD criteria (chapter 11). Methodological quality of test 
accuracy studies included in systematic reviews in Obstetrics reviewed in this thesis: 
Sources of bias (chapter 12).  
 
PART C: REVIEW OF SYSTEMATIC REVIEWS OF THE EVIDENCE ON 
EFFECTIVENESS OF AVAILABLE INTERVENTIONS FOR PREVENTION OF 
SMALL FOR GESTATIONAL AGE AND COMPROMISE OF FETAL/NEONATAL 
WELLBEING 
Review of systematic reviews of the existing evidence on the effectiveness of available 
interventions for prevention of small for gestational age fetuses and compromise of 
fetal/neonatal wellbeing (chapter 13).  
 
PART D: COST EFFECTIVENESS ANALYSIS WITH ECONOMIC MODELLING 
Cost effectiveness analysis with economic modelling to assess test and treatment 
strategies for the management of the small for gestational age fetus and compromise of 
fetal/neonatal wellbeing (chapter 14). 
 
Volume 2 
Appendices and references. 
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1.3 Methods 
The thesis employed systematic reviews and decision-analytic modelling based on 
prospective study protocols. Primary importance is given to reviews of test accuracy 
looking at individual tests, and included methodological research looking at the impact of 
study quality on test accuracy. Research was also performed to determine the 
effectiveness of available interventions for SGA fetuses and fetal/neonatal compromise. 
Finally, the results from the systematic reviews of test accuracy and effectiveness were 
combined in a decision tree model to allow economic based evaluation, an essential part 
of health technology assessment. Figure 1.1 summarises the HTA conducted in this PhD 
thesis. 
 
Figure 1.1: Process of health technology assessment for the prediction and 
prevention of fetal growth restriction and compromise of fetal/neonatal wellbeing 
Prediction and 
prevention of 
fetal growth 
restriction and 
compromise of 
fetal wellbeing
Part A
Systematic reviews of 
test accuracy e.g. Downs 
syndrome serum markers, 
maternal and fetal Doppler 
studies
Part D
Cost-effectiveness 
analysis and decision 
analytic modelling
PART C
Review of systematic 
reviews of the evidence 
on effectiveness of 
available interventions
Part B
Methodological 
research into reporting 
and methodological 
quality in test accuracy
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CHAPTER 2: BACKGROUND 
 
2.1 Health Technology Assessment 
Health services research is concerned with the relationship between provision, 
effectiveness and efficient use of health services and the health needs of the population. It 
aims to produce reliable and valid research data on which to base effective, efficient and 
acceptable health services. “Health technologies” are broadly defined as all interventions 
to promote health, prevent and treat disease, and improve rehabilitation and long-term 
care
1
. Health technology assessment (HTA) involves the systematic appraisal and 
evaluation of health technologies through primary research, systematic reviews and 
model based synthesis of available evidence. It asks four fundamental questions
1
: 
 Does the technology work? 
 For whom does it work? 
 What is the cost? 
 How does it compare with the alternatives? 
 
The steps in an HTA are
2
: 
1. Clearly define the question 
2. Search for available information 
3. Generate a “decision tree” 
4. Find the evidence 
5. Sort and appraise the evidence 
6. Search for cost information 
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7. Extract and summarise/synthesise data 
8. Perform an economic evaluation 
9. Consider the wider ethical, legal and social implications 
10. Write an HTA report 
 
2.1.1 HTA of diagnostic technologies 
Timely prediction of SGA and compromise of fetal wellbeing is of essence in antenatal 
care. Without accurate prediction, clinicians are handicapped and unable to institute 
appropriate management. Wrong or delayed prediction puts the baby at risk of an adverse 
outcome whereas correct prediction provides an opportunity to optimise care. If high-risk 
groups are accurately and efficiently identified, they could benefit from monitoring of 
wellbeing and appropriate interventions such as steroid administration and timely 
delivery. However, decision-making is hampered due to lack of precise information on 
estimates of risk.  
 
Obstetrics has seen rapid growth in the development of new tests in the area of fetal 
growth restriction (FGR) particularly advances in ultrasound imaging and first trimester 
screening
3
 (table 2.1). A key aspect of research on these is presented in the form of test 
accuracy studies
4
, which generate a comparison of measurements made by an index test 
against those of an accepted reference standard test – the “gold standard”. These 
comparisons enable an assessment of the accuracy of an index test, which are often 
expressed as sensitivity, specificity, likelihood ratios (LRs), diagnostic odds ratio (DOR), 
positive predictive value (PPV) and negative predictive value (NPV) or area under 
receiver operator characteristic curve (AUC)
5
.  These measures of test accuracy take into  
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Table 2.1: Table of available tests for prediction of restriction of fetal growth and 
compromise of fetal wellbeing. 
 Tests for restriction of fetal growth  Tests for compromise of 
wellbeing  
Tests   
History and 
Examination 
 Clinical risk scoring 
 Palpation of abdomen to assess size 
 Symphyseal fundal height (SFH) 
measurement 
 
 Clinical risk scoring 
 Fetal movement counting 
Ultrasound Biometry (anthropometric measures) 
 Single measures: Abdominal circumference 
(AC),  Head circumference (HC), Biparietal 
diameter (BPD), Femur length (FL), 
Thoracic diameter, Abdominal diameter, 
Abdominal area, Chest area, Liver size, 
Thigh circumference, Subcutaneous fat 
 Ratio measures: FL/AC, HC/AC, FL/HC, 
Head area/abdominal area, FL/ thigh 
circumference 
 Composite measures: Estimated fetal 
weight (EFW), Fetal ponderal index, Total 
intrauterine volume, Trunk area x Crown 
Rump Length,  
 Growth velocity measurements 
Doppler 
 Uterine artery 
 Umbilical artery 
 Middle cerebral artery 
 Descending aorta 
 Internal carotid artery 
Other 
 Amniotic fluid volume 
 Placental grade 
 
Doppler 
 Uterine artery 
 Umbilical artery 
 Middle cerebral artery 
 Venous Doppler 
 Uteroplacental 
Other 
 Amniotic fluid volume 
 Biophysical profile 
 
Biochemical 
and 
Haematological 
 Oestriols, Human placental lactogen, 
Plasma fibronectin, Alpha Feto Protein, 
Human chorionic gonadotrophin, Beta-1 
glycoprotein, Placental protein 10, 
Pregnancy Associated Plasma Protein A, 
dehydroepiandrosterone sulphate loading 
test, Epidermal growth factor, Amniotic 
fluid C-amino peptide, Serum cystine 
aminopeptidase, Schwangerschafts protein 
1, Serum alpha 2 – macroglobulin, 
Maternal leukocyte zinc level, Form 
stability index 
 
 
Other tests  Customised growth charts of SFH and 
ultrasound EFW 
 
 Cardiotocography (CTG) 
 Fetal ECG 
 Fetal magnetocardiography 
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account the false positive and false negative results from a test and the relationship 
between these two values thus helping to determine the usefulness of a test in clinical 
practice. It is thus important that these summary measures of accuracy are obtained 
through systematic reviews of the highest quality of evidence available. 
 
2.1.2 HTA of therapeutic interventions 
The ability to accurately predict or diagnose disease is only one step in the clinical 
pathway. Following testing there needs to be effective, safe and acceptable intervention 
with the purpose of either preventing development of the condition, improving or 
maintain the current health status or avoiding further deterioration, or in some instances to 
provide palliation. Evaluation of a therapy must therefore include an assessment of its 
efficacy usually within the context of a randomised controlled trial (RCT), investigation 
of its safety, assessment of the economic costs, assessment of its acceptability to patients 
and consideration of the wider social, legal and ethical implications. Once a therapy has 
been found to be effective, safe and acceptable to parents it must then be proven to be 
cost-effective within a wider population before it can be considered as part of the clinical 
pathway. The gold standard for assessment of the efficacy of interventions is the 
systematic review of RCTs e.g. Cochrane reviews of effectiveness. 
 
2.1.3 Decision modelling for economic evaluation of health technologies 
Any diagnostic tool will have false positive and false negative results and all treatments 
will have a cost attached to them. When assessing a health technology, it is thus important 
that the tests and treatments are assessed as part of a cost-effectiveness analysis. Resource 
use within the NHS cannot only be dictated by effectiveness but must also take into 
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account cost and be able to assess new technologies, treatments and management 
pathways in a comparative manner
6
. The National Institute for Health and Clinical 
Excellence (NICE) uses economic evaluation to provide guidance to the NHS on the 
introduction of new technologies. 
 
To enable the diagnostic and therapeutic information to be integrated, a model is used to 
provide a framework for all potential levels of effects and associated costs. Advantages of 
using a model are that all possible combinations of outcomes may be considered and 
advanced statistical techniques, such as Monte Carlo simulations may be used. Even with 
slight values of effectiveness for available treatments, as can be the case in Obstetrics, 
model-based decision analysis provides the most objective way to assess whether a test 
and a treatment should be employed. This also allows extrapolation of the data beyond 
the time scale of any original studies. Finally, an appropriately structured model-based 
economic analysis can also help decide which research to invest in in the future via value 
of information analysis. This aims to quantify the total uncertainty in terms of the value of 
removing that uncertainty via probabilistic sensitivity analysis. The model can thus 
provide a hierarchy of most promising test/treatment combinations and identify areas in 
which additional data collection, and hence the reduction of uncertainty, would be of 
most value. 
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2.2 Description of the underlying health problem 
2.2.1. The importance of small for gestational age fetuses and compromise of 
fetal/neonatal wellbeing in Obstetrics 
Restriction of fetal growth and compromise of its wellbeing remain significant causes of 
perinatal death and childhood disability
7-9
. The most recent confidential enquiry into 
perinatal deaths reported a neonatal mortality rate of 32.5 per 1,000 live births for 
babies with birth weight < 2500g (compared to 0.8 per 1,000 live births for birth weight 
> 2500g) and determined that 37.9% of the unexplained stillbirths were small for 
gestational age (birth weight less than 10th centile for gestation)
10
. These babies on 
reaching adulthood are at greater risk of developing cardiovascular disease, 
hypertension, and non-insulin dependent diabetes
11;12
.  
 
2.2.2 Definitions of the growth restricted baby 
There are various centile based thresholds (2.5
th
, 3
rd
, 5
th
, 10
th
, 15
th
 and 25
th
) for defining 
SGA and absolute birth weight thresholds for defining low birth weight (<2500g, <1750g, 
<1500g, mean < 2 standard deviations). The most commonly accepted and used standard 
is the 10
th
 centile
13
.  However, by definition this standard will represent 10% of the 
population being assessed. This will thus constitute a very heterogeneous population 
including both the constitutionally small baby, the abnormal baby with, for example, 
chromosomal defects and the truly growth restricted baby (FGR). In this context FGR 
refers to a fetus that has failed to achieve its genetic growth potential usually because of 
placenta-mediated disease restricting nutrient supply. 
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Where a fetus is assessed as small for gestational age, up to 50-70% of these fetuses are 
constitutionally small
14;15
, not truly growth restricted. Studies have shown that perinatal 
mortality is eight times higher when birth weight is below the 10
th
 percentile
16
. If stricter 
criteria, such as birth weight less than the 3
rd
 centile are used then this is associated with a 
twenty times increase in mortality
16
. Customised growth charts that are adjusted for sex, 
gestational age, parity, maternal weight and height and ethnicity, have been shown to 
improve the detection of at risk of stillbirth
17
. Neonatal indices, such as skin fold 
thickness, have been shown to identify the malnourished infant at risk of peripartum 
asphyxia
16
 and long term neurological sequelae
18
.  
 
2.2.3 Aetiology 
The aetiology of FGR remains unclear (figure 2.1) but can be split into two main areas: 1) 
fetal factors causing the fetus not to achieve its full growth potential e.g. chromosomal 
defects, fetal infections, structural abnormalities and 2) extrinsic factors affecting the 
supply of nutrients and oxygen via the placenta to the fetus. This “placental insufficiency” 
may be related to placental factors such as inadequate trophoblast invasion of the spiral 
arteries as is seen in conditions such as pre-eclampsia (PE)
19
 or related to maternal factors 
limiting the supply. This may be systemic maternal diseases, such as cardiac and renal 
disease, or social factors such as severe maternal malnutrition, smoking or drug abuse
20
.  
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Figure 2.1: Aetiology of fetal growth restriction 
 
 
2.3 Current service provision 
2.3.1 The current investigation of pregnancies at risk of a small for gestational age 
fetus or compromise of fetal/neonatal wellbeing and the current evidence on 
accuracy of diagnostic tools in this area 
Screening and diagnosis of FGR and prediction and monitoring for compromise of fetal 
wellbeing in a clinical setting includes a combination of patients‟ characteristics, 
symptoms, physical signs and tests, which form the basis of clinical care
21
. For instance, 
methods employed to screen for and detect FGR might include obtaining previous history 
of small babies, recording symphyseal fundal height on a customised growth chart and 
estimating fetal weight with ultrasound
21
 . Similarly, current history of fetal movements, 
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abdominal palpation to assess liquor volume, ultrasound amniotic fluid index, Doppler 
flow velocimetry and cardiotocography might be used to assess fetal wellbeing
21
. Tests of 
wellbeing are aimed at predicting fetal acidaemia, which is perceived, at least in the 
model of chronic placental failure, to lead ultimately to organ damage and death. Data 
from cord blood sampling studies confirm there is a correlation between cord pH and 
neurodevelopmental outcome in small fetuses
22-24
. This implies that the accuracy of tests 
for FGR need to be assessed separately to those used for assessment of fetal wellbeing, 
but existing reviews often do not make this distinction.  
 
Prior to the commencement of this work, formal searches (MEDLINE 1966-2003) were 
undertaken to identify existing systematic reviews and evidence based guidelines in this 
area to avoid duplication. This search revealed numerous non-systematic reviews and 
non-evidence based guidelines. There were nine relevant publications consisting of seven 
systematic reviews
13;25-30
 and two evidence based guidelines
21;31
.  Assessment of the 
methods of these reviews with standard checklists revealed five main deficiencies: i) 
reviews covered a limited number of tests, ii) search strategies were limited, iii) scientific 
strategies to limit bias were not employed, iv) with a few exceptions, meta-analyses were 
not employed to summarise the findings, v) there was a lack of clinically meaningful 
measures of test accuracy, such as likelihood ratios
32
.  
 
In 2002 the Royal College of Obstetricians and Gynaecologists (RCOG) published an 
evidence based guideline on “The Investigation and Management of the Small for 
Gestational Age Fetus”21. This guideline was developed using robust guideline 
methodology however, the recommendations were limited due to a lack of systematic 
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collation of diagnostic information on the subject. The current guideline recommends the 
use of customised fundal height charts for prediction of SGA fetuses; abdominal 
circumference and estimated fetal weight <10
th
 centile on customised charts to diagnose 
SGA and the use of umbilical artery Doppler as the primary surveillance tool
21
.  
 
The variation in the design of research on accuracy of tests for identification of growth 
restriction and compromise of wellbeing, the scatter of this research across many 
databases and languages, and the dearth of clear collated up-to-date summaries of this 
literature contribute to the uncertainty about the best diagnostic and monitoring 
strategies
21
. The role of systematic reviews of test accuracy in this area is thus at the 
forefront of research. The Cochrane collaboration have initiated such reviews and 
published guidelines on the methods for test accuracy reviews
33
. The last decade has seen 
many improvements in the methods of these reviews with the introduction of checklists 
for reporting
34
 and methodological quality
35;36
 and advances in the statistical methods 
used in meta-analysis
37
.  
 
A comprehensive systematic review of the literature on available tests, using 
contemporary methods, will improve the ability to identify those pregnancies at greatest 
risk of developing clinically relevant intra-partum and neonatal consequences of impaired 
fetal growth. NICE have also recommended further prospective research to evaluate the 
diagnostic value and effectiveness of predicting small for gestational age fetuses
38
. 
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2.3.2 Current interventions available for pregnancies at risk of a small for 
gestational age fetus or compromise of fetal/neonatal wellbeing. 
The potential for a therapy to be effective depends on the nature of the underlying 
aetiology (section 2.2.3). A thorough assessment of the fetus and mother must be 
performed to identify those causes that will not be amenable to therapy e.g. 
chromosomal anomalies, and in those cases where therapy might be an option, to 
determine which may be the most appropriate. The major difficulties in this area are 
however the lack of accurate predictive and diagnostic tests for the growth restricted 
fetus and the potential for there to be more than one contributory cause e.g. pre-term 
labour and fetal growth restriction or fetal growth restriction and pre-eclampsia. 
 
Previous reviews of effectiveness of interventions for fetal growth restriction have 
concluded that there are few interventions that are likely to be beneficial and that further 
high quality research is required
39
. The same conclusion was reached in the RCOG 
guideline (2002)
21
which states that smoking cessation programmes, particularly 
behavioural strategies, can be effective for a small minority of smokers in increasing 
birth weight but there are no data to suggest that this intervention improves perinatal 
outcome. Further trials are needed to assess the value of aspirin in the treatment of FGR; 
there is not enough evidence to assess the value of oxygen therapy, nutrient therapy, 
hospitalisation and bed rest, betamimetics, calcium channel blockers, hormonal therapy 
and plasma volume expansion in treating growth restriction
21
. 
 
Since this guideline was written there has been further research in this area including the 
updating of many of the reviews of the Cochrane Pregnancy and Childbirth group in 
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2009
40
. When evidence is spread across many databases, and in the case of fetal growth 
restriction evidence may be related to other conditions such as pre-eclampsia, it can be 
difficult to access appropriate up to-date robust evidence for clinical decision making. 
Systematic reviews provide a technique to allow individual pieces of research to be 
collected and if appropriate subjected to meta-analysis
41
. It is essential that these 
reviews are performed with rigorous methods and include an assessment of study 
quality of they are to have valid inferences and produce usable summaries to guide 
medical practice
41
. A review of systematic reviews of effectiveness for interventions for 
fetal growth restriction and compromise of fetal wellbeing will thus help summarise the 
most up to-date evidence and allow an assessment of the quality of the evidence.          
 
2.4 Development of this thesis 
The charity Wellbeing of Women funded an evidence synthesis project to 
systematically review the accuracy data for available tests for fetal growth restriction. 
The author worked on this project grant performing the systematic reviews. This work 
was then developed into a Clinical Research Training Fellowship funded by the Medical 
Research Council. This fellowship developed the original work to incorporate 
systematic reviews of effectiveness and decision analytic modelling. 
 
2.5 Nomenclature used in thesis 
As discussed in section 2.2.2 there is a lack of a standardised definition for FGR thus 
throughout the literature the terms SGA and FGR are used interchangeably. To try and 
ensure consistency through this thesis, the term SGA has been used when referring to 
infants/fetuses determined as small by being below a predetermined centile e.g. 10
th
 and 
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FGR when describing those that may be SGA and/or definitely FGR from postnatal 
measuremnts. 
 
As the objective of this thesis is to assess antenatal tests and make recommendations for 
obstetric practice the term SGA fetus has been employed as the tests are assessing the 
fetus not an infant. It is recognised that the eventual diagnosis is only made once the 
“fetus” has been delivered and thus the tests are in effect predicting/diagnosing SGA 
infants. As the primary literature assessed in this thesis uses the term SGA or SGA fetus, 
the decision was made to employ this terminology in this thesis. 
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CHAPTER 3: RESEARCH QUESTIONS ADDRESSED IN 
THE THESIS 
 
3.1 Research questions addressed in this thesis by systematic review 
3.1.1 Questions addressed in thesis by reviews of diagnostic test accuracy 
1. What is the accuracy of Down‟s syndrome serum screening markers to predict 
small for gestational age fetuses? 
2. What is the accuracy of uterine artery Doppler to predict small for gestational age 
fetuses? 
3. What is the accuracy of umbilical artery Doppler to predict small for gestational 
age fetuses and compromise of fetal/neonatal wellbeing? 
4. What is the accuracy of middle cerebral artery Doppler to predict small for 
gestational age fetuses and compromise of fetal/neonatal wellbeing? 
5. What is the accuracy of ductus venosus Doppler to predict small for gestational 
age fetuses and compromise of fetal/neonatal wellbeing? 
6. What is the summary of the evidence reviewed of test accuracy for prediction of 
small for gestational age fetuses and compromise of fetal wellbeing? 
7. What is the reporting quality of primary studies of test accuracy in Obstetrics 
reviewed in this thesis and how has this changed over time? 
8. What are the methodological quality of primary test accuracy studies in Obstetrics 
reviewed in this thesis and the sources of bias and variation and have these 
changed with the introduction of quality standards? 
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3.1.2 Questions addressed in the thesis by systematic review of reviews of 
effectiveness 
9. How effective are the available treatments for preventing small for gestational age 
fetuses and compromise of fetal/neonatal wellbeing? 
 
3.2 Question addressed in the thesis by decision analytic model based 
economic evaluation 
10. What is the cost effectiveness of the antenatal tests and various treatment 
combinations to prevent small for gestational age fetuses and compromise of 
fetal/neonatal wellbeing? 
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PART A: SYSTEMATIC REVIEWS 
OF TEST ACCURACY 
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CHAPTER 4: METHODS FOR SYSTEMATIC REVIEWS 
OF DIAGNOSTIC TEST ACCURACY 
 
4.1 Introduction 
Chapters 5-10 of this thesis evaluates the test accuracy of antenatal tests to predict small 
for gestational age fetuses and compromise of fetal/neonatal wellbeing in pregnant 
women at varying levels of risk for these conditions. Systematic reviews of the available 
evidence were performed to assess test accuracy using a common methodology. This 
chapter provides an overview of the methods employed, where adaptations were 
necessary these are detailed in the chapters relevant to each test. 
 
All reviews were performed with reference to the existing recommended methods and 
guidelines
42-46
 and based on a prospective protocol
47
. The reviews were performed using 
the following steps
48
: (i) Framing the question, (ii) Study identification, (iii) Study quality 
assessment, (iv) Data synthesis and (v) Interpreting the findings.  
 
This work has been published Morris R, Khan KS, Coomarasamy A, Robson S, Kleijnen 
J. The value of predicting restriction of fetal growth and compromise of its wellbeing: 
Systematic quantitative overviews (meta-analysis) of test accuracy literature. BMC 
Pregnancy and Childbirth 2007;7:3.  
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4.2 Framing the question 
To ensure that the systematic review is correctly designed and ensure that the question is 
fully answered the research questions must be formulated appropriately. A clearly defined 
research question has four key components relating to the population under study, the test 
or intervention, the reference standard or comparator and the type of study designs to be 
included. When posing the question for the review the reviewer must construct the 
question so that all these components are included and thus all problems that need to be 
answered are identified. A comprehensive research question will then help determine the 
components of the search strategy. The questions posed in the systematic reviews of 
diagnostic test accuracy included in this thesis have common components as summarized 
below: 
 
Population:  Pregnant women in any health care setting, at any level of risk. 
Index test: Down‟s syndrome serum screening markers - alpha feto protein (AFP), human 
chorionic gonadotrophin (HCG), unconjugated oestriol, inhibin A, pregnancy associated 
plasma protein A (PAPP-A). Doppler ultrasound – uterine artery (UA), umbilical artery 
(Umb), middle cerebral (MCA), ductus venosus (DV).  
Reference standard: Any measurement of birth weight or nutritional status of newborn 
performed postnatally. 
Study designs: Randomised controlled trials or observational studies where the results of 
the index test are compared with the results of the reference standard, allowing generation 
of 2x2 tables of accuracy. 
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4.2.1 Population 
For each review the population was pregnant women. To ensure full assessment of the 
included tests as screening methods was made there were no restrictions made on 
healthcare setting nor level of risk of the women for complications. These factors were 
however considered in sub-group analyses. 
 
4.2.2 The tests 
The tests to be investigated were prioritised on the basis of clinical relevance after 
consultation with experts in the field and investigation of the available evidence in a 
preliminary search (appendix 1) and consideration of their use in pregnancy (figure 4.1). 
For all the tests investigated all methods of analysis, imaging modalities and thresholds 
reported by the authors of the included studies were assessed. Sub-group meta-analyses of 
individual techniques and cut off values were employed in this thesis to give a full 
assessment of the tests under investigation. 
 
4.2.3 Reference standards 
As discussed in the background of this thesis (section 2.2.2), reference standards for SGA 
and FGR vary with no consensus on the best outcome measure to use for prediction of 
short term and long term mortality and morbidity in the infant. For the purpose of the test 
accuracy reviews the reference standards used were any reported in the included studies 
(birth weight centiles, absolute birth weight cut-offs and neonatal anthropometric 
measures) with meta-analysis only employed with studies using the same outcome 
measure.  
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Figure 4.1: Flow diagram of testing in pregnancy 
Outcomes: assessments at 
birth
e.g. birth weight, cord pH
Screening for fetal growth and 
compromise of wellbeing 
e.g. serum screening, uterine artery Doppler
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Neonate
Diagnosing abnormal fetal 
growth 
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fetal wellbeing 
e.g. umbilical artery Doppler, amniotic fluid index
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Reference standards for neonatal wellbeing were any outcome measure performed after 
birth relating to neonatal wellbeing reported by the study authors. In many studies a 
composite outcome measure, adverse perinatal outcome (APO) was used. Composite 
outcomes bring together two or more events that are considered as a single outcome. For 
neonatal wellbeing this was usually a combination of outcome measures such as birth 
weight, Apgar scores, cord pH values etc. Where the authors did not report outcomes for 
APO then results were constructed using a hierarchy of outcomes, this technique 
maximised the number of events that could be included in the analyses. One problem with 
composite outcome measures is the assumption that the significance of the result applies 
to all components
49
. To address this issue a separate analysis was also performed using 
the component outcomes of the composite outcome measure. When the composite 
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outcome measure was used, care was taken to ensure that each individual was only 
counted once in each analysis. The use of composite outcome measures is an accepted 
technique in systematic reviews as long as the direction of effect for each of the included 
outcomes is in the same direction and separate analysis is performed looking at the 
individual components
50
. 
 
4.2.4 Study design 
Acceptable study designs were RCTs and observational test accuracy studies (cohorts, 
case-control prospective) allowing generation of 2x2 tables of accuracy. Case series <10 
cases and case-control studies defined by reference standard outcome (birth weight 
measurement) were excluded as these study designs have been shown to be associated 
with bias
 
as sampling based on diseased (cases) and non-diseased (controls) can introduce 
spectrum effects
51
. 
 
 
4.3 Identification of the literature 
The search protocol was designed with the aim of identifying literature concerning 
diagnostic tests to predict or diagnose small for gestational age fetuses/fetal growth 
restriction or compromise as using the elements of the framed question (section 4.2). Pilot 
searches were performed to ensure that the search strategies gave an acceptable level of 
specificity without compromising sensitivity.  
 
The first database search performed used terms for FGR/SGA and combined them with 
methodological filters for identification of aetiologic and diagnostic test studies
52;53
 
(appendix 2). This search was to identify all tests performed for prediction and diagnosis 
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of the condition and was used for the reviews of serum markers (chapter 5) and uterine 
artery Doppler (chapter 6) as these reviews were performed in collaboration with 
researchers in Amsterdam who were looking at prediction of pre-eclampsia
54
. This search 
was performed by an experienced clinical librarian from the Amsterdam Medical Center 
(see Acknowledgements). Databases were searched from inception to April 2006 (see 
appendix 2 for databases).  
 
The final search strategies (performed by the author for chapters 7, 8, 9) used relevant 
medical subheadings (MeSH), text words and word variants for FGR/SGA or fetal 
wellbeing and combined these with terms for the index tests using the AND operator. The 
individual search strategies for each review are detailed with each review chapter and 
databases were searched from inception to 2009. 
 
Literature was identified via the following sources: 
(a) General bibliographic databases including MEDLINE and EMBASE.  
(b) Specialist computer databases – DARE, MEDION (a database of diagnostic 
test reviews set up by Dutch and Belgian researchers), the Cochrane Library 
and relevant specialist registers of the Cochrane Collaboration, particularly the 
Pregnancy and Child Birth Group;  
(c) Contact with individual experts and those with an interest in this field to 
uncover grey literature; 
(d) Contact with manufacturers of tests; 
(e) Hand-searching of selected specialist journals;  
(f) Checking of reference lists;  
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(g) SCISEARCH and Web of Science to identify frequently cited articles and 
conference abstracts.    
 
All searches were made without language restrictions. A comprehensive database of 
articles relevant to each test was constructed using Reference Manager 11.0 software.  
 
The titles and abstracts of the citations were scrutinised by the author, copies of full 
manuscripts of the citations that were likely to meet the selection criteria were obtained. 
The author then selected the studies, which met predefined and explicit criteria regarding 
populations, tests, reference standards and study design using a checklist, the items of 
which were based on selection criteria related to the question as detailed above in section 
4.2 (population, diagnostic test, reference standard and study design). This checklist was 
piloted to ensure that all eligible studies were included and that the process was 
reproducible and reliable. Ideally whenever possible this process was repeated by a 
second reviewer independently (see acknowledgments). When disagreements occurred, 
the two reviewers met and if a consensus could not be reached the opinion of a third 
reviewer (Professor Khalid Khan) was sought. In the case of duplicate publications the 
most recent or up to date manuscript was selected. All foreign language papers were 
translated (see acknowledgements). 
 
 
4.4 Assessment of the quality of the literature 
The papers meeting the inclusion criteria were assessed for quality using well developed 
and validated tools for diagnostic research
34-36
 by two independent reviewers (including 
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author). Each manuscript was assessed for reporting quality using the Standards for 
Reporting of Diagnostic Accuracy (STARD)
34
 checklist (appendix 3).  Methodological 
quality was defined as the confidence that the study design, conduct and analysis had 
minimized biases in addressing the research question, thereby focusing on the internal 
validity (i.e. the degree to which the results of an observation are correct for the patients 
being studied). Methodological quality was assessed using the Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS)
35
 checklist (appendix 4).  
 
In the assessment of study quality for the population, consecutive or random recruitment 
of pregnant women was considered ideal. Prospective recruitment was considered to 
introduce less bias than retrospective recruitment. The description of the population was 
considered ideal if the there was sufficient information about the pregnant women given 
to assign a level of obstetric risk, ideally this risk level was stated by the authors in the 
study‟s methods. The incidence of FGR was calculated for each study (reported in the 
table of study characteristics for each review) and used as a check for the authors‟ 
quantification of the risk category of the population. 
 
Assessing the quality of performance and reporting of the index standard was 
individualised for each review enabling the assessment to look at individual aspects of 
each test that might introduce bias. Further details on the assessment of quality relating to 
individual tests can be found in the respective chapters. For the reference standard, any 
representation of birth weight or nutritional status of the newborn was considered 
acceptable. Information was collected on method of determination of reference standard, 
execution and blinding. 
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Ideal study design were trials or cohort studies, case-control studies were included but 
wherever possible, when the number of studies allowed it, they were excluded from meta-
analysis due to the risk of introducing bias as discussed in section 4.2.4.  
 
Verification bias was assessed using a flow chart for each study which documented the 
number of eligible women for the study, the number of women subjected to the index test, 
the number of women receiving the reference standard and the number of exclusions, 
withdrawals and uninterpretable results. Due to the large number of included studies these 
flow charts cannot be reported individually thus an assessment of verification was made 
with ideal verification when all women could be accounted for and the number of eligible 
women progressing to the reference standard was >90%.  
 
The assessment of quality was represented by a bar chart. No attempt was made to apply 
a quality score as this has been shown to have little validity with the possibility of 
obscuring the strengths and weaknesses of a study
55
 and quality was not used as an aspect 
in inclusion/exclusion of studies. Instead, an individual assessment was made of the most 
important quality items for each individual test under review and studies defined as high 
or low quality. This definition was used in the sub-group analysis. If the number of 
studies allowed then meta-regression analysis based on quality items was performed. 
 
4.5 Data extraction 
The extraction of a study‟s findings was conducted using a pre-designed and piloted data 
extraction form to avoid any errors. Data were recorded on an Excel spreadsheet. In at 
least 10% of studies the data extraction was repeated by another independent reviewer 
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(see acknowledgements). The form was used to extract clinical, methodological 
(QUADAS and STARD) and statistical data and varied only slightly during the reviews 
according to the test under review (see individual review chapters for data extraction 
forms). Any disagreements between reviewers were resolved by consensus or arbitration 
by a third reviewer (Professor Khalid Khan). Where multiple publications of the same 
study were identified, the most complete, relevant and up to-date study was included to 
avoid duplication.  
 
4.6 Quantitative data synthesis 
4.6.1 Summary measures for test accuracy 
From the 2x2 tables, the true positive rate (sensitivity), false positive rate (1-specificity) 
and likelihood ratios (LRs) were calculated for each study along with their 95% 
confidence intervals (CIs). Where 2x2 tables contained zero cells, 0.5 was added to each 
cell to enable calculations
56
. MetaDisc
57
 was used for calculations and STATA 10 
(StataCorp, College Station, Tx, USA) for bivariate meta-analysis, meta-regression and 
drawing receiver operating characteristic curves (ROC).  Statsdirect (Statsdirect Ltd.) was 
used to draw Forest plots. 
 
4.6.2 Exploration of heterogeneity 
Heterogeneity of results between studies was assessed graphically by looking at the 
distribution of sensitivities and specificities in the ROC space and LRs as measurement 
of accuracy size using a forest plot. Extreme values, outliers and threshold phenomena 
were explored. The loglikelihood and X
2 
test were used to assess for heterogeneity 
statistically. The reasons for heterogeneity were explored using meta-regression and 
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sub-group analyses planned a priori. This was carried out using factors considered to be 
important beforehand, including: 
 Variations in population – high and low risk defined by prevalence of FGR within 
the population. 
 Variations in index test – e.g. type of test parameter, cut-off used 
 Variations in reference standard – test used, threshold used 
 Study quality 
 Study design – cohort studies only. 
 
4.6.3 Meta-analysis 
Where sensitivity and specificity were independent of each other, meta-analysis was used. 
Pooled summary estimates were produced in the form of the summary LR as this is the 
measure which is most applicable clinically, in keeping with recommendations from 
Evidence-based Medicine Groups
4;58
. The LRs allow estimation of the probability of FGR 
or neonatal compromise with a specific test result. To generate the practical application of 
these LRs the post test probability of having the disease was generated (for either a 
positive or negative test result) using Bayes‟ theorem and the following formula: post test 
probability = likelihood ratio x pre-test probability/ [1-pre-test probability x (1-likelihood 
ratio)]
59
. Estimates of pre-test probability were made using reports from previous studies 
and taking into account the risk rates for the population in question. The range of 
uncertainty was calculated using the 95% confidence intervals of the LRs for each test.  
 
The bivariate meta-regression model
37;60;61
 was used to meta-analyse estimates of 
sensitivity, specificity and LRs. The model assumes a bivariate normal distribution for the 
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logit transformed sensitivity and specificity values across studies by directly analysing the 
logit transformed sensitivity log (sens/(1-sens)) and specificity log (spec/(1-spec)) of each 
study in a single model. It preserves the two dimensional nature of the data produced in 
test accuracy studies and incorporates the inherent correlation that exists between 
sensitivity and specificity due to threshold effect. The model also accounts for 
heterogeneity beyond chance due to clinical or methodological differences in studies, 
employing a random effects model. In addition, the model acknowledges the difference in 
precision by which sensitivity and specificity have been measured in each study. This 
means that studies with a larger number of patients with the target condition receive more 
weight in the calculation of the summary estimate of sensitivity, while studies with more 
patients without the target condition are more influential in the pooling of specificity. 
 
Sensitivity analysis was performed to check the robustness of all results. A p value of 
<0.05 was used throughout for statistical significance. 
 
4.6.4 Publication bias 
Analysis for assessing the risk of publication bias was carried out by producing funnel 
plots of log diagnostic odds ratios verses inverse of variance
62
. When no publication bias 
is present the plots will be shaped like a funnel because studies of smaller size are 
expected to have increased variation in the estimates of accuracy. The bigger the study 
variance, the lower the weighting of the study and the less information it provides. This 
means that in addition to small sample size of included primary studies, those studies 
reporting very high accuracy will also have a relatively big variance and thus be weighted 
less. The interpretation of the funnel plots took into account the debate surrounding their 
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use in diagnostic reviews
63
. The Harbord regression test for asymmetry based on the 
efficient score and its variance, Fisher‟s information, was performed64. 
 
4.6.5. Clinical application 
The clinical impact of estimates of accuracy for a screening test depend on how the 
results of the test alter the patient‟s pre-test probability of disease, based on disease 
prevalence. The post-test probability can then be combined with estimates of 
effectiveness for known treatments
65
. From this data the number of women needed to be 
tested (number needed to test- NNTest) can be calculated, using a particular test, to 
prevent one case of an SGA fetus with a particular treatment and the number needed to 
treat (NNTreat), the number of test positive women needed to be treated to prevent one 
case of SGA. In the reviews of Down‟s syndrome serum markers (chapter 5) and uterine 
artery Doppler (chapter 6) (i.e. first and second trimester tests) clinical application was 
assessed using aspirin as this treatment is accepted as of potential use in SGA 
fetuses
39;66
. 
 
 
4.7 Description of data 
For each test, information on individual studies was summarised as follows:  
 Table with methodological and reporting characteristics of included studies.  
The table states the number of women tested in each study, the incidence of fetal 
growth restriction (based on the number of analysed cases divided by the total 
number of women at baseline (cohort studies and nested case-control studies)) 
and maternal age (given as mean (± SD) for the whole group unless otherwise 
stated). 
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 Summary of quality and reporting items of the included studies.  
Results were presented as 100% stacked bars, where figures in the stacks 
represent the number of studies.  
 Forest plots of sensitivities (%), specificities (%) and LRs with their 
corresponding 95% CIs.  
Numbers of women analysed are true positives/(true positives + false negatives) 
for sensitivity and true negatives/(false positives + true negatives) for specificity. 
Positive likelihood ratio = (LR+ve) sensitivity/(1-specificity) and negative 
likelihood ratio =  (LR-ve) (1-sensitivity)/specificity. In chapter 6 the data for 
uterine artery Doppler is presented in tabular form to allow sensitivity and 
likelihood ratio data to be demonstrated.  
 HSROC (hierarchical summary ROC) curve.  
A summary HSROC curve was drawn (according to the bivariate model) and 
example of which is shown in figure 4.2. In the summary ROC curve the vertical 
axis shows sensitivity, while the horizontal axis shows 1-specificity. The square 
represents the summary point of accuracy. The closer the index values are to the 
upper left corner, the greater the accuracy of the test.  The ellipses represent the 
region containing likely combinations of mean values of sensitivity and 
specificity for the summary point (95% confidence region) and the likely value 
for the true operating point
 
in a single future study (95% prediction region) . In 
chapter 6 the results are presented as an ROC plot to allow the results for the 
different Doppler indices to be presented. 
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Figure 4.2: Example of a hierarchical summary receiver operating 
characteristic curve drawn using the bivariate method. 
 
 
 Table with subgroup analyses. (If applicable.) 
 Significance of publication bias. 
The significance of publication bias is demonstrated using Harbord regression 
test of asymmetry p value. 
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CHAPTER 5: SYSTEMATIC REVIEW OF ACCURACY OF 
DOWN’S SYNDROME SERUM MARKERS TO PREDICT 
SMALL FOR GESTATIONAL AGE FETUSES 
5.1 Abstract 
5.1.1 Background  
The purpose of this systematic review was to determine the accuracy of five serum 
analytes used in Down‟s syndrome serum screening for the prediction of small for 
gestational age fetuses. 
 
5.1.2 Methods   
These included searching of electronic data sources (inception to February 2007), hand 
searching of relevant journals, reference list checking of included articles and contact 
with experts. Articles in which the accuracy of an analyte used in Down‟s syndrome 
serum screening before the 25
th
 gestational week was associated with the occurrence of 
small for gestational age fetuses were selected. Two authors independently extracted 
data on study characteristics, quality and results.  
 
5.1.3 Results  
Five serum screening markers were evaluated. 86 studies, testing 382,005 women 
(20,339 FGR cases) met the selection criteria. The results showed low predictive 
accuracy overall. For small for gestational age fetuses the best predictor was 
AFP>2.0MoM to predict birth weight <10
th
 centile with birth <37 weeks; positive 
likelihood ratio 27.96 (8.02,97.48) and negative likelihood ratio 0.78 (0.55,1.11) (single 
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study). A potential clinical application using aspirin as a treatment is given as an 
example. There were methodological and reporting limitations in the included studies 
thus studies were heterogeneous giving pooled results with wide confidence intervals.  
 
5.1.4 Conclusion  
Down‟s syndrome serum screening analytes have low predictive accuracy for small for 
gestational age fetuses. They may be a useful means of risk assessment or of use in 
prediction when combined with other tests. 
 
5.1.5 Publications arising from this work 
Morris R K, Cnossen JS, Langejans M, Robson SC, Kleijnen J, Ter Riet G, Mol BW, 
van der Post JA, Khan KS. Serum screening with Down‟s Syndrome markers to predict 
pre-eclampsia and small for gestational age: Systematic review and meta-analysis. BMC 
Pregnancy Childbirth 2008 Aug 4;8(1):33.  
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5.2 Introduction 
Second trimester serum screening for Down‟s syndrome is routinely offered to women in 
the United Kingdom and United States, either with the triple test (alpha-fetoprotein 
(AFP), human chorionic gonadotrophin (HCG) and unconjugated oestriol) or with the 
addition of inhibin A as the quadruple test. More recently first trimester screening with 
fetal nuchal translucency, HCG and pregnancy associated plasma protein A (PAPP-A) 
has provided an earlier, more effective screening method
67
. Due to their origin and sites 
of metabolism these biochemical markers may be useful in the prediction of SGA fetuses, 
there are however conflicting reports in the literature. Maternal serum levels of these 
analytes have been shown to be associated with adverse outcome
68;69
 with low levels of 
PAPP-A having been suggested as a marker for impaired placental function and 
placentation
70
. There are studies however reporting contrasting views
71
.  
 
The purpose of this review was to investigate the accuracy of serum biochemical markers 
used in first and second trimester Down‟s syndrome serum screening in predicting SGA 
fetuses.  
 
5.3 Methods 
The methods used are outlined in chapter 4 with those specific to this review detailed 
below. 
 
5.3.1 Data sources and searches 
Electronic searches were performed with the assistance of experienced clinical 
librarians targeting the prediction of SGA fetuses. Medline, Embase, the Cochrane 
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Library (2006;4) and Medion from inception until February 2007 were searched. The 
search strategy is detailed in appendix 2.  
 
5.3.2 Study selection  
Criteria for included studies were those that reported on singleton pregnancies at any 
level of risk in any healthcare setting using any serum biochemical test used in Down‟s 
syndrome serum screening before the 25
th
 week of gestation.  
 
5.3.3 Data extraction and Study Quality Assessment 
 
The data extraction form for this review can be found in appendix 5. For the index test 
any methods of laboratory analysis at any threshold was accepted (centiles and 
multiples of the median (MoM)). Acceptable reference standards for SGA fetuses 
included birth weight < 10
th
 centile adjusted for gestational age and based on local 
population values and absolute birth weight threshold < 2500g. Severe SGA was 
defined as birth weight < 5
th
 or < 3
rd
 centile or < 1750g or and preterm SGA for SGA 
leading to delivery  < 37 weeks. Neonatal ponderal index < 10
th
 centile, skin fold 
thickness, and mid-arm circumference/head circumference were also assessed.  
 
Items considered important for a good quality paper were prospective design with 
consecutive recruitment, full verification of the test result with reference standard 
(>90%), adequate description of the index test, use of appropriate reference standard, 
application of any preventative treatments, whether cases of pre-eclampsia were 
excluded from the results, whether fetuses with chromosomal and structural anomalies 
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were excluded and whether stillbirths and intrauterine deaths were excluded from the 
results. Further explanation of the quality assessment can be found in appendix 6.  
 
5.3.4 Data synthesis and analysis 
Results were pooled among groups of studies with similar characteristics, the same 
threshold for the index test, same reference standard threshold for SGA and the same 
trimester for testing. Bivariate meta-analysis was used to produce overall summary 
results. 
 
Sub-groups were defined at the start of the review based on clinical criteria known to 
affect prognosis, method of index test or study quality: level of risk of population (high 
or low based on authors assessment and calculated incidence rates from results); type of 
assay used for index test; whether babies with chromosomal anomalies were excluded 
from the results; use of preventative treatment; quality of study. Sub-group analyses 
were performed where there were at least 3 studies with similar characteristics within 
that group. Funnel plots and the regression test for asymmetry were used to assess for 
publication bias. 
 
5.3.5 Clinical application 
In this review clinical application was assessed using aspirin as this treatment is 
accepted as of potential use in SGA fetuses
39;66
 as detailed in section 4.6.5. 
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5.4 Results 
5.4.1 Literature identification and study characteristics. 
Figure 5.1 summarises the process of literature identification and selection. The 
references of the included papers are listed in appendix 7. Tables detailing the 
individual study characteristics of the included studies are available in appendix 8.  
 
There were 86 included studies for SGA, reporting on 382,005 women (20,339 cases of 
SGA fetuses, incidence 5.32%). Among these studies, there were 61 cohort studies and 
25 case control studies. Thirty-one studies were prospective, 17 retrospective and 38 of 
unclear design. Calculated incidence rates of SGA correlated well with the threshold 
used in 78 of studies and poorly in 8, incidence range for birth weight <10
th
 centile was 
1.2-63%. Three of the studies were performed in high risk populations, whereas the 
remainder were performed in low risk or screening populations. Due to the inclusion 
criteria of the studies the majority of tests were performed between 15 to 20 weeks. 
There were ten studies reporting on first trimester screening. Fifty studies reported on 
birth weight <10
th
 centile, 13 on birth weight <5
th
 centile, 27 on birth weight <2500g, 1 
on birth weight <1500g, 1 on birth weight < 15
th
 centile and 12 reported no threshold. 
The twelve studies with not threshold for SGA were excluded from the meta-analysis. 
 
5.4.2 Study Quality 
The quality assessment of included studies for SGA revealed deficiencies (figure 5.2). 
Only 40 studies contained an adequate description of the performance of the index test. 
None of the studies reported clearly on the performance of the reference standard. 
Blinding of the reference test was also poorly reported as was the use of any treatment  
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Figure 5.1: Study selection process for systematic review of accuracy of Down’s 
syndrome serum markers to predict small for gestational age fetuses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary articles retrieved for detailed evaluation  
- from electronic searches           n= 257 
- from reference lists                      n= 8 
        
Articles excluded     n= 179 
- not prediction/ not test accuracy   n= 87 
- reviews/ letters/ comments/ editorials  n= 13 
- SGA/FGR not separate outcome              n= 4 
- (mean) gestational age > 25 weeks/ unclear            n= 46 
- insufficient data to construct 2x2 table  n= 14 
- other        n= 11 
- twins only      n=4 
Primary articles included in systematic review  n= 86 
Primary articles included in meta-analysis              n=53 
Potentially relevant citations identified from electronic searches to capture primary articles 
on all tests used in the prediction of  
               n= 20,167 
Potentially relevant citations on hCG/ AFP/ ooestriol/ PAPP-A/ Inhibin A/ in the prediction 
of  
                      n= 1,769 
References excluded after screening titles and/ or abstracts  
                  n= 1,504 
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Figure 5.2: Bar chart illustrating the compliance with quality items for included 
studies in a systematic review of accuracy of Down’s syndrome serum markers to 
predict small for gestational age fetuses. (Numbers in bars represent actual number 
of studies compliant). 
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in between the index test and reference standard. These items of quality of study design 
are important in diagnostic accuracy reviews. 
 
Four papers only distinguished between SGA with PE and SGA alone; intrauterine 
deaths and stillbirths were excluded from the results for SGA in only 16 papers, in the 
remainder it was unclear; chromosomal and structural anomalies were excluded from 62 
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studies, unclear in 24. Twenty-five case control studies and eight studies in which 
thresholds for SGA were not defined were excluded from the final meta-analysis, 
leaving 53 studies. 
 
5.4.3 Data analysis 
The results for all serum markers are summarised in forest plots in figure 5.3 and 
summary receiver operating characteristic curves in figure 5.4.  
 
Maternal serum alpha fetoprotein (AFP) 
The results for AFP are summarized in appendix 9. All studies were performed in the 
second trimester. There were thirty studies included in the meta-analysis. The 
commonest threshold used were >2.0MoM (10 studies) and >2.5MoM (five studies) to 
predict birth weight <10
th
 centile. The best predictor for birth weight <10
th
 centile was 
AFP<10
th
 centile; LR+ 8.80 (5.57, 13.91), LR- 0.02 (0.00,0.34), this was a single study.  
For birth weight<5
th
 centile and birth weight <2500g, AFP>3.0MoM was the most 
accurate predictor. The most accurate predictor overall was AFP>2.0MoM to predict 
severe SGA (birth weight<10
th
 centile with birth <37 weeks): LR+ 27.96 (8.02, 97.48), 
LR- 0.78 (0.55, 1.11). 
 
Maternal serum human chorionic gonadotrophin (HCG) 
The results for HCG are summarized in appendix 10. There were 22 included studies in 
the meta-analysis, five looked at testing in the first trimester. The commonest thresholds 
used were HCG>2.0MoM (seven studies) and HCG>2.5MoM (four studies) for birth 
weight <10
th
 centile. The most accurate predictor for birth weight <10
th
 centile was 
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HCG>2.0MoM; LR+ 1.74 (1.48,2.04), LR- 0.95 (0.93,0.96). For birth weight <5
th
 
centile HCG>2.0MoM in the second trimester was the most accurate and for birth 
weight <2500g HCG>2.5MoM.  
 
Maternal serum unconjugated Oestriol 
The results for unconjugated oestriol are summarized in appendix 11. All studies were 
performed in the second trimester. There were seven included studies, the commonest 
threshold was oestriol<0.75MoM (2 studies) for birth weight <10
th
 centile. The most 
accurate predictor for birth weight <10
th
 centile was oestriol<0.75MoM; LR+ 2.54 
(1.54, 4.19), LR- 0.75 (0.63,0.89). For birth weight <5
th
 centile there were two studies 
for oestriol<0.5 MoM; LR+ 6.54 (0.98, 43.91), LR- 0.59 (0.03,13.28). 
 
Maternal serum pregnancy associated plasma protein A (PAPP-A) 
The results for PAPP-A are summarized in appendix 12. There were 10 included 
studies, seven were performed in the first trimester, the commonest thresholds were 
PAPP-A <5
th
 centile (four studies), PAPP-A<10
th
 centile (five studies) for birth 
weight<10
th
 centile. The most accurate predictor for birth weight <10
th
 centile was 
PAPP-A<1
st
 centile; LR+ 3.50 (2.53, 4.82), LR- 0.98 (0.97,0.99). For birth weight <5
th
 
centile, the most accurate predictor was again PAPP-A<1
st
 centile; LR+ 4.36 (3.27, 
5.80), LR- 0.97 (0.96, 0.98). 
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Figure 5.3 Forest plot summarising the accuracy results of Down’s syndrome serum markers to predict small for gestational age 
fetuses. Open triangles represent overall pooled result, shaded triangles represent sub-groups. 
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Figure 5.4: Summary receiver operating characteristic curves for Down’s 
syndrome serum markers to predict small for gestational age fetuses produced 
using the bivariate method.  
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Maternal serum inhibin A 
The results for inhibin A are summarized in appendix 13. There was only one study, 
looking at second trimester testing, using a cut-off of inhibin A>2.0MoM, the results for 
prediction of birth weight<10
th
 centile were LR+ 4.45 (3.92, 5.06), LR- 0.92 (0.91,0.93) 
and birth weight <5
th
 centile; LR+ 4.91 (4.20,5.73), LR- 0.89 (0.87,0.91). As there was 
only one study for inhibin A there is no corresponding HSROC curve. 
 
Triple test (serum AFP, HCG and unconjugated oestriol) 
There were two studies, second trimester testing, with different cut-offs for prediction of 
birth weight<10
th
 centile: triple test >1:190 LR+ 1.07 (0.60, 1.91), LR- 0.98 (0.82,1.17) 
and triple test>1:250 LR+ 2.71 (1.77,4.17), LR- 1.19 (0.01,2.47). 
 
Gestation at which testing performed 
The table in appendix 14 shows the different results achieved where testing was 
performed in both the first and second trimester. Overall for HCG, testing in the second 
trimester had improved positive likelihood ratios. 
 
Sub-group and sensitivity analysis. 
For sub group analysis, a sub-group had to include at least three studies within each 
analyte and threshold and thus it was only possible to conduct a sub-group analysis for 
calculated incidence of disease (incidence >10% or incidence ≤ 10%). The results for 
sub-group analysis are shown in appendix 15. There was no significant difference 
between the subgroups. Most of the studies included in the review excluded fetuses with 
other structural or chromosomal anomalies from the results and included live births 
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only, thus subgroup analysis could not be performed in these areas. Sensitivity analysis 
including only those studies with these characteristics showed no significant difference. 
The same was true for the assessment of study quality i.e. most studies were of an 
overall similar quality to make sub-group analysis impossible but sensitivity analysis 
showed no difference when extremely low quality studies were excluded. 
 
Publication bias 
Funnel plots (not shown) and the regression test for asymmetry showed no significant 
publication bias (p=0.6). 
 
Clinical application with aspirin 
The results for clinical application with aspirin for SGA fetuses are shown in table 5.1. 
The results show that by testing with inhibin A in a low risk population the number of 
women needed to treat to prevent one case of SGA can be reduced from 90 to 30, 
having to test 909 women. 
 
5.5 Discussion 
 
This review evaluated the accuracy of five serum screening markers used in Down‟s 
syndrome screening and a composite triple test. The results showed low predictive 
accuracy overall. The best predictor for SGA overall for birth weight <10
th
 centile was 
AFP<10
th
 centile while AFP>3.0MoM was the best predictor of birth weight <5
th
 
centile. These results were both based on single studies. AFP showed improvement in 
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predictive accuracy when looking at severe disease (birth weight <3
rd
 centile). HCG 
showed improved prediction when comparing second trimester to first trimester testing.  
 
The strength of this review and validity of its findings lie in the methodological 
strengths used. It complied with existing guidelines for the reporting of systematic 
reviews
43
 and also guidelines specific to the reporting of systematic reviews of 
observational studies
42
.  
 
Extensive literature searches without language restrictions were performed. Careful 
attention to assessment of quality of study design and reporting was made.  
 
Previously published reviews in this area are restricted to a systematic review evaluating 
predictive tests for pre-eclampsia
72
. The review by Conde Agudelo concluded that the 
tests investigated had a low predictive value. The methods used in this review have 
however been criticized
73
 and it was restricted in the thresholds and tests it reviewed. To 
our knowledge there are no previously reported systematic reviews in this area for SGA. 
 
This review primarily reported likelihood ratios, as discussed in section 4.6.3, as they 
are thought to be more clinically meaningful than sensitivities and specificities. Recent 
research suggests that independently pooled likelihood ratios should be interpreted with 
caution as positive and negative likelihood ratios are related statistics (just like 
sensitivity and specificity)
74
. Bivariate analysis
37
 was employed to account for this, as 
was sensitivity analysis with pooled sensitivity and specificity. This found no difference 
in the interpretation of the results.  
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Table 5.1: Serum screening among pregnant women and number of women needed 
to be tested and treated with aspirin to prevent one case of SGA fetus (birth weight 
<10
th
 centile). 
Test 
result 
Prevalence  
SGA (%) 
Probability 
of 
SGA after 
testing 
positive (%) 
Risk of 
SGA after 
treatment* 
Probability 
of SGA 
after 
treatment 
NNTest¹ NNTreat² 
 
No test, no 
treatment³ 
10.0 10.0 - 10.0 - - 
No test, 
treat all³ 
10.0 - 0.90 9.0 - 90 
Alpha feto-protein>2.0MoM: Sensitivity 60%; Specificity 98% 
Test all, 
treat test 
positives 
10.0 28.3 0.90 25.4 167 35 
Human chorionic gonadotrophin>2.0MoM: Sensitivity 12%; Specificity 94% 
Test all, 
treat test 
positives 
10.0 16.2 0.90 14.6 833 62 
Unconjugated oestriol<0.75MoM: Sensitivity 37%; Specifcity 88% 
Test all, 
treat test 
positives 
10.0 22.0 0.90 19.8 270 45 
Pregnancy associated plasma protein A (PAPP-A)<1
st
 centile: Sensitivity 3%; Specificity 
99% 
Test all, 
treat test 
positives 
10.0 28.0 0.90 25.2 3333 36 
Inhibin A>2.0MoM: Sensitivity 11%; Specificity 98%. 
Test all, 
treat test 
positives 
10.0 33.1 0.90 29.8 909 30 
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Alpha feto-protein>2.0MoM to predict severe FGR: Sensitivity 22%, Specificity 99% 
Test all, 
treat test 
positives 
1.0 22.0 0.90 19.8 454 45 
* RR 0.90 (95% CI 0.83-0.98) Askie et al
66
.  
¹ NNTest is number needed to test and treat with aspirin to prevent one case of SGA calculated 
by 1/ (proportion true positives (TP) – (proportion TP * RR)).  
² NNTreat is number need to treat if only treat test positives with aspirin calculated by 1/ 
(probability after testing positive – probability after treatment). 
³ Numbers are equal for all tests regardless of threshold, sensitivity and specificity. 
MoM multiples of median 
SGA small for gestational age 
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The assessment of study quality was hindered by a lack of clear reporting, which is a 
common problem in diagnostic reviews as standards for quality and checklists for 
assessing it are fairly new. It has been previously reported that poor study design and 
conduct can affect the estimates of diagnostic accuracy
51;75
.  However, it is not entirely 
clear how individual aspects of quality may affect this and to what magnitude, 
particularly in the area of Obstetrics. Application of quality scores has been shown to be 
of little value on diagnostic reviews
55
. 
 
However, due to the lack of clear reporting, it 
was not possible to perform sub-group analysis based on individual quality criteria. 
 
One of the areas in which reporting was uniformly poor was in the details provided 
regarding performance of the reference standard. For FGR there is still no convincing 
evidence as to which is the best definition of the condition at birth nor which is the best 
predictor of future infant and childhood morbidity and mortality for term. Population-
based birth weight standards were the most commonly used, however it is important to 
realize that these do not distinguish between the small healthy infant and the 
compromised infant. Customised growth charts that are adjusted for sex, gestation, 
parity, maternal weight and height and ethnicity, have been shown to improve the 
detection of  at risk of stillbirth
17
 while neonatal indices have been shown to identify the 
malnourished infant at risk of peripartum asphyxia
16
. Unfortunately these were rarely 
used as outcome measures in the included studies.  
 
Confounding factors in the measurement of serum screening markers, but mainly AFP, 
is the association with these markers with intrauterine death, preterm labour and 
chromosomal and structural anomalies
76-78
. Ideally all the included papers in this review 
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should have included only women with live births and fetuses with no other 
chromosomal or structural anomalies, this however was not always clearly reported. 
Sensitivity analysis, including only studies that did report exclusion of these subjects, 
showed no significant difference in estimates of test accuracy. 
 
In this review it was assumed that the markers act independently but this may not be the 
case. The relationship between PE and SGA must also be taken into account. For HCG 
measurement the risk of SGA has been shown by logistic regression to be dependent on 
the presence of PE
79
. Ideally, included cases of SGA for this review would have been 
those where there was no PE but this was again poorly reported. 
 
When assessing the clinical relevance of these tests it is important to look at severe 
disease as this causes the majority of maternal, fetal and neonatal complications, and 
thus prediction and prevention of this form of disease would have the greatest health 
impact. For the studies included in the meta-analysis there were only three that had 
results for severe SGA and these were insufficient to make an accurate assessment of 
the prediction of this form of disease. 
 
The calculations of NNTreat and NNTest show that the number of women needed to 
treat with aspirin to prevent one case of a SGA fetus can be reduced by testing with a 
serum screening marker and then only treating the test positives. As aspirin is not 
routinely used as a treatment, these calculations serve to contextualize the predictive 
value of these markers as individual tests. The costs of introducing aspirin as a 
treatment would need to be balanced against the costs of the test, costs of failing to treat 
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the women with a false negative result that then go on to develop disease and any 
patient costs in terms of anxiety from screening and over treatment in the false positive 
category. To thus calculate the true clinical effectiveness of these tests these results 
would need to be incorporated in to a full cost-effectiveness analysis. Before any 
treatment is introduced into clinical practice an assessment of its side effects must be 
made e.g. gastric bleeding for the mother, risk of placental abruption. 
 
As SGA is a condition with relatively low prevalence a clinically useful test would need 
to have a high positive LR (>10) and low negative LR (<0.10)
59
. From the results of this 
review it is unlikely that any one serum screening marker in isolation will provide this. 
Future research should thus concentrate in two areas. The first should be to address the 
limitations within the primary literature as identified by this review; poor reporting, 
exclusion of intrauterine deaths and chromosomal and structural anomalies from the 
results, separation of PE and SGA and prediction of severe disease. This may not 
necessarily require further primary research as there are sufficient large, cohort studies 
available, but meta-analysis based on individual patient data to address the deficiencies 
in reporting could be performed. Secondly future research should focus on combinations 
of markers as predictors and combinations of tests such as serum screening markers and 
uterine artery Doppler
80 
to improve the predictive accuracy to a clinically useful value.  
 
As Down‟s serum screening is routinely performed in many developed countries the 
cost of implementing use of these results as a predictive test for SGA would be small. 
However as aspirin is the only preventative treatment with any proven benefit in these 
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conditions and has minimal adverse events this cost has to be compared to that of 
implementing aspirin treatment to all pregnant women. 
 
5.6 Conclusion 
Down‟s serum screening analytes have low predictive accuracy for small for gestational 
age fetuses. They may be a useful means of risk assessment or of use in prediction when 
combined with other tests. 
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CHAPTER 6: SYSTEMATIC REVIEW OF ACCURACY OF 
UTERINE ARTERY DOPPLER TO PREDICT SMALL FOR 
GESTATIONAL AGE FETUSES 
 
6.1 Abstract 
6.1.1 Background  
Alterations in uterine artery waveforms are associated with development of 
preeclampsia and small for gestational age fetuses, which are important causes of 
maternal and perinatal morbidity and mortality. The purpose of this review was to 
evaluate the accuracy of uterine artery Doppler to predict small for gestational age 
fetuses. 
 
6.1.2 Methods  
Searches in Medline, Embase, Cochrane Library, MEDION (all from inception to April 
2006), reference lists of eligible articles, and contact with experts. Without language 
restrictions, all studies on uterine artery Doppler in first and second trimester that 
allowed 2x2 table construction were selected. Multiple reviewers independently selected 
studies, extracted data on participants, Doppler indices, and outcomes, and assessed 
study validity. Bivariate meta-analysis of sensitivity and specificity was conducted and 
likelihood ratios were calculated. 
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6.1.3 Results  
There were 61 studies testing 41,131 women (3,723 cases) for SGA fetuses. Second 
trimester testing performed better than first trimester testing. Increased pulsatility index 
(PI) with notching best predicted SGA in low-risk populations and increased PI (with 
notching) best predicted severe SGA fetuses, range of LR+ 9.1 to 14.6, LR- 0.34 to 
0.89. Most Doppler indices showed low predictive accuracy. Estimates vary across 
population risk and severity of outcome. 
 
6.1.4 Conclusions 
Abnormal uterine artery waveforms show low predictive accuracy overall for small for 
gestational age fetuses with moderate predictive accuracy when predicting more severe 
forms. Pulsatility index alone or in combination with (bilateral) notching, are the most 
predictive Doppler indices. The use of these indices in clinical practice should not 
hamper execution of meta-analysis based on individual patient data or of new 
methodological high quality primary studies combining Doppler with other tests. 
 
6.1.5 Publications arising from this work 
Cnossen JS, Morris RK, Mol BWJ, ter Riet G, van der Post JAM, Bindels PJE, Robson 
S, Kleijnen J, Coomarasamy A, Khan KS. Uterine artery Doppler to predict fetal growth 
restriction: a systematic review and bivariate meta-analysis. Canadian Medical 
Association Journal 2008;178(6):701-11 
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6.2 Introduction 
Pregnancies affected by SGA fetuses are characterized by a failure of the second wave 
trophoblast invasion (at 16-22 weeks) of the endometrio-myometrial vasculature
19
. This 
results in abnormal uteroplacental blood flow, which has led to the idea of using 
Doppler assessment of the uterine artery blood flow velocity waveforms as part of 
routine ultrasound screening
81
. Non-pregnant and first-trimester uterine artery blood 
flow velocity waveforms are characterized by low end-diastolic velocities and an early 
diastolic notch. Persistence of a diastolic notch (beyond 24 weeks‟ gestation) or 
abnormal flow velocity ratios are associated with inadequate trophoblast invasion
82
. 
However, the results of uterine artery Doppler studies show considerable variation. 
Several factors, for example variation in design and population, have been reported in 
relation to conflicting results
82
.  
 
The objective of this review was to investigate the accuracy of all uterine artery Doppler 
indices in predicting small for gestational age.  
 
6.3 Methods 
The methods used are outlined in chapter 4 those specific to this review are detailed 
below. 
 
6.3.1 Data Sources  
The electronic searches were performed from inception to April 2006. The electronic 
search strategy consisted of MeSH or keyword terms related to the topic (SGA/FGR) 
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combined with methodological filters for identification of studies on diagnostic tests 
and aetiology
53
. The search is detailed in appendix 3.  
 
6.3.2 Study selection 
Criteria for included studies were that they reported on singleton pregnancies at any 
level of risk in any healthcare setting using uterine artery Doppler screening before the 
25
th
 week of gestation. 
 
6.3.3 Data extraction and Study quality assessment 
The data extraction form for this review can be found in appendix 16. For description of 
the index test for uterine artery Doppler, the paper had to clearly state the route of 
measurement (transvaginal or transabdominal), the site of measurement, the 
measurement parameter used (e.g. pulsatility index) and the cut-off point used. For site 
of measurement, only the papers that used the main uterine artery branch were included, 
thus papers reporting on uteroplacental, placental bed, arcuate or spiral arteries were 
excluded. Ideally the site of measurement in the main uterine artery was further defined 
as the apparent crossover of the uterine artery with the internal iliac artery for trans-
abdominal scanning, as this is the point of measurement that is considered the most 
reproducible thus reducing inter-operator variation (used as an assessment of quality not 
for inclusion/exclusion). The corresponding point for trans-vaginal measurement was 
the internal cervical os. 
 
For this review the following quality items, assessing quality of the study design, were 
considered to not be applicable due to the nature of the test; time period between tests 
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(review was using test for prediction not diagnosis), partial verification bias (reference 
standard is equal to outcome), differential verification bias (non invasive reference test), 
incorporation bias (uterine artery Doppler is always independent of the measurement of 
birth weight). When assessing quality of reporting of the study, the following were 
considered not applicable; adverse events from performing index test or reference 
standard due to the non-invasive nature of the tests being reviewed. Acceptable 
reference standards for SGA/FGR included birth weight <10
th
, <5
th
, or 3
rd
 centile 
adjusted for gestational age and based on local population values; neonatal ponderal 
index <10
th
 centile; skin fold thickness; mid-arm circumference/head circumference and 
absolute birth weight thresholds. Further explanation of the quality assessment can be 
found in appendix 17. 
 
6.3.4 Data synthesis and analysis 
Results were pooled among groups of studies with similar Doppler indices (table 6.1), 
similar outcome, and according to risk using a bivariate regression model. In cases 
where there were several reported thresholds for a particular Doppler index, the most 
commonly reported threshold was selected for meta-analysis. Subgroup analyses as 
defined a priori was performed: outcome (severe; mild/overall), risk (low 
risk/unselected population; high-risk) and gestational age at testing (before and after 16 
weeks). Sensitivity analyses were performed for application of preventative treatment 
(yes; no/unclear) and high quality studies. Studies were considered of high quality when 
they scored positive on at least four out of the following items: prospective design with 
consecutive recruitment, appropriate reference standard, adequate description of the  
index test, follow-up > 90%, and reporting of preventative treatment. 
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Table 6.1: Explanation of Doppler indices. 
A/C ratio peak systolic / early diastolic ratio (A/C) 
Any notching presence of early diastolic notching, unilateral or bilateral not 
specified 
Bilateral notching presence of early diastolic notching in both main uterine arteries 
D/S ratio diastolic/ systolic ratio 
D/S or notching D/S ratio with or without presence of unilateral of bilateral early 
diastolic notching 
Notch (Depth) Index (notch – early diastolic flow) / notch ((D-C)/D) 
Pulsatility index (PI) (peak systolic flow – end diastolic flow) / mean flow ((A-B)/M) 
PI and notching pulsatility index combined with presence of unilateral or 
bilateral early diastolic notching 
PI or notching pulsatility index with or without presence of unilateral or 
bilateral early diastolic notching 
Resistance index 
(RI) 
(peak systolic flow – end diastolic flow) / peak systolic flow 
((A-B)/A) 
RI and notching resistance index combined with presence of unilateral or 
bilateral early diastolic notching 
RI or notching resistance index with or without presence of unilateral or 
bilateral early diastolic notching 
S/D ratio peak systolic/ late diastolic ratio (also known as A/B ratio) 
S/D or notching S/D ratio with or without presence of unilateral of bilateral early 
diastolic notching 
Unilateral notching presence of early diastolic notching in one main uterine artery 
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6.3.5 Clinical Application 
Clinical application using aspirin therapy was performed as for the review of Down‟s 
syndrome serum screening described in section 4.6.5.  
 
6.4Results 
6.4.1 Literature identification and study characteristics  
Figure 6.1 summaries the process of literature identification and selection. The 
electronic search generated 18,871 citations, screening on title and abstract identified 
311 potentially relevant manuscripts and reference list checking identified a further 
eight, the full papers of all these articles were obtained. After reading the full 
manuscripts a total of sixty papers were included in this review, the references of the 
included papers are listed in appendix 18. Tables detailing the individual study 
characteristics are available in appendix 19 (low risk and unselected population) and 
appendix 20 (high risk population). The sixty included studies tested 40,637 pregnant 
women (4067 SGA cases). Fifty-seven cohort studies and three randomised trials were 
included. Forty-eight studies were prospective, ten were retrospective, and two were 
unclearly designed. Calculated incidences of SGA fetuses correlated poorly with the 
thresholds (birth weight in centiles) based on local population charts. The mean 
incidences for an unselected, a low risk, and high risk population with a birth weight 
threshold < 10
th
 centile were 9.6%, 8.2% and 20.7% respectively. Doppler 
measurements were mainly performed between 18 and 24 weeks at a routine prenatal 
care scan. Ten studies reported data on testing prior to 16 weeks. Thirty-five studies 
reported data on more than one Doppler index or a combination of Doppler indices. 
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6.4.2 Study Quality 
The quality assessment of included studies for SGA fetuses showed deficiencies in 
some areas (figure 6.2). Over 70% of studies met the following QUADAS items: 
avoidance of partial and differential verification, independent reference test, and blind 
assessment of index test. Many studies scored poorly on the following items: adequate 
descriptions of selection criteria and reference test, blind assessment of the reference 
test, and availability of clinical data. Application (or not) of preventative treatment was 
reported in 18 publications. Preventative treatment was applied in the three included 
randomized trials after performing Doppler tests in a series of women.  
 
6.4.3 Data Analysis 
Table 6.2 and 6.3 show the estimates for prediction of SGA fetuses in low 
risk/unselected populations and high risk populations respectively, these are 
demonstrated as tables rather than forest plots as in the other reviews to allow more data 
to be presented. Overall an increased PI with notching in the second trimester best 
predicted SGA (LR+ 9.1 (95% CI 5.0-16.7); LR- 0.89 (95%CI 0.85-0.93)) in low-risk 
populations. Severe SGA in low risk populations was best predicted by an increased PI 
(LR+ 13.7 (95% CI 10.3-16.9); LR- 0.34 (95%CI 0.23-0.48)) or an increased PI with 
notching (LR+ 14.6 (95% CI 7.8-26.3); LR- 0.78 (95%CI 0.68-0.87)) in the second 
trimester. Doppler testing to predict SGA in high-risk populations showed low estimates 
of accuracy. An increased RI (> 0.58 or > 90th centile) in the second trimester best 
predicted severe SGA (LR+ 10.9 (95% CI 10.4-11.4); LR- 0.20 (95%CI 0.14-0.26)). 
Figure 6.3 shows the ROC plots for (pooled) results of Doppler testing in the second 
trimester according to risk and for severe disease. 
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Figure 6.1: Process from initial search to final inclusion for uterine artery Doppler 
studies to predict SGA fetuses/FGR. FGR fetal growth restriction; SGA small for 
gestational age.
Primary articles retrieved for detailed evaluation  
- from electronic searches      n= 311 
- from reference lists     n=8 
      
Articles excluded     n=259 
- not prediction/ not test accuracy   n=123  
- reviews/ letters/ comments/ editorials  n= 29 
- SGA/FGR not separate outcome   n= 25 
- (mean) gestational age > 25 weeks/ unclear  n= 44 
- insufficient data to construct 2x2 table  n= 26 
- other       n= 12 
Primary articles included in meta-analysis    n= 60 
Potentially relevant citations identified from electronic searches to capture primary articles 
on all tests used in the prediction of  SGA/FGR 
n= 18,871 
Potentially relevant citations on uterine artery Doppler in the prediction of SGA/FGR 
      n= 1,366 
References excluded after screening titles and/ or abstracts  
      n= 1,055 
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Figure 6.2: Bar chart illustrating the compliance with quality items for included 
studies in the systematic review of accuracy of uterine artery Doppler to predict 
small for gestational age fetuses. (Numbers in bars represent actual number of 
studies compliant). 
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Sub-group and sensitivity analysis 
Sensitivity analysis, excluding studies that applied preventative treatment, did not 
improve the predictive accuracy (appendix 21). When the criteria for high quality 
studies were applied results showed low to moderate accuracy estimates in both low-
risk (appendix 22) and high-risk populations (appendix 23). 
 
Publication bias 
Funnel plots (not shown) and the regression test for asymmetry showed no significant 
effect of publication bias (p=0.67). 
 
Clinical application with aspirin 
Table 6.4 shows the impact in clinical practice with the use of aspirin in women at risk 
of a SGA fetus. The absolute effect of aspirin depends on the risk of fetal growth 
restriction. The higher the risk, the lower the number of women needed to treat to 
prevent one case of fetal growth restriction and vice versa. As shown in the table, if 
aspirin were to be used for all pregnant women (prevalence 10%) without Doppler 
testing then 91 women would need to be treated with aspirin to prevent one case of a 
SGA fetus. If only those women with a positive test result were treated (pulsatility 
index, sensitivity 23%, specificity 91%) then 41 women would need to be treated, a 
number considerably lower than that without testing. However, to obtain this 395 
women need to be tested to prevent this one case. Using a test such as resistance index 
and notching, which has a much higher sensitivity (40%) but same specificity (91%) 
will lead to a lower number needed to treat (28), and a similar number needed to test 
(227).  
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Table 6.2: Pooled and single estimates for uterine artery Doppler predicting fetal growth restriction in low risk/ unselected 
populations. 
Doppler Index No. of studies No. of 
women 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
LR positive  
(95% CI) 
LR negative  
(95% CI) 
Birth weight < 10
th
 centile or < 2500g/ 2
nd
 trimester Doppler testing 
RI (0.58 or 90
th
) 9 3304 53 (42-64) 87 (79-94) 4.0 (0.68-23.1) 0.54 (0.27-1.1) 
RI (0.7 or 95
th
) 2 665 16 (10-23) 91 (86-97) 1.9 (0.5-3.3) 0.92 (0.83-1.0) 
PI 3 12097 18 (16-19) 95 (92-97) 3.4 (1.7-5.1) 0.87 (0.84-0.90) 
Bilateral notching 11 10229 24 (14-34) 91 (86-97) 2.8 (0.26-30.0) 0.83 (0.53-1.3) 
Unilateral notching 2 3819 18 (12-24) 91 (90-92) 2.4 (1.6-3.7) 0.89 (0.84-0.94) 
Any notching 4 2162 44 (32-57) 82 (72-92) 1.8 (0.61-5.6) 0.73 (0.45-1.2) 
RI or notching 5 5043 37 (33-40) 89 (81-96) 3.3 (0.72-15.2)  0.71 (0.59-0.87) 
RI and notching 1 946 45 (37-53) 82 (79-84) 2.4 (1.9-3.0) 0.68 (0.58-0.77) 
PI or notching 2 2116 12 (8-16) 94 (93-95) 3.9 (3.0-4.7) 0.82 (0.77-0.87) 
PI and notching 1 1757 12 (7-18) 99 (98-99) 9.1 (5.0-16.7) 0.89 (0.85-0.93) 
S/D ratio 3 1661 34 (10-57) 88 (79-96) 2.7 (0.53-13.9) 0.76 (0.42-1.4) 
Notch index 1 288 33 (13-59) 92 (88-95) 4.3 (1.9-8.4) 0.72 (0.49-0.91) 
S/D or notching 3 2173  29 (25-33) 83 (79-93)              2.1 (1.0-3.2)         0.82 (0.74-
0.90) 
Birth weight < 10
th
 centile or < 2500g/ 1
st
 trimester Doppler testing 
RI (0.70 or 95
th
) 1 1008 67 (35-90) 75 (72-78) 2.7 (1.6-3.5) 0.44 (0.18-0.81) 
PI 1 3045 12 (8-16) 96 (95-96) 2.7 (1.9-3.8) 0.92 (0.88-0.96) 
Bilateral notching 3 1420  74 (55-93) 42 (0-84) 1.3 (0.35-4.7) 0.62 (0.08-4.7) 
Any notching  (H) 2 866 85 (80-89) 50 (49-50) 1.7 (0.60-4.8) 0.31 (0.07-1.4) 
Birth weight < 5
th
 centile, < 3
rd
 centile or < 1750g/ 2
nd
 trimester Doppler testing 
RI (0.58 or 90
th
)  (H) 3 1551 66 (64-67) 88 (82-94) 5.6 (0.86-36.5) 0.39 (0.21-0.73) 
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PI 1 1757 67 (53-80) 95 (94-96) 13.7 (10.3-16.9) 0.34 (0.23-0.48) 
Bilateral notching (H) 2 2657 22 (17-27) 96 (95-96) 4.9 (0.66-37.0) 0.82 (0.47-1.4) 
Any notching 1 890 53 (27-79) 83 (80-85) 3.1 (1.7-4.4) 0.57 (0.30-0.85) 
RI or notching (H) 3 3650 45 (31-59) 88 (79-98) 3.8 (0.96-14.9) 0.63 (0.52-0.76) 
RI and notching (H) 2 1404 44 (36-52) 87 (85-89) 3.4 (0.86-13.3) 0.64 (0.52-0.79) 
PI or notching 1 1757 31 (19-45) 93 (92-95) 4.7 (2.9-7.0) 0.74 (0.60-0.86) 
PI and notching 1 1757 23 (13-37) 98 (98-99) 14.6 (7.8-26.3) 0.78 (0.68-0.87) 
S/D or notching 1 768 26 (12-43) 91 (89-93) 2.9 (1.5-4.9) 0.82 (0.64-0.95) 
Birth weight < 5
th
 centile, < 3
rd
 centile or < 1750g/ 1
st
 trimester Doppler testing 
PI 1 999 24 (12-41) 95 (94-97) 5.3 (2.8-9.5) 0.79 (0.64-0.91) 
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Table 6.3:  Pooled and single estimates for uterine artery Doppler predicting fetal growth restriction in high risk populations. 
Doppler Index No. of studies No. of 
women 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
LR positive  
(95% CI) 
LR negative  
(95% CI) 
Birth weight < 10
th
 centile or < 2500g/ 2
nd
 trimester Doppler testing 
RI (0.58 or 90
th
) 6 885 74 (55-94) 68 (56-81) 2.4 (0.72-7.8) 0.37 (0.07-2.0) 
RI (0.7 or 95
th
) 4 527 38 (18-58) 85 (78-92) 2.6 (0.78-8.6) 0.73 (0.41-1.3) 
PI 2 445 60 (33-86) 74 (69-78) 2.3 (1.1-4.8) 0.55 (0.19-1.6) 
Bilateral notching 4 588 29 (6-52) 92 (91-94) 3.8 (0.7-7.0) 0.77 (0.51-1.0) 
Unilateral notching 2 151 45 (23-67) 85 (76-94) 3.0 (0.72-12.8) 0.65 (0.25-1.6) 
Any notching 10 989 55 (42-69) 78 (72-83) 2.5 (0.93-6.7) 0.57 (0.25-1.3) 
RI or notching 4 629 69 (54-83) 69 (48-90) 2.2 (0.55-9.1) 0.45 (0.17-1.2) 
RI and notching 4 444 62 (23-100)  89 (80-98) 5.7 (0.87-37.2) 0.42 (0.07-2.7) 
PI or notching 2 138 68 (47-89) 81 (75-87) 3.6 (2.0-5.1) 0.40 (0.14-0.65) 
D/S ratio 1 48  78 (40-97) 62 (45-77) 2.0 (1.1-2.7) 0.36 (0.10-0.94) 
D/S or notching 1 48 89 (52-100) 54 (37-70)  1.9 (1.1-2.2) 0.21 (0.04-0.85) 
Birth weight < 10
th
 centile or < 2500g/ 1
st
 trimester Doppler testing 
PI 3 785 34 (31-37) 76 (73-80) 1.5 (0.43-4.8) 0.86 (0.47-1.6) 
Bilateral notching 1 72 75 (19-99) 41 (29-54) 1.3 (0.50-1.7) 0.61 (0.11-1.8) 
Birth weight < 5
th
 centile, < 3
rd
 centile or < 1750g/ 2
nd
 trimester Doppler testing 
RI (0.58 or 90
th
)  (H) 2 362 82 (76-87) 92 (92-93) 10.9 (0.7-168.9) 0.20 (0.11-0.35) 
PI 1 351 6 (2-14) 95 (92-97) 1.2 (0.47-3.2) 0.99 (0.92-1.03) 
Bilateral notching 1 351 6 (2-14) 97 (95-99) 2.3 (0.79-6.7) 0.97 (0.92-1.0) 
RI or notching 1 182 64 (41-83) 29 (22-37) 0.90 (0.61-1.2) 1.2 (0.64-2.1) 
RI and notching 1 170 42 (23-63) 80 (72-86) 2.1 (1.2-3.4) 0.72 (.50-0.95) 
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Figure 6.3: Receiver operating characteristics plots for pooled and single accuracy 
estimates with 95% confidence intervals for second trimester Doppler indices 
predicting small for gestational age fetuses (SGA) according to risk and for 
predicting severe SGA. Note: x-axis shows reversed specificity. 
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When looking at a more severe outcome, that of fetal growth restriction leading to 
preterm delivery, sensitivity and specificity of the test improve and thus only 142 
women are needed to undergo the test and 15 treated with aspirin to prevent one case of 
severe FGR. 
 
6.5 Discussion 
This review evaluates the accuracy of 15 uterine artery Doppler indices used to predict 
SGA fetuses. An increased pulsatility index alone or in combination with notching 
predicts (severe) SGA best in low-risk populations, whereas in high-risk populations the 
best predictor is an increased resistance index. Other Doppler indices show low to 
moderate accuracy estimates. 
 
Strengths and weaknesses of the review 
These are as discussed in the previous chapter (section 5.5) and in the summary of test 
accuracy reviews chapter (chapter 10). Due to the lack of clear reporting it was not 
possible to perform multivariate subgroup analysis based on individual quality criteria. 
Therefore this review reports the overall results. Areas in which reporting was 
uniformly poor in this review were in the details regarding performances of the index 
test and the reference standard.  
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Table 6.4: Doppler testing among pregnant women and number of women needed to be tested and treated with aspirin to prevent 
one case of small for gestational age fetus.
Test result Prevalence  
SGA (%) 
Probability of 
SGA after testing 
positive (%) 
Risk of SGA after 
treatment* 
Probability of SGA 
after treatment 
NNTest¹ NNTreat² 
 
No test, no 
treatment³ 
10.0 10.0 - 10.0 - - 
No test, treat all³ 10.0 - 0.90 8.9 - 91 
Pulsatility Index: Sensitivity 23%; Specificity 91%     
Test all, treat test 
positives 
10.0 22.1 0.90 19.7 395 41 
Resistance Index and notching: Sensitivity 40%; Specificity 91%    
Test all, treat test 
positives 
10.0 33.1 0.90 29.4 227 28 
Pulsatility Index, delivery < 34 weeks: Sensitivity 64%; Specificity 95% 
Test all, treat test 
positives 
10.0  0.90  142 15 
* Treatment benefit, relative risk (RR) 0.90 (95% CI 0.83-0.98) Askie et al
66
. ¹ Number needed to test calculated by 1/ (proportion true 
positives (TP) – (proportion TP * RR)).  
² Number needed to treat calculated by 1/ (probability after testing positive – probability after treatment). 
³ Numbers are equal for all tests regardless of threshold, sensitivity and specificity. 
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Strengths and weaknesses in relation to other studies 
Previously published reviews concluded that the tests investigated had limited 
predictive accuracy for SGA fetuses
25;26
. The reviews were restricted in the thresholds 
and Doppler indices they reviewed. Two reviews reported on preeclampsia, FGR and 
perinatal death and were both restricted to Medline. One
26
 was based on a systematic 
search until January 1997, the other
25
 included only unselected populations until 2001. 
Since these reviews, substantial new evidence has emerged in particular on some 
Doppler indices, e.g. pulsatility index, allowing for more robust and specific inferences 
for clinical practice. 
 
Unanswered questions, future research and implications 
When considering whether a predictive test should be applied in clinical practice the 
following must be considered: the prevalence of the disease and the predictive accuracy 
of the test, the cost and patient acceptability of the test and the treatments available for 
the disease in question. SGA is a disease with relatively low prevalence and a clinically 
useful test would thus need to have a high positive LR (>10) and low negative LR 
(<0.10)
59
. From the results of this review pulsatility index and (bilateral) notching are 
the most promising Doppler indices to provide this and thus these are the indices that 
should be used in daily clinical practice. However, it should be recognized that the 
results vary according to population risk (tables 6.2 and 6.3). Uterine artery Doppler is a 
non-invasive test and thus acceptable to patients. It is a specialized test both in terms of 
the equipment required and the expertise of the operator. In Western countries uterine 
artery Doppler could be fairly easily performed at the time of the detailed anomaly scan, 
for developing countries it would be a difficult test to introduce into routine antenatal 
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practice. For mothers being identified as “at risk” of SGA from an antenatal test can 
cause considerable anxiety. At present there is no pharmacological treatment or 
management strategy (e.g. regular ultrasound scanning, early delivery) that has been 
shown to effectively prevent the development of these diseases or ameliorate their 
complications. However, research into aspirin as a treatment has shown a small 
preventative effect [RR 0.90 (0.83-0.98)]
66
 in the absence of any serious side effects, it 
is a cheap and readily available treatment. In this instance, a false negative test result is 
potentially more harmful than a false positive test result and this must be considered in 
the future when looking at predictive test accuracy and test/treatment combinations in 
SGA. The clinical impact of the estimates of accuracy that are produced depends on 
how the resultant changes in probabilities due to Doppler testing alter therapeutic 
effectiveness in decision making
65
. This impact can be illustrated with an example of 
decision making in clinical practice about the use of aspirin in women at risk of 
preeclampsia (table 6.4). The absolute effect of aspirin depends on the risk of a SGA 
fetus. The higher the risk, the lower the number of women needed to treat to prevent one 
case of SGA and vice versa. The risk, and hence the therapeutic benefits, depends on the 
post-test probabilities, calculated from sensitivity and specificity, of SGA associated 
with Doppler testing. To calculate the real effectiveness of such strategies, economic 
and patient costs and benefits of both test(s) and treatment should be incorporated.  
 
The results of this meta-analysis are limited by the quality of the primary included 
studies. This poor quality may be due to poor quality of the design and conduct of the 
original study or due to poor reporting. This quality issue may be resolved in two ways; 
in the first instance a meta-analysis based on individual patient data (IPD) should be 
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performed
83
. IPD meta-analysis can overcome problems due to poor reporting and study 
heterogeneity. If however, following an IPD meta-analysis it is found that the design 
and conduct of the individual studies is poor then a large prospective primary research 
study must be recommended. Any future research should also concentrate on the 
application of combinations of tests e.g. biochemical tests and uterine artery Doppler; 
this is the diagnostic process that is used in clinical care and may also help improve the 
predictive accuracy of the tests to clinically important values. 
 
6.6 Conclusion 
Abnormal uterine artery waveforms show low predictive accuracy overall for small for 
gestational age fetuses with moderate predictive accuracy when predicting more severe 
forms. Pulsatility index alone or in combination with (bilateral) notching, are the most 
predictive Doppler indices. The use of these indices in clinical practice should not 
hamper execution of meta-analysis based on individual patient data or of new 
methodological high quality primary studies combining Doppler with other tests. 
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CHAPTER 7: SYSTEMATIC REVIEW OF UMBILICAL 
ARTERY DOPPLER TO PREDICT SMALL FOR 
GESTATIONAL AGE FETUSES AND COMPROMISE OF 
FETAL/NEONATAL WELLBEING 
 
7.1 Abstract 
7.1.1 Background 
Alterations in umbilical artery waveforms are associated with the small for gestational 
age fetus and the fetus at risk of compromise, which are important causes of perinatal 
morbidity and mortality. The purpose of this review was to evaluate the accuracy of 
umbilical artery Doppler to predict the fetus at risk of compromise. 
 
7.1.2 Methods 
Electronic searches of Medline, Embase, Cochrane library, Medion (inception-March 
2009), hand searching of relevant journals, reference list checking of included articles, 
contact with experts to identify relevant literature. Two reviewers independently 
selected relevant articles without language restrictions. The proportion of initially 
identified studies that met the selection criteria was 3.5%. Data were extracted on study 
characteristics, quality and results to construct 2x2 tables. Likelihood ratios for positive 
and negative test results, sensitivity and specificity were generated for different Doppler 
indices at various thresholds and the different reference standards using bivariate meta-
analysis. 
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7.1.3 Results 
One hundred and forty studies met the selection criteria. 11 were in a low-risk 
population (8042 fetuses); 104 in a high-risk population (19,191 fetuses); 15 in a mixed 
risk population (4350 fetuses) and 10 studies exclusively in multiple pregnancies (1709 
fetuses). Umbilical artery Doppler showed better prediction of small for gestational age 
[pooled positive likelihood ratio 3.76 (2.96, 4.76), pooled negative likelihood ratio 0.52 
(0.45, 0.61)] and for compromise of fetal/neonatal wellbeing [pooled positive likelihood 
ratio 3.41 (2.68, 4.34), pooled negative likelihood ratio 0.55 (0.48, 0.62)] in a high risk 
population. Sub-group analysis in a high risk population showed clinically useful 
accuracy for prediction of intra-uterine death, acidosis and admission to neonatal 
intensive care. 
 
7.1.4 Conclusions 
Umbilical artery Doppler is a moderately useful test in a high risk population to predict 
the fetus/neonate at risk of compromise. Further research should concentrate on its use 
within a series of tests e.g. with biophysical profile and other fetal Doppler indices. 
 
7.1.5 Publications arising from this work 
Morris RK, Malin GL, Robson SC, Kleijnen J, Zamora J, Khan KS. Fetal umbilical 
artery Doppler to predict compromise of fetal/neonatal wellbeing in a high risk 
population: systematic review and bivariate meta-analysis. Archives of Disease in 
Childhood Fetal and Neonatal 2010;95(suppl 1): Fa13-Fa14. In press with Ultrasound 
in Obstetrics and Gynaecology. 
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7.2 Introduction 
The majority of the research in this area has been to find an antenatal test that can 
distinguish between the normal SGA fetus and the fetus at risk that may benefit from 
intervention. The most investigated technique is umbilical artery Doppler which at 
present forms the mainstay of risk assessment in this area
21;84
. Previous systematic 
reviews and meta-analyses have reported varying results in different populations
27;85-88
, 
most strikingly in a high risk population a series of Cochrane reviews have culminated 
in an odds ratio (OR) of 0.71 (95% confidence interval 0.50-1.01) for perinatal 
mortality
85;87
. The lack of observed effect in randomized controlled trials (RCT) could 
be due to poor accuracy of tests as the RCT design evaluates both the effectiveness of 
the test and any intervention
89
. 
 
The purpose of our review was to investigate the accuracy of umbilical artery Doppler in 
all pregnant populations in predicting SGA fetuses and compromise of fetal/neonatal 
wellbeing.  
 
7.3 Methods 
The methods used are outlined in chapter 4 those specific to these review are detailed 
below. 
 
7.3.1 Data Sources 
Electronic searches were performed targeting the prediction of FGR/SGA and 
fetal/neonatal compromise. The databases searched were Medline, Embase, the 
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Cochrane Library (2009;1) and Medion from inception until March 2009. The search 
strategies are detailed in appendix 24. 
 
7.3.2 Study selection 
Criteria for selection were studies that reported on pregnancies at any level of risk in 
any healthcare setting using umbilical artery Doppler at any gestation. Test accuracy 
studies allowing generation of 2x2 tables were included. Acceptable reference standards 
for SGA fetuses included birth weight < 10
th
 centile adjusted for gestational age and 
based on local population values, birth weight mean less than two standard deviations 
and absolute birth weight threshold < 2500g. Severe FGR was defined as birth weight < 
5
th
 or < 3
rd
 centile or < 1500g. Neonatal ponderal index < 10
th
 centile, skin fold 
thickness, and mid-arm circumference/head circumference were also assessed. 
Reference standards for wellbeing were any outcome measure performed after birth 
relating to neonatal wellbeing that was reported by the study authors. Any outcome 
measure was accepted as there is no consensus as to which is the best measure at birth 
to predict long term morbidity and mortality. A composite outcome measure adverse 
perinatal outcome (APO) was used by some authors (see section 4.2.3). For 
multiple/duplicate publication of the same data set, the most recent and/or complete 
study was included only. 
 
7.3.3 Data Extraction and Study Quality Assessment 
The data extraction form for this review can be found in appendix 25. See appendix 26 
for further explanation of the quality assessment. As there were a sufficient number of 
cohort studies, case control studies were excluded from the statistical analysis as this 
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type of design in diagnostic test accuracy studies has been shown to be associated with 
bias
51
. 
 
7.3.4 Data Synthesis and analysis 
Results were pooled among groups of studies with similar characteristics; population 
(high, low, mixed risk or multiple gestations based on investigators description) and the 
same reference standard threshold for SGA fetus/compromise of wellbeing. To allow 
the maximum number of studies to be included in the meta-analysis two composite 
outcome measures were used. The measure SGA utilized birth weight<10
th
 centile 
where possible, where this was not reported the nearest measure of birth weight reported 
was used. For wellbeing the outcome APO was used where reported. For studies that 
did not report this measure, outcomes were used in a hierarchy using the severest form 
of neonatal compromise reported. 
 
 Heterogeneity was assessed graphically by looking at the distribution of the 
sensitivities and specificities in the receiver operating characteristic (ROC) space and 
LRs as a measurement of accuracy size using a Forest plot. The X
2 
test and Cochrane Q 
test were used to assess for heterogeneity statistically. The reasons for heterogeneity 
were explored using meta-regression and subgroup analyses. Sub-groups were defined 
at the start of the review based on clinical criteria known to affect prognosis (SGA 
population versus pre-eclamptic (PE) population), method of index test, study quality, 
gestation, singleton gestations only, whether babies with chromosomal anomalies were 
excluded from the results and timing of test used for analysis to delivery. Sub-group 
analyses were performed where there were at least 3 studies with similar characteristics 
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within that group. Studies were considered to be high quality when they reported 
positively on 4 or more of the items as listed previously. Threshold effect (when 
bivariate meta-analysis was not possible, less than 4 studies) was explored by observing 
the ROC curves and by calculating Spearman correlation coefficients
46
.  
 
7.4 Results 
7.4.1 Literature identification and study characteristics 
Figure 7.1 summarises the process of literature identification and selection. Tables 
detailing the citations of the included studies and the individual study characteristics are 
available in appendices 27 and 28 respectively.  
 
High risk population 
There were 104 included studies investigating 19,191 fetuses. These studies generated 
444 2x2 tables; 59 reported on SGA fetuses of which 26 reported on SGA alone, 78 
reported on wellbeing (45 wellbeing alone). There were 102 cohort studies and 2 cross-
sectional. Thirty-eight studies used prospective recruitment, 14 retrospective and 52 
unclearly designed. Fifty-three studies reported on singleton pregnancies only. Fifty-
three were performed in the third trimester, five in the second, 23 mixed, seven post-
term and 19 unclearly reported.  
 
Low risk population 
There were 11 included studies
 
reporting on 8042 fetuses, generating 44 2x2 tables. 
Four studies looked at both SGA and wellbeing, six SGA alone and one wellbeing 
alone. Among these 11 studies, there was one RCT and 10 cohort studies. There were 
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three prospective studies, one retrospective and eight where the study design was 
unclear. Eight studies reported on singleton pregnancies only. Five studies were 
performed in the third trimester, one in the second trimester, three mixed gestation and 
two gestation not reported.  
 
Mixed, unselected, unreported population 
There were 7 studies in an unselected population, 5 mixed risk and 3 unreported risk; 
4350 fetuses were investigated generating 55 2x2 tables. Nine studies reported on SGA, 
5 on SGA alone; 10 on wellbeing, 6 on wellbeing alone. There was one RCT, 14 cohort 
studies of which 7 reported prospective recruitment, 1 retrospective and 7 unclearly 
designed. Eleven studies reported on singleton pregnancies only. 13 studies were 
performed in the third trimester, 2 in a mixed gestation population.  
 
Multiple pregnancies 
There were 10 studies that included multiple pregnancies only, 1709 fetuses were 
investigated generating 31 2x2 tables. Ten studies reported on SGA, 3 on SGA alone 
and 7 studies on wellbeing combined with SGA. All studies were cohort studies, one 
reported prospective recruitment. Six studies were performed in the third trimester, 4 in 
mixed gestation. 
 
7.4.2 Study Quality 
The quality assessment of included studies is summarized in figure 7.2. There was poor 
reporting of description of index and reference tests and blinding of the reference test. 
Only twenty studies reported clearly whether preventative treatment had been used. 
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Figure 7.1: Process from initial search to final inclusion for umbilical artery 
Doppler studies to predict small for gestational age fetuses and compromise of 
fetal/neonatal wellbeing (up to March 2009). 
Primary articles retrieved for detailed evaluation  
- from electronic searches       n= 419 
- from reference lists      n= 6 
        
Articles excluded      n= 285 
- not prediction/ not test accuracy    n= 218 
- reviews/ letters/ comments/ editorials   n= 27 
- Paper/translation unobtainable    n= 12 
- Case series<10      n=5 
- Case control studies     n=14 
- Duplications      n=9 
 
 
Primary articles included in systematic review   n= 140 
 
Population     Number of studies      Number of 2x2 tables Number 
of fetuses 
High risk  104         444   19,191 
Low risk  11         44   8042 
Unselected  7         29   3017 
Mixed/unreported 8         26   1333 
Multiple pregnancies 10         31   1709 
Potentially relevant citations identified from electronic searches to capture 
primary articles on umbilical artery Doppler to predict FGR/compromise of fetal 
wellbeing 
        n= 4169 
 
References excluded after screening titles and/ or abstracts n= 3750l 
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Figure 7.2: Bar chart illustrating the compliance with quality items for included studies in the systematic review of accuracy of 
umbilical artery Doppler to predict small for gestational age fetuses and compromise of fetal/neonatal wellbeing. (Numbers in bars 
represent actual number of studies compliant). 
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7.4.3 Data Analysis 
Table 7.1 summarises the results from bivariate meta-analysis for small for gestational 
age fetuses and compromise of fetal/neonatal wellbeing respectively in the different 
populations. For small for gestational age there was improved prediction in the high risk 
population and for the severe measures of SGA (e.g. birth weight<3rd centile). For 
prediction of APO the best results were in the mixed population for APO overall and a 
low risk population for prediction of apgar at 5 minutes<7. However, these meta-
analyses involved only three studies and there were wide confidence intervals 
suggesting imprecision of results.  As there was significant heterogeneity the ROC 
curves are presented in figures 7.3 and 7.4 as the summary measures of accuracy.   
 
Univariable bivariate meta-regression was performed for the high risk population for 
both prediction of SGA fetuses and for compromise of fetal/neonatal wellbeing using a 
composite outcome measure, APO, as there were sufficient studies. Meta-regression 
was also performed looking at the effect of study quality on accuracy. The covariates 
used were the same as for the planned sub-group analysis and the QUADAS items 
respectively. No variable was significantly associated with accuracy however, there was 
still significant statistical heterogeneity. Thus subgroup analysis according to reference 
standard for the high risk population was performed and this accounted for a significant 
amount of the heterogeneity. Figure 7.5 summarises the results of this analysis where 
there was a significant/clinically relevant result.  
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Table 7.1: Subgroup analysis according to reference standard for umbilical artery Doppler to predict small for gestational age 
fetuses and compromise of fetal/neonatal wellbeing. 
  Population definition 
  
 
Low risk High risk Mixed risk Unselected 
  Likelihood ratio (LR) 
(95% Confidence interval) 
  
 
Positive LR Negative LR Positive LR Negative LR Positive LR Negative LR Positive LR Negative LR 
Reference standard      
 Subgroup 
         SGA all  2.39 (1.74-3.28) 0.79 (0.69-0.90) 3.76 (2.96-4.76) 0.52 (0.45-0.61) 3.78 (1.96-7.27)a 0.73 (0.43-1.23)a 3.58 (2.49-5.14) 0.77 (0.66-0.91) 
Birth weight<10th centile 2.12 (1.65-2.73) 0.87 (0.80-0.95) 4.13 (3.08-5.56) 0.52 (0.44-0.62) 3.78 (1.96-7.27)a 0.73 (0.43-1.23)a 3.58 (2.49-5.14) 0.77 (0.66-0.91) 
Birth weight<5th centile - - 3.06 (1.87-5.01) 0.54 (0.39-0.76) - - - - 
Birth weight<3rd centile - - 4.91 (3.41-7.07)a 0.58 (0.49-0.69)a - - - - 
Birth weight<2 sd mean - - 4.37 (3.16-6.05)a 0.43 (0.28-0.65)a - - - - 
Wellbeing all 
Apgar 1 minute<7 
Apgar at 5 minutes<7 
Admission to neonatal intensive care 
Perinatal mortality 
Acidosis 
Necrotising enterocolitis 
Intra-uterine death 
Neonatal death 
Ventilation 
Respiratory distress 
Neonatal morbidity 
Intra-ventricular/cranial haemorrhage 
SGA small for gestational age 
Sd standard deviations 
a univariate meta-analysis 
3.11 (0.48-20.0) 0.81 (0.45-1.46) 3.41 (2.68-4.34) 0.55 (0.48-0.62) 5.98 (1.73-20.61)a 0.35 (0.02-7.75)a 3.93 (2.33-6.61)a 0.65 (0.44-0.96)a 
- - 2.42 (1.68-3.50) 0.62 (0.47-0.81) - - 2.67 (1.17-6.06)a 0.83 (0.51-1.37)a 
9.97 (3.24-30.69)a 0.62 (0.24-1.63)a 2.34 (1.83-3.01) 0.53 (0.38-0.74) - - 3.93 (2.33-6.61)a 0.65 (0.44-0.96)a 
- - 3.35 (2.58-4.36) 0.46 (0.39-0.55) - - - - 
- - 2.50 (1.88-3.31) 0.26 (0.10-0.67) - - - - 
- - 2.75 (1.48-5.11) 0.58 (0.36-0.94) - - - - 
- - 1.54 (1.03-2.29) 0.62 (0.35-1.09) - - - - 
- - 4.37 (0.88-21.8) 0.25 (0.07-0.91) - - - - 
- - 1.88 (1.34-2.41) 0.61 (0.43-0.87) - - - - 
- - 2.38 (1.41-4.00) 0.03 (0.00-13.77) - - - - 
- - 2.50 (1.63-3.81) 0.54 (0.38-0.75) - - - - 
- - 3.05 (1.68-5.52) 0.53 (0.36-0.80) - - - - 
- - 1.65 (1.19-2.30) 0.60 (0.26-1.38) - - - - 
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Figure 7.3: Bivariate analysis of the accuracy of umbilical artery Doppler to 
predict small for gestational age fetuses in different populations according to risk.  
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Figure 7.4: Bivariate analysis of the accuracy of umbilical artery Doppler to 
predict adverse perinatal outcome in different populations according to risk.  
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Figure 7.5: Forest plot of likelihood ratios (LR) with 95% confidence intervals (CI) for umbilical artery Doppler to predict 
compromise of fetal/neonatal wellbeing in a high risk population, bivariate meta-analysis according to reference standard with 
subgroup analysis (
a 
meta-analysis using univariate method). 
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In a high risk population subgroup analysis showed clinically relevant results for 
prediction of admission to neonatal intensive care unit (NICU) and acidosis and 
prediction of intra-uterine death (figure 7.5). For admission to NICU prediction was 
better in pregnancies affected by PE rather than those with suspected SGA, in high 
quality papers and when the test was performed within 7 days of delivery. For acidosis 
prediction was greatly improved when the test was performed within 24 hours of 
delivery and a systolic diastolic (SD) ratio was more accurate than the pulsatility index 
(PI). For an Apgar score less than 7 at 5 minutes prediction was improved in PE 
pregnancies versus SGA. For perinatal mortality there was improved prediction with 
high quality papers and the use of the PI. For respiratory distress syndrome and 
necrotizing enterocolitis there was improved prediction in SGA pregnancies versus PE. 
For prediction of intra-uterine death absent reversed end-diastolic flow showed 
improved prediction.  
 
In multiple pregnancies the results for SGA were LR+ve 3.37 (2.18-5.22), LR-ve 0.65 
(0.59-0.72) and for adverse perinatal outcome LR+ve 8.08 (2.63-24.77), LR-ve 0.58 
(0.49-0.68). 
 
Funnel plots and the regression test for asymmetry for SGA as an outcome were 
symmetrical/not significant in all populations (p=0.3). When assessing papers reporting 
on wellbeing as an outcome there was asymmetry across all populations however, when 
the tests were restricted to sub-groups according to outcome the plots were symmetrical 
suggesting the asymmetry was due to use of a combined reference standard introducing 
heterogeneity rather than publication bias. 
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7.5 Discussion 
This review evaluated the accuracy of umbilical artery Doppler to predict small for 
gestational age fetuses and compromise of fetal/neonatal wellbeing. In a high risk 
population the test showed moderately useful results for prediction of severe forms of 
SGA and intra-uterine death, and in certain sub-groups clinically useful results for 
prediction of admission to NICU and acidosis. The results showed low predictive 
accuracy overall for a low risk/unselected population. In multiple pregnancies the 
results suggest the test may be clinically useful to predict adverse perinatal outcome.  
 
This review complies with existing guidelines for the reporting of systematic reviews
43
 
and also guidelines specific to the reporting of systematic reviews of observational 
studies
42
. Extensive literature searches were performed without language restrictions, 
used validated methods for quality assessment, investigated for potential sources of 
heterogeneity and employed new advanced statistical techniques all planned a priori. In 
1994 Neilson et al were the first to report a systematic review in this area in a high risk 
population as a Cochrane review, reporting a 49% reduction in perinatal mortality
90
, this 
was later updated in 1995 by Alfirevic et al and the reduction found to be 38%
85
. Later, 
with the exclusion of a small study, the Cochrane group reported that this reduction had 
fallen to 29%, OR 0.71 (95% confidence interval 0.50-1.01)
91
. The conclusion of the 
final update was that umbilical artery Doppler in a high risk population appeared to 
improve a number of obstetric care outcomes and appeared promising in reducing the 
number of perinatal deaths. The authors made a case for the need for a larger trial
91
. In 
unselected and low risk populations the previously published evidence has not 
supported the routine use of umbilical artery Doppler
86;87
. There has been one published 
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test accuracy study, looking at the use of intrapartum umbilical artery Doppler and 
concluded that it was a poor predictor of adverse outcome
27
. As discussed previously, 
RCTs assess the effectiveness of both the test and any subsequent intervention on 
outcome. This review shows that umbilical artery Doppler is useful clinically in a high 
risk population as a predictive test for neonatal/fetal compromise.  
 
The assessment of study quality and reporting in diagnostic reviews has advanced over 
the last ten years with the development and validation of the QUADAS and STARD 
checklists. It has been previously reported that poor study design and conduct can affect 
the estimates of diagnostic accuracy
51;75
. However, it is not entirely clear how individual 
aspects of quality may effect this and to what magnitude particularly in the area of 
Obstetrics. Application of quality scores has been shown to be of little value on 
diagnostic reviews
55
. The assessment of study quality in this review was hindered by 
lack of clear reporting, which is a common problem in diagnostic reviews. The areas in 
which reporting was uniformly poor were in the details provided regarding performance 
of the index test and reference standard, blinding of the assessors of the reference 
standard and whether interventions were used e.g. early delivery. Meta-regression 
showed no effect of study quality on results in a high risk population however, in light 
of the poor reporting the true effect of study quality cannot truly be assessed. As 
interventions were poorly reported there is the possibility of a treatment paradox (where 
the application of a treatment affects the outcome/reference standard and thus the test 
accuracy results) being introduced however, as there as so few interventions that may be 
used for these conditions and that reporting was globally poor the likelihood is that any 
paradox will be uniform. 
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This review was also limited by the reference standards used as discussed in section 5.5 
and chapter 10.  
 
In clinical practice tests are not applied in isolation, the clinician makes an assessment 
of the likelihood of an outcome/disease based on history, examination, test results and 
their own experience/beliefs. A test alone cannot alter the clinical course of a pregnancy 
but provides information for the clinician to make a decision on clinical management 
based on the analysis of this information. To truly assess the value of a test a clinician 
thus needs to know where it fits into a diagnostic pathway and what management 
decisions may be made based on its results. This can be modelled in the form of a 
decision tree and combined with economic analysis to give a true assessment of the tests 
value in clinical practice.  Future research thus needs to address the limitations in 
primary research as identified in this review and the need to consider tests in 
combination with other investigations and as part of the management pathway with 
interventions. 
 
7.6 Conclusion 
Umbilical artery Doppler is a moderately useful test in a high risk population to predict 
the fetus/neonate at risk of compromise. Further research should concentrate on its use 
within a series of tests e.g. with biophysical profile and other fetal Doppler indices. 
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CHAPTER 8: SYSTEMATIC REVIEW OF MIDDLE 
CEREBRAL ARTERY DOPPLER TO PREDICT SMALL 
FOR GESTATIONAL AGE FETUSES AND COMPROMISE 
OF FETAL/NEONATAL WELLBEING 
 
8.1 Abstract 
8.1.1 Background 
The accuracy of fetal middle cerebral artery (MCA) Doppler for prediction of the fetus at 
risk of compromise of wellbeing is not known. The purpose of this review was to 
determine the accuracy of MCA Doppler to predict SGA fetuses and compromise of 
fetal/neonatal wellbeing. 
 
8.1.2 Methods 
The following electronic databases were searched: Medline, Embase, Cochrane library, 
Medion (inception to May 2009), hand searching of journal and reference lists, contact 
with experts. Two reviewers independently selected articles in which the results of 
middle cerebral artery Doppler were associated with the occurrence of compromise of 
fetal/neonatal wellbeing. There were no language restrictions applied. Data were 
extracted on study characteristics, quality and results to construct 2x2 tables. Likelihood 
ratios for positive and negative test results, sensitivity, specificity and their 95% 
confidence intervals were generated for the different indices and thresholds.  
 
  
96 
 
8.1.3 Results 
Thirty one studies, testing 3337 fetuses met the selection criteria. Meta-analysis showed 
low predictive accuracy. The best result was for the prediction of need for neonatal 
intensive care with a positive likelihood ratio 4.00 (2.13, 7.50) and negative likelihood 
ratio 0.61 (0.50, 0.75). For prediction of adverse perinatal outcome and perinatal 
mortality the results were positive likelihood ratios 2.79 (1.61, 3.07) and 1.36 (1.10, 
1.67) and negative likelihood ratios 0.56 (0.43, 0.72) 0.51 (0.29, 0.89) respectively. 
 
8.1.4 Conclusion 
Abnormal middle cerebral artery Doppler showed limited predictive accuracy for 
compromise of fetal/neonatal wellbeing. High quality primary research or individual 
patient data meta-analysis looking at this test in combination with other tests is required. 
 
8.1.5 Publications arising from this work 
Morris RK, Say R, Robson SC, Kleijnen J, Khan KS. Systematic review of middle 
cerebral artery Doppler to predict fetal growth restriction/compromise of fetal 
wellbeing. Archives of Disease in Childhood: Fetal and Neonatal Edition 2008; 93 
(supplement 1): Fa 31-36. 
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8.2 Introduction 
Animal studies have shown that in response to hypoxia, there is a redistribution of 
cardiac output with preferential flow to the heart, brain and adrenal glands
92;93
. Doppler 
studies of the human fetal circulation have shown similar results
94-97
. Cerebral 
vasodilatation is a manifestation of the increase in cerebral diastolic flow, a sign of the 
„brain-sparing effect‟ of chronic hypoxia, and results in decreases in Doppler indices of 
the middle cerebral artery (MCA) such as the pulsatility index (PI)
94
. Previous studies 
looking at the value of MCA Doppler in the detection of the at risk fetus have 
conflicting conclusions, some report poor predictive value
98;99
 while others report that 
MCA Doppler may be a useful tool
95;100
.  
 
The purpose of this review was to investigate the accuracy of MCA Doppler used in 
predicting compromise of fetal/neonatal wellbeing. 
 
8.3 Methods 
The methods used are outlined in chapter 4 with those specific to this review detailed 
below. 
 
8.3.1 Data Sources 
Electronic searches were performed targeting citations on the prediction of SGA/FGR and 
fetal/neonatal compromise. Medline, Embase, the Cochrane Library (2009;2) and Medion 
database were searched from inception until May 2009. The search strategies are detailed 
in appendix 29. 
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8.3.2 Study Selection 
Criteria for inclusion were studies that reported on singleton and multiple pregnancies at 
any level of risk in any healthcare setting undergoing MCA Doppler at any gestation. 
Test accuracy studies allowing generation of 2x2 tables were included. The reference 
standards used were those reported by the authors. Reference standards for wellbeing 
were any outcome measure performed after birth relating to neonatal wellbeing that was 
reported by the study authors. The outcome measure APO was used as detailed in 
sections 4.2.3.  
 
8.3.3 Data Extraction and Study Quality Assessment 
The data extraction form for this review can be found in appendix 30. Quality 
assessment was performed as described in section 4.4. See appendix 26 for further 
explanation of the quality assessment. 
 
8.3.4 Data Synthesis and Analysis 
This was performed as detailed in section 7.3.4. 
 
8.4 Results 
8.4.1 Literature Identification and Study Characteristics 
Figure 8.1 summarises the process of literature identification and selection. Tables 
detailing the citations of the included studies and the individual study characteristics are 
available in appendices 31 and 32 respectively. There were 31 studies included overall, 
testing 3337 fetuses and producing 85 2x2 tables. The majority of studies were 
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performed in the third trimester (28) with 10 reporting on second trimester testing and 
five reporting data on post-dates pregnancies. In 87.1% (27/31) of included studies the 
population under investigation was classified by the author as high-risk, one low risk, 
one unselected, one mixed and one paper had no classification. In the high risk 
populations 14 included patients with suspected FGR, four with hypertensive diseases 
and five included patients with both risk factors. 18 papers reported on singleton 
pregnancies only and one paper on multiple pregnancies only, in the remaining 12 
papers the authors did not state whether multiple pregnancies were excluded. Only 55% 
(17/31) papers excluded fetuses with structural and chromosomal anomalies from the 
results. Twenty-seven of the included studies reported measures of fetal/neonatal 
wellbeing. There were 13 studies for SGA (11 reported birth weight<10
th
 centile, two 
birth weight <5
th
 centile and one birth weight <3
rd
 centile).  None of the included studies 
used anthropometric measurements other than birth weight.  
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Figure 8.1: Process from initial search to final inclusion for middle cerebral artery 
Doppler to predict small for gestational age/compromise of fetal wellbeing (up to 
May 2009). (SGA small for gestational age).  
 
 
 
Primary articles retrieved for detailed evaluation  
- from electronic searches     n= 96 
- from reference lists     n= 9 
        
Articles excluded     n= 65 
- not prediction/ not test accuracy   n= 60 
- reviews/ letters/ comments/ editorials  n= 3 
- Paper/translation unobtainable   n= 2 
 
 
Primary articles included in systematic review  n= 31 
Potentially relevant citations identified from electronic searches to 
capture primary articles on middle cerebral artery Doppler to 
predict SGA/compromise of fetal wellbeing 
       n= 2135 
 
References excluded after screening titles and/ or abstracts  
      n= 2039 
  
101 
 
8.4.2 Study Quality 
The quality assessment of included studies revealed deficiencies (figure 8.2). Only 12 
studies used prospective data collection, 21 were of a cohort design and only nine 
studies used both. Only seven studies contained an adequate description of the 
performance of the index test and only four reported clearly on the performance of the 
reference standard. Blinding of the reference test was also poorly reported (5/31). 
Availability of clinical data were reported in 16 studies and 20 reported on intermediate 
results and withdrawals. Only one study reported adequately on all these quality items. 
One reported adequately on the use of any treatment in between the performance of the 
MCA Doppler and delivery, stating the use of betamethasone.  
 
8.4.3 Data Analysis 
Fetal/Neonatal Compromise 
Statistical analysis could be performed for the following outcome measures: adverse 
perinatal outcome (figure 8.3), Apgar at 1 minute and 5 minutes <7 (appendix 33), cord 
blood gas analysis/requirement for neonatal resuscitation (appendix 34), admission to 
neonatal intensive care unit (NICU)/neonatal complications (appendix 35) and perinatal 
morbidity and mortality (appendix 36). 
 
The best result obtained was for prediction of admission to NICU LR+ 4.40 (2.13, 7.50) 
LR-ve 0.61 (0.50, 0.75). Disappointingly meta-analysis using a composite outcome 
measure, adverse perinatal outcome, did not show good predictive accuracy LR+ve 2.79 
(1.61, 3,07) LR –ve 0.56 (0.43, 0.72) and there was significant heterogeneity X2=37.96 
(p=0.00).   
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Figure 8.2: Bar chart illustrating the compliance with quality items for included studies in the systematic review of accuracy of 
middle cerebral artery Doppler to predict small for gestational age fetuses and compromise of fetal/neonatal wellbeing. (Numbers 
in bars represent actual number of studies compliant). 
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When looking at one of the most important outcome measures, perinatal mortality, the 
results were again disappointing, LR+ve 1.36 (1.10, 1.67) and LR-ve 0.51 (0.29, 0.89).  
 
Sub-group analysis for these measures did account for some of the heterogeneity and 
allow an improvement in prediction. For neonatal cord blood acidosis, restricting the 
threshold to pH<7.20 and a high risk population [LR+ve 2.29 (0.74, 7.11) LR-ve 0.66 
(0.40, 1.10)]; and for adverse perinatal outcome use in an unselected population [LR+ve 
5.53 (2.88, 10.64) LR-ve 0.68 (0.54, 0.65)] and use of pulsatility index<5
th
 centile 
[LR+ve 3.66 (1.04, 12.96) and LR-ve 0.48 (0.34, 0.70)]. 
 
Where ROC curves were plotted the area under the curve (AUC) were all between 0.70-
0.80, and assessed as a moderate test. Summary receiver operating characteristic curves 
are shown in figure 8.5 for APO and SGA (other outcomes are shown in appendix 37). 
 
Small for gestational age fetuses (SGA) 
The results for SGA fetuses are summarized in figure 8.4. For prediction of birth weight 
<10
th
 centile, there was significant heterogeneity in results. Sub-group analysis was 
performed based on population risk, Doppler index parameter used, singletons only and 
MCA within 2 weeks of delivery. The most predictive test was a systolic/diastolic 
ratio<10
th
 centile in any risk population LR+ve 9.32 (3.91, 22.19) LR-ve 0.53 (0.43, 
0.65), X
2 
= 1.91 (p=0.17).  There did not appear to be an improvement in prediction 
with the more severe forms of SGA i.e. birth weight <5
th
 or <3
rd
 centile. 
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Sub-group and sensitivity analysis. 
Sensitivity analysis including only those studies which excluded chromosomal and 
structural anomalies showed no significant difference. When assessing study quality, 
sub-group analysis based on study quality could only be performed for the meta-
analyses with a large number of included studies; sensitivity analysis showed no 
difference when extremely low quality studies were excluded.  
 
Publication bias 
Funnel plots (not shown) and the regression test for asymmetry showed no significant 
publication bias (p=0.1). 
 
8.5 Discussion 
This is the only published systematic review and meta-analysis of the value of MCA 
Doppler to predict perinatal wellbeing. Disappointingly MCA Doppler was found to 
have a low predictive accuracy overall. For fetal/neonatal compromise the best predictor 
was any Doppler parameter in any risk population to predict need for neonatal intensive 
care. For SGA fetuses the best predictor was SD ratio<10
th
 centile in any risk 
population. 
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Figure 8.3: Forest plot of positive and negative likelihood ratios for middle cerebral artery Doppler to predict compromise of fetal 
wellbeing (adverse perinatal outcome). Single studies are represented by a filled box, pooled results by an open diamond and 
subgroup analysis by a filled diamond. 
Author  Year       Population   Index Test       Positive Likelihood Ratio (95% CI)                      Negative Likelihood Ratio (95% CI)
No of studies
Negative Likelihood Ratio
Adverse Perinatal Outcome
2 studies c High risk, PI<5th centile, within 2 weeks of delivery
6 studies a High risk, any index parameter within 2 weeks of delivery
3 studies b High risk, singletons only, PI<5th centile
9 studies a High risk, singletons only, any index parameter
2 studies c Any risk SD<10th centile
3 studies b High risk PI<5th centile
4 studies a High risk PI<2sd
2 studies c Unselected Any index parameter
13 studies a High risk Any index parameter
Sub-group analysis
16 studies a Any risk Any index parameter
Meta-analysis
1.87 (1.50, 2.33)
1.98 (1.29, 3.05)
3.66 (1.04, 12.94)
2.41 (1.59, 3.65)
2.66 (1.80, 3.92)
3.66 (1.04, 12.94)
1.68 (1.15, 2.47)
5.53 (2.88, 10.64)
2.22 (1.61, 3.07)
2.79 (1.61, 3.07)
Strigini 1997 High risk PI<1.5 sd 3.70 (2.14, 6.41)
Ozeren 1999 High risk PI<2sd
Miyashita  2002 High risk RI<4.0 sd
Meyberg 2001 High risk SD<10th centile
Meyberg 2000 Unselected SD<10th centile
Mari  1992 High risk PI<2sd
Lakhkar 2006 High risk PI<5th centile Minor adverse outcome
Lakhkar 2006 High risk PI<5th centile Major and minor adverse outcome
Joern 1997 High risk PI<1.3
1.39 (0.71, 2.70)
3.86 (1.63, 9.17)
2.29 (1.41, 3.73)
3.71 (1.96, 7.02)
4.60 (1.43, 14.83)
2.83 (1.45, 5.53)
4.58 (1.16, 18.16)
1.19 (0.72, 1.99)
Gramellini 1992 Unselected PI 33.00 (1.93, 565.06)
Fong 1999 High risk PI<5th centile 1.73 (1.40, 2.13)
Chandran 1993 High risk PI<2sd
Arduini 1992 High risk PI<5th centile
1.65 (0.85, 3.18)
7.24 (3.31, 15.83)
Del Rio   2008 High risk Not reported 1.17(0.88, 1.57)
Hernandez 2008 High risk PI<2sd 1.27 (0.98, 1.65)
Spinillo 2008 High risk PI<10th centile 1.73 (1.27, 2.36)
Tchirikov 2009 Mixed risk PI<5 centile 11.66 (4.47, 30.45)
Positive Likelihood Ratio
0.5 1 2 5 10 100 1000
0.52 (0.39, 0.69)
0.50 (0.38, 0.65)
0.48 (0.34, 0.70)
0.55 (0.40, 0.71)
0.55 (0.40, 0.75)
0.48 (0.34, 0.70)
0.52 (0.31, 0.88)
0.68 (0.54, 0.85)
0.63 (0.50, 0.79)
0.56 (0.43, 0.72)
0.83 (0.56, 1.23)
0.69 (0.47, 1.02)
0.52 (0.33, 0.81)
0.58 (0.36, 0.92)
0.46 (0.21, 1.00)
0.46 (0.23, 0.95)
0.64 (0.47, 0.87)
0.95 (0.83, 1.10)
0.76 (0.61, 0.94)
0.48 (0.33, 0.70)
0.35 (0.11, 0.17)
0.36 (0.24, 0.52)
0.56 (0.17, 1.82)
0.35 (0.09, 1.44)
0.44 (0.20, 0.95)
0.85 (0.76, 0.94)
0.63 (0.48, 0.70)
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Figure 8.4: Forest plot of positive and negative likelihood ratios for middle cerebral artery Doppler to predict small for gestational 
age fetuses (Birth weight <10
th
/5
th
/3
rd
 centile). Single studies are represented by a filled box, pooled results by an open diamond and 
subgroup analysis by a filled diamond. 
0.35 (0.11, 1.17)
0.61 (0.36, 1.04)
0.45 (0.26, 0.77)
0.75 (0.58, 0.97)
0.72 (0.57, 0.91)
0.78 (0.70, 0.89)
0.53 (0.43, 0.65)
0.74 (0.58, 0.95)
0.74 (0.39, 1.40)
0.69 (0.58, 0.83)
0.72 (0.60, 0.81)
0.80 (0.70, 0.87)
0.80 (0.53, 1.20)
0.46 (0.36, 0.60)
0.58 (0.43, 0.78)
0.17 (0.01, 2.31)
0.88 (0.76, 1.00)
0.74 (0.42, 1.31)
0.91 (0.81, 1.02)
0.64 (0.51, 0.81)
0.73 (0.51, 1.04)
0.75 (0.57, 1.00)
0.71 (0.52, 0.99)
Negative likelihood ratio
1.65 (0.85, 3.18)
3.30 (1.22, 8.92)
5.31 (2.89, 9.78)
2.02 (1.04, 3.92)
Birth weight <5th centile
4.24 (1.45, 12.38)
3.09 (0.75, 12.74)
9.32 (3.91, 22.19)
3.18 (0.55, 18.52)
5.93 (2.93, 12.00)
3.72 (2.03, 6.79)
4.71 (2.61, 8.50)
6.28 (3.62, 10.91)
1.48 (0.76, 2.88)
28.53 (1.82, 447.60)
6.06 (2.87, 12.79)
3.22 (1.67, 6.22)
1.78 (1.05, 3.01)
3.53 (0.87, 14.41)
5.00 (0.61, 41.11)
31.74 (1.96, 513.60)
2.86 (1.19, 6.85)
2.88 (1.39, 5.96)
8.84 (1.95, 40.16)
Positive likelihood ratio
Chandran 1993 High risk PI<2sd
Birth weight <3rd centile
2 studiesb Any risk Any index parameter
Meta-analysis
Meyberg 2000 Unselected SD<10th
Dubiel 2000 High risk PI<2sd
2 studiesb High risk, test within 2 weeks of delivery, any parameter
2 studiesb High risk, singletons only PI
2 studiesc Any risk SD<10th
2 studiesb High risk PI<2sd
2 studiesb Unselected Any index parameter
8 studiesa High risk Any index parameter
Sub-group analysis
11 studiesa Any risk Any index parameter
Meta-analysis
Strigini 1997 High risk PI<1.5sd
Ozeren 1999 High risk PI<2sd
Meyberg 2001 High risk SD<10th centile
Meyberg 2000 Unselected SD<10th centile
Luzi 1996 High risk PI<1sd
Joern 1997 High risk PI<1.3
Joern 1993 High risk PI<1.0
Gramellini 1992 Unselected PI
Cavero 1996 Mixed risk Not reported
Arias 1994 High risk RI
Alatas 1996 Low risk PI<2sd
Alatas 1996 High risk PI<2sd
Birth weight <10th centile
Author  Year         Population         Index Test             Positive Likelihood Ratio (95% CI) Negative Likelihood Ratio (95% CI)
No of studies
0.5 1 2 5 10 100 1000 0.01 0.1 0.2 0.5 1 2 5
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Figure 8.5: Summary receiver operating characteristic curves for middle cerebral 
artery Doppler to predict small for gestational age fetuses (SGA) and adverse 
perinatal outcome (APO) produced using the bivariate method. (*SGA birth 
weight <10
th
 centile) 
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The use of pooled likelihood ratios as summary measures has been discussed in section 
5.5.  When analyzing the results, pooled sensitivity and specificity were used in a 
sensitivity analysis and no difference in the interpretation of the results was found. The 
bivariate technique was used in the meta-analysis to overcome the concerns about 
pooling related statistics. 
 
In this review, sub-group analysis using the aspects of study quality that are best 
reported (study design, recruitment, description and blinding of index and reference 
standard) showed no significant difference in results when excluding the “low quality” 
studies. Areas of study design where reporting was uniformly poor were in the 
description of the index test and reference standard, blinding of the reference standard 
and use of any intervention between the index test and reference standard.  
 
In this review results are analysed and reported according to absolute cut-offs for MCA 
Doppler indices. Sub-group analysis was performed where possible looking at 
individual indices as it is known that changes for instance in the MCA PSV and PI 
occur at different stages in the progression of fetal compromise
101
. Although some of 
the included papers investigated trends in MCA Doppler in an individual fetus the test 
accuracy data for this was not reported. MCA Doppler is also used with umbilical artery 
Doppler as the cerebroplacental ratio, although outside the scope of this review there 
were 11 included papers that reported on cerebroplacental ratio, this test showed greatly 
improved accuracy for prediction of adverse perinatal outcome LR+ve 4.42 (1.88, 
10.37) and LR-ve 0.36 (0.22, 0.60).  
 
  
109 
 
In the included studies it was disappointing that only population based birth weight 
standards were used as these do not distinguish between the small healthy infant and the 
compromised infant. Thus although this review set out to evaluate the accuracy of MCA 
Doppler to predict FGR, it is accepted that the results reported in this review can only 
be considered to be predictive of SGA fetuses rather than FGR. It is important that 
future research in this area uses customised growth charts that are adjusted for sex, 
gestation, parity, maternal weight and height and ethnicity and neonatal indices of 
malnutrition as the former have been shown to improve the detection of at risk of 
stillbirth
17
 and the latter to identify the malnourished infant at risk of peripartum 
asphyxia
16
.  
 
As FGR and severe compromise of fetal wellbeing are diseases with relatively low 
prevalence a clinically useful test would need to have a high positive LR (>10) and low 
negative LR (<0.10)
59
. At present the results of this review show low predictive 
accuracy.  Future research should concentrate on addressing the limitations as already 
identified within the primary literature in particular in the choice of reference standards 
for FGR and should utilize individual patient data meta-analysis. This research should 
also look at the use of antenatal tests in combination e.g. umbilical and MCA Doppler to 
improve predictive accuracy and thus clinical value. It must also be recognized that 
when considering implementing MCA Doppler as a clinical test, researchers will need 
to take into account the cost of implementing such a specialized test and the lack of 
effective interventions in this area.  
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8.6 Conclusion 
Abnormal middle cerebral artery Doppler showed limited predictive accuracy for 
compromise of fetal/neonatal wellbeing. High quality primary research or individual 
patient data meta-analysis looking at this test in combination with other tests is required. 
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CHAPTER 9: SYSTEMATIC REVIEW OF DUCTUS 
VENOSUS DOPPLER TO PREDICT SMALL FOR 
GESTATIONAL AGE FETUSES AND COMPROMISE OF 
FETAL/NEONATAL WELLBEING 
 
9.1 Abstract 
9.1.1 Background 
The accuracy of ductus venosus Doppler for prediction of the fetus at risk of 
compromise of wellbeing is not known. The purpose of this review is to determine the 
accuracy of ductus venosus Doppler to predict small for gestational age fetuses and 
compromise of fetal/neonatal wellbeing.  
 
9.1.2 Methods 
Electronic searches of the following databases were performed: Medline, Embase, 
Cochrane library, Medion (inception to May 2009), hand searching of journal and 
reference lists, contact with experts. Two reviewers independently selected articles in 
which the results of ductus venosus Doppler were associated with the occurrence of 
compromise of fetal/neonatal wellbeing. There were no language restrictions applied. 
Data were extracted on study characteristics, quality and results to construct 2x2 tables. 
Likelihood ratios for positive and negative test results, sensitivity, specificity and their 
95% confidence intervals were generated for the different indices and thresholds.  
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9.1.3 Results 
Twenty studies, testing 13,273 fetuses met the selection criteria. Meta-analysis showed 
moderate predictive accuracy. The best result was for the prediction of perinatal 
mortality, positive likelihood ratio 4.21 (1.98, 8.96) and negative likelihood ratio 0.43 
(0.30, 0.61). For prediction of adverse perinatal outcome the results were positive 
likelihood ratio 3.15 (2.19, 4.54) and negative likelihood ratio 0.49 (0.40, 0.59). 
 
9.1.4 Conclusion 
Abnormal ductus venosus Doppler showed moderate predictive accuracy for 
compromise of fetal/neonatal wellbeing and perinatal mortality in high risk pregnancies 
with placental insufficiency.  
 
9.1.5 Publications arising from this work 
R.Katie Morris, Tara J Selman, Meenakshi Verma, Stephen C Robson, Jos Kleijnen, 
Khalid S Khan. Systematic review and meta-analysis of the test accuracy of ductus 
venosus Doppler to predict compromise of fetal/neonatal wellbeing in high risk 
pregnancies with placental insufficiency. Eur J Obstet Gynecol Reprod Biol 2010 In 
press.   
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9.2 Introduction 
Systematic Doppler application, can predict placental dysfunction in the form of FGR, 
preeclampsia or both
102
.
 
The importance of venous Doppler (especially ductus venosus 
(DV)) in FGR stems from its dual capacity to evaluate cardiac function. As FGR worsens, 
rising afterload affects cardiac systolic and diastolic function. Forward venous flow is 
normally reduced during right atrial contraction (depicted as the a-wave in the DV 
waveform). A retrograde a-wave signifies the onset of overt fetal cardiac failure. While 
arterial Doppler evaluation provides important detail about placental function and its impact 
on regional fetal circulation, venous Doppler is essential to a complete understanding of fetal 
condition by quantifying fetal cardiovascular compromise102. DV is perceived to be the 
optimal test to predict fetal acidaemia and is used by many as the test on which to base 
decisions regarding delivery in preterm FGR103.  
 
The purpose of this review was to investigate the accuracy of ductus venosus Doppler to 
predict compromise of fetal/neonatal wellbeing.  
 
9.3 Methods 
The methods used are outlined in chapter 4 those specific to these review are detailed 
below. 
 
9.3.1 Data Sources 
Systematic searches were performed in Medline (Ovid), Embase (Ovid), the Cochrane 
Library (2009; 2) and MEDION from inception until May 2009. 
 
Search terms relating to 
SGA/FGR and fetal/neonatal compromise were combined with methodological filters for 
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identification of all primary articles reporting on the accuracy of ductus venosus Doppler 
(appendix 38). 
 
9.3.2 Study Selection 
Test accuracy studies reporting on ductus venosus Doppler allowing generation of 2x2 
tables of accuracy (true positives, false positives, false negative, true negatives) were 
included. Criteria for inclusion were studies that reported on pregnancies at any level of 
risk in any healthcare setting using the ductus venosus Doppler to predict compromise 
of fetal/neonatal wellbeing. Case series <10 cases were excluded. The outcome 
measures used were those reported by the authors. Reference standards for wellbeing 
were any outcome measure performed after birth relating to neonatal wellbeing that was 
reported by the study authors. The outcome measure APO was used as detailed in 
sections 4.2.3.  
 
9.3.3 Data Extraction and Study Quality Assessment 
The data extraction form for this review can be found in appendix 39. Quality 
assessment was performed as described in section 4.4. See appendix 26 for further 
explanation of the quality assessment. 
 
9.3.4 Data Synthesis and Analysis 
This was performed as detailed in section 4.6 and 7.3.4. 
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9.4 Results 
9.4.1 Literature Identification and Study Characteristics 
Figure 9.1 summarises the process of literature identification and selection. The 
references for the included studies and the details of the individual study characteristics 
can be found in appendix 40 and 41 respectively. There were 20 studies
 
included overall 
for ductus venosus Doppler, reporting on 13,273 pregnancies and producing 79 2x2 
tables. The Doppler results used for analysis were performed within two weeks of 
delivery with a range of gestational age from 11-41 weeks. All but one of the studies 
was performed in a high risk population (suspected placental insufficiency) and only 
one study reported exclusively on multiple pregnancies.  In the remaining studies, 15 
reported exclusively on singleton pregnancies and in four studies it was unclear whether 
multiple pregnancies were excluded. Fourteen studies excluded fetuses with 
chromosomal and structural anomalies. There were 18 cohort studies and two cross-
sectional. There were 10 prospective, one consecutive, four retrospective, and six 
studies of unclear design. Five studies were identified as being from the same research 
group and had potential overlap between patients, despite contact with the authors it was 
not possible to determine the exact nature of this overlap thus each meta-analysis only 
included the most appropriate study ensuring patients were only counted once
102;104-107
. 
One paper reported exclusively on multiple pregnancies (Maiz et al 2009 appendix 40) 
and one on first trimester testing (Maiz et al 2008 appendix 40). These were excluded 
from the main meta-analysis as it was felt that this gave a more homogenous population 
and the first trimester ductus venosus testing represents a different pathological process. 
This left 18 studies, testing 2267 pregnancies all performed in high risk pregnancies 
between 20-41 weeks. 
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Figure 9.1: Process from initial search to final inclusion for ductus venosus Doppler 
to predict compromise of fetal/neonatal wellbeing (up to May 2009). 
 
9.4.2 Study Quality 
Figure 9.2 shows a summary of the quality assessment of included studies which 
revealed deficiencies. Only 13 studies contained an adequate description of the 
performance of the index test and three on the outcome measure. Blinding of the 
assessors of the outcome measure to the results of the Doppler was also poorly reported 
(5/20 studies). No studies reported on the use of any treatment in between the Doppler 
Primary articles retrieved for detailed evaluation  
- from electronic searches      n= 52 
- from reference lists      n= 0 
        
Articles excluded     n= 32 
- not prediction/ not test accuracy   n= 24 
- reviews/ letters/ comments/ editorials  n= 6 
- Paper/translation unobtainable   n= 2 
 
 
Primary articles included in systematic review          n= 20 
 
Number of fetuses              n=13,273 
 
Number of 2x2 tables of accuracy            n=79 
Potentially relevant citations identified from electronic searches to 
capture primary articles on ductus venosus Doppler to predict 
compromise of fetal/neonatal wellbeing  n= 668 
 
References excluded after screening titles and/ or abstracts  
       n= 616 
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and delivery. These items of quality of study design are important in diagnostic 
accuracy reviews. Verification bias was minimized as the number of eligible women 
progressing to the reference standard in included studies was >90% in 19/20. 
 
9.4.3 Data Analysis 
The results are summarized in figure 9.3 and table 9.1. An abnormal ductus venosus 
waveform predicted adverse perinatal outcome with a pooled positive likelihood ratio 
(LR+) of 3.15 (95% CI 2.19-4.54) and negative likelihood ratio (LR-) of 0.49 (95% CI 
0.40-0.59), there was significant statistical heterogeneity. Sub-group analysis was 
performed based on for the following outcome measures: acidaemia, Apgar at 1 minute 
and 5 minutes <7, neonatal resuscitation, perinatal morbidity and mortality (table 9.1). 
This did account for some of the heterogeneity. Sub-group analysis according to type of 
waveform index could only be performed for absent or reversed a-wave and pulsatility 
index for veins>95th centile (table 9.1). To investigate the use of ductus venosus Doppler in 
preterm pregnancies sub-group analysis was performed using those studies including 
fetuses <37 weeks (table 9.1), sub-group analysis was not possible for severe preterm (<32 
weeks) growth restriction (only 2 studies). Accuracy for prediction of acidaemia also 
improved when the Doppler was performed within 48 hours of delivery LR+ 4.25 (95% 
1.01-16.47), LR- 0.64 (95% CI 0.46-0.88). The measures of adverse perinatal outcome, 
abnormal ductus venosus best predicted perinatal mortality with a LR+ 4.21 (95% CI 1.98-
8.96), LR- 0.43 (95% CI 0.30-0.61). The receiver operating characteristic curve for this is 
shown in figure 9.4.  
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Figure 9.2: Bar chart showing quality of evidence on ductus venosus Doppler to predict compromise of fetal/neonatal wellbeing. 
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When assessing study quality, sub-group analysis could not be performed as there were 
too few studies of a high quality. For the purpose of this review it was felt to be 
important to look particularly at those studies in which ductus venosus Doppler had not 
been used in the management of the pregnancies (n=7 studies), that had blinded the 
investigators to the Doppler results (n=5 studies) and those studies that looked at 
preterm fetuses only/ did not use Doppler in management (n=4 studies). These results 
(table 9.1) show that test accuracy did decrease for adverse perinatal outcome [(LR+ve 
2.10, LR-ve 0.49 for exclusion from management) (LR+ve 2.60, LR-ve 0.49 for studies 
with blinding) (LR+ve 2.31, LR-ve 0.41 for exclusion from management/preterm)].  
 
Sensitivity analysis including only those studies which categorically stated they 
excluded chromosomal and structural anomalies or where the authors stated that 
singleton pregnancies only were included showed a slight improvement in results (table 
9.1).  
 
One paper
 
(Maiz et al 2009 appendix 40) reported exclusively on multiple pregnancies 
and thus was excluded from the meta-analysis. The results were very imprecise; for 
prediction of single fetal death in monochorionic twins LR+ 74.57 (95% CI 3.33-1672); 
LR- 0.79 (0.54-1.16) and in dichorionic twins LR+ 169.7 (95% CI 7.4-3889), LR- 0.83 
(0.62-1.12). 
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Sub-group and sensitivity analysis. 
Sensitivity analysis including only those studies which excluded chromosomal and 
structural anomalies or where the authors stated that singleton pregnancies only were 
included showed a slight improvement in results (table 9.2). When assessing study 
quality, sub-group analysis based on study quality could not be performed as there were 
too few studies of a high quality.  
 
Publication bias 
Funnel plots (not shown) and the regression test for wellbeing as an outcome showed 
asymmetry (p=0.02). However, when the tests were restricted to sub-groups according 
to outcome, the plots were symmetrical suggesting the asymmetry was due to use of a 
combined reference standard introducing heterogeneity rather than publication bias 
(p=0.2). 
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Figure 9.3: Forest plot of abnormal ductus venosus Doppler in second/third trimester to predict compromise of fetal/neonatal 
wellbeing with subgroup analysis. Diamonds represent pooled results, squares represent individual studies. 
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Figure 9.4: Bivariate analysis of the accuracy of ductus venosus Doppler to predict 
perinatal death.  
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Table 9.1: Sub-group analysis for ductus venosus Doppler to predict compromise of fetal/neonatal wellbeing. 
Outcome measure Subgroup n=number of studies   LR+ (95% CI)                    LR- (95% CI)             Sensitivity (95% CI)       Specificity (95% CI) 
Adverse perinatal outcome n=14 3.15 (2.19-4.54)               0.49 (0.40-0.59)                  0.61 (0.50-0.70)                0.81 (0.70-0.88) 
Congenital abnormalities excluded n=12 3.75 (2.48-5.67)   0.47 (0.38-0.59)      0.60 (0.49-0.70)      0.84 (0.74-0.91) 
Singleton pregnancies only n=10 3.93 (2.32-6.66)   0.41 (0.29-0.58)      0.66 (0.50-0.79)      0.83 (0.69-0.92) 
Preterm delivery only n=11 3.79 (2.18-6.60)   0.51 (0.43-0.60)      0.57 (0.47-0.67)      0.85 (0.72-0.93) 
Test to delivery within 24 hours n=5 3.14 (1.46-6.74)   0.45 (0.33-0.61)      0.64 (0.48-0.78)      0.79 (0.54-0.93) 
Absent or reversed a-wave n=7 3.46 (1.67-7.16)   0.46 (0.35-0.61)      0.62 (0.46-0.75)      0.82 (0.61-0.93) 
Pulsatility index for veins>95
th
 centile n=3 3.74 (1.49-9.39)   0.57 (0.4-0.82)      0.54 (0.45-0.63)      0.87 (0.81-0.92) 
DV Doppler not used in management/blinding and preterm n=4 2.31 (1.25-4.28)                0.41 (0.28-0.60)               0.72 (0.57-0.83)                0.69 (0.44-0.86) 
Acidaemia n=6 2.76 (1.70-4.50)                0.59 (0.50-0.69)                0.53 (0.45-0.60)                 0.81 (0.69-0.89) 
Congenital abnormalities excluded n=6 3.10 (1.67-5.77)   0.55 (0.46-0.66)      0.54 (0.46-0.63)      0.82 (0.67-0.91) 
Singleton pregnancies only n=4 3.87 (1.70-8.79)   0.51 (0.36-0.72)      0.57 (0.40-0.72)      0.85 (0.67-0.94) 
Test to delivery within 48 hours n=3 4.25 (1.10-16.47)   0.64 (0.46-0.88)      0.45 (0.34-0.56)      0.89 (0.81-0.94) 
Umbilical cord pH<7.20 n=5 4.39 (1.26-15.30)   0.60 (0.50-0.72)      0.53 (0.44-0.62)      0.76 (0.70-0.81) 
Apgar score at 5 minutes<7 n=5 2.26 (1.52-3.34)                0.58 (0.42-0.79)                0.57 (0.42-0.70)                 0.75 (0.64-0.83) 
Congenital abnormalities excluded n=3 2.81 (1.37-5.76)   0.54 (0.37-0.78)      0.61 (0.45-0.76)      0.68 (0.63-0.72) 
Singleton pregnancies only n=3 2.44 (1.31-4.55)   0.60 (0.43-0.84)      0.59 (0.43-0.74)      0.67 (0.63-0.72) 
Absent or reversed a-wave n=3 3.17 (1.42-7.05)   0.64 (0.39-1.06)      0.52 (0.31-0.72)      0.78 (0.71-0.85) 
Perinatal mortality n=5 4.21 (1.98-8.96)                0.43 (0.30-0.61)                0.63 (0.47-0.77)                 0.85 (0.66-0.94) 
Congenital abnormalities excluded n=4 5.48 (2.17-13.84)   0.44 (0.29-0.66)      0.61 (0.42-0.77)      0.89 (0.70-0.96) 
Singleton pregnancies only n=4 3.80 (1.76-8.19)   0.44 (0.30-0.65)      0.63 (0.44-0.79)      0.83 (0.62-0.94) 
Absent or reversed a-wave n=3 5.18 (0.97-27.61)   0.60 (0.41-0.86)      0.53 (0.36-0.70)      0.78 (0.69-0.85) 
Neonatal death n=3 2.05 (1.63-2.60)                0.57 (0.41-0.80)                0.59 (0.49-0.68)                  0.67 (0.63-0.71) 
LR+ positive likelihood ratio; LR- negative likelihood ratio, CI confidence interval, DV ductus venosus 
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9.5 Discussion  
For the prediction of compromise of fetal/neonatal wellbeing overall ductus venosus 
Doppler was found to have moderate predictive accuracy in a high risk pregnancy due 
to placental insufficiency. The best predictor was abnormal ductus venosus Doppler to 
predict perinatal mortality. Restricting the Doppler waveform to absent or reversed a 
wave and to tests performed within 24 hours of delivery showed improvement in 
accuracy. This review suggests that ductus venosus Doppler is a useful test in the 
management of the pregnancy at risk of fetal/neonatal compromise. 
 
 The strengths of this review lie in the methodology used which complies with existing 
guidelines for the reporting of systematic reviews
43
 and also guidelines specific to the 
reporting of systematic reviews of observational studies
42
. The literature searches were 
extensive and designed to be sensitive rather than specific and were performed without 
language restrictions. Careful attention was paid to assessment of quality of study 
design and reporting. There are no previously published systematic reviews looking at 
ductus venosus Doppler in this area. There is debate as to whether pooled LRs or pooled 
estimates of sensitivity and specificity should be used due to the correlation between the 
paired statistics
74
. To account for this the bivariate method was utilised in the meta-
analysis and sensitivity analysis with pooled sensitivities and specificities performed, no 
significant difference was found. 
 
The limitations due to lack of clear reporting have been previously discussed (section 
5.5 and chapter 10). Due to the smaller number of primary studies included in this 
review it was not possible to apply meta-regression thus sub-group analysis using the 
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aspects of study quality deemed important for this review was performed and no 
significant difference was found when analysis was restricted to “high” quality studies. 
Areas of study design where reporting was uniformly poor were in the description of the 
outcome measure and use of any intervention between the performance of the Doppler 
and delivery and whether decision to deliver was based on the results of the ductus 
venosus Doppler.  Subgroup analysis using only those studies that blinded the results of 
the investigation did show a significant reduction in test accuracy. An argument could 
be made for not performing meta-analysis due to the significant heterogeneity. The 
decision to perform meta-analysis was based on the belief that there were sufficient 
similarities in the included populations, performance of the index test and outcome 
measure used to make this appropriate. Rigorous sub-group analysis was performed 
using those characteristics of the included studies that may have a significant impact on 
accuracy and shown varying results. These limitations do allow potential for bias within 
this review. 
 
As FGR and severe compromise of fetal wellbeing are diseases with relatively low 
prevalence a clinically useful test would need to have a high positive LR (>10) and low 
negative LR (<0.10)
59
. At present the results of this review show moderate predictive 
accuracy however, it is important to stress the limitations of the meta-analysis in light of 
the significant heterogeneity. It is still important to report these results as it can help to 
determine those areas of study design that will be important for future research.  In the 
future research in this area should take into account the limitations identified in this 
review; suitable populations; use of appropriate well defined outcome measures, 
utilization of treatments in between test and outcome and consider the use of tests in 
combination and the way they interact in the individual patient. Recent publications 
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have highlighted the importance of using Doppler measurements in combination and the 
use of an appropriate threshold
108
. A randomised controlled trial (TRUFFLE 
www.truffle.org) is currently recruiting to determine the use of ductus venosus Doppler 
in the timing of delivery of preterm growth restricted  and to determine which is the 
most appropriate threshold to ensure that delivery is timed to minimise not only 
mortality but also neurological morbidity. The need for such a threshold must be taken 
into account in future systematic reviews of accuracy in this area as the best 
test/threshold may not necessarily therefore be the most accurate. Implementation of 
any testing/screening strategy within the pregnant population will need to take into 
account the cost of performing such a test and the availability of acceptable 
interventions including a consideration of side effect profiles and patient acceptability.  
 
9.6 Conclusion 
Abnormal ductus venosus Doppler showed moderate predictive accuracy for 
compromise of fetal/neonatal wellbeing and perinatal mortality in high risk pregnancies 
with placental insufficiency.  
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CHAPTER 10: SUMMARY OF REVIEWS OF TEST 
ACCURACY FOR PREDICTION OF SMALL FOR 
GESTATIONAL AGE FETUSES AND NEONATAL/FETAL 
COMPROMISE  
 
10.1 Abstract 
 
10.1.1 Background 
In 2002 the ROCG published an evidence based guideline on “The Investigation and 
Management of the Small for Gestational Age Fetus”. This guideline was developed 
using robust guideline methodology however, the recommendations were limited due to 
a lack of systematic collation of diagnostic information on the subject. Since this time 
Obstetrics has seen rapid growth in the development of new tests in the area of FGR 
particularly advances in ultrasound imaging and first trimester screening. The aim of 
this review is to summarise the systematic reviews performed with the objective of 
improving our understanding of the accuracy of the tests available to identify 
pregnancies at greatest risk of developing clinically relevant intrapartum and neonatal 
consequences of impaired fetal growth. 
 
10.1.2 Methods 
The accuracy of nine tests for prediction of fetal growth restriction and compromise of 
fetal wellbeing was evaluated. Tests were reviewed for test accuracy according to 
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prospective protocols including assessment of a study‟s methodological and reporting 
quality and bivariate meta-analysis to synthesise data. The main outcome measures were 
positive and negative likelihood ratios with 95% confidence intervals. 
 
10.1.3 Results 
In total 1,157 papers were read in full with 337 included in the reviews with 472,544 
women tested. The median number of women included was 33,292 (interquartile range 
13,273-40,637). The median number of studies per test was 60 (interquartile range 31-
86). The quality of studies was variable as shown in figure 10.1 with the overall quality 
being poor. The main deficiencies were in the areas of description of the index test and 
reference standard, blinding of the reference standard and reporting of any intervention in 
between the index test and reference standard. The tests overall for prediction of small 
gestational age and adverse perinatal outcome demonstrated low predictive accuracy with 
no tests having a positive LR>5 and a negative LR<0.5. 
 
10.1.4 Conclusion 
The results show that the tests reviewed have a limited use in screening/diagnosis for 
these conditions when used in isolation but that special consideration has to be given to 
the prediction of particular conditions and in particular at risk groups.
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10.2 Introduction 
As discussed in chapter 2, fetal growth restriction is one of the commonest 
complications to affect pregnancies and represents a major cause of perinatal morbidity 
and mortality
7;8
. Birth weight remains a significant predictor of perinatal outcome even 
when other factors such as maternal obstetric complication and gestation are taken into 
account
109
. There are various definitions for fetal growth restriction including absolute 
birth weight thresholds and centile thresholds to classify the small for gestational age 
baby however both definitions are associated with an increased risk.  
 
By definition however, babies born with a birth weight less than the 10
th
 centile will 
constitute 10% of the population and not all these babies will have an increased risk of 
morbidity and mortality. The aetiology of fetal growth restriction is also diverse with 
intrinsic fetal causes, maternal causes and placental causes. The challenge is thus to 
determine which tests available to Obstetricians antenatally will help to determine the 
fetus that will be small for gestational age but also compromised either in utero or at 
birth affording the option for intervention using effective treatment or timely delivery.  
 
Currently screening and diagnosis of fetal growth restriction and prediction and 
monitoring for compromise of fetal wellbeing in a clinical setting includes a 
combination of patients‟ characteristics, symptoms, physical signs and tests, which form 
the basis of clinical care
21
. For instance, methods employed to screen for and detect 
FGR might include obtaining previous history of small babies, recording symphyseal 
fundal height on a customised growth chart and estimating fetal weight with 
ultrasound
21
. Similarly, current history of fetal movements, abdominal palpation to 
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assess liquor volume, ultrasound amniotic fluid index, Doppler flow velocimetry and 
cardiotocography might be used to assess fetal wellbeing
21
 . Tests of wellbeing are 
aimed at predicting fetal acidaemia, which is perceived, at least in the model of chronic 
placental failure, to lead ultimately to organ damage and death. Data from cord blood 
sampling studies confirm there is a correlation between cord pH and 
neurodevelopmental outcome in small fetuses
22-24
.  
 
In 2002 the ROCG published an evidence based guideline on “The Investigation and 
Management of the Small for Gestational Age Fetus”21. This guideline was developed 
using robust guideline methodology however, the recommendations were limited due to 
a lack of systematic collation of diagnostic information on the subject. Since this time 
Obstetrics has seen rapid growth in the development of new tests in the area of FGR 
particularly advances in ultrasound imaging and first trimester screening
3
. 
 
The aim of this chapter is to summarise the systematic reviews performed with the 
objective of improving our understanding of the accuracy of the tests available to 
identify pregnancies at greatest risk of developing clinically relevant intrapartum and 
neonatal consequences of impaired fetal growth. 
 
10.3 Methods 
The methods for the systematic reviews are detailed in chapter 4 with details pertaining 
to the individual reviews in the relevant chapters (chapter 5-9). In all reviews bivariate 
meta-analysis and sub-group analysis was employed. For the reviews of tests performed 
in the first and/or second trimester [Down‟s syndrome serum markers (chapter 5) and 
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uterine artery Doppler (chapter 6)] a clinical application with aspirin was explored. In 
the review on umbilical artery Doppler (chapter 7), there were sufficient studies to allow 
meta-regression analysis to explore heterogeneity. 
 
10.4 Results 
10.4.1 Summary of literature identification and study selection 
Table 10.1 summarises the process from search to inclusion of papers in the five 
systematic reviews. In total 1157 papers were read in full with 337 included in the 
reviews with 472,544 women tested. The median number of women included was 
33,292 (interquartile range 13273-40637). The median number of studies per test was 
60 (interquartile range 31-86). 
 
10.4.2 Summary of study quality 
The quality of studies was variable as shown in figure 10.1 with the overall quality 
being poor. The main deficiencies were in the areas of description of the index test and 
reference standard, blinding of the reference standard and reporting of any intervention 
in between the index test and reference standard.
  
 
 
1
3
2
 
  
Table 10.1: Process from initial search to final inclusion for accuracy reviews 
 
a 
Search until April 2006 
b 
Search until March 2009 
c 
Search until May 2009 
d 
Search until February 2007 
e 
Other reasons for exclusion include duplicate publication, paper or translation unobtainable or case control studies for some reviews, no threshold SGA 
*  Where marked this includes papers excluded as no 2x2 table could be constructed 
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Figure 10.1: Quality of all tests reviewed for prediction of small for gestational age fetuses and compromise of fetal/neonatal 
wellbeing. 
35
274
241
200
69
336
16
127
337
337
317
337
302
308
334
3
25
51
75
34
0
320
209
0
0
11
0
26
8
0
299
38
45
62
234
1
1
1
9
9
21
3
0% 20% 40% 60% 80% 100%
Intervention
Withdrawals from study explained
Intermediate results explained
Availiability of clinical data
Blinding of reference test
Blinding of index test
Adequate description of reference standard
Adequate description of index test
Independant reference standard
Number of reference standards used
Verification bias absent
Time period between tests acceptable
Appropriate reference standard
Selection criteria described
Population spectrum appropriate
Yes
No
UnclearQ
ua
lit
y I
te
m
Percentage compliance
(numbers on bars represent absolute values, notes some studies may be included twice as in several reviews)
  
134 
 
Areas where methodology was of a high quality were in the selection of patients, use of 
an appropriate reference standard and in achieving >90% verification. In all reviews the 
meta-analysis was hampered by the lack of clear reporting and methodological quality 
reducing the number of studies that could be included in the analysis.  
 
One major criticism of the included studies in all reviews was the choice of reference 
standards used for determination of fetal growth. The protocol for the test accuracy 
reviews (chapter 4) allowed the inclusion of results from any reference standard as long 
as there was an appropriate population, index test and extractable 2x2 data. However, the 
majority of included studies used population based indices and usually birth weight <10
th
 
centile, no studies used customised charts. Indices that are said to be more indicative of 
nutritional status such as ponderal index were rarely reported and were not reported often 
enough to be used in any of the meta-analyses. 
 
10.4.3 Summary of test accuracy findings 
Figures 10.2 and 10.3 show the final summary results for the tests reviewed according to 
reference standard and population risk for prediction of small for gestational age fetuses 
and compromise of fetal/neonatal wellbeing respectively. These were the results that were 
considered for the decision analytic model (chapter 14). The tests overall for prediction of 
small gestational age fetuses and adverse perinatal outcome demonstrated low predictive 
accuracy with no tests having a positive LR>5 and a negative LR<0.5. 
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Small for gestational age fetuses 
 For Down‟s syndrome serum screening markers the predictive accuracy was low with 
improved prediction for severe forms of SGA (birth weight <5
th
 and 3
rd
 centiles). For 
uterine artery Doppler the predictive accuracy was again low with improved prediction 
for more severe forms and when looking at individual Doppler indices (pulsatility index 
with or without notching and resistance index). Umbilical artery Doppler showed 
improved prediction in a high risk population and for birth weight <3
rd
 centile. Middle 
cerebral artery Doppler showed improved prediction in unselected versus high risk 
populations. 
 
Adverse perinatal outcome 
Umbilical artery Doppler showed moderate predictive accuracy in a high risk population 
with moderate prediction of intra-uterine death, acidosis and admission to neonatal 
intensive care unit. Middle cerebral artery Doppler showed low predictive accuracy with 
improved prediction in unselected populations. Ductus venosus Doppler showed 
moderate predictive accuracy in a high risk population in particular for prediction of 
perinatal mortality. 
 
Despite sub-group analysis there was significant unexplained heterogeneity in most cases 
this affected the interpretation of the results and confidence in the predictive ability of the 
tests under review. In all of the reviews sub-group analysis could be performed based on 
population risk thus allowing an assessment of test accuracy across different populations. 
This has been translated into different decision analytic models according to population 
risk (chapter 14) and allowed recommendations for clinical practice. 
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The significant unexplained heterogeneity led to the decision to re-analyse all data using 
the bivariate method as this accounts for this type of heterogeneity in its random effects 
model.  
 
Tests performed in the first and second trimester to screen for SGA (Down‟s syndrome 
serum markers and uterine artery Doppler) showed high specificities (>90% for some 
indices) and very low sensitivities (<25%). There was wide variation in the precision of 
the estimates. Tests performed in later pregnancy for the diagnosis of SGA (umbilical 
artery and middle cerebral artery Doppler) showed improvement in the sensitivity 
estimates (0.29-0.55 depending on risk of population) but with a decrease in the 
specificity estimates (0.74-0.92). Tests performed in later pregnancy to diagnose 
compromise of fetal wellbeing (umbilical, middle cerebral and ductus venosus Doppler) 
showed better sensitivities (0.25-0.65) but with a decrease in specificities (0.8-0.84). 
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Figure 10.2: Forest plot of accuracy estimates from all tests reviewed for prediction of small for gestational age fetuses (diamonds 
represent pooled results, squares individual studies) 
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Figure 10.3: Forest plot of accuracy estimates from all tests reviewed for prediction of fetal/neonatal compromise (adverse 
perinatal outcome) (diamonds represent pooled results, squares individual studies. 
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10.5 Discussion  
The results show that the tests reviewed have a limited use in screening/diagnosis for 
these conditions when used in isolation but that special consideration has to be given to 
the prediction of particular conditions and in particular at risk groups. The strength of the 
evidence lies in the methodology and rigorous statistical analysis using contemporary 
methods.  
 
Limitations arising from problems with primary data 
The interpretation of the results presented must take into account the deficiencies 
identified in study quality and the association between design quality and diagnostic 
performance
51;75
. There was rigorous assessment of methodological and reporting quality 
for all included studies and appropriate assessment to take into account the unique 
situation of screening for conditions in pregnancy that cannot be verified by a reference 
standard until the end of the pregnancy e.g. blinding of index test assessment from results 
of reference standard was always considered to have occurred. Thus when assessing 
whether a study was of high quality special consideration was given to those aspects of 
design/reporting that were felt to have potentially more impact on test accuracy e.g. 
blinding of reference standard, description of index test and reference standard. Despite 
research being performed to study the effect of study methodology and reporting on 
accuracy estimates there has been no research done in the specific area of obstetrics
51;75
. 
The decisions as to which items of quality were the most important had to be made based 
on clinical and epidemiology experience. This deficiency in the published literature has 
been addressed in chapters 11 and 12.  
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Due to lack of clarity in the description of included populations it was not always possible 
to adequately identify populations as high or low risk and this has implications for any 
future recommendations for practice. The same can be said for the lack of adequate 
description of index and reference standards. One significant deficiency was the lack of 
use of reference standards such as ponderal index, this leads to the conclusion therefore 
that the results as shown in figure 10.2 relate to prediction of small for gestational age not 
fetal growth restriction. This is a major limitation in the use of these tests in clinical 
practice as the ideal test would discriminate between those fetuses that are small for 
gestational age from those that are growth restricted allowing intervention in the latter 
group only. To determine which fetuses might benefit from intervention the clinician 
would need to look at the tests performed in later pregnancy for diagnosis (umbilical, 
middle cerebral artery and ductus venosus Doppler) of adverse perinatal outcome. In 
many studies there was also a lack of description of the use of any treatment throughout 
the course of the pregnancy e.g. giving aspirin to test positive patients with abnormal 
uterine artery Doppler or early elective delivery in those with abnormal ductus venosus 
Doppler. This meant that it was impossible to assess for the risk of treatment paradox, this 
however has to be interpreted in the light of the data presented in chapter 13 showing that 
treatments in this area are not proven to be effective. 
 
Sub-group analysis was limited due to the number of included studies in each of the 
reviews limiting the number of patients within each sub-group. While the majority of 
heterogeneity could be accounted for by sub-group analysis looking at population risk or 
particular reference standard it was not possible to account for all possible confounding 
factors and often the author of the primary papers definition of risk had to be relied upon 
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as there was insufficient information about the included populations to discriminate. 
Ideally meta-regression analysis as performed in the review of umbilical artery Doppler 
(chapter 9) would have been performed in all reviews to explore the heterogeneity but the 
number of studies with each variable precluded this and would have meant that the meta-
regression was underpowered
110
. 
 
The data analysed within these reviews was also limited due to potential diagnostic 
confounding by other diagnostic information e.g. patient history, obstetric risk profile, 
and other test results. This information from the clinical history as well as other test 
results all contains diagnostic information as well as that obtained from the test under 
investigation. Confounding occurs when there is a relationship between the 
predictive/diagnostic capabilities of the different measures so that it is difficult to assess 
the actual independent predictive value of the test under investigation. The issue of 
diagnostic confounding can be dealt with in two ways – multivariable analysis of the 
primary study data or individual patient data meta-analyses (IPD)
111
. These techniques 
require considerable extra resources and time which was outside the scope of this work. 
In an attempt to counteract this potential confounding, patient groups that were as 
homogenous as possible for these characteristics were created for the analysis. 
 
The included studies reported many different test thresholds which limited the summaries 
of test accuracies that could be generated. To account for this the bivariate method was 
employed which estimates the correlation in sensitivity and specificity due to threshold 
effect as well as accounting for unexplained statistical heterogeneity. Many studies 
provided estimates of more than one diagnostic indicator for each individual patient (e.g. 
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uterine artery Doppler results for resistance index and pulsatility index) this meant that a 
valid statistical comparison of the accuracy of the different diagnostic indicators within 
tests as the compared study samples were not statistically independent. 
 
Limitations arising from review methods 
As demonstrated in table 2.1, chapter 2 there is a wide range of tests available in the 
literature for prediction of fetal growth restriction and compromise of fetal wellbeing. 
While there is published evidence relating to these tests the majority of them are not used 
in clinical practice. For the purpose of this thesis the tests chosen for review of test 
accuracy were selected on the basis of opinion of the research team and expert clinical 
opinion from experts within the field of Fetal medicine known to the researchers. There 
was then consideration of the evidence already published to determine the tests where the 
evidence either did not exist or it needed updating (appendix 1). Ideally a Delphic survey 
of practice would have been performed. This technique involves the collection and 
aggregation of expert opinion using questionnaire rounds, feed-back responses and the 
opportunity for participants to modify their responses and anonymity of responses
112
. 
Whilst the scientific merit and validity of this technique has been questioned it can be 
useful where there is no conclusive evidence available by relying on and sharing expert 
opinion
113;114
.  
 
To increase the number of studies that could be included in analysis a composite outcome 
measure was employed as discussed in 4.2.3. It is recognised that one of the hazards of 
composite outcome measures is the assumption that the significance of the result applies 
to all components
49
. To address this issue a separate analysis was also performed using 
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the component outcomes of the composite outcome measure with care taken to ensure 
that each individual was only counted once in each analysis. While the use of composite 
outcome measures is an accepted technique in systematic reviews as long as the direction 
of effect for each of the included outcomes is in the same direction and separate analysis 
is performed looking at the individual components
50
, it must be accepted that ideally 
individual reference standards would be used to reduce heterogeneity due to the varying 
components of the composite. 
 
Limitations arising from things not done 
As demonstrated in appendix 1 there were some tests where too few studies were 
identified to make a review worthwhile considering the restraints on time and resources. 
Conversely in some of reviews the relatively large number of studies identified (uterine 
and umbilical artery Doppler) meant that these reviews required a lot of time to extract all 
the data and ensure that appropriate meta-analysis was performed. This meant that two 
reviews that were planned to be completed as part of this thesis had to be postponed to be 
completed at a later date as it was felt that to assign the correct amount of time to 
complete them would have been to the detriment of the other parts of this thesis namely 
the effectiveness reviews and the decision model analysis. These two reviews looked at 
amniotic fluid measurements and the biophysical profile and after the searches had been 
performed and inclusion of papers had been completed there were 115 and 62 papers 
included respectively. It is recognised that these are two important tests that are 
performed in clinical practice where there is suspected FGR or fetal compromise and that 
any guidelines on management of these clinical problems must include the evidence 
available on the use of these tests
115;116
. Ideally if time had allowed a test accuracy review 
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looking at combination testing using Down‟s syndrome serum markers and uterine artery 
Doppler in combination in the same patient would also have been performed. 
 
As discussed above ideally the analyses would have been limited to high quality studies 
and techniques such as meta-regression and multivariable analyses would have been 
performed but the small number of studies per test/variable and the poor 
reporting/methodological quality of included studies meant that these methods could not 
be employed. 
 
There have also been developments in meta-analytic techniques since these reviews were 
performed such as the calculation of the estimated predictive interval which relates to the 
effect of a new study that would be eligible for inclusion in the meta-analysis and 
therefore allows the full uncertainty around inferences to be calculated, including both 
magnitude and consistency
117
. 
 
Findings in the light of these limitations 
The reviews performed present the best available evidence for the value of these tests in 
the prediction of small for gestational age fetuses and compromise of fetal/neonatal 
wellbeing at the time of completing the work. Although substantial limitations can be 
identified, mainly in the quality and quantity of the available primary evidence it can be 
concluded that overall the tests reviewed have limited value in the prediction of small for 
gestational age and compromise of fetal wellbeing. However, the true value of a test has 
to be assessed in light of its use in the clinical pathway – is it to be used for 
screening/prediction or diagnosis? What actions will be taken on the basis of a positive 
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result – will further testing be offered or will treatment be implemented? What is the 
effectiveness of available treatments? (chapter 13). These questions will be considered in 
the decision-analytic model in chapter 14.  
 
Recommendations for research 
As no one test had proved to be accurate for either screening or diagnosis there is a need 
for further primary research to look at new markers and tests for FGR and fetal 
compromise. Once identified from primary laboratory studies these tests should be 
investigated with robustly designed diagnostic accuracy studies that must include a 
sample size calculation to ensure sufficient statistical power to estimate test sensitivity 
and specificity/likelihood ratios precisely in study groups as a whole and in clinically 
relevant subgroups
118;119
. Future research should look at the place of these tests in the 
clinically pathway and assess them for their added value to clinical data obtained from 
history or examination (risk profile) using appropriate statistical analysis.  
 
Future systematic reviews in this area should consider the use of a Delphic survey of 
practice to identify the tests to be examined. These reviews should also ideally use 
individual patient data meta-analysis to help overcome the problems of unclear reporting, 
composite outcome measures, appropriate sub-group analysis and diagnostic 
confounding. There is a need for systematic review of the evidence for combination 
testing in this clinical area. It is likely however that any such review will be hampered by 
the same limitations and potential for bias as the test accuracy reviews of individual tests 
performed as part of this work. 
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Considerations for future research 
A test with perfect accuracy would have a sensitivity of 100% and a specificity of 100% 
i.e. no false negatives nor false positives. In reality these perfect tests do not exist and 
tests are designed with an accepted error rate based on the nature of the test, the disease 
under investigation and the consequences of a false positive or false negative test result. 
This error will take into account the nature of the correlation between sensitivity and 
specificity i.e. that as sensitivity increase the specificity will decrease and vice versa. 
 
For FGR and compromise of fetal wellbeing one must consider the implications of a false 
negative and false positive result to determine what levels of sensitivity and specificity 
might be acceptable. In current clinical practice a false positive result will lead to 
increased surveillance of the pregnancy (e.g. growth scans, Dopplers) and the potential 
interventions of aspirin and early delivery. While there may be an increase in anxiety for 
the mother and inconvenience due to the enhanced surveillance the treatments are not 
associated with serious side effects. There may potentially be a side effect to the fetus of 
iatrogenic prematurity from early delivery with false positive tests for wellbeing later in 
pregnancy. With a false negative result, women and clinicians are falsely reassured that 
the fetus is not at risk of being growth restricted or its wellbeing compromised and thus 
the increased surveillance and treatments are not implemented. This fetus is thus at 
increased risk of perinatal morbidity and mortality as well as the longer term implications 
for its infant and adult life. Thus it can be argued on balance that for FGR and 
compromise of fetal wellbeing a test should have a level of accuracy that has an error rate 
with a preference for a low number of false negative results i.e. a high sensitivity. The 
relationship between preference for low false positives and negatives and whether 
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sensitivity or specificity most reduces error rate is also influenced by the frequency of 
disease. The ideal requirements of a test for a particular disease/condition can be further 
refined by considering the costs of the tests and treatments that might be instituted via 
modelling (chapter 14). Any new test can thus be assessed for its added value to the 
existing antenatal care system and how its implementation will reduce the number of 
unwanted screening errors. 
 
10.6 Conclusion 
The results show that the tests reviewed have a limited use in screening/diagnosis for 
these conditions when used in isolation but that special consideration has to be given to 
the prediction of particular conditions and in particular at risk groups. The main 
implications are thus not for recommendations for practice but for future research.
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PART B: METHODOLOGICAL 
RESEARCH INTO THE EFFECTS 
OF REPORTING AND 
METHODOLOGICAL QUALITY OF 
SYSTEMATIC REVIEWS OF TEST 
ACCURACY 
 
  
149 
 
CHAPTER 11: THE QUALITY OF REPORTING OF 
PRIMARY TEST ACCURACY STUDIES IN OBSTETRICS 
REVIEWED IN THIS THESIS: APPLICATION OF THE 
STARD CRITERIA. 
 
11.1 Abstract 
 
11.1.1 Background 
In obstetrics there has been a rapid growth in test accuracy studies.  It is important that 
the reporting of these studies is transparent so that a valid assessment of the reported 
results can be made. The purpose of this study was to determine the quality of reporting 
in diagnostic test accuracy studies in obstetrics using the Standards for Reporting of 
Diagnostic Accuracy – STARD checklist. 
 
11.1.2 Methods 
The included studies of seven systematic reviews were assessed for reporting quality 
using the STARD checklist. The compliance with each of the reporting criteria was 
assessed. Using appropriate statistical tests it was investigated whether there was an 
improvement in reporting quality since the introduction of the STARD checklist, 
whether a correlation existed between study sample size, country of origin of study and 
reporting quality.  
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11.1.3 Results 
A total of 195 studies were included. The overall reporting quality of included studies to 
the STARD criteria was poor. The studies reported adequately >50% of the time for 
62.1% (18/29) of the items. There was a positive correlation (p<0.0001) between study 
sample size and reporting quality. No correlation between geographical area of 
publication and compliance with the reporting criteria could be demonstrated. 
 
11.1.4 Conclusions 
The reporting quality of papers in Obstetrics is improving. This may be due to 
initiatives such as the STARD checklist as well as historical progress in awareness 
among authors to accurately report studies. There is however considerable scope for 
further improvement.  
 
11.1.5 Publications arising from this work 
Selman TJ, Morris RK, Zamora J, Khan KS. The quality of reporting of primary test 
accuracy studies in Obstetrics and Gynaecology: application of the STARD criteria. 
BMC Women’s Health 2010 (In press). 
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11.2 Introduction 
In obstetrics there has been a rapid growth in the development of new tests and primary 
studies of their accuracy.  These studies generate a comparison of the result from an 
index test against an accepted reference standard or outcome measure
4
. The accuracy of 
the index test is usually expressed as sensitivity and specificity or other measures like 
the diagnostic odds ratio (DOR), likelihood ratio (LR) or area under a receiver-operator 
characteristics curve
5
. These allow clinicians to judge the usefulness and suitability of 
testing in clinical practice. It is imperative that such studies are reported with 
transparency allowing the detection of any potential bias that may invalidate the 
results
120;121
. Guidelines for the reporting of other study types have widely been 
accepted e.g. CONSORT
122
 for randomised control trials.  There has been a format for 
reporting evaluations of tests called Standards for Reporting of Diagnostic Accuracy – 
STARD
34
, introduced in 2003.   
 
The object of the STARD initiative is to improve the reporting of test accuracy studies 
to allow for the detection of potential bias in a study and to make a judgement on the 
applicability of the index test results. One of the benefits of using the STARD initiative 
is to develop a consistent reporting format across all types of tests.   The STARD group 
identified 33 previously published checklists for diagnostic research.  From an initial 75 
point check list a consensus meeting formulated a 25 point list that could be employed 
to accuracy studies.  This list was designed to help readers judge the studies and to act 
as a study design tool for authors.  Points were specifically chosen on evidence 
supporting their ability to show variations in measures of diagnostic accuracy
34
.   
Further supplementing the checklist was flow diagram which aids the assessment of the 
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study population, the recruitment method and indicates the numbers receiving the index 
test, those excluded and those compared with the reference standard at different stages 
of the study.  STARD should allow a reader to critically appraise the study design, 
analysis and results.   
 
Previous studies have looked at the impact of STARD in specific clinical areas
123-127
 
with varying outcomes and the overall quality of reporting of studies which was 
generally found to be poor. There is no published research looking at the impact of 
STARD in Obstetrics. 
 
This chapter aims to assess the reporting quality of test accuracy studies in obstetrics 
that form part of this thesis and the impact of the STARD statement. 
 
11.3 Methods 
A protocol to assess the impact of STARD on studies included in seven systematic 
reviews performed over the period 2005-2007, as part of this thesis, was developed. The 
studies covered the time period 1977-2007. The included reviews assessed the accuracy 
of Down‟s syndrome serum screening markers and uterine artery Doppler to predict 
small for gestational age fetuses in obstetrics
 
(chapters 5 and 6)
128;129
. These reviews 
were chosen as they had all been performed by the author who had received training in 
use of the STARD checklist and had reached a consensus a priori as to how compliance 
with the checklist should be assessed for each review. The STARD checklist was 
applied to each of the studies included in all the reviews with the reporting item being 
determined as either present, absent, unclear or not applicable (appendix 3). All studies 
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were assessed in duplicate by the author and a second reviewer (Dr Tara Selman) who 
had received the same training and been involved in the discussions as to how 
compliance would be assessed, where there was disagreement consensus was achieved 
following assessment by a third reviewer (Professor Khalid Khan). In the event that 
several tests had been applied to the same patient, the results including the largest 
number of patients were used in the study or where there was no difference, one index 
test was selected at random, this ensured patients were only included once.   
 
The following questions were addressed: Has the introduction of STARD improved 
reporting quality?; does study size correlate with reporting quality?; is there a 
geographical pattern to reporting quality?; is there a relationship between reporting 
quality and methodological quality?. The percentage compliance of studies with 
STARD items was compared before and after the introduction of STARD and over time 
using the unpaired t test to assess the effect of STARD on the reporting quality of 
studies.  With the publication of STARD in 2003 the assumption was made that all 
studies published pre 2004 were published without the benefit of this directive.  
 
The relationship between sample size and compliance with STARD was examined 
using Spearman‟s rank correlation coefficient (Rho). Kruskal Wallis was used to 
investigate any relationship between geographical distribution and reporting quality. 
The country of origin of a study was determined by the country of the corresponding 
author. Where a significant result was found, pairways comparison was made using 
Conover Inman. Countries were grouped depending on the number of articles published 
and the mean journal impact factor and adjusted for gross domestic product and 
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population, based on a previous publication
130
. Where there was a large disparity in 
number of studies per geographical area, some studies were re grouped to avoid large 
differences in group size and potentially spurious results.  The geographical areas were 
Oceania, USA, Canada, Asia, Japan, Africa, Eastern Europe and Western Europe.  
 
In the initial analysis those reporting items coded as unclear and not applicable were 
excluded. For all of the above analysis, due to the uncertainty of whether reporting 
items coded as unclear represented methodological failure, sensitivity analysis was 
performed excluding this code and adding it to the not reported group for all 
comparisons. Similarly sensitivity analysis was also performed to assess the effect of 
those items assessed as not applicable, with their initial exclusion to the analysis and 
then addition as if they were reported so as not to penalise studies which had a larger 
number of not applicable items and would therefore potentially have a seemingly lower 
compliance with STARD. 
 
11.4 Results 
A total of 195 studies were identified and included in this analysis (figure 11.1).  82% 
(160/195) were published prior to the STARD initiative. The overall percentage 
compliance with individual reporting items is shown in table 11.1. The included studies 
reported adequately >50% of the time for 62.1% (18/ 29) of the items as assessed in this 
review. Items where reporting was uniformly poor ( <50%) were participant sampling, 
description of technique of reference standard, description of expertise of people 
performing index and reference standard, blinding of results of index test to those 
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interpreting reference standard, assessment of test reproducibility, tabulation of results 
and description of adverse events.  
 
Figure 11.1: Process from initial search to final inclusion for papers from obstetric 
systematic reviews for assessment of compliance with STARD. 
 
There was significant improvement in the reporting quality of studies after the 
introduction of STARD (p=0.0004). Figure 11.2 shows the trend in compliance with the 
STARD criteria over time. Analysis of the correlation between sample size and 
compliance with STARD revealed a positive correlation (Rho = 0.37, p = <0.0001) 
(figure 11.3). Investigation in to the relationship between geographical area of 
publication and the compliance with STARD showed no relationship (Kruskal-Wallis 
5.05 p=0.65) figure 11.4. Sensitivity analysis showed no significant difference in any of 
the results. 
       
 
Primary articles included       n= 195 
 
Total number of patients included                  n= 433,588 
 
 
Number of systematic reviews included   n=7 
 
Potentially relevant citations identified from   n= 20,167 
electronic searches for these reviews 
      
 
Total number of 2x2 tables included in reviews n=574 
 
2x2 tables excluded due to duplication  
 n=379 
Of patients       
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Table 11.1: Percentage compliance with individual STARD criteria for included 
test accuracy studies in obstetrics. 
STARD 
item 
Description Percentage compliance obstetric 
studies (%) 
1 Article is identified as study of diagnostic 
accuracy 
27.2 
2 States research question/aims 94.9 
3 Describes study population 74.4 
4 Describes participant recruitment 85.1 
5 Describes participant sampling 36.4 
6 Describes index standard 59.5 
7 Describes reference standard 86.7 
8a Describes technique of index test 45.1 
8b Describes technique of reference standard 0 
9a Describes cut-off for index test 96.9 
9b Describes cut-off for reference standard 75.9 
10a Describes persons executing index test 8.2 
10b Describes persons executing reference 
standard 
0 
11a Were results of index test blinded? 100 
11b Were results of reference test blinded? 8.2 
12 Describes methods for statistics used 53.3 
13 Describes methods for calculating test 
reproducibility 
12.3 
14 Reports dates of study 65.1 
15 Reports characteristics of study population 67.2 
16 Reports number of eligible patients that 
did not undergo either test 
69.2 
17 Time interval between tests and any 
treatment 
11.8 
18 Reports distribution of severity of disease 86.7 
19 Reports cross tabulation of results 49.2 
20 Reports adverse events 0 (100% not applicable) 
21 Reports estimates of diagnostic accuracy 54.4 
22 Reports how missing results were handled 63.6 
23 Reports estimates of variability of 
accuracy 
56.4 
24 Reports estimates of test reproducibility 12.8 
25 Discuss clinical applicability of findings 99.5 
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Figure 11.2: Bar chart showing mean percentage compliance of studies with 
STARD criteria, line shows trend over time. 
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Figure 11.3: Scatter plot showing total compliance with STARD reporting criteria 
according to sample size. 
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Figure 11.4: World map showing mean percentage compliance of studies with STARD according to geographical area of 
publication. 
Canada
56.3% n=8
USA
49.7% n=44
Western Europe
49.1% n=104
Eastern Europe
51.7% n=16
Asia
49.3% n=8
Japan
50% n=7
Oceania
56.3% n=8
Africa
66.7% n=1
Countries were grouped depending on the number of articles published and the 
mean journal impact factor and adjusted for gross domestic product and 
population. Percentage compliance for obstetrics, n=number of studies
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11.5 Discussion 
The reporting of included studies in this review overall was poor.  The geographical 
origin had no effect on the reporting quality; however the study size showed a positive 
correlation. There has been a trend in improvement in reporting quality. This may be 
due to initiatives such as the STARD checklist as well as historical progress in 
awareness among authors of the need to accurately report studies. There is however still 
significant room for improvement.  
 
There was poor compliance with STARD in many of the studies in this review, in many 
studies it was unclear whether the study complied with the reporting item. This lack of 
clarity could potentially affect the inferences, but in other fields it is well known that 
unclear reporting is associated with bias
131
.  The studies were limited to a subset of 
conditions within these fields. It is likely that these results can be translated across 
obstetrics, however care should be taken as to the generalisability of this study. 
 
Poor reporting of a study does not necessarily correlate with bad quality. This is 
evaluated in chapter 12.  Accurate reporting is necessary to allow transparency of a 
study and to ensure the results are interpreted correctly. The application of the STARD 
checklist may help prevent the implementation of unnecessary or inaccurate tests which 
can lead to unnecessary financial expenditure and potentially serious consequences for 
patients.   
 
 
 
  
160 
 
11.6 Conclusion 
The reporting quality of papers in Obstetrics is improving. This may be due to 
initiatives such as the STARD checklist as well as historical progress in awareness 
among authors to accurately report studies. There is however considerable scope for 
further improvement. 
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CHAPTER 12: METHODOLOGICAL QUALITY OF TEST 
ACCURACY STUDIES INCLUDED IN SYSTEMATIC 
REVIEWS IN OBSTETRICS REVIEWED IN THIS THESIS: 
SOURCES OF BIAS. 
 
12.1 Abstract 
12.1.1 Background 
In obstetrics there has been a rapid growth in the development of new tests with 
research on these presented as test accuracy studies.  It is important that the 
methodology of these studies is such that the potential for bias is minimised. The 
purpose of this study is to determine the methodological quality of test accuracy studies 
in obstetrics using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) 
checklist and to assess sources of bias. 
 
12.1.2 Methods 
The included studies of seven systematic reviews, performed as part of this thesis were 
assessed for methodological quality using the QUADAS checklist. The compliance with 
each one of the QUADAS criteria was assessed. Using appropriate statistical tests it was 
investigated whether there was an improvement in study quality since the introduction 
of the QUADAS checklist, whether a correlation existed between study sample size, 
country of origin of study and its quality. This study also investigated whether there was 
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a correlation between reporting and methodological quality and by the use of meta-
regression analyses explored for items of quality that were associated with bias. 
 
12.1.3 Results 
A total of 195 studies were included. The overall quality of included studies was poor 
(>50% compliance with 57.1% of quality items). However, the mean compliance with 
QUADAS showed an improvement post-publication of QUADAS checklist (55.5% 
versus 59.2%), this did not however reach statistical significance (p=0.1). There was no 
correlation between study sample size and methodological quality. There was no 
association with country of origin and methodological quality. Meta-regression analysis 
showed that no individual quality item had a significant impact on accuracy. There was 
an association between reporting and methodological quality (r=0.51 p<0.0001).  
 
12.1.4 Conclusions 
A combination of poor methodological quality and poor reporting affects the inferences 
that can be drawn for test accuracy studies. Further compliance with quality checklists is 
required to ensure that bias is minimised. 
 
12.1.5 Publications arising from this work 
Morris RK, Selman TJ, Zamora J, Khan KS. Methodological quality of test accuracy 
studies included in systematic reviews in obstetrics and gynaecology: sources of bias. 
BMC Women’s Health 2010 (In press). 
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12.2 Introduction 
As discussed in chapter 11 obstetrics has seen rapid growth in the development of new 
tests
3
. For instance, tests designed to detect small for gestational age fetuses have grown 
in recent years
128;129
.  The reporting of the study should allow for the detection of any 
biases by providing a complete and transparent description of the study participants, 
methodology and results.  Guidelines for the reporting of other study types have widely 
been accepted e.g. CONSORT
122
 for randomised control trials and QUOROM
132
 and 
MOOSE
42
 for systematic reviews.  When studies of this type are incorporated in 
systematic reviews, assessment of their methodological quality is necessary to ensure 
that potential bias is identified and errors in judgement avoided. This allows 
methodological flaws that can lead to bias and sources of variation that might lead to 
heterogeneity to be identified. An evidence based methodological quality assessment 
tool has been developed for such assessments called Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS)
35
. The need for quality appraisal of included studies in 
systematic review has been recognised for many years, however how deficiencies in 
study quality should be addressed in meta-analysis is not as clear
48;133
. 
 
The QUADAS initiative provides an assessment tool for the quality of test accuracy 
studies required when using these in systematic reviews.  It combines empirical 
evidence and expert opinion into a checklist of 14 quality items. As these quality items 
should be adhered to and then reported in a study, they are directly and indirectly 
duplicated in the STARD checklist. Chapter 11 assesses the standard of reporting 
quality in obstetrics using the STARD checklist. Although gaps in reporting of quality 
item themselves do not necessarily mean that the methodological quality is poor, 
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interpretation is made difficult.  The use of one standard checklist for assessment of 
study quality in all diagnostic reviews should allow clinicians to make comparable 
assessment of different studies. Where previous studies have attempted to assess 
methodological or reporting quality of test accuracy studies, a strong relationship has 
been found between various quality items and test accuracy results
134
. This study aims 
to assess the impact of the QUADAS initiative on test accuracy studies in antenatal 
screening.  
 
12.3 Methods 
A prospective protocol was developed to assess the impact of QUADAS on seven 
systematic reviews performed over the period 2005-2007 as part of this thesis. The 
included reviews were reviews of Down‟s syndrome serum screening markers and 
uterine artery Doppler to predict small for gestational age fetuses in obstetrics
128;129
. 
These reviews were chosen as they had all been performed by the author who had 
received training in use of the QUADAS checklist and had reached a consensus a priori 
as to how compliance with the checklist should be assessed for each review. The 
following questions were addressed: What is the quality of studies in this field? Did the 
introduction of QUADAS improve quality? Does study size correlate with quality? Is 
there a geographical pattern to quality? Is there a relationship between compliance with 
STARD and QUADAS?  Which quality items are associated with bias? 
 
The QUADAS checklist was applied to each of the studies included in all the reviews 
with the reporting item being determined as either present, absent, unclear or not 
applicable (appendix 4). All studies were assessed in duplicate by the author and by a 
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second reviewer (Dr Tara Selman) who had received the same training and been 
involved in the discussions to determine how compliance would be assessed. Where 
there was disagreement this was resolved by consensus with a third reviewer (Professor 
Khalid Khan). Results of individual studies were summarized in two by two tables from 
which the DOR was calculated as a measure of diagnostic accuracy
5
.  DOR is the odds 
of a positive result in a diseased person relative to the odds of a positive result in a non 
diseased person. In the case of zero entities in the two by two tables 0.5 was added to 
the cells to enable calculation of DOR
56
.  In the event that several tests had been applied 
to the same patient, the results including the largest number of patients were used in this 
study or where there was no difference, one index test was selected at random, this 
ensured patients were only included once. 
 
The percentage compliance of studies with QUADAS items was determined before and 
after the introduction of QUADAS using the unpaired t test to assess the effect of 
QUADAS on the methodological quality of studies.  With the publication of QUADAS 
in 2003 the assumption was made that all studies published pre 2005 were published 
without the benefit of this directorate.  
 
The relationship between sample size and compliance was assessed with QUADAS 
using Spearman‟s rank correlation coefficient (Rho). Kruskal Wallis was used to 
investigate any relationship between geographical distribution and reporting quality. 
The country of origin of a study was determined by the country of the corresponding 
author. Where a significant result was found, pairways comparison was made using 
Conover Inman. Countries were grouped depending on the number of articles published 
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and the mean journal impact factor and adjusted for gross domestic product and 
population, based on previous publication
130
. Where there was a large disparity in 
number of studies per geographical area, some studies were re grouped to avoid large 
differences in group size and potentially spurious results.  The geographical areas used 
were Oceania, USA, Canada, Asia, Japan, Africa, Eastern Europe and Western.  
 
If the standard of reporting of a study is poor then this can potentially limit the 
assessment of the quality of study design. To investigate the relationship between 
reporting and methodological quality, the studies‟ compliance with STARD and 
QUADAS was compared using Spearman correlation coefficient.  
 
The final analysis performed was a meta-regression analysis to assess which quality 
items were associated with bias.  Multiple logistic regression models were adjusted to 
test the effect of individual QUADAS quality items on diagnostic accuracy, measured 
as DOR. This methodology
135
 has been used successfully in demonstrating empirically 
the effect of bias related to methodological flaws in clinical trials
131;136;137
 and in 
diagnostic studies
75
.  The dependent variable in each logistic model was a binary 
variable representing disease status (diseased verses non diseased) from each meta-
analysis. The independent variables included a variable representing test threshold (i.e. 
the sum of logits of sensitivity and 1-specificity) ; a binary variable for test result 
(positive verses negative); indicator variables to control for the effect of the primary 
studies; terms for the “meta-analysis by test result” interaction to control for the 
different summary diagnostic odds ratios estimating diagnostic accuracy in the included 
meta-analysis; and the “QUADAS item (dichotomized as Yes verses all other) by test 
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result” interaction terms to analyze its association with estimates of diagnostic accuracy. 
The estimated effect of quality characteristic on average diagnostic accuracy is given by 
the coefficient of the QUADAS test result interaction, which estimates the log of the 
ratio of diagnostic odds ratios (RDOR) in studies with and without the quality item. 
Exponentiation of the coefficient yields the RDOR.  RDOR greater than 1 are 
interpreted as follows: those studies which fulfil the quality item overestimate test 
accuracy compared to those studies not fulfilling that item. RDOR lower than 1 means 
that those studies without the methodological quality characteristic overestimate 
diagnostic test performance. This effect is assumed to be constant across meta-analyses. 
Only meta-analyses that contained studies with and without the characteristic could 
contribute to this estimate. The RDOR was used as the summary measure of accuracy 
and dependant variable in the analyses as it is useful as a single indicator of test 
performance.  
 
In the initial analysis those quality items coded as unclear and not applicable were 
excluded. For all of the above analysis, due to the uncertainty of whether reporting 
items coded as unclear represented methodological failure, sensitivity analysis was 
performed excluding this code and adding it to the not reported group for all 
comparisons. Similarly sensitivity analysis was also performed to assess the effect of 
those items assessed as not applicable, with their initially exclusion to the analysis and 
then addition as if they were reported so as not to penalise studies which had a larger 
number of not applicable items and would therefore potentially have a seemingly lower 
compliance with QUADAS. 
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12.4 Results 
A total 195 studies were identified and included in this study (figure 11.1).   85.6% 
(167/195) of the studies were published prior to the QUADAS initiative. The overall 
percentage compliance with individual quality items is shown in figure 12.1. The 
included studies complied adequately >50% of the time for 57.1% (8/14) of the items 
assessed. Items where quality was uniformly poor (<50%) were an adequate description 
of the performance of the reference standard, reporting whether the reference test results 
were interpreted blind to the index test results and whether clinical data were available 
at the time of test interpretation. 
 
There was an improvement in the mean compliance with quality items after publication 
of the QUADAS checklist (55.5% versus 59.2%), this did not however which reach 
statistical significance (p=0.1). Analysis of the correlation between sample size and 
QUADAS revealed no correlation (Rho=0.14, p=0.06).  For these analyses sensitivity 
analysis as described in the methods section showed no significant difference. 
 
The mean compliance with QUADAS according to country of publication of study is 
shown in figure 12.2.  Investigation in to the relationship between geographical area of 
publication with QUADAS showed no association between compliance and area (p 
=0.73). In the meta-regression analysis only QUADAS item 3 (appropriate reference 
standard) had a marginal impact on diagnostic accuracy (p=0.05) with studies in which 
an inappropriate reference standards were used overestimated the diagnostic accuracy 
by 10%. The results are illustrated in figure 12.3.  
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All included papers were assessed for reporting standard and overall this was poor. The 
included studies reported adequately >50% of the time for 62.1% (18/ 29) of the items 
as assessed in this review. There was significant correlation between the percentage 
compliance of studies with STARD and QUADAS checklists (Rho=0.51, p=<0.0001) 
which is illustrated in figure 12.4. This figure shows that when studies had a higher 
standard of reporting it did not necessarily equate to improved quality of methods. 
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Fig 12.1: Bar chart showing percentage compliance with individual QUADAS criteria for included test accuracy studies in 
obstetrics. 
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Figure 12.2: World map showing mean percentage compliance of studies with QUADAS according to geographical area of 
publication. 
Canada
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Countries were grouped depending on the number of articles published and the 
mean journal impact factor and adjusted for gross domestic product and 
population. Percentage compliance for obstetrics, n=number of studies
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Figure 12.3: Effect of compliance with QUADAS quality item on the ratio of the diagnostic odds ratio in studies of test accuracy in 
obstetrics. 
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Figure 12.4: Scatter plot showing the level of agreement between the percentage 
compliance of test accuracy studies in obstetrics with the STARD and QUADAS 
check lists. 
 
 
12.5 Discussion 
This study showed that there was not statistically significant improvement in the 
methodological quality of test accuracy studies in obstetrics with the introduction of 
QUADAS. Unsurprisingly, due to the overlap in quality items between the two 
checklists there was a positive correlation between compliance with STARD and 
QUADAS.  Sample size showed no correlation with compliance. No correlation with 
Line of 
agreement 
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geographical area was seen. Meta regression did not show any significant correlation 
between compliance with QUADAS item and test accuracy. 
 
The strengths of this study lie in the large number of included studies and meta-
analyses, the continuity in assessment using the same two reviewers throughout and the 
use of tailored checklists to take into account the differences in studies in studies (e.g. 
the use of the not applicable category). Limitations to this study include the small 
proportion of included studies that were reported after publication of the QUADAS tool 
and the overall poor reporting standard of the included papers. As true assessment of a 
study‟s methodological quality relies on good reporting thus it must be concluded that 
the poor methodological quality of the papers in this review may actually reflect a 
combination of poor study design as well as poor reporting. The investigation into the 
effect of individual items of study quality on diagnostic accuracy could find no 
significant relationship between any individual quality item and accuracy. Although it 
was demonstrated that there was an improvement in methodological quality since the 
introduction of QUADAS it cannot be concluded that this improvement is due to the 
QUADAS initiative or due to other factors such as a historical progression in improved 
methodological techniques. 
 
Recommendations are that all future test accuracy studies adhere to the QUADAS 
guidelines and that when studies are being included in systematic reviews, reviewers 
must assess for reporting and methodological quality using the QUADAS items that are 
relevant to their study area and consider additional items where necessary. As adherence 
to QUADAS becomes more widespread, the effect of items of methodological quality 
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on diagnostic accuracy should be reassessed to enable clinicians to interpret the validity 
and generalisability of results. This type of research will also help to improve test 
accuracy study design. 
 
12.6 Conclusion 
A combination of poor methodological quality and poor reporting affects the inferences 
that can be drawn from test accuracy studies. Further compliance with quality checklists 
is required to ensure that bias is minimised. 
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PART C: REVIEW of SYSTEMATIC 
REVIEWS OF THE EVIDENCE ON 
EFFECTIVENESS OF AVAILABLE 
INTERVENTIONS FOR 
PREVENTION OF SMALL FOR 
GESTATIONAL AGE AND 
COMPROMISE OF 
FETAL/NEONATAL WELLBEING 
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CHAPTER 13: REVIEW OF SYSTEMATIC REVIEWS OF 
THE EXISTING EVIDENCE ON THE EFFECTIVENESS OF 
AVAILABLE INTERVENTIONS FOR PREVENTION OF 
SMALL FOR GESTATIONAL AGE FETUSES AND 
COMPROMISE OF FETAL/NEONATAL WELLBEING. 
 
13.1 Abstract 
13.1.1 Background 
Previous narrative reviews of effectiveness of interventions for fetal growth restriction 
have concluded that there are few interventions that are likely to be beneficial and that 
further high quality research is required. A review of systematic reviews of 
effectiveness for interventions for fetal growth restriction and compromise of fetal 
wellbeing was performed to summarise the most up to date evidence and assess the 
quality of the evidence.          
 
13.1.2 Methods 
Electronic searches of the following databases were performed: Medline, Embase, 
Cochrane Library, DARE (inception to July 2009), hand searching of journal and 
reference lists, contact with experts. Two reviewers independently selected articles 
which were systematic reviews of randomised controlled trials reporting on the 
effectiveness of interventions for prevention of fetal growth restriction and/or 
compromise of fetal wellbeing. Quality assessment for methodological quality and 
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reporting quality were assessed for the included reviews. There were no language 
restrictions applied. Data were extracted on study characteristics, quality and results to 
construct 2x2 tables. Summary data were presented as relative risks and their 95% 
confidence intervals for the different interventions.  
 
13.1.3 Results 
There were 71 systematic reviews included of which 69 were systematic reviews and one 
health technology assessment on screening and prevention of pre-term birth which included 
updated data for two Cochrane reviews. There were 4 non Cochrane systematic reviews. 
These articles included a total of 733 randomised controlled trials reporting on 42 different 
interventions. Forty –four reviews included outcomes for fetal growth reporting on 30 
different interventions. Sixty one reviews reported on outcomes for adverse perinatal 
outcome using a total of 15 different outcome measures. For perinatal mortality there were a 
total of 49 reviews reporting on the effectiveness of 30 different interventions. 
 
13.1.4 Conclusion 
After considering the results and the quality of evidence antiplatelets and multiple 
micronutrient supplements were the interventions that were considered to be effective in 
preventing the small for gestational age fetus and suitable for use in all pregnant 
women. For high risk pregnant women the following were considered to be effective: 
antiplatelets, multiple micronutrient supplements, smoking cessation interventions and 
progesterone therapy. For prevention/reduction of perinatal mortality antiplatelets and 
antenatal corticosteroids were the interventions shown to be effective. 
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13.2 Introduction 
Pregnancy and the period of intrauterine growth are a critical and vulnerable time in the 
life cycle of an individual. Fetuses that are born small for gestational age of low birth 
weight are known to be at increased risk of intrauterine death, peripartum asphyxia, 
neonatal morbidity and mortality and even in later life are at increased risk of adult 
diseases
8;11;12;138
. Low birth weight  may be born preterm or at term and within the low 
birth weight category are those  that are appropriately grown or “constitutionally small” 
and  that have failed to achieve their growth potential - the “fetal growth restriction” . 
When associated with prematurity the outcomes for the growth restricted category are 
worse
139
. 
 
Fetal growth restriction has a broad aetiology and may be classified as being due to 
fetal, placental or maternal causes. Fetal causes include chromosomal and structural 
anomalies, inborn errors of metabolism and congenital infections. Maternal factors are 
those that affect placental transfer e.g. low pre-pregnancy weight, under nutrition, 
substance abuse, severe anaemia. There are also maternal medical conditions that affect 
placental implantation and vasculature and hence transfer e.g. pre-eclampsia, 
autoimmune disease, thrombophilias, renal disease, diabetes and essential hypertension. 
Of all these factors pre-eclampsia is associated with the most severe impact on fetal 
growth
140
. 
 
The potential for a therapy to be effective thus depends on the nature of the underlying 
aetiology. A thorough assessment of the fetus and mother must be performed to identify 
those causes that will not be amenable to therapy i.e. chromosomal anomalies and in 
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those cases where therapy might be an option determine which may be the most 
appropriate. The major difficulties in this area are however the lack of accurate 
predictive and diagnostic tests for the growth restricted fetus and the potential for there 
to be more than one contributory aetiology e.g. pre-term labour and fetal growth 
restriction or fetal growth restriction and pre-eclampsia. 
 
Previous narrative reviews of effectiveness of interventions for fetal growth restriction 
have concluded that there are few interventions that are likely to be beneficial and that 
further high quality research is required
39
. The same conclusion was reached in the 
RCOG guideline published in 2002
21
. Since this time there has been further research in 
this area including the updating of many of the reviews of the Cochrane Pregnancy and 
Childbirth group in 2009
40
. When evidence is spread across many databases and in the 
case of fetal growth restriction evidence may be related to other conditions such as pre-
eclampsia it can be difficult to access appropriate up to date robust evidence for clinical 
decision making. Systematic reviews provide a technique to allow individual pieces of 
research to be collected and if appropriate subjected to meta-analysis
41
. It is essential 
that these reviews are performed with rigorous methods and include an assessment of 
study quality if they are to have valid inferences and produce usable summaries to guide 
medical practice
41
. A review of systematic reviews of effectiveness for interventions for 
fetal growth restriction and compromise of fetal wellbeing was performed to summarise 
the most up to date evidence and assess the quality of the evidence.          
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13.3. Methods 
The review was based on a prospective protocol designed following recommendations 
from the NHS Centre for Reviews and Dissemination
141
 and the Cochrane 
collaboration
41
.  
 
13.3.1 Framing the question 
A clearly defined question was based on the PICOS criteria: 
Population: Pregnant women in any health care setting, at any level of risk. Populations 
that only included multiple pregnancies were excluded. 
Intervention: Any intervention or combination of interventions, applied at any gestation 
to pregnant women to improve fetal growth or fetal wellbeing. Due to the underlying 
aetiology and pathophysiology of fetal growth restriction, interventions that were 
applied to pregnant women for the purposes of reducing their risk of preterm labour or 
pre-eclampsia were also included. 
Comparator: No intervention or placebo or usual care. 
Outcomes: Any outcome determined for the baby after birth looking at growth or 
wellbeing. Percentage deviation from estimated fetal weight at a given gestational age, 
mean birth weight and birth weight z scores were excluded as these outcomes could not 
be related to test accuracy data. 
Study design: Systematic reviews of randomised controlled trials. Reviews had to be 
based on a clearly formulated question and use systematic and explicit methods to 
identify, select and critically appraise the relevant primary research, and to extract and 
analyse data to be included. Meta-analysis was not a pre-requisite to inclusion. 
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13.3.2 Identifying the literature 
The search was designed using a structured approach with the aim of identifying 
literature concerning interventions for FGR and compromise of fetal wellbeing using 
the elements of the framed question (section 13.3.1). Pilot searches were performed to 
ensure that the search strategies gave an acceptable level of specificity without 
compromising sensitivity. The search strategy is detailed in appendix 42.  
 
Literature was identified via the following sources: 
(a) General bibliographic databases including MEDLINE and EMBASE; from 
inception to July 2009. 
(b) Specialist computer databases – DARE (Database of Abstracts of Reviews of 
Effectiveness), the Cochrane Library (issue 2009:3) and relevant specialist 
registers of the Cochrane Collaboration, namely the Pregnancy and Child Birth 
Group, Health Technology Assessment (HTA) database. 
(c) Contact with individual experts and those with an interest in this filed to uncover 
grey literature and identify any reviews in progress. 
(d) Hand- searching of relevant specialist journals in Obstetrics 
(e) Checking of reference lists of included articles and narrative review articles 
(f) SCISEARCH and Web of Science to identify frequently cited articles and 
conference abstracts. 
All searches were made without language restrictions. A comprehensive database of 
articles was constructed using Reference Manager 11.0 software. 
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The titles and abstracts of the citations were assessed for inclusion by two reviewers 
independently. Potentially relevant citations were obtained and the paper read in full by 
the two reviewers. Reviews were selected for inclusion by the two reviewers 
independently using a checklist, the items of this checklist were based on the question 
elements as stated in section 13.3.1. Disagreements were resolved by consensus with a 
third reviewer. In the case of duplicate publications or reviews on the same subject 
published by different groups then a decision was made by the three reviewers as to the 
most up to date review and/or the review of higher methodological quality for selection. 
All foreign language papers were translated. 
 
13.3.3 Assessment of the quality of the literature 
Included reviews were assessed for methodological quality using a checklist based on 
the CASP checklist (Critical Appraisal Skills Programme)
142
. The issues assessed when 
considering the quality of the review were: 
1. Did the review ask a clearly structured and focused question? 
2. Were selection criteria clearly described? 
3. Were all relevant studies identified? 
4. Were the included studies synthesized? 
5. Was the validity of the included studies assessed? 
6. Are sufficient details about the individual included studies presented? 
The full checklist with further details on how quality was assessed is shown in appendix 
43.  Quality assessment was performed independently by two reviewers. Where there 
were two systematic reviews reporting the same data the review with the highest quality 
was included only. 
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13.3.4 Data Extraction 
Data were extracted on number of studies included in the review, the methodological 
quality of the review and the summary results of the review. Data were then extracted 
from the reviews on the study characteristics, methodological quality and results of the 
individual included studies. Data were extracted in duplicate by another independent 
reviewer to ensure accuracy. Disagreements were resolved by consensus. 
 
13.3.5 Description of data 
The data extracted from the systematic reviews were presented as tables according to 
the outcome measure detailing the intervention, population characteristics, comparator 
and the number of relevant included RCTs. The relative risk (RR) along with 95% 
confidence intervals and the p value of the z statistic (overall measure of effect) were 
presented as the summary measure. To enable a meaningful presentation of the data and 
discussion of the results it was decided to present the data as two tables, one for 
outcome measures related to fetal growth and the other for perinatal mortality as the 
main outcome measure for compromise of wellbeing. 
 
13.4 Results 
13.4.1 Literature identification and review characteristics 
Figure 13.1 summarises the process of literature identification and selection. The 
references for the included reviews and the details of the individual review 
characteristics can be found in appendix 44 and 45 respectively. There were 71 
systematic reviews included of which 69 were systematic reviews and one health 
technology assessment on screening and prevention of pre-term birth which included 
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updated data from two Cochrane reviews. There were 4 non Cochrane systematic reviews. 
These articles included a total of 733 randomised controlled trials reporting on 42 different 
interventions. Forty –four reviews included outcomes for fetal growth reporting on 30 
different interventions. Small for gestational age (with no threshold noted) was the 
commonest outcome reported (n=21 studies) followed by birth weight <2500g (n=20 
studies). A total of 7 different outcome measures were used across the different reviews. 
The results for interventions for fetal growth are shown in appendix 46 and figure 13.3 and 
13.4. 
 
Sixty one reviews reported on outcomes for adverse perinatal outcome using a total of 15 
different outcome measures. For perinatal mortality there were a total of 49 reviews 
reporting on the effectiveness of 30 different interventions. The results for perinatal 
mortality are shown in appendix 47 and figure 13.5. 
 
13.4.2 Review Quality 
Figure 13.2 summarises the quality of the included reviews. Overall the quality of 
reviews was good. Fifty-one reviews were assessed as not having asked a structured 
question based on PICOS (population, intervention, comparator, outcome, study 
design). In Cochrane reviews, instead of a question, an objective is stated. This was 
assessed for its compliance with PICOS and in many reviews there was no clear 
statement of the population or comparator. For a clear statement of selection criteria, 15 
reviews were assessed as not being compliant as there was no clear statement of the 
comparator.  
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Primary articles retrieved for detailed evaluation  
- from electronic searches       n= 199 
- from reference lists       n= 10 
        
Articles excluded      n= 138 
- Systematic reviews of observational data   n= 4 
- Systematic reviews with duplicate data  
    updated in another review     n=46 
- reviews/ letters/ comments/ editorials 
    /individual RCTS/case reports    n=60  
- Paper/translation unobtainable    n=2  
- Protocol for systematic review    n= 8 
- No intervention/ incorrect population/no relevant outcome n=11 
- Comparator another treatment    n=7 
 
 
Total number of systematic reviews      n= 71 
Systematic reviews       n=69 
Health technology assessment     n=1 
- Number of systematic reviews in HTA   n=2 
Number of included RCTs      n=733 
      
Potentially relevant citations identified from electronic searches to capture 
primary articles on effectiveness of interventions to predict fetal growth 
restriction and compromise of fetal/neonatal wellbeing 
         n=9088
      
        n= 668 
 References excluded after screening titles and/ or abstracts n= 8879 
Figure 13.1: Process from initial search to final inclusion for review of systematic 
reviews of effectiveness for interventions for prevention of fetal growth restriction 
and compromise of fetal/neonatal wellbeing (up to July 2009). (HTA Health 
technology assessment; RCT randomised controlled trial). 
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Figure 13.2: Bar chart showing quality assessment of included studies in review of systematic reviews of effectiveness of 
interventions for fetal growth restriction and compromise of its wellbeing 
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In 34 reviews it was decided that there was a possibility that not all studies may have 
been identified as there was no statement regarding additional methods to search grey 
literature and additional study information e.g. contact with authors and experts within 
the field. For assessment of appropriateness of data synthesis there were 10 reviews in 
which there were either no or only one included studies and thus this was assessed as 
not applicable. In five reviews it was not possible to fully assess the appropriateness of 
the pooling of data as there had been no statements made about planned sub-group or 
sensitivity analysis. In 64 of the reviews the validity of the included studies was deemed 
to have been assessed appropriately i.e. using an appropriate tool, two independent 
assessors, planned a priori. There were two reviews in which there were in-sufficient 
data presented relating to the individual included studies in the review, neither of these 
systematic reviews were Cochrane reviews. 
 
13.4.3 Summary of results of effectiveness reviews for prevention of fetal growth 
restriction 
Figure 13.3 summarises the results for effectiveness of interventions for prevention of 
fetal growth restriction in a general pregnant population and figure 13.4 for a high risk 
population. The number of included trials in each review ranged from one to 23, with 
the number if included participants ranging from 10 to 21426. For 11 interventions the 
reviews included only one RCT.  
 
For a general pregnant population the following interventions had a RR and confidence 
intervals compatible with an overall positive effect: 
 Antiplatelets 
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 Balanced protein/energy supplementation 
 Orally administered magnesium 
 Multiple micronutrient supplementation 
Antiplatelet agents were extensively reviewed both by a Cochrane review
143
 and an 
individual patient data meta-analysis
144
 with the conclusion that they have moderate 
benefits for prevention of PE and its consequences, with further information required to 
assess which women are most likely to benefit, when treatment is best started, and at 
what dose. However, for balanced protein/energy supplementation the authors of the 
review were concerned regarding the heterogeneity within the included trials and 
concluded that it was impossible to know whether the benefit was only for women who 
were undernourished or not
145
.  
 
For orally administered magnesium the review authors concluded that the evidence was 
all of a poor quality and that after excluding one trial from the meta-analysis the effect 
of benefit was removed
146
. The review on multiple micronutrient supplementation 
identified nine trials involving 15378 women, there was evidence of an effect on 
reduction of low birth weight and small for gestational age infants. The review authors 
however recommended further research in particular to assess adverse effects
147
. 
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Figure 13.3: Summary forest plots of relative risks of various interventions for prevention of fetal growth restriction in a general 
pregnant population. (Squares represent individual RCTs and diamonds pooled RCTs). 
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Figure 13.4: Summary forest plots of relative risks of various interventions for prevention of fetal growth restriction in a high risk 
pregnant population. (Squares represent individual RCTs and diamonds pooled RCTs) 
Intervention Outcome measure Relative risk (95% CI)
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There were two interventions that appeared to have an adverse effect on birth weight: 
 Antihypertensives and in particular oral beta-blockers 
 High protein and iso-caloric balanced protein supplementation. 
For beta-blockers the increase in SGA fetuses was largely due to one small trial of 
atenolol versus placebo and the conclusion of the review authors was that further 
research was required
148
. For high protein and iso-caloric balanced protein 
supplementation the authors advised that there was no potential benefit but a potential 
for harm
145
. 
 
For a high risk population the following interventions had a RR compatible with an 
overall positive effect: 
 Abdominal decompression 
 Antibiotics for women with bacterial vaginosis 
 Prophylatic antibiotics to prevent infectious morbidity and mortality for women 
with previous preterm labour 
 Antibiotics for women with asymptomatic bacteriuria 
 Antiplatelets for women at moderate or high risk of PE 
 Interventionist versus expectant care for women with severe PE before term 
 Home uterine monitoring for women at risk of preterm labour 
 Prenatal administration of progesterone for preventing preterm birth in women 
considered to be at risk of preterm birth 
 Interventions for promoting smoking cessation in pregnancy 
In the review on abdominal decompression the authors concluded that all studies had 
the potential for serious bias and that the therapeutic effect was not clear
149
. For 
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prophylactic antibiotics the effect was seen in one trial of 253 women who were high 
risk due to either a previous pre-term labour, low birth weight baby, stillbirth or 
neonatal death
150
. This trial had a high drop-out rate and thus the results must be 
interpreted with caution. For home uterine monitoring the authors concluded that the 
trials were of poor quality and thus the effect was not clear
151
.  
 
13.4.4 Summary of results of effectiveness reviews for prevention of perinatal 
mortality 
Figure 13.5 parts A and B summarise the results for effectiveness of interventions for 
prevention of perinatal mortality. The number of included trials in each review varied 
from one to 23. The number of included participants varied from 31 to 30672. For 14 
interventions the reviews included only one RCT. 
 
The following interventions had an RR and confidence intervals suggesting an overall 
beneficial effect on perinatal mortality: 
 Abdominal decompression in a high risk pregnancy 
 Antiplatelets 
 Elective caesarean section versus expectant management for delivery of a baby 
suspected to be small 
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Figure 13.5: Part A Summary forest plots of relative risks of various interventions for prevention of perinatal mortality (Squares 
represent individual RCTs and diamonds pooled RCTs) 
Intervention Population Relative risk (95% CI)
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Bed rest with or without hospitalisation for hypertension during pregnancy
Betamimetics
Betamimetics for inhibiting preterm labour
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Figure 13.5: Part B Summary forest plots of relative risks of various interventions for prevention of perinatal mortality. (Squares 
represent individual RCTs and diamonds pooled RCTs). 
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Women expected to deliver preterm
All pregnant women
All pregnant women
Normal pregnant women
Intervention Population Relative risk (95% CI)
1.03 (0.71, 1.51)
1.29 (0.67, 2.48)
1.16 (0.61, 2.18)
0.77 (0.67, 0.89)
1.13 (0.27, 1.77)
1.92 (0.18, 21.03)
1.92 (0.18, 21.03)
0.72 (0.21, 2.51)
0.65 (0.38, 1.11)
1.15 (0.89, 1.51)
3.50 (0.18, 67.45)
0.77 (0.21, 2.83)
2.25 (0.79, 6.40)
0.50 (0.32, 0.81)
0.19 (0.01, 3.63)
0.25 (0.03, 2.34)
1.05 (0.90, 1.23)
1.01 (0.67, 1.53)
1.02 (0.73, 1.43)
1.04 (0.92, 1.17)
5.00 (0.25, 99.16)
2.82 (1.20, 6.62)
0.93 (0.67, 1.29)
1.18 (0.56, 2.48)
0.45 (0.04, 4.55)
0.41 (0.06, 2.73)
0.25 (0.05, 1.18)
0.32 (0.03, 3.09)
0.30 (0.08, 1.18)
0.1 0.2 0.5 1 2 5 10
Relative risk (95% confidence intervals)
Delivery
Elective caesarean section versus expectant management for delivery of the small baby
Induction of labour for improving birth outcomes for women at or beyond term
Interventionist versus expectant care for severe pre-eclampsia before term
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 Maternal oxygen administration for suspected impaired fetal growth 
 Antenatal corticosteroids for accelerating fetal lung maturation for women at 
risk of pre-term birth. 
The limitations of the review on abdominal decompression and the reviews for 
antiplatelets have already been discussed in section 13.4.3. For elective caesarean 
section for the suspected small baby the review authors concluded that a policy of 
elective caesarean section could not be recommended at this time due to the uncertainty 
around any beneficial effect due to the small numbers of women recruited to the 
trials
152
. The review on maternal oxygen administration concluded that there were 
concerns regarding the methods of the included trials, in particular selection bias, and 
that the trials all had small sample sizes, so further trials with multicentre recruitment 
were recommended
153
.  
 
The evidence from the review on antenatal corticosteroids included 21 studies (3885 
women and 4269 ) and supported the use of single dose of corticosteroids to accelerate 
fetal lung maturation in women at risk of preterm birth
154
.  
 
The following interventions had an RR and confidence intervals suggesting a potential 
for harm: 
 Magnesium sulphate administration for preventing preterm birth in threatened 
preterm labour. 
The review on magnesium sulphate included 23 trials and over 2000 women and the 
authors concluded that magnesium sulphate was ineffective in delaying or preventing 
preterm birth, and its use is associated with an increased mortality for the infant
155
. 
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13.5 Discussion 
After considering the results and the quality of evidence antiplatelets and multiple 
micronutrient supplements were the interventions that were considered to be effective in 
preventing the small for gestational age fetus and suitable for use in all pregnant 
women. These were thus put forward to the decision analytic model for all pregnant 
women. For high risk pregnant women the following were put forward antiplatelets, 
multiple micronutrient supplements, smoking cessation interventions and progesterone 
therapy. Antibiotics for bacterial vaginosis and asymptomatic bacteriuria and 
interventionist care for severe PE were considered to represent interventions for very 
specific sub-groups of the high risk population and thus these interventions were not 
used in the model. For prevention/reduction of perinatal mortality, antiplatelets and 
antenatal corticosteroids were the interventions shown to be effective. 
 
Limitations arising from problems with included trials 
The assessment of quality of the included reviews was good overall. However, as some of 
the reviews included only a small number of RCTs this led to relative risks being reported 
that were based on small sample sizes thus increasing the error rate and decreasing the 
statistical power. The inferences regarding effectiveness that can be drawn from these 
reviews are thus limited. It must therefore be concluded that for these interventions there 
is a lack of evidence on which to determine effectiveness. 
 
For all interventions there was an attempt to determine which pregnant populations (i.e. 
level of risk) the intervention was most effective or useful for to help determine which 
interventions should be put forward to the economic model. To determine level of risk the 
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authors of the included reviews relied upon the description of risk given in the primary 
RCTs. This description was often inadequate and varied between included trials and 
across reviews particularly for the high risk population. In order to assess the 
generalisability of the interventions under review there was careful assessment of the 
included populations of the individual RCTs and the conclusions of the authors of the 
systematic reviews was taken into account. There was also significant heterogeneity in 
the outcome measures used for assessing growth restriction and fetal/neonatal 
compromise both within included RCTs and across systematic reviews. Caution must thus 
be exercised when comparing the effectiveness of different interventions to ensure that 
outcome measures are comparable. 
 
The majority of the included reviews had been updated within the last 5 years. There were 
however some reviews, particularly those assessing non-contemporary interventions, that, 
despite an up-date of the search, included non-contemporary data. This introduces 
concerns regarding the methods of the included RCTs and the applicability of the results 
to the current pregnant population within the context of modern clinical practice. 
 
Limitations arising from review methods 
The review methods employed had strengths as well as weaknesses. The quality of this 
review is limited by the quality of the included systematic reviews. As 94% of the 
included systematic reviews were Cochrane reviews they can be considered to have 
adhered to a rigorous set of methods including a comprehensive search strategy, 
primary studies restricted to RCTs, peer reviewed and published protocol and have been 
regularly updated. The fact that they are regularly updated led to the high proportion of 
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Cochrane reviews within this review. The majority of Cochrane effectiveness reviews 
within the Pregnancy and Childbirth group were updated in January 2009 thus although 
a large number of other systematic reviews were identified by the search strategy the 
vast majority were excluded as the Cochrane reviews were more up to date. 
 
The methods used for this review also allowed a large number of interventions to be 
assessed as it included any review that assessed an intervention in a pregnant population 
with a relevant outcome measure for growth restriction and/or fetal/neonatal 
compromise. This meant that reviews primarily directed at the management of fetal 
growth restriction were identified and included but also reviews targeted at pre-
eclampsia, pre-term labour as well as general antenatal care.  
 
As this was a review of systematic reviews it is a comprehensive summary of the 
available evidence on interventions that have been systematically reviewed and 
evaluated by RCTs. It does not however summarise the literature on all available 
interventions as there are some interventions that may have been assessed by only 
observational data or not subjected to systematic review. 
 
A weakness of the review methods was that the quality of the individual RCTs was not 
assessed. This was due to the large number of RCTs being prohibitive within the 
timescale available. In an attempt to ameliorate this opportunity for bias, the quality of 
the included trials within the reviews of an intervention determined to be effective was 
taken into account in decisions regarding whether an intervention should be put forward 
to the model. This was not however performed for those interventions with a relative 
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risk suggesting an ineffective intervention and thus there is the potential that the quality 
of included trials was such that the true effect may be different from that reported. It 
would be difficult however to assess the probability of this and the conclusion would be 
that the evidence was not sufficient to confidently determine true effectiveness. 
 
This review only included results for comparison of an intervention against placebo or 
in a few cases against standard care for antenatal care and delivery interventions. This 
decision was made due to the large number of interventions under review and the large 
number of outcome measures used, with the aim of keeping the number of results and 
hence conclusions manageable and coherent. It is thus possible that some interventions 
that are effective have not been included in this review as they were compared to other 
interventions only. 
 
The limitation of this review to systematic reviews of RCTs and exclusion of 
observational data means that important information that may only truly be revealed by 
observational studies such as side effect data and longer term outcomes/morbidity is not 
considered. It must be concluded therefore that this work and the resulting model look 
only at effectiveness and cost-effectiveness of the interventions and that their use in 
clinical practice should take into account the side effect profiles and long term 
outcomes. 
 
Limitations arising from things not done 
The decision to include all reviews and interventions with a relevant outcome meant 
that a considerable number of interventions were considered for this review and hence 
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for entry to the model. While this is a strength, as the likelihood of an effective 
intervention being omitted is very small, it does not address the issue of which 
interventions are important to clinicians and more importantly which are important and 
acceptable to parents. This could be addressed by a survey of clinicians and parents or 
consumer groups to identify what is important to them. 
 
Findings in light of these limitations 
This review represents the most comprehensive and up to date review of systematic 
reviews of effectiveness of interventions for fetal growth restriction and compromise of 
fetal/neonatal wellbeing. It presents good evidence for the effectiveness of a small 
number of interventions e.g. antioxidants, antiplatelets, antihypertensive, smoking 
cessation and progesterone. It has also determined that there is considerable uncertainty, 
either due to concerns regarding the reliability of the evidence or lack of RCTs, for the 
effectiveness of other interventions e.g. hormones, bed rest, delivery interventions, 
plasma volume expansion, abdominal decompression. 
 
Considerations for the economic model 
As discussed earlier in considering which interventions were to be put forward to the 
model the following were considered: effectiveness, reliability of evidence and 
generalisability to the study population.  
 
Recommendations for practice 
The 2002 RCOG guidelines recommended the use of antenatal steroids to reduce the 
incidence of respiratory distress syndrome and delivery in a unit where optimal neonatal 
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expertise and facilities are available
21
. They concluded that there was insufficient 
evidence for most interventions and that in the case of aspirin further trials were needed. 
The evidence in this review shows that antiplatelets and multiple micronutrients in all 
pregnant women and in addition smoking cessation programmes and progesterone 
therapy in high risk women reduce the risk of fetal growth restriction compared to 
placebo. It must be noted however, that of these, only antiplatelets and corticosteroids 
have been shown to have any effect on perinatal mortality. This information along with 
information on potential side effects should be discussed with women prior to 
implementation. 
 
Recommendations and considerations for future research 
All interventions discussed here and reported in the literature have looked at prevention 
of fetal growth restriction and not treatment as this is the ideal. Further research should 
look at the regulation of fetal growth to allow specific therapies for those cases where 
growth restriction has developed. Interventions have so far been considered in isolation 
and it may be that benefit from any single one intervention is always going to be small 
and that multiple interventions used in combination will be necessary to find a truly 
effective intervention. This will require careful consideration of side effect profiles and 
possible adverse interactions of interventions. 
 
Fetal growth restriction and compromise of fetal wellbeing are strongly related to other 
pregnancy complications such as pre-eclampsia and pre-term labour and women will 
often have more than one of these complications. It is thus important that future 
research considers the impact of interventions on other important maternal and neonatal 
  
203 
 
outcome measures. Future research in this area also needs to be carefully designed with 
attention paid to population risk and outcome measures to ensure that results are reliable 
and generalisable. 
 
A difficulty in future research can arise when new interventions are compared in 
different ways i.e. either randomised against placebo or against an active control. As the 
number of interventions available increases so does the number of comparisons required 
to truly assess the effectiveness of the intervention. This can be a considerable burden 
on resources and can be particularly difficult in the area of obstetric research where 
recruitment to RCTs can be hampered by the maternal concern regarding the unborn 
child. A contemporary meta-analytic technique called network meta-analysis
156
 or 
mixed treatment comparisons
157
 may need to be considered to allow a unified, coherent 
analysis of direct and indirect evidence. 
 
13.6 Conclusion 
After considering the results and the quality of evidence antiplatelets and multiple 
micronutrient supplements were the interventions that were considered to be effective in 
preventing the small for gestational age fetus and suitable for use in all pregnant 
women. For high risk pregnant women the following were considered to be effective: 
antiplatelets, multiple micronutrient supplements, smoking cessation interventions and 
progesterone therapy. For prevention/reduction of perinatal mortality antiplatelets and 
antenatal corticosteroids were the interventions shown to be effective. 
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PART D: COST EFFECTIVENESS 
ANALYSIS WITH ECONOMIC 
MODELLING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
205 
 
CHAPTER 14: COST EFFECTIVENESS ANALYSIS WITH 
ECONOMIC MODELLING TO ASSESS TEST AND 
TREATMENT STRATEGIES FOR THE MANAGEMENT 
OF SMALL FOR GESTATIONAL AGE FETUSES AND 
COMPROMISE OF FETAL/NEONATAL WELLBEING. 
 
14.1 Abstract 
14.1.1 Background 
Identification of the fetus at risk of compromise is crucial to judicious allocation of 
monitoring resources and use of preventative treatment with the prospect of improving 
perinatal outcome. To investigate the potential cost-effectiveness of alternative „test and 
treat‟ strategies in the prevention of fetal growth restriction compared to a strategy of no 
screening in the UK. 
 
14.1.2 Methods 
Economic evaluation using a decision tree model based on data from systematic reviews 
in a population of all pregnant women with sub-group analysis based on population risk. 
Setting of clinics, General Practices, Health Centres or any setting delivering antenatal 
care to pregnant women.  The main outcome measure was cost-effectiveness based on 
an outcome of fetal growth restriction avoided.  
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14.1.3 Results 
105 studies were reviewed on the accuracy of 6 different tests; Cochrane reviews and 
systematic reviews of effectiveness, 44 in total, were used for effectiveness data of a 
possible 30 interventions. Cost data were based on secondary evidence, supplemented 
with primary data from local sources. Testing prior to intervention was not shown to be 
the most cost-effective strategy in the analyses for all pregnant women. Anti-platelet 
therapy, without prior testing, was highlighted as potentially cost-effective in preventing 
fetal growth restriction in this population. In high risk women, testing with serum 
human chorionic gonadotrophin followed by anti-platelet therapy in those that test 
positive was a potentially cost-effective strategy. 
 
14.1.4  Conclusion 
An effective, affordable and safe intervention applied to all mothers without prior 
testing is likely to be the most cost-effective strategy in the prevention of fetal growth 
restriction. The results reported in this paper are important for prioritising future 
research, world-wide.  
 
14.1.5 Publications arising from this work 
Morris RK, Malin GL, Tsourapas A, Roberts TE, Khan KS. An economic evaluation of 
alternative test-intervention strategies to prevent fetal growth restriction in singleton 
pregnancies. Archive of Disease in Childhood Fetal and Neonatal 2010;95(suppl 1): 
Fa12. 
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 14.2 Introduction 
Restriction of fetal growth and compromise of fetal wellbeing remain significant causes 
of perinatal death and childhood disability
8;138
. On reaching adulthood, these babies are at 
greater risk of developing cardiovascular disease, hypertension, and non-insulin 
dependent diabetes
11;12
. Thus FGR has major direct and indirect costs. 
 
Reliable antenatal identification of FGR is crucial to judicious allocation of monitoring 
resources and use of preventative treatment
129
 with the prospect of improving perinatal 
outcome. Currently, there is a lack of scientific consensus about the best diagnostic and 
monitoring strategies for predicting FGR and compromise of fetal wellbeing before birth. 
Consequently, this has lead to uncertainty regarding the best management of pregnant 
women with a growth-restricted baby with various strategies proposed. There has 
however been no formal assessment of the cost-effectiveness of these strategies.  
 
This chapter reports the results of an economic evaluation which used evidence from 
systematic reviews
128;129
 (chapters 5 and 6) on the accuracy of all first and second 
trimester tests and on the effectiveness of all available interventions (chapter 13) to 
explore the relative cost-effectiveness of a wide range of potentially available „test and 
treat‟ strategies. The economic evaluation took the form of a cost-effectiveness analysis, 
using decision analytic modelling based on a primary outcome of cost per case of FGR 
avoided. The comparator was no screening/testing and no intervention because there is 
currently no routine UK screening policy for the prevention of FGR. The perspective 
adopted was that of the NHS.  
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14.3 Methods 
14.3.1 Model structure 
An economic evaluation was performed using a decision analytic model to compare test 
– treatment strategies. The evaluation took the form of a cost-effectiveness analysis 
based on the outcome cost per case of FGR avoided. The analysis was performed from a 
health care provider perspective, assessing the financial cost of each strategy; this 
evaluation did not consider private out-of-pocket costs to patient as there are no data 
available to estimate this. The model allowed the full range of alternatives, the 
probabilities and uncertainties of these and the outcomes of each strategy to be 
considered. It provided a framework for each action to be assigned a cost, with the 
overall cost of each being the sum of the costs of the consequence weighted by the 
probability of that consequence.  The clinical problem was addressed by constructing 
two separate decision tree models according to population risk (all pregnant women-
model 1 and high risk- model 2). The models were used to synthesise the data on test 
accuracy and intervention effectiveness in order to highlight the potentially most cost-
effective „test and treat‟ strategies for the prevention of FGR based on all the available 
data for each population.   
A decision tree was the chosen modelling approach because the time horizons available 
for both testing and providing the appropriate intervention to women, being within the 
pregnancy time period, were relatively short and there was no interaction between 
individuals. The models were constructed in DATA TreeAge Pro Suite 2009
158
, an 
example of one of the models is given in figure 14.1 showing the branches for testing 
with uterine artery Doppler and treatment with anti-platelets. In this figure each branch 
to the right of the chance node (round symbol) indicates one way in which the test under 
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consideration and the treatment can be used together. The diamonds indicate a terminal 
node or outcome. The box beneath the population under investigation on the far left of 
the tree, indicates the model parameters being used which will differ depending on the 
model. Thus for each test and treatment combination, the number of resulting cases of 
FGR and the associated cost are estimated for the following pathways: 
1. No test and no intervention  
2. Intervention given to all with no preceding testing  
3. Test to all, but no subsequent intervention  
4. Test applied to all, followed by the intervention for all those who tested positive  
5. Test to all followed by the intervention to all (regardless of test result).  
The first pathway represents the comparator for all the other pathways and the common 
comparator indicating the costs for current clinical practice i.e. no systematic testing and 
treatment. Pathways 2 and 4 represent the main clinically relevant alternative test 
treatment strategies. Pathways 3 and 5 are not clinically relevant but are included to 
give a complete understanding of the relationship between benefits, disbenefits and 
costs. 
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Figure 14.1: Example of decision analysis tree showing five pathways for uterine artery Doppler 
FGR
prev_FGR
c_FGR / 0
no FGR
#
0 / 1
No Test / No Intervention
FGR
prev_FGR*RR_Antiplat
(c_Antiplat + c_FGR) / 0
no FGR
#
c_Antiplat / 1
No Test / Antiplatelets
#
FGR
PPV_UAD
(c_UAD+c_FGR) / 0
no FGR
#
c_UAD / 1
Test +ve
p_UAD
FGR
#
(c_UAD+c_FGR) / 0
no FGR
NPV_UAD
c_UAD / 1
Test -ve
#
Uterine artery Doppler/ No intervention
FGR
PPV_UAD*RR_Antiplat
(c_UAD+c_Antiplat+c_FGR) / 0
no FGR
#
(c_UAD+c_Antiplat) / 1
Test +ve (treat)
p_UAD
FGR
#
(c_UAD+c_FGR) / 0
no FGR
NPV_UAD
c_UAD / 1
Test -ve
#
Uterine artery Doppler/Antiplatelets (+ve)
FGR
PPV_UAD*RR_Antiplat
(c_UAD+c_Antiplat+c_FGR) / 0
no FGR
#
(c_UAD+c_Antiplat) / 1
Test +ve (treat)
p_UAD
FGR
(1-NPV_UAD)*RR_Antiplat
(c_UAD+c_Antiplat+c_FGR) / 0
no FGR
#
(c_UAD+c_Antiplat) / 1
Test -ve (treat)
#
Uterine artery Doppler/Antiplatelets (All)
All Pregnant Women                                                                                            
c_Antiplat=6.5
c_FGR=2652
c_UAD=26.97
LR_Neg_UAD=mLR_neg_UAD*exp(zLR_neg_UAD*sigmaLR_neg_UAD)
LR_pos_UAD=mLR_pos_UAD*exp(zLR_pos_UAD*sigmaLR_pos_UAD)
mLR_neg_UAD=0.74
mLR_pos_UAD=2.69
mRR_Antiplat=0.9
NPV_UAD=(1-prev_FGR)/(LR_Neg_UAD*prev_FGR+1-prev_FGR)
PPV_UAD=(LR_pos_UAD*prev_FGR)/(LR_pos_UAD*prev_FGR+1-prev_FGR)
prev_FGR=Dist(15)
p_UAD=((1-LR_neg_UAD)*(LR_pos_UAD*prev_FGR+1-prev_FGR))/(LR_pos_UAD-LR_neg_UAD)
RR_Antiplat=mRR_Antiplat*exp(zRR_Antiplat*sigmaRR_Antiplat)
sigmaLR_neg_UAD=0.0334
sigmaLR_pos_UAD=0.0641
sigmaRR_Antiplat=0.0434
zLR_neg_UAD=Dist(13)
zLR_pos_UAD=Dist(14)
zRR_Antiplat=Dist(1)
OPTION IV
OPTION I
OPTION II
OPTION III
OPTION V
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14.3.2 Inputs to model 
Test accuracy 
The results from systematic reviews assessing the accuracy of the uterine artery Doppler 
and Down‟s syndrome (chapters 5 and 6) serum screening markers were the source of 
the sensitivity and specificity model parameters
128;129
. These reviews included a total of 
105 studies assessing 6 different tests. The actual values used were pooled likelihood 
ratios generated using the bivariate method of meta-analysis
37
. These values and their 
associated 95% confidence intervals (CI) are given in table 14.1.  
 
Effectiveness 
Systematic reviews of effectiveness as identified by the review of systematic reviews in 
chapter 13 were the source of data on the effectiveness of interventions. Interventions 
were eligible for inclusion in the model if the intervention was used in pregnant women 
with a relevant outcome. The following were also considered: effectiveness, reliability 
of evidence and generalisability to the population under investigation. The values used 
were the summary relative risks (RR) along with their 95% CI as shown in table 14.2. 
The interventions were split into two groups as these are dealt differently by the model. 
Group 1 includes those treatments in which the 95% CI do not include values>1.0, 
indicating that the true value of the RR for the treatment is compatible with reducing the 
number of FGR cases. In group 2, the 95% CI do include values >1.0, i.e. the true value 
of the RR may be compatible with a worsened outcome. 
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Table 14.1: Diagnostic test accuracy results for each test provided by systematic reviews of test accuracy – inputs to model 
Test (Subgroup) Sensitivity 95% CI Specificity 95% CI LR+ve 95% CI LR-ve 95% CI 
Maternal serum AFP 0.14 (0.10-0.18) 0.94 (0.91-0.96) 2.20 (1.94-2.96) 0.92 (0.90-0.94) 
High risk population 0.31 (0.17-0.48) 0.94 (0.88-0.98) 4.54 (1.75-11.81) 0.70 (0.34-1.44) 
Low risk population 0.13 (0.09-0.17) 0.94 (0.91-0.96) 2.16 (1.73-2.69) 0.93 (0.91-0.95) 
Birth weight<10
th
 centile 0.15 (0.10-0.22) 0.92 (0.87-0.96) 1.97 (1.48-2.62) 0.92 (0.88-0.95) 
Birth weight<5
th
 centile 0.07 (0.05-0.10) 0.97 (0.96-0.98) 2.71 (1.79-4.12) 0.95 (0.93-0.98) 
Birth weight<2500g 0.14 (0.09-0.21) 0.94 (0.89-0.97) 2.52 (1.74-3.09) 0.91 (0.88-0.95) 
Maternal serum HCG 0.15 (0.10-0.22) 0.90 (0.86-0.94) 1.57 (1.38-1.78) 0.94 (0.91-0.98) 
High risk population 0.28 (0.17-0.41) 0.89 (0.84-0.93) 2.94 (1.20-7.17) 0.82 (0.69-0.99) 
Birth weight<10
th
 centile 0.15  (0.10-0.23) 0.91 (0.87-0.94) 1.76 (1.54-2.01) 0.93 (0.89-0.97) 
Birth weight<5
th
 centile 0.10 (0.06-0.15) 0.93 (0.90-0.96) 1.49 (1.13-1.97) 0.97 (0.94-0.99) 
Birth weight<2500g 0.19 (0.14-0.24) 0.85 (0.83-0.86) 2.70 (1.24-5.89) 0.89 (0.79-1.01) 
Maternal serum unconjugated estriol 0.22 (0.07-0.51) 0.94 (0.86-0.98) 3.88 (1.83-8.22) 0.82 (0.64-1.06) 
Birth weight<10
th
 centile 0.16 (0.05-0.40) 0.94 (0.82-0.98) 2.46 (1.90-3.17) 0.90 (0.79-1.03) 
Birth weight<5
th
 centile 0.34 (0.32-0.35) 0.98 (0.98-0.98) 6.54 (0.98-43.91) 0.59 (0.03-13.28) 
Maternal serum PAPPA 0.17 (0.12-0.22) 0.92 (0.88-0.94) 1.98 (1.60-2.45) 0.91 (0.87-0.95) 
Birth weight<10
th
 centile 0.17 (0.12-0.24) 0.91 (0.87-0.94) 1.93 (1.53-2.44) 0.91 (0.86-0.95) 
Birth weight<5
th
 centile 0.18 (0.14-0.22) 0.92 (0.89-0.94) 2.17 (1.88-2.51) 0.90 (0.8-,0.92) 
Maternal serum inhibin A 0.11 (0.09-0.12) 0.98 (0.98-0.98) 4.45 (3.92-5.06) 0.92 (0.91-0.93) 
Birth weight<10
th
 centile 0.11 (0.09-0.12) 0.98 (0.98-0.98) 4.45 (3.92-5.06) 0.92 (0.91-0.93) 
Birth weight<5
th
 centile 0.13 (0.11-0.15) 0.97 (0.97-0.98) 4.91 (4.20-5.73) 0.89 (0.87-0.91) 
Doppler uterine artery: abnormal waveform 0.34 (0.33,0.36) 0.89 (0.89,0.90) 2.69 (2.37,3.05) 0.74 (0.71,0.79) 
High risk population 0.53 (0.44-0.63) 0.78 (0.71-0.83) 2.39 (1.90-3.00) 0.60 (0.50-0.72) 
Low risk population 0.42 (0.30-0.54) 0.87 (0.81-0.92) 3.32 (2.39-4.62) 0.67 (0.56-0.80) 
Birth weight<10
th
 centile 0.45 (0.38-0.52) 0.83 (0.79-0.87) 2.68 (2.17-3.30) 0.66 (0.59-0.74) 
Birth weight<5
th
 centile 0.51 (0.32-0.70) 0.85 (0.75-0.92) 3.43 (2.07-5.70) 0.57 (0.39-0.84) 
Birth weight<3
rd
 centile 0.41 (0.12-0.78) 0.86 (0.60-0.96) 3.00 (1.88-4.80) 0.69 (0.42-1.12) 
Birth weight<2500g 0.52 (0.31-0.73) 0.86 (0.76-0.92) 3.80 (2.10-6.87) 0.55 (0.36-0.86) 
LR likelihood ratio; 95% CI confidence intervals; AFP alpha feto-protein; HCG human chorionic gonadotrophin; PAPPA pregnancy associated plasma protein A 
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Table 14.2 : Effectiveness data from review of systematic reviews of effectiveness used to inform the model. 
 
  
Intervention 
 
Population 
Number 
of RCT 
Number 
of 
women 
Outcome  
RR 
 
95% CI 
Group 
1
† 
 
 
 
 
 
 
 
 
Group 
2
‡
 
Antiplatelets vs placebo/no 
intervention 
All pregnant women 36 
 
 
23638 
 
 
SGA 
 
 
0.9 
 
 
(0.83-0.98) 
Interventions for promoting 
smoking cessation 
All pregnant women that 
smoke 
16 9916 BW<2500g 0.83 (0.73-0.95) 
Multiple micronutrient 
supplementation vs control 
All pregnant women 2 2826 SGA 0.92 (0.86-0.99) 
Progesterone vs placebo Women at increased risk of 
preterm labour 
2 501 BW<2500g 0.64 (0.49-0.83) 
Antiplatelets vs placebo/no 
intervention 
Women at risk of developing 
PE 
13 
 
4239 
 
SGA 
 
0.89 
 
(0.74-1.08) 
 
RCT randomised controlled trial 
RR relative risk 
CI  confidence interval 
PE pre-eclampsia 
SGA small for gestational age 
BW birth weight 
† Group 1 are those treatments with an RR whose upper 95% CI is <1.0 
‡ Group 2 are those treatments with an RR whose upper 95% CI includes a value compatible with a worsened outcome 
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Costs  
The cost estimates for each test and the outcome are summarised in Table 14.3 and 14.4. 
All costs were converted to 2009 prices (£ Sterling) using the combined hospital and 
community index
159
. Since the time horizon of the model was within one year, the 
discounting of costs and outcomes was not required. The cost data for the tests was 
retrieved from literature reviews
160;161
 and the Birmingham Women‟s Hospital NHS 
Foundation Trust (BWH), Birmingham, estimated from the UK Department of Health‟s 
latest Health Resource Groups (HRGs) 2009
162
. The cost associated with treatments was 
estimated based on information on dose and duration described in the included studies 
in the systematic reviews of effectiveness in the Cochrane library. Where no dose or 
duration was available, the recommendation in the British National Formulary (BNF) 
(Volume 57, 2009) was used
13
.  Where a dose range was presented the cost of the upper 
and the lower limit of the dose was used. Costs estimated for hospitalisation associated 
with treatments were also included. There was no estimate of the cost involved for 
clinician‟s time to prescribe the intervention as this was presumed to be constant across 
all the interventions. 
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Table 14.3: Estimated costs of diagnostic tests (all models).  
 
   Costs from literature (UK£ 2009) 
Test Description/Nature 
of test 
Unit cost from 
Birmingham 
Women’s  
Hospital (UK£ 
2009) 
Unit cost (upper 
and lower 
estimates) 
Source 
Maternal serum 
alpha fetoprotein 
Phlebotomoist 
performs test (5 
minutes) -  venous 
blood 2.5ml. Lab 
technician to 
analyse (1 hour as 
part of batch) 
 
 
 
14.17  
 
 
 
49.11 
(42.30-55.91) 
 
 
 
Literature
a 
 
Maternal serum 
human chorionic 
gonadotrophin 
 
Phlebotomoist 
performs test (5 
minutes) -  venous 
blood 2.5ml. Lab 
technician to 
analyse (1 hour as 
part of batch) 
 
 
12.50 
 
 
49.11 
(42.30-55.91) 
 
 
Proxy based on 
AFP literature
a 
 
Maternal serum 
unconjugated 
estriol 
 
Phlebotomoist 
performs test (5 
minutes) -  venous 
blood 2.5ml. Lab 
technician to 
analyse (1 hour as 
part of batch) 
 
 
12.50 
 
 
 
49.11 
(42.30-55.91) 
 
 
Proxy based on 
AFP literature
a 
 
Maternal serum 
pregnancy 
associated plasma 
protein A 
 
Phlebotomoist 
performs test (5 
minutes) -  venous 
blood 2.5ml. Lab 
technician to 
analyse (1 hour as 
part of batch) 
 
 
12.50  
 
 
49.11 
(42.30-55.91) 
 
 
Proxy based on 
AFP literature
a 
 
Maternal serum 
inhibin A 
 
Phlebotomoist 
performs test (5 
minutes) -  venous 
blood 2.5ml. Lab 
technician to 
analyse (1 hour as 
part of batch) 
 
 
10.00 
 
49.11 
(42.30-55.91) 
 
 
 
Proxy based on 
AFP literature
a 
 
Uterine artery 
Doppler 
 
Ultrasound scan 
lasting 10 minutes 
 
26.97 
 
23.07 
(20.03-26.13) 
 
Literature
a 
AFP  alpha fetoprotein  NA not applicable 
a
Roberts T, Henderson J, Mugford M, Bricker L, Neilson J, 
Garcia J. Antenatal ultrasound screening for fetal abnormalities: a systematic review of cost and cost 
effectiveness studies. BJOG 2002;109(1):44-56 
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Table 14.4: Estimated costs of interventions  
 
Treatment  Nature and dose Duration 
Total Cost 
UK £ 2009 
Bases for cost estimate 
(comment) 
Source of  
unit 
Antiplatelets 
(principally 
aspirin)  
75-150mg/day 20 weeks  6.23 
[4.15 (75mg) 
- 8.30 (150 
mg)] 
Aspirin 75mg; 28 tablets @ £0.83 ; 
5 packs needed for 140 days. For 
150 mg per day, 10 packs required. 
 
BNF
a 
Multiple 
micronutrients 
Multivitamins one capsule per day 
(ascorbic acid 15mg, nicotinamide 
7.5mg, riboflavin 500µg, thiamine 
hydrochloride 1mg, vitamin A 2500 
units, vitamin D 300 units) 
 
Throughout pregnancy, average 30 
weeks treatment 
2.42 Multivitamin capsules, 20 capsule 
pack @£0.22- 11 packs required 
BNF
a 
Progesterone  300mg IM injection daily to 50 mg 
IM injection on alternate days 
Given for 1 week and then offered 
again at subsequent visits (therefore 
cost is 7-14 days of progesterone) 
stopped if symptoms disappeared or 
labour started. 
130.00 
[85.00 
(50mg)-
175.00 
(300mg)] 
50mg /ml in 1 ml ampule = £4.50;  
2ml ampule (100mg) = £4.50.  
Assume 10 days for all.  
Cost includes the cost of injection 
at outpatients/clinic for 10 days 
plus the cost of the drug for 10 
days. Cost varies depending on 
dose. Cost of drug £45.00 (50mg) – 
£135.00 (300mg) 
10 minutes practice nurse time 
assumed to administer injection. 
Hourly rate of practice nurse is 
£24/hour. Thus 10 minutes =£4.00, 
for 10 days=£40.00 
BNF
a 
 
 
 
 
 
 
 
 
 
 
Curtis and 
Netten
c 
 
 
Smoking 
cessation 
 
Nicotine patches, 14mg every 24 
hours for 4 weeks 
 
Start 1-2 weeks before target stop 
date, maximum period of treatment 4 
weeks 
 
35.80 
 
Nicotine patch, 7 patch pack @ 
£8.95 (2 packs required) 
 
BNF
a 
a 
British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. March 2009 
b
 Holland and Barrett. URL: http://www.hollandandbarrett.com 
c 
Curtis L, Netten A. Unit costs of health and social care 2005. Canterbury: PSSRU;2006. 
GTN glyceryl trinitrate 
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A systematic review of the literature was performed to search for relevant cost data 
related to the outcome. Medline, Embase, British Nursing Index, Cochrane Library 
(including economic databases) and grey literature databases were searched from 
inception until July 2009. The search strategy consisted of Medical Subject Heading 
(MeSH) and keywords related to terms for fetal growth restriction combined with terms 
related to costs and effectiveness. The full search strategy is shown in appendix 48. The 
search revealed 3445 citations, 51 of which were selected after scrutiny of the title and 
abstract by two reviewers (author and Dr Gemma Malin). These papers were obtained in 
full and one further paper was obtained after checking the reference lists of these 
papers. To be included in the review papers had to report on the cost of the birth of a 
baby in a singleton pregnancy at all gestations to the NHS where the baby was either 
small for gestational age or birth weight <2500g. Costs could be applied over any time 
period after birth. None of the 52 papers complied with all the inclusion criteria. Cost 
data were thus calculated from BWH data over a 5 year period, 2004-2008. All babies at 
BWH with a birth weight <2300g are admitted to either the neonatal intensive care, high 
dependency care or transitional care. Babies with a birth weight between 2300 and 
2500g will be admitted if clinically indicated, those that are well are sent straight to the 
post-natal ward with no further investigations and thus no extra cost to the NHS above a 
baby of birth weight >2500g. Over the 5 year time period average length of stay at each 
level of care was calculated for each baby and then stratified according to year, birth 
weight and gestation (Table 14.5). There were significant variations in cost according to 
gestation and birth weight. For the purposes of this analysis it was decided by the author 
that the most appropriate cost to use was an overall cost for babies born at term ≤ 2500g 
as this represents the most representative cost for a general pregnant population. The 
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cost of a normal delivery was removed from the estimate of cost of a baby with FGR as 
this was presumed to be constant for any outcome and mode of delivery was not being 
used within any of the comparators of the model. 
Prevalence 
The prevalence of fetal growth restriction for a general population was obtained from 
Office of National Statistics data for 2007 (defined as BW<2500g) and the systematic 
reviews of test accuracy
128;129
 giving an overall prevalence of 7.6% (95% CI 5.21-10.5). 
For the high risk populations the prevalence rate from the systematic reviews of test 
accuracy were used.  
 
14.3.3 Analysis 
The main outcome of each of the models was cost per case of FGR avoided. Quality of 
life data for this clinical condition were not available in the literature. For each model, a 
deterministic and probabilistic sensitivity analysis (PSA) was carried out
6
. The 
deterministic analysis uses the point estimate only, one way sensitivity analysis was 
performed to examine the impact of changing one variable across its entire plausible 
range, while keeping all other variables at the point estimate
163
. In PSA, each model 
parameter is assigned a distribution reflecting the amount and pattern of its variation 
and cost-effectiveness results are calculated by simultaneously selecting random values 
from each distribution. This process was repeated 10,000 times in a Monte Carlo 
simulation of the model to give an indication of how variation in the model parameters 
leads to variation in the incremental cost effectiveness ratios (ICERs) for a given  
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combination of a test and treatment pairing. The appropriate distribution to use for both 
the data on test accuracy (sensitivity and specificity) and for data on intervention 
effectiveness (RR of developing FGR) was a log normal distribution. The distribution 
applied for prevalence was a β distribution where overall prevalence ~β(n,r) where 
n=total number of cases and r=total number of studies size. For costs a gamma 
distribution was applied. 
Assumptions made in the models were that it was appropriate to include only the 
interventions for which the 95% CI of the relative risk was <1 to avoid including 
interventions which may be deemed as harmful.  
In summary the complete set of analyses performed were: 
 Case 1: As detailed above, a deterministic sensitivity analysis using data for all 
the tests and combined with treatments with costs as detailed in tables 14.1-14.5 
for model 1, all pregnant women using the appropriate disease prevalence and 
parameters for an unselected population. 
 Case 2: As detailed above, a PSA analysis of case 1. 
 Sensitivity analyses: Sensitivity analyses were performed for case 1 varying the 
parameters for cost of FGR and using the individual, rather than summary, test 
accuracy inputs recommended in each of the test accuracy chapters (5-9) e.g. 
Pulsatility index and notching for uterine artery Doppler in an unselected 
population. 
 Case 3: As detailed above, a deterministic sensitivity analysis using data for all 
the tests and combined with treatments with costs as detailed in tables 14.1-14.5 
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Table 14.5: Costs for a baby born with a birth weight ≤2500g, according to birth weight and gestation. 
 
Term ≥ 37 completed weeks of gestation 
Preterm < 37 completed weeks of gestation 
 Average cost (£ 2009/2010) 
Year All 
admission 
≤2500g 
Term 
≤2500g 
Term 
2000-
2500g 
Term 
1500-
1999g 
Term 
1000-
1499g 
Preterm 
≤2500g 
Preterm 
2000-
2500g 
Preterm 
1500-
1999g 
Preterm 
1000-
1499g 
Preterm 
500-
999g 
Preterm 
<500g 
2008 12793 2564 2616 1541 5499 14309 3743 8031 15248 33974 51257 
2007 12585 1979 2042 1624 NA 13638 4298 7173 13826 32776 NA 
2006 13690 3091 2945 3779 NA 14733 4644 8064 21721 35103 NA 
2005 14908 2368 2393 2327 NA 16359 4502 9199 20565 48413 23508 
2004 16532 3258 3015 4107 NA 17692 4069 8160 20875 42708 35591 
Average 
over 5 
years 
14101 2652 2602 2676 5499 15382 4251 8125 18447 38595 36785 
Cost of fetal growth restriction per case  
 (input for model) 
£2652 
(Incremental cost of health care from birth to discharge from hospital for a 
baby<2500g) 
  
221 
 
for model 2, high risk pregnant women using the appropriate disease prevalence 
and parameters for a high risk population. 
 Case 4: As detailed above, a PSA analysis of case 3. 
 Sensitivity analyses: Sensitivity analyses were performed for case 3 varying the 
parameters for cost of FGR and using the individual, rather than summary, test 
accuracy inputs recommended in each of the test accuracy chapters (5-9) . 
 Case 5: A threshold analysis to explore what test accuracy and test cost 
parameters would be required to optimise cost-effectiveness using the 
deterministic analysis presented in case 2 as a starting point. 
 
14.4 Results 
 
Main result 
The most cost-effective strategy for all pregnant women was “no test/antiplatelets all” 
and for high risk pregnant women “HCG/antiplatelets +ve” was the most cost-effective 
strategy. 
 
Case 1: base case for model 1 all pregnant women 
Table 14.6 presents the results for the deterministic analysis for all pregnant women. 
The results are presented incrementally compared to the previous best option. The “no 
test, antiplatelets to all” strategy dominated throughout as the most cost-effective option 
at a mean cost of £177 per women. This strategy saves 7 cases of FGR per 1000 
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women, a number needed to treat (NNT) to prevent one additional case of FGR of 132. 
When “no test/antiplatelets” is removed from the model “no test/multiple 
micronutrients” was dominant. Figure 14.2 demonstrates the results graphically with all 
the cost-effectiveness estimates for case 1 shown. The nearer an estimate is to the 
bottom right hand corner of the graph, the greater its effectiveness and the lesser its 
cost. The strategy “no test/antiplatelets” is seen to dominate all other strategies.  
 
Table 14.6: Case 1, base-case results: costs, effects and ICERs for test/treatment 
combinations for all pregnant women (model 1). 
Test/treatment 
combination 
Mean 
cost 
per 
women 
(UK 
£2009) 
Differe
nce in 
costs 
(UK 
£2009) 
Effecti
veness
a
 
Absolute 
risk 
reduction 
Cost 
effectiveness 
 
 
ICER
b
 
  
  
  
No Test / 
Antiplatelets 177.05 
 
0.94 0.007
#
 189.22 
    No Test / 
Multiple 
Micronutrients 177.34 0.29 0.93 0.006 189.82 
(Dominated by no 
test/antiplatelets) 
Inhibin 
A/Antiplatelets 
(All) 187.05 10.00 0.94 0.007 199.91 
(Dominates the rest of 
the strategies) 
#
 Compared to "no test/no treatment”        
a 
Effectiveness is defined as the proportion of women with a pregnancy where a fetal 
growth restricted (FGR) baby is avoided. Therefore, the difference in effectiveness 
between two strategies is the absolute risk reduction 
   
b 
ICER: incremental cost effectiveness ratio expressed as the additional 
cost per additional case of FGR avoided. 
    AFP alpha fetoprotein; HCG human chorionic gonadotrophin; PAPPA 
pregnancy associated plasma protein A         
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Figure 14.2: Case 1, base case results: costs, effects and ICERs on cost-
effectiveness plane for all combinations of test and treatment pairs in an all 
pregnant women population 
 
 
Case 2: probabilistic sensitivity analysis of case 1 
The results of case 2 are presented in table 14.7. The results of the PSA confirm that at 
all levels of willingness to pay the strategy “no test/antiplatelets” is the dominant option 
with “no test/multiple micronutrients” is the next dominant. The PSA demonstrates if a 
policy maker is willing to pay £30,000 per case of FGR avoided, there is a 64% chance 
that “no test/antiplatelets” is the preferred option with respect to its cost-effectiveness. 
At the same threshold there is only a 36% chance that “no test/multiple micronutrients” 
is the preferred option. At a threshold of £100,000 then the results are 65% and 35% 
respectively. Thus the results are robust for all threshold levels. These results are 
presented graphically in figure 14.3 as a cost-effectiveness acceptability curve (CEAC) 
to ensure that this figure is legible the strategies associated with a probability of zero at 
any threshold level have been removed.  
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Table 14.7: Case 2, PSA of case 1, results: probability that stated options are the most 
cost-effective option at different levels of willingness to pay per case of fetal growth 
restriction avoided. 
  Willingness to pay (UK £2009/10)a 
  0 10,000 30,000 50,000 80,000 100,000 
Test/Treatment option 
      No test/no intervention 0.002 0.0002 0.0002 0 0 0 
No test/antiplatelets (All) 0.51 0.623 0.638 0.642 0.644 0.646 
No test/multiple micronutrients (All) 0.489 0.377 0.362 0.358 0.356 0.354 
a 
Per case of fetal growth restriction avoided             
The other test/treatment combinations are not shown as all had a probability of zero for all willingness to 
pay thresholds 
 
 
Figure 14.3: Case 2, probabilistic sensitivity analysis of case 1, results for all 
pregnant women (results with probability of zero across all thresholds removed). 
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Sensitivity analysis for case 1  
As the literature searches had been unable to identify any costs for FGR that could be 
compared with the calculated costs from BWH data, it was felt appropriate to perform a 
sensitivity analysis around this cost. Also from the BWH data there were many different 
costs according to different birth weight thresholds and gestation. Thus the sensitivity 
analysis used different costs identified from BWH data as shown in table 14.5 as well as 
analyses to show what would happen to the results if the cost of FGR was reduced to 
zero.  
 
The results of the sensitivity analysis for case 1 are presented in table 14.8. They 
demonstrate that at a higher cost level (£14101 and £36785) “no test/antiplatelets” 
remains the dominant strategy. If the cost of FGR is reduced to £1000 the most cost-
effective option becomes “no test/multiple micronutrients”. The exact threshold at 
which the strategies changed was identified as £2450 for “no test/multiple 
micronutrients” being more effective than “no test/antiplatelets”. There was no change 
in the results when varying the test accuracy inputs. 
 
Case 3: base case for model 2 high risk pregnant women 
Table 14.9 presents the results for the deterministic analysis for high risk pregnant 
women. The results are presented incrementally compared to the previous best option. 
The “HCG, antiplatelets +ve” was the most cost-effective option at a mean cost of £140 
per women. This strategy saves 6 cases of FGR per 1000 women, a number needed to 
treat (NNT) to prevent one additional case of FGR of 20 compared to 33 for “no 
test/antiplatelets all”. The next most cost-effective options were “AFP/antiplatelets +ve”  
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Table 14.8: Sensitivity analysis for case 1: deterministic analysis for case 1 when the cost of fetal growth restriction (FGR) is varied from the 
base case level of £2652 
Strategy 
Mean cost per woman 
(UK £2009) 
Difference in costs 
(UK £2009) Effectiveness 
Absolute 
risk 
reduction Cost-effectiveness ICER
b
 
Cost of FGR £36785 
      No Test / Antiplateletsa 2372.13 
 
0.94 
 
2535.17 
 Cost of FGR £14101 
      No Test / Antiplateletsa 913.33 
 
0.94 
 
976.10 
 Cost of FGR £1000 
      No Test / Multiple Micronutrients 68.74 
 
0.93 
 
73.58 
 No Test / Antiplatelets 70.81 2.07 0.94 0.0014 75.68 1449.09 
Cost of FGR £500 
      No Test / Multiple Micronutrients 35.87 0.14 0.93 0.0057 38.39 24.80 
No Test / Antiplatelets 38.65 2.79 0.94 0.0014 41.31 1949.09 
Cost of FGR £50 
      No Test / Multiple Micronutrients 5.30 2.80 0.93 0.0057 5.67 489.80 
No Test / Antiplatelets 8.75 3.45 0.94 0.0014 9.35 2414.09 
a 
Strategy dominates all others             
b 
ICER incremental cost-effectiveness ratio           
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Table 14.9: Case 3, base-case results: costs, effects and ICERs for test/treatment combinations for high risk pregnant women (model 2). 
Test/treatment combination 
Mean cost 
per women 
(UK £2009) 
Difference in 
costs (UK 
£2009) Effectiveness
a
 
Absolute risk 
reduction 
Cost 
effectiveness ICER
b
 
HCG/Antiplatelets +ve 140.41 
 
0.79 0.0059
#
 177.31 
 AFP/Antiplatelets (+ve) 195.11 54.70 0.79 0.0025 245.63 22118.31423 
Uterine artery 
Doppler/Antiplatelets +ve 299.30 104.18 0.80 0.0042 374.79 24671.15045 
No Test/Progesterone 493.22 193.92 0.86 0.0645 571.49 3008.047974 
HCG/Progesterone (All) 505.72 12.50 0.86 0.0000 585.97 
(This and all subsequent 
strategies dominated by 
No test/progesterone) 
# 
Compared to "no test/no treatment"           
a 
Effectiveness is defined as the proportion of women with a pregnancy where a fetal growth restricted (FGR) baby is avoided. Therefore, the difference in 
effectiveness between two strategies is the absolute risk reduction 
b 
ICER: incremental cost effectiveness ratio expressed as the additional cost per additional case of FGR avoided. 
 AFP alpha feto-protein; HCG human chorionic gonadotrophin; PAPPA pregnancy associated plasma protein A   
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 with an ICER of 22118 and “uterine artery Doppler/antiplatelets +ve” ICER 24671. 
Figure 14.4 demonstrates the results graphically with all the cost-effectiveness estimates 
for case 1 shown. The graph shows that “no test/progesterone all” is more effective but 
much more costly at a mean cost of £493 per woman compared to £140 for HCG. 
However, treatment with progesterone can prevent 65 cases per 1000 women of FGR, 
an NNT of 10. 
 
Figure 14.4: Case 3, base case results: costs, effects and ICERs on cost-
effectiveness plane for all combinations of test and treatment pairs in a high risk 
pregnant population 
 
 
Case 4: probabilistic sensitivity analysis of case 3 
The results of case 4 are presented in table 14.10. The results of the PSA demonstrate 
that the dominant strategy across all thresholds is “no test/progesterone” with an 87%  
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Table 14.10: Case 4, PSA of case 3, results: probability that stated options are the most 
cost-effective option at different levels of willingness to pay per case of fetal growth 
restriction avoided. 
  Willingness to pay (UK £2009/10)a 
  0 10,000 30,000 50,000 80,000 100,000 
Test/Treatment option 
      No test/no intervention 0 0 0 0 0 0 
No test/antiplatelets (All) 0 0.023 0.02 0.017 0.016 0.016 
No test/smoking cessation (All) 0 0.056 0.052 0.048 0.045 0.045 
No test/multiple micronutrients (All) 0 0 0.001 0.001 0.001 0.001 
No test/progesterone (All) 0 0.867 0.928 0.934 0.938 0.939 
AFP/Antiplatelets +ve 0.391 0.026 0 0 0 0 
HCG/Antiplatelets +ve 0.598 0.029 0 0 0 0 
Uterine artery Doppler/antiplatelets 
+ve 0.011 0 0 0 0 0 
a 
Per case of fetal growth restriction 
avoided             
AFP alpha fetoprotein; HCG human chorionic gonoadotrophin 
    
The other test/treatment combinations are not shown as all had a probability of zero for all willingness to 
pay thresholds 
 
chance at £10,000 and a 94% chance at £100,000 of this being the most preferred 
option. These results are presented graphically in figure 14.5 as a CEAC.  Further 
analysis shows that the threshold at which “no test/progesterone” becomes likely to be 
the dominant option is at £4540. As progesterone is mainly a treatment for high risk 
women at risk of pre-term labour it was felt appropriate to repeat the PSA with this 
strategy removed and smoking cessation removed as this can only be used in smokers. 
The results demonstrated that at a level of £10,000 “HCG/antiplatelets +ve” was likely 
to be the most cost-effective with a chance of 53% at £30,000 this became “no 
test/antiplatelets +ve” at 58% and this was likely to be the most cost-effective strategy 
at all subsequent thresholds. 
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Figure 14.5: Case 4, probabilistic sensitivity analysis of case 3, results for high risk 
pregnant women (results with probability of zero across all thresholds removed). 
 
 
Sensitivity analysis for case 3 
This was performed as for case 1 and the results are presented in table 14.11. They 
demonstrate that at a higher cost level (£14101 and £36785) and at lower cost levels 
(£1000 and £500) “HCG/antiplatelets +ve” remains the dominant strategy. If the cost of 
FGR is reduced to £50 the most cost-effective option becomes “no test/multiple 
micronutrients”. The exact threshold at which the strategies changed was identified as 
£86. There was no change in results when varying the test accuracy inputs. 
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Table 14.11: Sensitivity analysis for case 3: deterministic analysis for case 3 when the cost of fetal growth restriction (FGR) is varied from the 
base case level of £2652 
Strategy 
Mean cost per woman 
(UK £2009) 
Difference in costs 
(UK £2009) Effectiveness 
Absolute risk 
reduction Cost-effectiveness ICER
a
 
Cost of FGR £36785 
      HCG/Antiplatelets +ve 1763.20 
 
0.79 
 
2226.61 
 AFP/Antiplatelets (+ve) 2500.93 737.73 0.79 0.00 3148.40 298285.31 
Uterine artery Doppler/Antiplatelets +ve 3771.33 1270.40 0.80 0.00 4722.59 300838.15 
No Test/Progesterone 5168.08 1396.75 0.86 0.06 5988.23 21665.87 
Cost of FGR £14101 
      HCG/Antiplatelets +ve 684.73 
 
0.79 
 
864.70 
 AFP/Antiplatelets (+ve) 968.54 283.81 0.79 0.00 1219.28 114751.13 
Uterine artery Doppler/Antiplatelets +ve 1463.90 495.36 0.80 0.00 1833.14 117303.97 
No Test/Progesterone 2061.28 597.38 0.86 0.06 2388.39 9266.31 
Cost of FGR £1000 
      HCG/Antiplatelets +ve 61.87 
 
0.79 
 
78.13 
 AFP/Antiplatelets (+ve) 83.51 21.65 0.79 0.00 105.14 8752.13 
Uterine artery Doppler/Antiplatelets +ve 131.25 47.74 0.80 0.00 164.36 11304.97 
No Test/Antiplatelets 196.96 65.71 0.81 0.01 243.30 5990.88 
No Test / Smoking cessation 211.48 2.02 0.82 0.01 256.49 134.84 
Uterine artery Doppler/Progesterone (+ve) 237.55 13.57 0.83 0.00 287.19 5167.31 
No Test/Progesterone 266.96 29.41 0.86 0.04 309.33 819.45 
Cost of FGR £500 
      HCG/Antiplatelets +ve 38.10 
 
0.79 
 
48.11 
 AFP/Antiplatelets (+ve) 49.74 11.64 0.79 0.00 62.61 4706.68 
Uterine artery Doppler/Antiplatelets +ve 80.39 30.66 0.80 0.00 100.67 7259.51 
No Test / Multiple Micronutrients 101.44 21.05 0.80 0.00 126.31 4627.97 
No Test/Antiplatelets 101.73 0.29 0.81 0.01 125.66 45.17 
No Test / Smoking cessation 123.74 9.51 0.82 0.01 150.08 634.84 
Uterine artery Doppler/Progesterone (+ve) 151.12 14.88 0.83 0.00 182.70 5667.31 
No Test/Progesterone 198.48 47.36 0.86 0.04 229.98 1319.45 
  
 
 
2
3
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Cost of FGR £50 
      No Test / Multiple Micronutrients 12.84 2.14 0.80 0.02 15.99 125.23 
No Test/Antiplatelets 16.02 3.18 0.81 0.01 19.79 495.17 
AFP/ Progesterone (+ve) 41.35 12.83 0.81 0.00 50.85 3389.84 
No Test / Smoking cessation 44.77 3.42 0.82 0.01 54.30 305.50 
Uterine artery Doppler/Progesterone (+ve) 73.33 16.06 0.83 0.00 88.66 6117.31 
No Test/Progesterone 136.85 63.51 0.86 0.04 158.57 1769.45 
a 
ICER incremental cost-effectiveness ratio             
AFP alpha fetoprotein; HCG human chorionic gonoadotrophin           
  
233 
 
Case 5: threshold analysis for potentially cost-effective test parameters 
This analysis was prompted by the finding that the most cost-effective strategies in all 
pregnant women involved no prior testing. The model presented in case 2 was used to 
explore the levels of test accuracy and test cost that would be required to make a 
“test/treatment” strategy be more effective than a “no test/treat all” strategy. This was 
performed using two hypothetical tests; test A with a cost of £20 was based on uterine 
artery Doppler and test B with a cost of £5 based on the costs of first trimester blood 
tests (e.g. Down‟s syndrome serum screening). The intervention was chosen as 
antiplatelets. Thus there were two strategies “hypothetical test A/antiplatelets +ve” and 
“hypothetical test B/antiplatelets +ve). The model was then run with varying test 
accuracy parameters. The results are presented in table 14.12 and demonstrate that for a  
test cost of £20.00 there were no levels of test accuracy that would make a 
“test/treatment” strategy cost-effective. The cost had to be reduced to £5 with a LR+ve 
of 20 and LR-ve of 0.02 i.e. an excellent test for the “hypothetical test B/antiplatelets 
+ve” to be the most cost-effective strategy however; this was only up to a willingness to 
pay threshold of £1000 (46% chance).  
 
 
14.5 Discussion 
The main finding of the economic evaluation is that in an unselected pregnant 
population testing using Down‟s syndrome serum markers or uterine artery Doppler is 
not cost-effective compared to the strategy of treating all women with antiplatelets in 
the prevention of FGR. In high risk pregnant women the most cost-effective strategy is 
to test women with HCG and treat with antiplatelets those with a positive result. 
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Table 14.12: Case 5, threshold analysis on characteristics of a test that would be cost-
effective when combined with the intervention antiplatelets ("hypothetical 
test/antiplatelets +ve) 
Necessary 
characteristics of test  
Test/treatment 
option 
Probability of being most cost-effective option 
at different levels of willingness to pay for a 
case of fetal growth restriction avoided 
    0 10,000 30,000 50,000 100,000 
Hypothetical test A 
      LR+ve 10.0 Test and treat all 
positives with 
antiplatelets 
0 0 0 0 0 
LR-ve 0.2 
     Cost=£20.00 
     
       LR+ve 10.0 Test and treat all 
positives with 
antiplatelets 
0 0 0 0 0 
LR-ve 0.02 
     Cost = £20.00 
     
       LR+ve 20.00 Test and treat all 
positives with 
antiplatelets 
0 0 0 0 0 
LR-ve 0.2 
     Cost = £20.00 
     
       LR+ve 20.00 Test and treat all 
positives with 
antiplatelets 
0 0 0 0 0 
LR-ve 0.02 
     Cost = £20.00 
     
       Hypothetical test B 
      LR+ve 10.0 Test and treat all 
positives with 
antiplatelets 
0 0 0 0 0 
LR-ve 0.2 
     Cost=£5.00 
     
       LR+ve 10.0 Test and treat all 
positives with 
antiplatelets 
0.326 0.0001 0 0 0 
LR-ve 0.02 
     Cost = £5.00 
     
       LR+ve 20.00 Test and treat all 
positives with 
antiplatelets 
0 0 0 0 0 
LR-ve 0.2 
     Cost = £5.00 
     
       LR+ve 20.00 
Test and treat all 
positives with 
antiplatelets 
0.523 0.0008 0.0002 0.0001 0.0001 
LR-ve 0.02 
     Cost = £5.00           
LR+ve positive likelihood ratio LR-ve negative likelihood ratio 
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These results were found to be robust in a PSA and sensitivity analysis. Threshold 
analysis revealed that for a test to be considered as an option prior to treatment in 
unselected pregnant women it would have to have high levels of accuracy and be 
relatively cheap (£5). This is likely to be due to the fact that the majority of treatments 
available are themselves relatively cheap (£2.60 for aspirin) and thus from a cost point 
of view it will always be preferential to apply treatment to all rather than test first. This 
has to be interpreted in light of the limitations of the model importantly the lack of 
inclusion of adverse effects of treatment. 
 
Strengths of the economic evaluation 
The model was populated with data acquired through high quality and up to date 
evidence i.e. the systematic reviews of test accuracy and review of systematic reviews 
of effectiveness. The model was developed by the author, who received formal training, 
with the help of an experienced health economist (Angelos Tsourapas, Professor Tracy 
Roberts) and advice from a modelling expert (Dr Pelham Barton). The model was tested 
at all stages of development to ensure that it was methodologically correct and clinical 
advice was taken where necessary regarding the clinical assumptions made (Professor 
Khalid Khan, Professor Mark Kilby). Interpretation of the results of the model was 
made by the author following discussion with Angelos Tsourapas.  
 
Limitations of the economic evaluation 
There are two main limitations to this work. The first is the constraints of the model and 
the assumptions made, the second is the limitations in the data used to populate the 
model. 
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Model design and assumptions 
The model assumes that each pregnant woman will receive multiple tests as is the case 
in clinical practice but it is assumed that these will be interpreted in isolation i.e. with no 
reference to risk factors, clinical features or the other test results as would normal 
happen in clinical practice. The same is true for the interventions. Thus strategies tested 
consist of a single test+/- single intervention and thus this model does not evaluate 
combination testing and combination treatments.  
 
The model considers a single outcome “cost per case of FGR avoided”. The tests and 
treatments evaluated are also used in the management of pre-eclampsia and pre-term 
labour as there is great overlap in the aetiology and management of these conditions. 
Thus the tests may have a greater value if the outcome used was a combined outcome 
and the same may be true for the effectiveness of the interventions. However, the 
converse may be true e.g. in the case of some hypertensives for management of pre-
eclampsia there is an increased risk of an FGR baby. The model does also not consider 
the medium and long term outlooks for these babies e.g. perinatal mortality, 
neurodevelopmental outcome. 
 
The model does not take into account side effects and adverse events as a result of 
intervention or indeed testing e.g. increased maternal anxiety. The assumption made 
was that the side effects of the tests would be negligible as they were not invasive tests 
and they have been extensively evaluated in clinical practice. For the interventions there 
is evidence that the side effects of interventions such as aspirin is also negligible
164
, 
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however this is an important consideration particularly when one is advocating a policy 
of “test none/treat all”.  
 
The comparator used in the model was “no test/no intervention”. While this is necessary 
to allow comparison across strategies within the model it is recognised that in clinical 
practice all pregnant women will have some sort of testing in pregnancy. This may 
simply be assessment of risk factors or testing may be performed for other reasons but 
have implications for the outcome of FGR e.g. Down‟s syndrome serum screening. This 
is likely to have led to an overestimate of the cost-effectiveness of the strategies 
investigated compared to that which could be achieved in clinical practice but gain does 
allow comparison of strategies. 
 
The model cannot take into account any qualitative data e.g. the impact on a woman and 
her family of testing, the acceptability of the test etc. and thus all interpretations of 
“cost-effectiveness” are restricted to the perspective of the healthcare payer, in this case 
the NHS. This will limit the generalisability of the model to other countries and 
healthcare models however, the information gained from the model regarding the levels 
of test accuracy and costs required given the available interventions is important for 
health care researchers and policy makers worldwide. 
 
To the best of the author‟s knowledge there are no other published economic 
evaluations in this area with which to make comparisons. 
 
Limitations of primary data within model 
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Despite the strengths of the methods used to acquire this data it must be recognised that 
the inputs are limited by the quality of the primary data from which they arise. These 
limitations have been discussed in chapters 11 and 12. Particular considerations for the 
model are the wide confidence intervals associated with some of the tests and 
interventions and the applicability of some of the interventions to subsets of pregnant 
women. To overcome some of these limitations two models were used with some 
interventions only being included in the model for high risk women however some 
intervention e.g. progesterone and smoking cessation might be applied to subgroups 
only. Attempts to account for this were made in the sensitivity analyses. 
 
Data available within the literature for all costs was sparse despite systematic attempts 
to find this data. The main conclusions of the model arise due to the low cost of the 
available treatments thus if these costs were much higher the results may favour testing. 
The costs for pharmacological treatments were obtained from the BNF and thus can be 
considered as reasonable estimates and it is highly unlikely that the costs would vary 
enough to affect the model outputs. It is noted that other costs were not included within 
the cost of treatments e.g. consultation and prescription time however these costs are 
considered to be constant across the treatments and would exist for any future 
interventions. Again due to the very low costs of the treatments it is unlikely that the 
inclusion of these additional costs would have affected the model outputs.  
 
One of the major limitations is the cost attributed to a case of FGR. As discussed earlier 
there was no evidence available within the literature to inform this parameter. Cost data 
were thus obtained from BWH data and this necessitated the use of birth weight<2500g 
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as the threshold for disease. The limitations of this reference standard have been 
previously discussed. Attempts were made to make these costs as robust as possible by 
looking at sufficient years of data to get adequate numbers but to ensure data were 
contemporary. The costs could only include duration of stay on a neonatal unit or 
transitional care ward. Thus costs were not captured for mode of delivery, midwifery 
input, consultant obstetrician input, in-utero or ex-utero transfer etc. Costs were also 
determined according to birth weight threshold and gestation to give a range of costs 
and a very conservative cost of £2652 was used to populate the model. Sensitivity 
analysis around this cost parameter had no effect on the model outputs. Finally as this 
data were obtained from BWH data it must be recognised that this represents a regional 
tertiary referral unit and costs may be different for instance at a district general hospital.  
 
This economic evaluation can only be used to assess the cost-effectiveness of the 
strategies included within in it. Thus the value of new tests and treatments must be 
assessed as they are developed and their test accuracy and effectiveness has been 
properly evaluated e.g. first trimester serum screening markers. 
 
Recommendations for practice 
In light of the limitations and assumptions that were made within this health economic 
evaluation there is insufficient evidence to recommend changes to current clinical 
practice. However, there are considerable recommendations for future research. 
 
Recommendations for research 
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The results of this health economic evaluation suggest that research should be directed 
in three areas. The first is for clinical programmes to assess the use of interventions that 
are effective and of a low-cost with no prior testing in a pregnant population. One such 
intervention is aspirin. To implement such a policy would require careful consideration 
of side effects and patient preferences. 
 
There is further research needed to evaluate test accuracy of low-cost first trimester tests 
that may have levels of accuracy and costs compatible with a testing strategy and can be 
employed early enough in gestation to allow preventative treatment to be used. 
 
Finally there is a need for more comprehensive evaluation of currently available tests 
and treatments and their use in combination within a model, in particular using a 
comprehensive model that looks at multiple outcomes e.g. pre-eclampsia and FGR. 
 
14.6 Conclusion 
The conclusion of this health economic evaluation is that at present there are no tests 
that are suitable for prior testing in an unselected pregnant population. Considering the 
current available tests and treatments the most likely cost-effective option will be a low-
cost effective treatment with an excellent side-effect profile offered to all pregnant 
women in the first trimester. 
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CHAPTER 15: CONCLUSION 
15.1 Introduction 
This thesis performed an HTA in Obstetrics through evaluation of a range of tests and 
interventions for SGA fetuses and compromise of fetal/neonatal wellbeing. The thesis 
achieves the main objectives in that it reports: 
1. Summary estimates of accuracy of the following tests for restriction of fetal 
growth and compromise of fetal wellbeing: five serum screening markers, 
uterine artery Doppler, umbilical artery Doppler, middle cerebral artery Doppler 
and ductus venosus Doppler. 
2. An evaluation of the relationship between study quality and test accuracy 
3. Summary estimates of available treatments for restriction of fetal growth and 
compromise of its wellbeing. 
4. A health economic evaluation and decision analytic model of the combined 
effects of test and treatments on small for gestational age fetuses. 
 
 Each of the previous chapters in this thesis included detailed discussion of the main 
findings and the conclusions in light of any limitations.  This chapter focuses on the 
main findings of the work undertaken and discusses its strengths and limitations leading 
to general recommendations for research and practice. 
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15.2 Summary of main findings 
15.2.1 Test accuracy findings 
 In total 1,157 papers were read in full with 337 included in the reviews with 
472,544 women tested. The median number of women included was 33,292 
(interquartile range 13,273-40,637). The median number of studies per test was 60 
(interquartile range 31-86). The quality of studies was variable with the overall 
quality being poor.  
 The tests overall for prediction of small gestational age fetuses and adverse 
perinatal outcome demonstrated low predictive accuracy with no tests having a 
positive LR>5 and a negative LR<0.5. 
 
15.2.2  Effects of study quality on test accuracy  
 A total of 195 studies were included. The overall reporting quality of included 
studies to the STARD criteria was poor (adequate reporting >50% of the time 
for 62.1% (18/29) of the items.  The overall methodological quality was poor 
(>50% compliance with 57.1% of quality items).  
 There was a positive correlation (p<0.0001) between study sample size and 
reporting quality but not with methodological quality. No correlation with 
geographical area of publication and compliance with quality criteria could be 
demonstrated. 
 Meta-regression analysis showed that no individual quality item had a 
significant impact on accuracy. There was an association between reporting and 
methodological quality (r=0.51 p<0.0001).  
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 This work demonstrated that the reporting and methodological quality of papers 
in Obstetrics is improving but that there is still considerable scope for 
improvement.  
 
15.2.3 Effectiveness of interventions findings 
 There were 71 systematic reviews including a total of 733 RCTs reporting on 42 
different interventions.  
 After considering the results and the quality of evidence anti platelets and 
multiple micronutrient supplements were the interventions that were considered 
to be effective in preventing the small for gestational age fetus and suitable for 
use in all pregnant women. For high risk pregnant women the following were 
considered to be effective: anti platelets, multiple micronutrient supplements, 
smoking cessation interventions and progesterone therapy. For 
prevention/reduction of prenatal mortality ant platelets and antenatal 
corticosteroids were the interventions shown to be effective. 
 
15.2.4 Health economic evaluation and decision analytic modelling findings 
 Testing prior to intervention was not shown to be the most cost-effective 
strategy in the analyses for all pregnant women. Anti-platelet therapy, without 
prior testing, was highlighted as potentially cost-effective in preventing fetal 
growth restriction in this population. 
  In high risk women, testing with serum human chorionic gonadotrophin 
followed by anti-platelet therapy in those that test positive was a potentially 
cost-effective strategy. 
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15.3 Strengths of the thesis 
To the best of the author‟s knowledge there have been no previously reported 
systematic assessments of test accuracy and effectiveness of interventions in this subject 
area with decision analytic modelling. This thesis used robust and contemporary 
methods to achieve the aims and objectives. The evaluation of tests and treatments using 
a decision analytic model allows the combination of testing with many different 
treatments and allows them to be systematically assessed and compared. It thus allows a 
very comprehensive overview of the knowledge to date and by consideration of the 
strengths and limitations allows important recommendations for future research and 
clinical practice to be made. 
 
15.4 Limitations of the thesis 
15.4.1 Test accuracy limitations 
The limitations in the test accuracy systematic reviews were related to: 
 The primary data- general poor quality of the included primary studies, the 
unexplained heterogeneity within and across studies. 
  The review methods- the need to assess tests in isolation and thus not assess for 
diagnostic confounding, the fact that some important tests could not be 
reviewed in the timescale (section 10.5) and that tests were not assessed in 
combination. 
It is felt however, that the robust methods used within these reviews accounted for some 
of the limitations and that these reviews still represent the most up to date synthesis of 
the available evidence for the tests investigated. The work performed in this thesis 
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looking at effect of quality on results of test accuracy suggests that the impact of poor 
quality may be minimal. These results are thus still valid despite the limitations. 
 
15.4.2 Effectiveness of interventions limitations 
The main limitations in the review of systematic reviews of effectiveness in this subject 
area were: 
 The small number of RCTs for some interventions and the small number of 
participants in some of the RCTs. 
 Heterogeneity in populations and outcome measures. 
 The exclusion of observational data and thus possible adverse event data and 
data on some interventions only assessed by observational studies. 
 The lack of assessment of the quality of the individual RCTs. 
 The lack of data for combinations of interventions. 
 
15.4.3 Limitations for the economic analysis and decision model 
The limitations for the economic analysis and decision model are two fold; the 
limitations attached to the primary test accuracy and effectiveness data that informed the 
model and limitations due to model design. The design of the model was limited by: 
 Assessment of test-treatment combinations in isolation i.e. with no reference to 
other clinical data such as risk factors. 
 The consideration of a single outcome measure of FGR may have led to an 
underestimate of the cost-effectiveness of the test-treatment strategies. 
 The model does not take into account the acceptability of the strategies to 
women and clinicians nor does it assess side effects. 
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 The cost data used to inform the model was of poor quality with little 
information in the literature available with which to compare and validate the 
costs. 
This economic analysis is still valid despite these limitations due to the robust methods 
used to determine the test accuracy and effectiveness inputs and the use of sensitivity 
and PSA analysis to assess the uncertainty around the results. 
 
15.5 Recommendations for practice 
Despite the limitations identified it is felt that the methods used ensure that the results 
are still valid. This thesis has demonstrated that the tests reviewed have a limited use in 
screening/diagnosis for SGA/compromise of fetal and neonatal wellbeing when used in 
isolation. The main implications of this work are thus not for recommendations for 
practice but for future research. An effective, affordable and safe intervention applied to 
all mothers without prior testing is likely to be the most cost-effective strategy in the 
prevention of fetal growth restriction. At present aspirin appears to be the most likely 
intervention however further research needs to be performed particularly looking at 
interventions in combination and side effects prior to recommending a policy of treating 
all pregnant women without testing. 
 
15.6 Recommendations for research 
Further research in this area needs to consider the use of tests in combination and the 
role that other diagnostic tools, such as risk factor assessment and clinical features, add 
to the clinical decision making process. This research needs to be robustly designed, 
primary test evaluation strategies with reference to the quality criteria of the QUADAS 
  
247 
 
checklist and include a sample size calculation to ensure that results have sufficient 
power. There is a particular need for researchers in the area of fetal growth restriction to 
determine the most appropriate reference standards/outcome measures to be used that 
truly identify the growth restricted fetus. This will ensure that the primary research is 
not only directed at the fetuses/pregnancies at risk but will facilitate future systematic 
reviews and meta-analysis. 
 
To ensure that the results of any future economic analysis and decision model analysis 
can be translated into recommendations for practice there will be a need for models, and 
the primary research that informs them, to be able to compare both directly and 
indirectly all combinations of tests and treatments with consideration of side effects. 
There will also need to be further primary research to determine accurate costs of the 
outcomes. This research will also need to be directed to look at the impact of these 
clinical management strategies on multiple outcomes e.g. pre-eclampsia, pre-term birth 
and fetal growth restriction to ensure that a truly comprehensive clinical management 
pathway, that is applicable to a general pregnant population within the NHS can be 
devised. 
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Appendix 1: Table summarising the available literature on tests for prediction of fetal growth restriction and compromise of fetal 
wellbeing. (* These reviews were for fetal growth restriction and compromise of fetal wellbeing). 
Search for tests to predict fetal growth restriction/compromise of fetal wellbeing up to April 2008 – 21,437 citations 
Index Test  Number of citations 
identified in Reference 
Manager 11.0 
Number of relevant 
citations 
Number of existing 
systematic reviews of test 
accuracy 
 
 
History and examination 
Clinical risk scoring 15 6 6 
Abdominal palpation 5 2 0 
Symphyseal fundal height 
measurement 
79 28 1 
Fetal movement counting Not searched - 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ultrasound Biometry 
Abdominal circumference (AC) 16,361 Not screened 1 
Head circumference (HC) 916 Not screened 1 
Biparietal diameter (BPD) 246 Not screened 1 
Femur length (FL) 5171 Not screened 0 
Thoracic diameter 16 2 0 
Abdominal diameter 55 5 0 
Abdominal area 22 5 0 
Chest area 3 0 0 
Liver size 8 0 0 
Thigh circumference 15 3 0 
Subcutaneous fat 34 1 0 
FL/AC Not searched - - 
HC/AC Not searched - - 
FL/HC Not searched - - 
Head area/abdominal area Not searched - - 
FL/thigh circumference Not searched - - 
Estimated fetal weight (EFW) 166 24 1 
Fetal ponderal index 5 4 0 
Total intrauterine volume 13 5 0 
Trunk area x crown rump length Not searched - 0 
Growth velocity 56 2 0 
 Uterine artery 1366 311 Revised in this thesis 
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Ultrasound Doppler 
Umbilical artery 3896* 393* Revised in this thesis 
Middle cerebral artery 2004* 75* Revised in this thesis 
Descending aorta 65 9 0 
Internal carotid artery 5 0 0 
Ductus venosus 637* 46 Revised in this thesis 
 
Ultrasound Other 
Amniotic fluid measurements 4869* 310 Revised in this thesis 
Placental grade 3 1 0 
Biophysical profile 4417* 110* Revised in this thesis 
 
 
 
 
 
 
 
 
 
Biochemical and 
haematological 
Ooestriol  
 
 
 
1769 
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Revised in thesis 
Alpha fetoprotein 
Human chorionic gonadotrophin 
Pregnancy associated plasma protein 
A 
Inhibin A 
Beta-1 gylcoprotein 1 1 0 
Human placental lactogen 109 39 0 
Plasma fibronectin 4 1 0 
Placenta protein 10 3 1 0 
Dehydroepiandrosterone sulphate 
loading test 
11 2 0 
Epidermal growth factor 21 3 0 
Amniotic fluid C amnio peptide 0 0 0 
Serum cystine aminopeptidase 4 2 0 
Schwangerschafts protein 1 0 0 0 
Serum alpha 2-macroglobulin 0 0 0 
Maternal leuokocyte zinc 1 0 0 
Form stability index 0 0 0 
 
 
Other Tests 
Customised growth charts 2 2 1 
Cardiotocography Not searched - 1 
Fetal ECG Not searched - 0 
Fetal magnetocardiography Not searched - 0 
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Appendix 2: Search strategy for electronic database identification of diagnostic test 
accuracy studies for prediction of small for gestational age fetuses/fetal growth 
restriction for reviews of serum markers and uterine artery Doppler. 
Host: Ovid 
Date of search: April 2006 
Years covered by search: 1950-2006 
MEDLINE  
1. (("Small-for-Gestational Age") OR (Small-for-Gestational Age) OR (lbw) OR (small for 
gestational age) OR (sgr) OR (small for date*) OR (small for gestation*) OR (fgr) OR (iugr) OR 
(intrauterine growth retard*) OR (intrauterine growth restrict*) OR (fetal growth retard*) OR 
(fetal growth restrict*) OR (growth restrict*) OR (growth retard*) OR ("Placental 
Insufficiency"[MeSH]) OR ("Fetal Growth Retardation"[MeSH]) OR ("Infant, Low Birth 
Weight"[MeSH])) OR (low birth weight) 
2. ("Pregnant Women"[MeSH] OR "Pregnancy"[MeSH] OR "Pregnancy Outcome"[MeSH]) OR 
(pregnan*) 
3. Sensitivity and Specificity[MeSH] OR predict* OR diagnose* OR diagnosi* OR diagnost* OR 
accura* 
4. 1 AND 2 AND 3 
5. ((((("cohort studies"[mh] OR "case-control studies"[MeSH Terms]) OR "risk"[mh]) OR 
"epidemiologic factors"[MeSH Terms]) OR ("odds"[tw] AND "ratio*"[tw])) OR ("relative"[tw] 
AND "risk"[tw])) OR ("case"[tw] AND "control*"[tw]) 
6. 1 AND 2 AND 5 
 
EMBASE  
1. exp Fetus Growth/  
2. low birth weight.mp. or exp Low Birth Weight/ 
3. exp Intrauterine Growth Retardation/  
4. Intrauterine Growth Retard$.mp.  
5. Growth Retard$.mp.  
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6. Fetal Growth Retard$.mp.  
7. intrauterine growth restrict$.mp.  
8. fetal growth restrict$.mp.  
9. growth restrict$.mp.  
10. exp Small for Date Infant/  
11. Small for gestational age.mp. 
12. Small for date$.mp.  
13. Small for gestation$.mp.  
14. fgr.mp.  
15. iugr.mp. 
16. sga.mp.  
17. or/1-16 
18. exp pregnancy/  
19. exp Pregnant Woman/  
20. pregnancy outcome.mp. 
21. pregnan$.mp.  
22. pregnant wom$.mp.  
23. exp Placenta Insufficiency/ 
24. or/18-23  
25. (sensitiv$ or detect$ or accura$ or specific$ or reliab$ or positive or negative or diagnos$).mp. 
or di.fs. 
26. 17 and 24 and 25   
27. cohort analysis/ 
28. exp risk/ 
29. (odds$ adj ratio$).mp. 
30. (relative adj risk).mp. 
31. case control study/ 
32. (case$ adj control$).mp. 
33. (causa$ or predispos$).mp. 
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34. or/27-33 
35. 17 and 24 and 34   
 
COCHRANE LIBRARY 
1. small for gestational age in All Fields in all products 
2. sga in All Fields in all products 
3. small for date in All Fields in all products 
4. fgr in All Fields in all products 
5. lbw in All Fields in all products 
6. iugr in All Fields in all products 
7. intrauterine growth retard* in All Fields in all products 
8. fetal growth retardation in All Fields in all products 
9. fetal growth retard* in All Fields in all products 
10. growth restrict* in All Fields in all products 
11. growth retard* in All Fields in all products 
12. low birth weight in All Fields in all products 
13. MeSH descriptor Placental Insufficiency explode all trees in MeSH products 
14. placental insufficiency in All Fields in all products 
15. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 
OR #14) 
16. pregnancy in All Fields in all products 
17. MeSH descriptor Pregnant Women explode all trees in MeSH products  
18. MeSH descriptor Pregnancy explode all trees in MeSH products  
19. MeSH descriptor Pregnancy Outcome explode all trees in MeSH products  
20. (#16 OR #17 OR #18 OR #19) 
21. MeSH descriptor Sensitivity and Specificity explode all trees in MeSH products  
22. predict* OR diagnose* OR diagnosi* OR diagnost* in All Fields in all products 
23. (#21 OR #22) 
24. (#15 AND #20 AND #23) 
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25. MeSH descriptor Cohort Studies explode all trees in MeSH products 
26. MeSH descriptor Case-Control Studies explode all trees in MeSH products 
27. MeSH descriptor Risk explode all trees in MeSH products 
28. MeSH descriptor Epidemiologic Factors explode all trees in MeSH products 
29. (odds AND ratio) OR (relative AND risk) OR (case AND control) in All Fields in all products 
30. (#25 OR #26 OR #27 OR #28 OR #29) 
31. (#15 AND #20 AND #30) 
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Appendix 3: The Standards of Reporting in Diagnostic Accuracy (STARD) 
checklist34. 
 
Section and Topic Item  Code 
 1         2            3               4 
TITLE, ABSTRACT AND KEYWORDS 
 1 Identify the article as a study of 
diagnostic accuracy (recommend 
MeSH heading “ sensitivity and 
specificity”) 
Yes  □  No  □  Unclear  □ 
N/A  □       
INTRODUCTION 
 2 State the research questions or aims, 
such as estimating diagnostic accuracy 
or comparing accuracy between tests 
or across participant groups 
Yes  □  No  □  Unclear  □ 
N/A  □       
METHODS 
Participants 3 Describe the study population: the 
inclusion and exclusion criteria and 
the settings and locations where the 
data were collected. 
Yes  □  No  □  Unclear  □ 
N/A  □       
 4 Describe participant recruitment: 
was this based on presenting 
symptoms, results from previous tests, 
or the fact that the participants had 
received the index tests or the 
reference standard? 
Yes  □  No  □  Unclear  □ 
N/A  □       
 5 Describe participant sampling: was 
this a consecutive series of participants 
defined by selection criteria in items 3 
and 4? If not, specify how participants 
were further selected. 
1= consecutive  2=random  
3= unclear        4=N/a     
 6 Describe data collection: was data 
collection planned before the index 
tests and reference standard were 
performed (prospective study) or after 
(retrospective study)? 
1= prospective   2= 
retrospective 
3= unclear  4= N/a       
Test Methods 7 Describe the reference standards and 
its rationale. 
Yes  □  No  □  Unclear  □ 
N/A  □       
 8 Describe technical specifications of 
material and methods involved, 
including how and when 
measurements were taken, or cite 
references for a) index test or b) 
reference test 
Yes  □  No  □  Unclear  □ 
N/A  □       
 9 Describe definition of and rationale for 
the units, cut-off points, or categories 
of the results of the a) index test and  
b) reference standard. 
Yes  □  No  □  Unclear  □ 
N/A  □       
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 10 Describe the number, training and 
expertise of the persons executing and 
reading the a) index tests and b) 
reference standards. 
Yes  □  No  □  Unclear  □ 
N/A  □       
 11 Were the readers of the a) index test 
and b) reference standards blind 
(masked) to the results of the other 
test? Describe any other clinical 
information available to the readers. 
Yes  □  No  □  Unclear  □ 
N/A  □       
Statistical Methods 12 Describe methods for calculating or 
comparing methods of a) diagnostic 
accuracy and the statistical methods 
used to b) quantify uncertainty (e.g. 
95% CI) 
Yes  □  No  □  Unclear  □ 
N/A  □       
 13 Describe methods for calculating test 
reproducibility, if done. 
Yes  □  No  □  Unclear  □ 
N/A  □       
RESULTS 
Participants 14 Report when study was done, 
including beginning and ending dates 
of recruitment 
Yes  □  No  □  Unclear  □ 
N/A  □       
 15 Report clinical and demographic 
characteristics of the study population 
(e.g. age, sex, spectrum of presenting 
symptoms, co morbidity, current 
treatments, recruitment centres) 
Yes  □  No  □  Unclear  □ 
N/A  □       
 16 Report the number of participants 
satisfying the criteria for inclusion that 
did or did not undergo the index tests 
and/or the reference standard; describe 
why participants failed to receive 
either test. 
Yes  □  No  □  Unclear  □ 
N/A  □       
Test results 17 Report time interval from the index 
tests to the reference standard, and any 
treatment administered between. 
Yes  □  No  □  Unclear  □ 
N/A  □       
 18 Report distribution of severity of 
disease (define criteria) in those with 
the target condition; other diagnoses in 
participants without the target 
condition. 
Yes  □  No  □  Unclear  □ 
N/A  □       
 19 Report a cross tabulation of the results 
of the index tests (including 
indeterminate and missing results) by 
the results of the reference standard; 
for continuous results, the distribution 
of the test results by the results of the 
reference standard. 
Yes  □  No  □  Unclear  □ 
N/A  □       
 20 Report any adverse events form 
performing the index tests or the 
reference standard. 
Yes  □  No  □  Unclear  □ 
N/A  □       
Estimates 21 Report estimates of a) diagnostic 
accuracy and b) measures of statistical 
uncertainty (e.g. 95% CI) 
Yes  □  No  □  Unclear  □ 
N/A  □       
 22 Report how indeterminate results, 
missing responses and outliers of the 
index tests were handled. 
Yes  □  No  □  Unclear  □ 
N/A  □       
 23 Report estimates of variability of 
diagnostic accuracy between 
Yes  □  No  □  Unclear  □ 
N/A  □       
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subgroups of participants, readers or 
centres, if done. 
 24 Report estimates of test 
reproducibility, if done. 
Yes  □  No  □  Unclear  □ 
N/A  □       
DISCUSSION    
 25 Discuss the clinical applicability of the 
study findings. 
Yes  □  No  □  Unclear  □ 
N/A  □       
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Appendix 4: The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist35. 
Description QUADAS Item Code 1         2               3 
Was the spectrum of patients representative of the patients who will receive the test in 
practice? 
1 Yes □        No  □      Unclear □ 
Were selection criteria clearly described? 2 Yes □        No  □      Unclear □ 
Is the reference standard likely to correctly classify the target condition? 3 Yes □        No  □      Unclear □ 
Is the time period between reference standard and index test short enough to be 
reasonably sure that the target condition did not change between the two tests? 
4 Yes □        No  □       Unclear □ 
Did the whole study population or a random selection of the sample, receive verification 
using a reference standard for diagnosis? 
5 Yes □        No  □        Unclear □ 
Did patients receive the same reference standard regardless of the index test result? 6 Yes □        No  □        Unclear □ 
Was the reference standard independent of the index test? 7 Yes □        No  □        Unclear □ 
Was the execution of the index test described in sufficient detail to permit replication of 
the test? 
8 Yes □        No  □       Unclear □ 
Was the execution of the reference standard described in sufficient detail to permit its 
replication? 
9 Yes □        No  □       Unclear □ 
Were the index test results interpreted without the knowledge of the results of the 
reference standard? 
10 Yes □       No  □        Unclear □ 
Were the reference standard results interpreted without knowledge of the index test 
results? 
11 Yes □       No  □       Unclear □ 
Were the same clinical data available when test results were interpreted as would be 
available when the test is used in practice? 
12 Yes □       No  □       Unclear □ 
Were uninterpretable / intermediate test results reported? 13 Yes □       No  □     Unclear □ 
Were withdrawals from the study explained? 14 Yes □       No  □     Unclear □ 
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Appendix 5: Data extraction form for review of Down’s syndrome markers to 
predict small for gestational age fetuses. 
Section A: Study Information 
 
1)Ref ID:  4)Publication year:  
2)Rev 
name: 
 5)First Author:  
3)Country:  6)Language:  
 
Section B: Data Retrieval for Down’s screening study 
 
Population 
7) Healthcare Centre: 
Primary care □1  Secondary care  □2  Mixed □3    Other   □4        Unreported  □5 
 
8) Setting: 
 In-patient  □1  Out-patient  □2  Mixed  □3  Unreported  □4       Other  □5 
________________ 
 
9) Number of participating centres: ____________________________________ 
 
10) Gestation at time of index test: 
<20 weeks   □1  20-24 weeks  □2   24-28 weeks □3    28-34 weeks □4   34-37 
weeks □5    37-40 weeks  □6   > 40 weeks  □7      Unreported  □8           Other 
_______________________ 
 
10.i) Mean (range)______________________________________         Unreported  
□3 
 
10.ii) Median (range) ____________________________________        Unreported  
□3 
 
11) Pregnancy: 
Low Risk      □1  High Risk    □2  Unselected  □3  Unreported  □4 
 
11.i) State high risk conditions:      Unreported  □3 
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12) Were patients with the following conditions excluded/not included? 
12.i) Previous IUGR:  Yes □1  No  □2 Unreported   □3 
12.ii) Insulin dependent diabetes mellitus:      Yes □1 No  □2 Unreported   
□3 
12.iii)   Chronic renal disease:      Yes □1 No  □2        Unreported   
□3 
12.iv)   Systemic lupus erythematosus:      Yes □1  No  □2        Unreported   
□3 
12.v)    Antiphospholipid syndrome:          Yes □1  No  □2        
Unreported   □3 12.vi)   Chronic hypertension:         Yes □1  No  □2        
Unreported   □3 12.vii)   Pre-eclampsia:       Yes □1  No  □2        
Unreported   □3 
12.viii)  Foetal chromosomal/structural anomalies:  Yes □1  No  □2        
 Unreported   □3 
 
13) Did all patients have singleton pregnancies?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
14) Were all patients primigravid?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
15) List other eligibility/ in-/exclusion criteria: 
 
 
 
 
16) Study population: (describe age (mean +/- SD or median/range), ethnicity, smoking, BMI 
etc.) 
 
 
 
   ----------/-------------            
   ----------/-------------            
 
 
 
Not applicable  □3 
 
 
 
 
 
 
Unreported  □3 
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17) Start of patient inclusion (year) :                        U    
Unreported □3  
18) End of patient inclusion (year) :              
Unreported □3 
19) Study Design:    
cohort  □1    case control  □2      RCT/CCT  □3        cross sectional  □4     before and 
after  □5         case series   □6  (no ______)      other  □7 
19.i) Data collection:  prospective □1      retrospective   □2      unreported  □3        
other  □4 
19.ii) Enrolment:    consecutive  □1       arbitary (random) □2      unreported  □3        
other  □4 
20) Numbers: 
 
21) Completeness of Verification: 
 
 
 
B Reasons 
________________ 
 
D Reasons 
________________ 
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(= E / C x 100 = %)> 90%  □1     81-90%  □2     < 81%  □3 
Index Test 
 
22) Description of technique:      
Adequate  □1   Inadequate  □2 
 
23) Timing of measurement (from delivery): 
< 7days □1  7-14 days  □2  14 -28 days □3  > 28 days  □4    Mixture  □5   
Unreported  □6 
 
23.i) Median gestational age at delivery   _____________________________ 
unreported  □3         
24) Measurement AFP: 
Method of sample analysis: 
24.i) Test/Analysis method: 
RIA  □1   EIA  □2       FEIA   □3    FIA  □4   MEIA   □5        Unreported   □6 
24.ii) Laboratory/Machine used_____________________________________ 
unreported  □3         
24.iii) Software used for calculating Mom: 
____________________________Unreported  □3 
24.iv) Cut-off used (and data-set if 
reported):__________________________________Unreported □3 
 
 
 
 
 
 
25) Measurement Beta HCG: 
Method of sample analysis: 
24.v) Any corrections made: (e.g. weight, height, race, IDDM etc) 
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25.i) Test/Analysis method: 
RIA  □1   EIA  □2       FEIA   □3    FIA  □4   MEIA   □5        Unreported   □6 
25.ii) Laboratory/Machine used_____________________________________ 
unreported  □3         
25.iii) Software used for calculating Mom: 
____________________________Unreported  □3 
25.iv) Cut-off used (and data –set if 
reported):_____________________________________Unreported □3 
 
 
 
 
 
26) Measurement Ooestriol: 
Method of sample analysis: 
26.i) Test/Analysis method: 
RIA  □1   EIA  □2       FEIA   □3    FIA  □4   MEIA   □5        Unreported   □6 
26.ii) Laboratory/Machine used_____________________________unreported  □3         
26.iii) Software used for calculating Mom: ________________ __unreported  □3 
26.iv) Cut-off used (and data-set if reported): _________________________unreported □3 
 
 
7) Measurement PAPP-A: 
Method of sample analysis: 
27.i) Test/Analysis method: 
RIA  □1   EIA  □2       FEIA   □3    FIA  □4   MEIA   □5        Unreported   □6 
26.v) Any corrections made: (e.g. weight, height, race, IDDM etc) 
25.v) Any corrections made: (e.g. weight, height, race, IDDM etc) 
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27.ii) Laboratory/Machine used____________________________ unreported  □3         
27.iii) Software used for calculating Mom: ___________________Unreported  □3 
27.iv) Cut-off used (and data-set if reported): 
__________________________________Unreported □3 
 
 
28) Measurement Inhibin: 
Method of sample analysis: 
28.i) Test/Analysis method: 
RIA  □1   EIA  □2       FEIA   □3    FIA  □4   MEIA   □5        Unreported   □6 
28.ii) Laboratory/Machine used____________________________ unreported  □3         
28.iii) Software used for calculating Mom: ___________________Unreported  □3 
28.iv) Cut-off used (and data-set if reported): 
__________________________________Unreported □3 
 
 
Reference Standard / Outcome 
25) Measured blind form diagnostic test:   Yes  □1    No  □2   Unclear  □3 
26) Measurement for FGR:   Birthweight  □1  Neonatal ponderal index  □2  
Skin fold thickness □3    MAC / OFC  □4    Other  □5  _____________________________ 
27) Threshold:   < 3rd centile  □1  < 5th centile  □2   < 10th centile  □3  < 25th 
centile □4  > 2SD  □5   Other □6 ________________________________________________      
Unclear   □7 
27.v) Any corrections made: (e.g. weight, height, race, IDDM etc) 
28.v) Any corrections made: (e.g. weight, height, race, IDDM etc) 
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28) What data set was used to define threshold? 
___________________________________________________________          
unreported  □3         
29)Timing of measurement:  At delivery  □1   Within 24 hrs  □2   > 24 hrs  □3  
Mixture  □4   Unreported  □5     
 
 
 
 
                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Results 
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Appendix 6: Guide to quality assessment of included studies in review of Down’s 
syndrome markers to predict small for gestational age fetuses.
Feature 
Quadas 
Number 
Applicability and criteria fulfilled when 
Population 
spectrum 
1 Refers to severity of underlying target condition, demographic 
features and presence of differential diagnoses and/or co-morbidity. 
For study to be classified as adequate: Appropriate spectrum – 
pregnant women, either unselected or selected (high or low risk) in 
any health care setting. Ideally there was prospective, consecutive 
recruitment. 
 
Selection Criteria 2 Refers to inclusion/exclusion criteria. For an unselected population 
this would not be applicable. For a selected population high risk 
conditions must be explicitly documented. If the inclusion criteria for 
the categories were not explicitly described then the category was 
unclear. 
 
Appropriate 
Reference 
standard 
3 SGA: birth weight < 10
th
 centile adjusted for gestational age and 
based on local population values and absolute birth weight threshold 
< 2500g. Severe SGA: birth weight < 5
th
 or < 3
rd
 centile or < 1750g. 
Neonatal ponderal index < 10
th
 centile, skin fold thickness, and mid-
arm circumference/head circumference were also assessed.  
 
Time period 
between tests 
4 Time period needs to be short enough to ensure that target condition 
does not change. For this review this was always graded as N/A. 
 
Verification Bias 5 If >90% of patients or a random selection of patients received 
verification with reference standard then answer was yes, even if the 
reference standard was not the same for all patients.   If the number 
was <90% or a non-random selection then the answer was no. 
Unclear was utilised when the percentage could not be calculated or 
no information was given. 
 
Number of 
reference 
standards used 
6 This is N/A to this review: no invasive reference test. 
 
 
Independent 
reference 
standard 
7 The results of the index test are not incorporated in the definition of 
small for gestational age/fetal growth restriction. For this review the 
answer will always be yes. 
 
Adequate 
description of 
index test 
8 To be graded as adequate the description must include: cut-off used, 
assay used and manufacturer of assay/machine used. 
 
Adequate 
description of 
reference 
standard 
9 Birth weight: timing of measurement, scales used, whether baby 
clothed or not. 
Neonatal ponderal index: description of birth weight and length 
measurement as above. 
Skin fold thickness: description of site of measurement, instrument 
used and timing of measurement. 
Mid-arm circumference/ head circumference: see skin fold thickness. 
If this information was not provided this was classified as unclear. 
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Blinding  
of index test 
10 For this review this answer will always be yes, as the reference standards 
can only be performed after delivery. In the case of retrospective analysis 
of blood samples this will also be yes as fully automated. 
 
Blinding of 
reference 
standard 
11 To confirm that blinding was present a statement in the text to the effect of 
“clinicians were blinded/unaware of the results of the --- test”. If there was 
a statement to the contrary the answer was no. If no statement existed the 
answer was unclear. If test were entirely objective (or an independent 
laboratory was used) then this was N/A.  
 
Availability of 
clinical data 
12 Clinical data refers to any information relating to the patient obtained by 
direct observation (e.g. age, sex, symptoms, BMI). If clinical data will be 
available when the test is interpreted in practice then this should be 
available when the test is evaluated. In this review the test was fully 
automated and thus is N/A.  
 
Intermediate 
results 
13 If uninterpretable, failed or intermediate results are documented or no such 
events occurred then the answer is yes. If it was apparent that such results 
have occurred but are not reported then the answer was no. If not clear 
whether all results were reported then answer was unclear. 
 
Withdrawals 
from study 
14 If clear what happened to all patients within the study e.g. flow diagram 
then answer was yes. If some did not receive both index and reference 
standard then answer was no.  
 
Intervention A If after receiving the index test patients received any medical or surgical 
intervention then the answer was yes, and the type of intervention 
recorded. If a statement existed that no intervention was given the answer 
was no. If no statement existed and no interventions were given then the 
answer was unclear. 
  
269 
 
Appendix 7: References for studies included in review of Down’s serum screening 
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Appendix 8: Study characteristics of included studies for maternal serum biochemical (Down’s syndrome) screening to predict small 
for gestational age fetuses. 
 
First Author 
(year) 
Population 
Age 
(country/study design) 
No of 
women 
analysed 
Gestational 
age at test 
(weeks) 
Incidence 
of SGA 
(%) 
Reference 
standard 
SGA 
 Details of Index test 
 
 
Akinbiyi  
(1996) 
 
INC: singletons, 12% primips, EXC: structural and chromosomal 
anomalies 
18-47 years 
(UK) (case control, matched, index test) 
 
300 
 
16-18 
 
7.33 
 
BW 
<2500g 
 
AFP,RIA 
>2.0 MoM 
 
Audibert  
(2005) 
 
INC: double test and uterine artery Doppler 18-26 weeks, 
singleton, primips 48.5% EXC: structural and chromosomal 
abnormalities, multiple pregnancies, increased NT, delivery<24 
weeks, 8 lost to follow up. 
Mean age 30.9+/-4.5 years (France) (cohort) 
 
2615 
 
14-18  
 
8.70 
 
BW<10
th
 
centile 
(local) 
 
Method not reported 
AFP>1.5MoM 
HCG>1.5 MoM, 
>2.0MoM 
       
 
Benn  
(1996) 
 
INC: singletons EXC: structural and chromosomal anomalies, 
IDDM 
Age not reported 
(USA) (case control, matched test) 
 
1079 
 
15-21.9 
 
3.06 
 
BW<10th 
centile 
 
HCG, Method not 
reported 
>3 MoM 
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Bernstein 
(1992) 
 
INC: singletons EXC: structural and chromosomal abnormalities 
26.3+/-4.3 years 
(USA) (cohort, prospective) 
 
234 
 
17-21 
 
10.7 
 
SGA (no 
threshold) 
 
AFP, Method not 
reported 
>2.0 MoM 
       
 
Bewley 
(1992) 
 
INC: singletons  
Age not reported 
(UK) 
(Cohort, prospective) 
  
 
172 
 
16-24 
 
14.5 
 
BW<10th 
centile 
(local) 
 
AFP and HCG,RIA 
>90th centile 
PAPP-A, RIA >90th 
and <10th centile 
 
Bloxam 
(1994) 
 
INC: singletons EXC: structural and chromosomal abnormalities 
Age not reported 
(UK)(cohort) 
 
 
 
147 
 
16-18 
 
14.3 
 
BW≤10th 
centile 
 
AFP, Method not 
reported 
>1.7MoM 
Brajenovic-
Milic  
(2004) 
INC: singletons, primips 58.5% EXC: IDDM, structural and 
chromosomal anomalies, false positive NTD screen (MSAFP≥2.o 
MoM), screen positive Down‟s test ≥1:250, smokers 
Mean age 27.9+/-4.3 years 
(Croatia) (cohort) 
1507 15-20 4.45 BW<10th 
centile 
Free ßHCG 
Method not reported 
≥2.0 MoM 
 
 
Brazerol  
(1994) 
 
 
INC: singletons EXC: structural and chromosomal abnormalities 
Mean 23.8 years 
 
 
774 
 
 
15-20 
 
 
4.52 
 
 
IUGR (no 
threshold) 
 
 
AFP, Method not 
reported 
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(USA)(cohort, prospective) ≥2.0MoM 
 
Bremme  
(1988) 
 
INC: singletons EXC: structural and chromosomal abnormalities 
Age not reported 
(Sweden)(case control) 
 
222 
 
16-17 
 
7.66 
 
SGA (no 
threshold) 
 
AFP, RIA 
(Behringwerke) 
>83.3µg/l 
 
Brock  
(1980) 
 
INC: singletons 
Age not reported 
(UK)(Case control, retrospective, outcome) 
 
226 
 
15-22 
 
50.0 
 
BW<2500g 
 
AFP, RIA 
≥1.0,1.5,2.0,2.5,3.0 
MoM 
 
Buckland  
(1984) 
 
INC: singletons 
Age not reported 
(UK)(Case control, retrospective, outcome) 
 
325 
 
16-20 
 
62.5 
 
BW<10th 
centile 
(sex, parity, 
local) 
 
AFP,RIA 
≥2.0 MoM 
 
Burton  
(1988) 
 
INC: screening programme EXC: oligohydramnios 
Age not reported 
(USA)(Case control, nested cohort) 
 
15512 
 
16-18  
 
7.33 
 
BW<2500g 
 
AFP, RIA/EIA 
(Amersham/Abbott) 
>2.5, <0.5 MoM 
 
Capeless  
(1992) 
 
INC: screening programme 
Age not reported 
(USA) (cohort, prospective) 
 
358 
 
16-20 
 
3.91 
 
BW<10th 
centile 
 
AFP, Method not 
reported 
>2.0 MoM 
 
Chapman  
 
INC: maternal age ≥30, amniocentesis EXC: structural and 
 
1135 
 
15-20 
 
3.44 
 
BW<10th 
 
Triple test, RIA 
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(1997) chromosomal anomalies 
(USA) (cohort, retrospective) 
centile 
(local) 
DS>1:190 
 
Chard  
(1986) 
 
INC: singletons EXC: delivery < 28 weeks 
Age not reported 
(UK) (cohort, prospective) 
 
476 
 
15-18 
 
10.3 
17.6 
 
BW≤2500g 
BW<10th 
centile 
(local) 
 
AFP, Method not 
reported 
≥90th centile 
 
Chitayat  
(2002) 
 
INC: singletons 
Age not reported 
(Canada) (case control, test) 
 
1134 
 
Second 
trimester 
 
3.35 
 
SGA no 
threshold 
 
DS≥1:385 and 
AFP≥2.2MoM 
Method not reported 
 
Cho  
(1997) 
 
INC: singletons EXC: structural and chromosomal abnormalities 
Mean 25.8 +/- 5.8 years 
(USA) (case control, prospective, matched index test) 
 
255 
 
14-20 
 
8.23 
 
BW<10th 
centile 
 
AFP, RIA 
(Kallastaad) 
≤0.5, ≥2.5, 4.0 
MoM 
 
Cox  
(1995) 
 
INC: singletons EXC: structural and chromosomal anomalies, 
invasive procedures, birth < 24 weeks 
Age not reported 
(Scotland) (cohort) 
 
15705 
 
16-20 
 
2.29 
 
BW<5th 
centile 
(local) 
 
AFP, RIA 
>2.0 MoM 
 
Cusick  
(1996) 
 
INC: singletons, 47% primips, no fetoplacental abnormality EXC: 
structural and chromosomal anomalies, 2 placental abruption, TOP 
 
333 
 
15-20 
 
10.8 
 
BW<10th 
centile 
 
AFP, Method not 
reported 
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Mean age 27.1 (15-42) years 
(USA) (cohort, retrospective) 
(local, sex) ≥2.5 ≥3.0 MoM 
 
Di Mario  
(1998) 
 
INC: singletons EXC: structural and chromosomal anomalies, 
previous PE, IDDM, delivery < 26 weeks 
Mean 30.6 +/- 3.6 years 
(Italy) (cohort) 
 
547 
 
16-18 
 
11.6 
 
BW<10th 
centile 
(local) 
 
RIA (Johnson and 
Johnson) 
AFP and HCG ≥2.0 
MoM 
UE3 ≤0.7MoM 
 
Doran  
(1987) 
INC: patients at low genetic risk, singleton 
Age not reported 
(Canada) (cohort, prospective) 
7307 16-18 1.35  BW<10th 
centile 
AFP, RIA (WHO 
Behring) 
>2.0 MoM 
 
Dugoff  
(2004) 
 
INC: singletons, 45.1% primips EXC: IDDM, structural and 
chromosomal anomalies 
Mean age 30.1+/-5.77 years (16-53) 
(USA) (cohort, prospective) 
 
33995 
 
10+3-13+6 
 
8.80 
 
3.82 
 
BW<10th 
centile 
(local) 
BW<5th 
centile 
(local) 
 
PAPP-A ELISA 
(Diagnostics, Texas) 
≤10th, <5th, ≤ 1st 
centile 
 
Dugoff  
(2005) 
 
EXC: structural and chromosomal anomalies 
Mean age 30.2 +/- 5.71 (16-53) years 
(USA) (cohort, prospective) 
 
33145 
 
15-18+6 
 
8.90 
 
3.90 
 
BW<10th 
centile 
(local) 
BW≤5th 
 
AFP and HCG, 
Chemiluminescent 
immunoassay 
(Diagnostics) 
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centile ≥2.0 MoM 
UE3 RIA 
(Diagnostics) 
≤0.5MoM 
Inhibin A, ELISA 
(Serotec) ≥2.0MoM 
 
Dungan  
(1994) 
 
INC: singleton EXC: structural and chromosomal abnormalities, 
maternal age >35 years 
(USA) (case control, matched test) 
 
198 
 
15-20 
 
5.66 
 
BW<5th 
centile 
 
DS≥1:270 
 
Duric  
(2003) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Age <35 years 
(Croatia) (cohort, retrospective) 
 
673 
 
15-22 
 
5.20 
 
BW<10th 
(local) 
 
RIA 
AFP≥2.0 MoM 
Total HCG 
≥2.02MoM 
UE3 ≤0.74MoM 
 
   Endres  
(2003) 
 
INC: AFP>0.5 but <2.0 MoM, HCG≤0.5 MoM and oestriol >0.6 
and <2.0 MoM 
Mean age 30+/-6 years 
(USA) (case control matched) 
 
438 
 
15-20 
 
7.30 
 
BW<2500g 
 
ßHCG 
Method not reported 
≤0.5 MoM 
 
Evans  
(1984) 
 
INC: screening programme  
Age not reported 
 
220 
 
16-18 
 
7.73 
3.18 
 
BW<2500g 
BW<10th 
 
AFP, RIA 
(Amersham) 
  
290 
 
(UK) (case control, unmatched, index test) centile >95th centile 
 
Ghosh 
(1986) 
 
EXC: structural and chromosomal anomalies 
Age not reported 
(Hong Kong) (cohort, prospective) 
 
9838 
 
15-20 
 
3.03 
 
SGA (no 
threshold) 
 
AFP, RIA 
>2.0,≥2.8,3.0,4.0 
MoM 
 
Gonen  
(1992) 
 
INC: HCG>2.5 MoM, singleton, USS dating EXC: structural and 
chromosomal anomalies, AFP>2.5 MoM 
Age not reported 
(Israel) (cohort) 
 
493 
 
16-20 
 
7.91 
 
BW<10th 
centile 
 
HCG, method not 
reported, (Delfia), 
>2.5MoM 
 
Gordon  
(1979) 
 
INC: singletons EXC: structural and chromosomal anomalies, 
delivery < 28 weeks 
Age not reported 
(UK) (cohort, prospective) 
 
828 
 
16-22 
 
4.35 
 
BW<2500g 
 
AFP, RIA 
>95th centile 
 
Haddad  
(1999) 
 
INC: singleton, IVF, primips 86% 
Mean age 33.6+/-4.2 
(France) (cohort, retrospective) 
 
180 
 
13-35 days 
 
10.60 
 
BW<10th 
(local) 
 
HCG, Method not 
reported  
<10th, >90th centile 
 
Haddow  
(1983) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Age not reported 
(USA) (cohort, prospective) 
 
2984 
 
15-20 
 
4.50 
 
BW<2500g 
 
AFP, RIA (Oxford) 
≥2.0,3.0 MoM 
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Haddow  
(1986) 
INC: singletons EXC: neural tube defects 
Age not reported 
(USA) (cohort) 
6531 15-20 3.94 BW<2500g AFP, RIA 
≥2.0MoM 
 
   Haddow 
(1987) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Age not reported 
(USA) (cohort, prospective) 
 
9507 
 
15-20 
 
4.08 
 
BW<2500g 
 
AFP, RIA (Maine) 
≥2.0 MoM 
 
Hamilton  
(1985) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Age not reported 
(Scotland) (case control, prospective, matched, index test) 
 
372 
 
16-20 
 
15.90 
17.70 
 
 
4.30 
9.95 
 
BW<2500g 
BW<10th 
centile 
(sex, local, 
parity) 
BW<1500g 
BW<5th 
centile 
(sex, local, 
parity) 
 
AFP, Method not 
reported 
>2.5 MoM 
 
Hayashi  
(1992) 
 
INC: screening programme 
Age not reported 
(Japan) (cohort, prospective) 
 
532 
 
12-19 
 
1.50 
 
SGA (no 
threshold) 
 
AFP, Method not 
reported  
≥2.5 MoM 
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Heikkila 
(2001) 
INC: singletons, primips, pre-eclampsia EXC: structural and 
chromosomal anomalies 
Mean age 26.8+/-5.1 years 
(Finland) (cohort, prospective) 
487 
471 
15-16 2.22 
2.95 
BW<10th 
centile 
BW<2500g 
HCG,  
Immunoassay 
(Abbott) 
≥2.5MoM 
 
Heinonen 
(1996) 
 
INC: singletons EXC: structural and chromosomal anomalies, 
pregnancy loss < 24 weeks 
Mean age not reported 
(Finland) (case control, matched, test) 
 
5290 
 
15 
 
4.63 
 
BW<2500g 
 
Total ßHCG 
(IMX Abbott) 
≥2.0 MoM, >4 
MoM 
 
Heinonen  
(1999) 
 
INC: singletons EXC: structural and chromosomal anomalies, 
women that stopped smoking during study 
Mean age 27.4 years 
(Finland) (cohort) 
 
1421 
 
15-18 
 
12.30 
19.60 
 
BW<2500g 
BW<10th 
centile 
(sex) 
 
AFP< RIA (Clinical 
chemistry) 
>2.5 MoM 
 
Hershkovitz 
(2003) 
 
EXC: structural and chromosomal anomalies 
Mean age (AFP≥4.0MoM) 29.9+/-10.1 years 
(Canada) (cohort, prospective) 
 
121 
 
15-18 
 
3.31 
 
BW<10th 
centile 
 
HCG, Method not 
reported 
≥4.0MoM 
 
Hershkovitz  
(2005) 
 
INC: chronic hypertension, previous PE, thrombophilia 
Median age 29 (21-40) 
(Canada) (cohort) 
 
88 
 
15-18 
 
26.1 
 
BW<10th 
centile 
(sex) 
 
Method not reported 
AFP >2.0 MoM 
HCG ≥3.0MoM 
 
   Jauniaux 
 
INC: singletons, abnormal uterine artery Doppler EXC: structural 
 
41 
 
20-24 
 
39.00 
 
BW<10th 
 
AFP, FEIA 
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(1996) and chromosomal anomalies 
Age not reported 
(UK) (Cohort) 
centile (Hybritech) 
≥2.5 MoM 
IRMA (Biomeriuex) 
Total 
ßHCG>2.5MoM 
Free 
ßHCG>2.5MoM 
 
Kavak  
(2006) 
 
INC: singletons, 50-4% primips EXC: IDDM, chronic 
hypertension, fetal abnormalities 
Mean age 30.4+/-5 years 
(Turkey) (cohort) 
 
476 
 
First 
trimester 
 
7.35 
 
BW<10th 
centile 
 
PAPP-A, Random 
access immunoassay 
(Kryptor) 
<0.69MoM, <0.4 
MoM(roc 
determined) 
 
Kiran  
(2005) 
 
INC: singletons, low risk EXC: structural and chromosomal 
anomalies 
Mean age not reported. 
(UK) (cohort) 
 
6297 
 
Second 
trimester 
 
4.10 
 
BW<2500g 
 
AFP, Method not 
reported >2.0 MoM 
 
Kowalczyk  
(1998) 
 
INC: singletons, 31.7% primips, AFP and HCG>2.0 MoM 
EXC: structural and chromosomal anomalies 
Age <35 years 
(USA) (cohort) 
 
309 
 
15-21 
 
8.74 
 
BW<10th  
 
UE3, RIA 
≤0.75 MoM 
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Krantz  
(2004) 
 
INC: first trimester screening EXC: chromosomal and structural 
anomalies 
Age not reported 
(USA) (cohort, retrospective) 
 
 
6276 
 
10+4 – 
13+6 
 
6.26 
 
BW<10th 
centile  
(ga, local, 
sex) 
 
Free ßHCG <1st and 
<5th centile, >90th 
and 99th centile 
Papp-a <1st and 5th 
centile, >90th and 
99th centile 
 
Kuo 
(2003) 
 
INC: singletons EXC: structural and chromosomal anomalies, 
abnormal HCG or Down‟s risk, IDDM. 
Mean age 28.3 +/-0.3 years 
(Taiwan) (case control, unmatched, index test) 
 
247 
 
15-20 
 
4.70 
8.80 
 
BW<2500g 
BW<10th 
centile 
 
AFP, Method not 
reported 
>2.0 MoM 
 
Kwik  
(2003) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Mean age 32.7 (15-42) 
(Australia) (Cohort retrospective) 
 
827 
 
77-97 days 
 
6.65 
 
BW<10th 
centile 
(local) 
 
PAPP-A ELISA 
(diagnostics) 
<0.3,<0.5 MoM 
 
Legge  
(1985) 
 
NC: singletons EXC: structural and chromosomal anomalies 
Age not reported 
(New Zealand) (cohort) 
 
507 
 
10-24 
 
8.68 
 
BW<10th 
centile 
 
AFP, RIA (Biodata) 
≥2.0 MoM 
 
Lepage  
(2003) 
 
INC: MSAFP<2.0 MoM EXC: structural and chromosomal 
anomalies, IDDM 
Age not reported 
 
2256  
 
Second 
trimester 
 
2.34  
 
BW<10th 
centile 
 
HCG, Method not 
reported 
≥ 4.0 MoM 
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(Canada) (case control, matched, test) 
 
Lieppmann  
(1993) 
 
INC: singleton, Down‟s risk >1:195 EXC: structural and 
chromosomal anomalies, women with normal HCG but raised 
AFP or oestriol 
Mean age not reported. 
(USA) (cohort, prospective) 
 
60 
 
15-18 
 
10.20 
 
5.87 
 
BW<10th 
centile 
(local) 
BW<2500g 
 
HCG, RIA 
(MAIAClone 
Serono) 
≥ 2.0 MoM 
 
Markestaad  
(1997) 
 
INC: multips 
Mean age if SGA 28.8+/-0.4 years, non-SGA 30.2+/-0.4 years 
(USA) (cohort, prospective) 
 
216 
 
<20 
 
47.22 
 
BW<15th 
centile 
(sex, parity, 
local) 
 
HCG, 
Immunoreactive 
(Seano) 
<10th centile 
UE3, RIA 
(Amersham) <10th 
centile 
 
Milunsky  
(1989) 
 
INC: singletons 
20-34 years (90%) 
 (USA) (cohort) 
 
13486 
 
15-20 
 
2.28 
 
BW<5.5 
pounds 
 
AFP, RIA (Clinical 
assays) 
≥2.0 MoM, 
≤0.4MoM 
 
Milunsky 
(1996) 
 
INC: singletons EXC:IDDM, structural and chromosomal 
anomalies 
Mean age 30.3 years 
 
78 
 
15-24 
 
10.20 
 
BW<2500g 
 
DS≥1:270 
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 (USA) (case control matched test) 
 
Miyakoshi  
(2001) 
 
INC: singletons, primips 70% EXC: structural and chromosomal 
anomalies 
Mean age 38.9+/-1.8 
(Japan) (cohort, retrospective) 
 
359 
 
15-18 
 
11.42 
 
BW<10th 
centile 
 
HCG, Method not 
reported 
>2.0 MoM 
 
Morssink  
(1995) 
 
INC: singletons EXC: structural and chromosomal anomalies, 
IDDM, delivery < 28 weeks 
Age not reported 
(Netherlands) (cohort) 
 
8892 
 
15-20 
 
10.10 
 
BW<10th 
centile 
(local) 
 
AFP and HCG, EIA 
(Abbott) 
>2.5 MoM 
 
Mwambingu  
(1985) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Age not reported 
(Scotland) (cohort) 
 
282 
 
16-18 
 
13.48 
 
SGA (no 
threshold) 
 
AFP, Method not 
reported 
>2.5 MoM or > 97th 
centile 
 
Naylor  
(2001) 
 
INC: singletons EXC: IDDM, hypertension, maternal illnesses 
associated with adverse pregnancy outcome 
Mean age 27.8+/-7.7 years 
(USA) (case control, prospective) 
 
150 
 
15-24 
 
5.33 
 
BW<10th 
centile 
 
DS>1:190 
 
Odibo  
(2006) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Mean age 25.8 +/-7.0 
 
2040 
 
Second 
trimester 
 
12.50 
 
BW<5th 
centile 
 
Method not reported 
AFP>2.0 MoM 
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(USA) (case control, retrospective, outcome) (local) HCG >2.5 MoM 
UE3≤0.9MoM 
 
Ogle  
(2000) 
 
INC: singletons, 53% primips EXC: structural and chromosomal 
anomalies 
Mean age not reported 
(UK) ( case control index test, nested cohort) 
 
544 
 
15-18 
 
3.31 
 
IUGR 
(threshold 
not 
reported) 
 
DS>1:270 
AFP MEIA 
Free βHCG ELISA 
 
Onderoglu  
(1997) 
 
INC: singletons EXC: IDDM, structural and chromosomal 
anomalies, MSAFP >2.0MoM, raised AFP and HCG 
Mean age 30.1+/-5.2 years 
(Turkey) (case control, nested) 
 
562 
 
15-20 
 
3.56 
 
BW<10th 
centile 
 
HCG, Dunzen 
method 
>2.0 MoM 
 
Ong  
(2000) 
 
INC: singletons,32.0% primips 
Mean age 29.2 (15-45) 
(UK) (cohort, retrospective) 
 
5297 
 
10-14 
 
7.46 
3.23 
 
BW<10th 
centile 
BW<5th 
centile 
 
Free ßHCG and 
PAPP-A, random 
access immunoassay 
(Kryptor) 
<5th, <10th centile 
and <median 
 
Pergament  
(1995) 
 
INC: singletons, age <35 years, amniocentesis EXC: structural and 
chromosomal anomalies 
Mean age cases 30.0+/-3.8, controls 30.0+/-3.7 years 
(USA) (cohort, retrospective) 
 
174 
 
15-20 
 
1.72 
 
BW<10th 
centile 
 
DS>1:250 
All RIA 
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Pilalis  
(2007) 
 
INC: singletons, Papp-a, TVS uterine artery Doppler, known 
outcome EXC: 4 miscarriages, 11 terminations 
Mean age 29 (15-45) 
(Greece) (cohort, prospective) 
 
878 
 
11-14 
 
10.7 
4.00 
 
BW<10th 
centile 
BW<5th 
centile 
 
PAPP-A, 
immunoassay 
(Kryptor) 
≤5th and <10th 
centile 
 
Roop  
(1991) 
 
EXC: lost to follow up 
Mean age 27.7 years 
(USA) (Cohort) 
 
1703 
 
15-20 
 
3.23 
 
IUGR (no 
threshold) 
 
AFP, RIA (Clinical 
assays) 
>2.3 MoM 
 
Secher  
(1985) 
 
INC: singletons, primips, birth > 28 weeks EXC: neural tube 
defects 
Age not reported 
(Denmark) (cohort) 
 
1739 
 
16-18 
 
10.60 
 
5.29 
 
BW<10th 
centile 
(local) 
BW<5th 
centile 
(local) 
 
AFP, RIA 
>1.0, 1.5, 2.0 MoM 
 
Simpson  
(1995) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Age not reported 
(USA) (cohort) 
 
650 
 
15-20 
 
10.50 
2.77 
 
BW<2500g 
BW<10th 
 
AFP, EIA 
(Hybritech Tandem 
ERA, Abbott) 
≥2.0 MoM 
 
Smith  
 
INC: singletons, primips 44.4%, EXC: structural and 
 
8839 
 
8-14 
 
4.18 
 
BW<5th 
 
Free ßHCG and 
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(2002) chromosomal anomalies 
Median age 30.7 years 
(UK) (cohort, prospective) 
centile PAPP-A, random 
access immunoassay 
(Kryptor) 
<5th centile 
 
Smith  
(2006) 
 
INC: singletons, screening programme, birth ≥24 weeks 
Median age 29 (25-33) 
(UK) (cohort, prospective) 
 
8483 
 
15-21 
 
4.16 
 
SGA (no 
threshold) 
 
AFP, Method not 
reported 
≥1.7 MoM (97th 
centile) 
PAPP-A, method 
not reported <5th 
centile 
 
Sritippayawan  
(2005) 
 
INC: singletons EXC: uninterpretable results, delivery at another 
hospital, bad obstetric or past medical or family history, structural 
or chromosomal anomalies 
Mean age cases 34.5(6.4) , controls 33.7 (5.2) years 
(Thailand) (case control, matched test) 
 
330 
 
14-21 
 
1.21 
5.15 
 
BW<10th 
centile 
BW<2500g 
 
DS>1:270 
AFP – RIA 
HCG - EIA 
 
Summers  
(2003) 
 
INC: singletons EXC: IDDM, structural and chromosomal 
anomalies, positive NTD screen 
Median age 34 years 
(Canada) (case control, retrospective, nested cohort, index test) 
 
23098 
 
115 days 
median 
 
1.68 
 
SGA (no 
threshold) 
 
DS>1:385 
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Tanaka  
(1994) 
INC: singletons 
Age not reported 
(Japan) (cohort) 
1097 15-18 10.00 BW<2500g AFP RIA, HCG 
TRFIA 
≥2.0 MoM 
 
Towner  
(2006) 
 
INC: screened, singleton 
EXC: pregnancy loss <20 weeks 
Mean age 26.7 +/-6 
(USA) (case control, matched, test) 
 
618 
 
<20 weeks 
 
8.41 
 
BW<10th 
centile (ga, 
local, sex) 
 
HCG, method not 
reported 
≥2.0 MoM 
 
Tul  
(2003) 
 
INC: singletons, 51% primips 
Mean age 30.4 (18-44) years 
(Slovenia) (cohort, retrospective) 
 
1004 
 
10-14 
 
5.07 
 
BW<10th 
centile 
(local) 
 
PAPP-A, Random 
access immunoassay 
(Kryptor) ≤0.5MoM 
 
Wald  
(1977) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Mean age not reported 
(UK) (case control, prospective, matched, index test) 
 
188 
 
4-22 
 
9.04 
 
BW<2500g 
 
AFP, RIA 
≥ 3.0 MoM 
 
Wald  
(1980) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Mean age not reported 
(UK) (cohort) 
 
4198 
 
16-18 
 
5.40 
 
BW≤2500g 
 
AFP, Method not 
reported 
> 2.0 MoM 
 
Waller  
(1996) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Mean age 27 years 
(USA) (cohort, retrospective) 
 
51008 
 
15-19 
 
5.16 
 
BW<5th 
centile 
 
AFP, EIA (Abbott) 
>1.0,2.0,2.5 MoM 
<0.44 MoM (1st 
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centile) 
 
Weiner  
(1991) 
 
INC: singletons, referred for amniocentesis EXC: structural and 
chromosomal anomalies, TOP, miscarriage 
Mean age 32.7 +/-6.0 
(USA) (cohort) 
 
144 
 
Second 
trimester 
 
6.94 
 
BW<10th 
centile 
 
AFP, RIA 
(Amersham) 
>2.0 MoM 
 
Wenstrom  
(1992) 
 
INC: singletons, screened with raised AFP and repeat sample 
EXC: structural and chromosomal anomalies 
Age not reported 
(USA) (Cohort) 
 
440 
 
15-20 
 
12.0 
 
SGA no 
threshold 
 
AFP, method not 
reported 
≥2.5 MoM 
 
Wenstrom  
(1996) 
 
INC: singletons EXC: raised AFP or acetylcholinesterase in 
amniotic fluid, blood contamination of amniotic fluid, structural or 
chromosomal anomalies 
Age not reported 
(USA) (cohort, retrospective) 
 
4336(FGR) 
 
4614 (PE) 
 
Second 
trimester 
 
3.48 
 
BW<10th 
(local) 
 
AFP< RIA (Sanofi 
Pasteur) 
≥2.5 MoM 
 
Westergaard  
(1984) 
 
INC: singletons 
Age not reported 
(Denmark) (cohort prospective) 
 
208 
 
18-22 
 
15.9 
 
BW<10th 
centile 
(local) and 
phenotypic 
signs of 
FGR 
 
PAPP-A, EIA, 
<10th centile 
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Williams  
(1992) 
 
INC: singletons EXC: structural and chromosomal anomalies 
Mean age 28.8 +/- 4.5 
(USA) (case control, prospective, unmatched test) 
 
412 
 
Second 
trimester 
 
18.70 
14.3 
 
BW<2500g 
BW<10th 
centile 
(local) 
 
AFP, EIA 
(Hybritech) 
≥2.0 MoM 
 
Yaron   
(1999) 
 
EXC: structural and chromosomal anomalies 
Age not reported 
(USA) (cohort) 
 
60040 
 
45565 
 
 
24504 
 
 
20907 
 
14-22 
 
2.47 
 
2.32 
 
 
4.93 
 
 
1.76 
 
BW<5th 
centile 
 
 
 
 
 
 
 
AFP, RIA (Sanofi) 
>2.5 MoM 
ßHCG  IRMA 
(Biodata) 
>2.5 MoM 
UE3 ComPEitive 
immunoasay 
<0.5 MoM 
Triple test 
 
Yaron  
(2002) 
 
INC: singletons 
EXC: structural and chromosomal anomalies 
Mean age 30.4+/-4.3 years 
(USA) (cohort) 
 
1622 
 
10-13 
 
3.02 
 
BW<5th 
centile 
 
Free ßHCG FIA 
(Delfia Wallace) 
>5.0,4.0,3.0,2.0,1.0 
MoM 
 
Yuong Kim 
(2000) 
 
INC: singletons EXC: IDDM, HCG>2MoM, AFP>2MoM 
Mean age 29.0+/-2.6 years 
(Korea) (cohort) 
 
1096 
 
15-21 
 
3.65 
 
BW<10th 
centile 
 
UE3, Method not 
reported ≤0.75 
MoM 
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Zarzour  
(1998) 
 
INC: amniocentesis EXC: abdominal wall defects 
Age not reported 
(USA) (cohort, retrospective) 
 
1904 
 
14-20 
 
8.25 
 
BW<2500g 
 
AFP, RIA 
>2.0 MoM 
FPR false positive rate; hrs hour; INC inclusion; EXC exclusion; AFP alpha-fetoprotein; HCG human chorionic gonadotrophin;UE3 unconjugated oestriol; PAPP-A 
pregnancy associated plasma protein A;  PE preeclampsia; PIH pregnancy induced hypertension; FGR fetal growth restriction; IDDM diabetes mellitus; AID auto 
immune disease; APS antiphospholipid syndrome; SLE systemic lupus erythematodes; MoM multiples of the median. TP true positives;  BW birth weight; TVS 
transvaginal; UK United Kingdom; USA United States of America; NA not applicable; RIA random access immunoassay; ELISA enzyme linked immunoabsorbent 
assay; EIA enzyme immunoassay; FEIA fluroenzyme immunoassay; IRMA immunoradiometric assay; MEIA microparticle enzyme immunoassay; IFMA 
immunoflurometric assay; TRFIA time resolved flurometricimmuno assay; mg milligrams; mmmHg millimetres of mercury; µg/l mircrograms per litre; pg/ml 
pictograms per millilitre; g grams; NT nuchal translucency; ROC receiver operating characteristic curve; SGA small for gestational age; NTD neural tube defects; 
MSAFP maternal serum alpha feto-protein; BP blood pressure; IUGR intrauterine growth restriction; DS Down‟s syndrome; TOP termination of pregnancy; USS 
ultrasound scan; IVF in-vitro fertilisation; ga gestational age; sd standard deviation, % percent
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Appendix 9: Forest plot of likelihood ratios and 95% confidence intervals for alpha feto-protein (AFP) to predict small for 
gestational age fetuses. (squares represent individual studies and diamonds pooled results). 
Index Test Study Details Likelihood ratio of positive test (95% CI)                         Likelihood ratio of negative test (95% CI)
0.78 (0.55, 1.11)
BW<10th centile, 37 weeks
0.99 (0.94, 1.04)
0.94 (0.89, 0.99)
0.88 (0.70, 1.11)
0.96 (0.94, 0.98)
0.92 (0.81, 1.05)
0.97 (0.87, 1.10)
Birth weight <2500g
0.99 (0.98, 0.99)
0.95 (0.74, 1.21)
0.92 (0.84, 1.01)
0.95 (0.92, 0.98)
0.98 (0.96, 0.99)
0.98 (0.96, 0.99)
Birth weight <5th centile
0.02 (0.00, 0.34)
0.81 (0.69, 0.95)
0.94 (0.90, 0.98)
0.92 (0.86, 0.99)
0.94 (0.75, 1.16)
0.96 (0.93, 0.98)
0.98 (0.91, 1.05)
0.78 (0.61, 0.98)
0.93 (0.85, 1.01)
1.00 (0.94, 1.07)
Birth weight <10th centile
0.01 0.1 0.2 0.5 1 2 5 10 100
27.96 (8.02, 97.48)
BW<10th centile, <37 weeks
1.22 (0.76, 1.96)
2.98 (2.34, 3.79)
2.12 (0.75, 5.98)
5.87 (3.44, 10.02)
1.79 (0.89, 3.60)
1.28 (0.49, 3.30)
Birth weight <2500g
2.20 (1.67, 2.92)
1.07 (0.83, 1.38)
1.73 (1.08, 2.76)
2.71 (1.28, 5.74)
2.20 (1.87, 2.58)
9.07 (4.62, 17.80)
Birth weight <5th centile
8.80 (5.57, 13.91)
1.25 (1.08, 1.45)
1.60 (1.25, 2.04)
1.73 (1.21, 2.46)
1.41 (0.53, 3.79)
3.55 (2.68, 4.69)
1.98 (1.09, 3.60)
2.36 (1.37, 4.05)
1.79 (1.09, 2.94)
0.96 (0.49, 1.99)
Birth weight <10th centile
Likelihood ratio of positive test
AFP>2.0MoM 1 7,307
Threshold No of studies No of women
AFP<0.44MoM 1 13,486
AFP>2.0MoM 3 23,694
AFP>2.5MoM 2 5,619
AFP>3.0MoM 2 4,424
AFP>90th centile 1 476
AFP>95th centile 1 220
Threshold No of studies No of women
AFP<0.44MoM 1 51,008
AFP>1.0MoM 2 52,747
AFP>1.5MoM 1 1,739
AFP>2.0MoM 4 101,597
AFP>2.5MoM 2 111,048
AFP>3.0MoM 1 15,705
Threshold No of studies No of women
AFP<10th centile 1 172
AFP>1.0MoM 1 1,739
AFP>1.5MoM 2 4,354
AFP>1.6MoM 1 358
AFP>1.7MoM 1 147
AFP>2.0MoM 10 45,158
AFP>2.5MoM 5 15,023
AFP>3.0MoM 1 333
AFP>90th centile 2 648
AFP>95th centile 1 828
Threshold No of studies No of women
0.01 0.1 0.2 0.5 1 2
Likelihood ratio of a negative test
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Appendix 10: Forest plot of likelihood ratios and 95% confidence intervals for human chorionic gonadotrophin (HCG) to predict 
small for gestational age fetuses. (squares represent individual results and diamonds pooled  results). 
0.01 0.1 0.2 0.5 1 2 5 10 100
1.78 (1.47, 2.16)
7.64 (2.86, 20.46)
Birth weight <2500g
1.61 (1.19, 2.17)
1.82 (1.27, 2.60)
0.98 (0.84, 1.14)
1.02 (0.79, 1.30)
2.08 (1.78,2,42)
1.26 (0.97, 1.65)
1.11 (0.48, 2.58)
0.28 (0.02, 4.53)
0.59 (0.04, 9.61)
Birth weight <5th centile
2.55 (1.21, 5.35)
1.31 (0.97, 1.77)
12.35 (0.80,6.92)
0.97 (0.88, 1.08)
1.29 (0.98, 1.70)
1.74 (1.48, 2.04)
1.49 (1.16, 1.90)
4.71 (1.22, 18.17)
4.17 (2.65, 6.54)
1.68 (0.37, 7.63)
0.99 (0.64, 1.54)
1.02 (0.37, 2.78)
Birth weight <10th centile
Likelihood ratio of positive test
HCG>2.0MoM 2                                    1,557
HCG>2.5MoM 1                                        471
Threshold           No of studies    No of women
HCG<5th centilea 2                                    14,136
HCG<10th centilea 1                                      5,297
HCG<mediana 1                                      5,297
HCG>1.0MoMa 1                                      1,622
HCG>2.0MoM 1                                   33,145
HCG>2.5MoM 1                                    45,565
HCG.3.0MoMa 1                                      1,622
HCG>4.0MoMa 1                                      1,622
HCG>5.0MoMa 1                                      1,622
Threshold        No of studies       No of women
HCG<1st centilea 1                                      6,276
HCG<5th centilea 2                                    11,573
HCG<10th centile 1                                      172
HCG<mediana 1                                      5,297
HCG>1.5MoM 1                                      2,615
HCG>2.0MoM 7                                    39,306
HCG>2.5MoM 4                                      9,913
HCG>3.0Mom 1                                           88
HCG>4.0MoM 1                                         121
HCG>90th centile 1                                        172
HCG>95th centilea 1                                      6,276
HCG>99th centilea 1                                      6,276
Threshold        No of studies       No of women
0.60 (0.17, 2.07)
0.89 (0.85, 0.96)
Birth weight <2500g
0.97 (0.95, 0.99)
0.92 (0.86, 0.99)
1.02 (0.88, 1.19)
0.98 (0.71, 1.36)
0.94 (0.92, 0.95)
0.99 (0.98, 1.00)
0.99 (0.90, 1.09)
1.03 (1.00, 1.06)
1.01 (0.98, 1.04)
Birth weight <5th centile
0.99 (0.97, 1.00)
0.99 (0.97, 1.00)
0.90 (0.76-1.00)
1.03 (0.93, 1.14)
0.95 (0.89, 1.01)
0.95 (0.93, 0.96)
0.95 (0.87, 1.03)
0.82 (0.66, 1.02)
0.13 (0.01, 1.77)
0.97 (0.86, 1.09)
1.00 (0.98, 1.03)
1.00 (0.99, 1.01)
Birth weight <10th centile
0.01 0.1 0.2 0.5 1 2
Likelihood of a negative test
Index Test           Study Details Likelihood ratio of a positive test (95% CI)              Likelihood ratio of a negative test (95% CI)
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Appendix 11: Forest plot of likelihood ratios and 95% confidence intervals for unconjugated oestriol to predict small for gestational 
age fetuses. (squares represent individual studies and diamonds pooled results). 
0.01 0.1 0.2 0.5 1 2 5 10 100
Likelihood ratio of positive test
Index Test Study Details Likelihood ratio of positive test (95% CI)                         Likelihood ratio of negative test (95% CI)
0.01 0.1 0.2 0.5 1 2
Likelihood ratio of a negative test
6.54 (0.98, 43.91)
Birth weight <5th centile
2.18 (1.68, 2.84)
3.07 (0.99, 9.51)
1.91 (1.13, 3.21)
2.54 (1.54, 4.19)
Birth weight <10th centile
Estriol<0.5MoM               2                          57,649
Estriol<0.5MoM 1                         33,145
Estriol<0.7MoM 1                           547
Estriol<0.74MoM 1                           673
Estriol<0.75MoM 2                         1,405
Threshold No of studies      No of women
Threshold No of studies      No of women
0.59 (0.03, 13.28)
Birth weight <5th centile
0.99 (0.98, 0.99)
0.96 (0.90, 1.02)
0.82 (0.65, 1.03)
0.75 (0.63, 0.89)
Birth weight <10th centile
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Appendix 12: Forest plot of likelihood ratios and 95% confidence intervals for pregnancy associated plasma protein A (PAPPA) to 
predict small for gestational age fetuses. (squares represent individual studies and diamonds pooled results). 
Likelihood ratio of positive test Likelihood ratio of a negative test
0.01 0.1 0.2 0.5 1 2 5 10 100
Index Test Study Details Likelihood ratio of positive test (95% CI)                         Likelihood ratio of negative test (95% CI)
0.01 0.1 0.2 0.5 1 2
Pappa<1st centilea 1 33,995
Pappa<5th centilea 4 49,009
Pappa<10th centilea 3 40,170
Pappa<mediana 1 5,297
Pappa<0.3MoMa 1 827
Pappa<0.4MoMa 1 476
Pappa<0.5MoMa 2 1,831
Pappa<0.69MoMa 1 476
Pappa<1st centilea 2 40,271
Pappa<5th centilea 4 46,446
Pappa<10th centile 2 380
Pappa<mediana 1 5,297
Pappa>90th centile 1 172
Pappa>95th centilea 1 6,276
Pappa>99th centilea 1 6,276
4.36 (3.27, 5.80)
2.49 (2.20, 2.83)
2.24 (1.65, 3.03)
1.18 (1.03, 1.35)
Birth weight <5th centile
3.37 (1.44, 7.87)
2.51 (0.91, 6.95)
2.71 (1.91, 3.83)
2.04 (1.40, 2.98)
3.50 (2.53, 4.82)
2.09 (1.66, 2.63)
1.82 (0.95,3.50)
1.07 (0.96, 1.18)
0.91 (0.22, 3.65)
0.97 (0.61, 1.54)
1.00 (0.37, 2.77)
Birth weight <10th centileThreshold No of studies No of women
Threshold No of studies No of women
0.97 (0.96, 0.98)
0.92 (0.91, 0.94)
0.89 (0.84, 0.93)
0.84 (0.70, 0.99)
Birth weight <5th centile
0.92 (0.84, 1.01)
0.93 (0.82, 1.05)
0.83 (0.71, 0.96)
0.68 (0.49, 0.94)
0.98 (0.97, 0.99)
0.95 (0.93, 0.97)
0.91(0.79, 1.05)
0.94 (0.85, 1.04)
1.01 (0.85, 1.21)
1.00 (0.98, 1.02)
1.00 (0.99, 1.01)
Birth weight <10th centile
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Appendix 13: Forest plot of likelihood ratios and 95% confidence intervals for inhibin A to predict small for gestational age fetuses. 
(squares represent individual studies and diamonds pooled results). 
Index Test         Study Details Likelihood ratio of positive test (95% CI)                    Likelihood ratio of negative test (95% CI)
0.01 0.1 0.2 0.5 1 2 5 10 100
Likelihood ratio of positive test
0.01 0.1 0.2 0.5 1 2
Likelihood ratio of a negative test
Inhibin A>2.0MoM 1 33,145
Inhibin A>2.0MoM 1 33,145
4.91 (4.20, 5.73)
Birth weight <5th centile
4.45 (3.92, 5.06)
Birth weight <10th centile
Threshold No of studies No of women
Threshold No of studies No of women
0.89 (0.87, 0.91)
Birth weight <5th centile
0.92 (0.91, 0.93)
Birth weight <10th centile
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Appendix 14: Analyses according to gestation of testing of accuracy of biochemical 
screening to predict small for gestational age fetuses. (CI confidence intervals, HCG 
human chorionic gonadotrophin, BW birth weight, MoM multiple of median, 
PAPPA pregnancy associated plasma protein A) 
 
 
 
Small for gestational age 
Analyte 
Subgroup  
 
Positive 
Likelihood Ratio 
(95% CI) 
Negative 
Likelihood Ratio 
(95% CI) 
Sensitivity (95% 
CI) 
Specificity (95% 
CI) 
HCG>90
th
 centile (BW<10th centile) 
Trimester  
First 
Second 
 
1.48 (0.57-3.81) 
1.68 (0.37-7.63) 
 
0.92 (0.72-1.17) 
0.97 (0.86-1.09) 
 
0.21 (0.06-0.46) 
0.08 (0.01-0.26) 
 
0.86 (0.79-0.91) 
0.95 (0.90-0.98) 
HCG<10
th
 centile (BW<10th centile) 
Trimester 
First 
Second 
 
1.29 (0.05-33.56) 
2.35 (0.80-6.92) 
 
1.14 (0.53-2.43) 
0.90 (0.76-1.08) 
 
0.13 (0.10-0.16) 
0.16 (0.05-0.36) 
 
0.60 (0.57-0.63) 
0.93 (0.88-0.97) 
HCG>2.0MoM (BW<5th centile) 
Trimester 
First                  0.96 (0.55-1.68)     1.01 (0.88-1.17)       0.20 (0.10-0.34)         0.79 (0.77-0.81) 
Second             2.08 (1.78-2.42)     0.94 (0.92-0.95)       0.12 (0.10-0.14)         0.94 (0.94-0.95) 
PAPPA<10
th
 centile (BW<10
th
 centile) 
Trimester 
First                 1.68 (1.25-2.27) 
Second             1.82 (0.95-3.50) 
 
0.93 (0.88-0.98) 
0.91 (0.75-1.05) 
 
0.17 (0.16-0.19) 
0.20 (0.10-0.33) 
 
0.90 (0.89-0.90) 
0.89 (0.85-0.92) 
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Appendix 15: Subgroup analyses of accuracy of biochemical screening to predict 
small for gestational age fetuses. (CI confidence intervals, AFP alpha feto-protein, 
HCG human chorionic gonadotrophin, BW birth weight, MoM multiple of median) 
 
 
Small for gestational age 
Analyte 
Subgroup  
 
Positive 
Likelihood Ratio 
(95% CI) 
Negative 
Likelihood Ratio 
(95% CI) 
Sensitivity (95% 
CI) 
Specificity (95% 
CI) 
AFP>2.0MoM (BW<10th centile) 
Incidence 
>10%  
≤10%  
 
 
2.69 (1.36-5.31) 
3.71 (2.66-5.16) 
 
0.98 (0.96-1.00) 
0.93 (0.88-0.97) 
 
0.04 (0.02-0.08) 
0.06 (0.05-0.07) 
 
0.98 (0.98-0.99) 
0.98 (0.98-0.98) 
HCG>2.0MoM(BW<10th centile) 
Incidence 
>10%  
≤10%  
 
1.53 (1.1-2.12) 
1.92 (1.72-2.13) 
 
0.89 (0.77-1.04) 
0.95 (0.94-0.96) 
 
0.29 (0.22-0.37) 
0.11 (0.1-0.12) 
 
0.79 (0.77-0.82) 
0.94 (0.94-0.95) 
  
311 
 
Appendix 16: Data extraction form for review of uterine artery Doppler to predict 
small for gestational age fetuses. 
Section A: Study Information 
 
1)Ref ID:  
 
4)Publication year:  
2)Rev 
name: 
 5)First Author:  
3)Country:  6)Language:  
 
Section B: Data Retrieval for Uterine Artery Doppler Study 
 
Population 
7) Healthcare Centre: 
Primary care □1  Secondary care  □2  Mixed □3    Other   □4        Unreported  □5 
 
8) Setting: 
 In-patient  □1  Out-patient  □2  Mixed  □3  Unreported  □4       Other  □5 
________________ 
 
9) Number of participating centres: ____________________________________ 
 
10) Gestation at time of index test: 
<20 weeks   □1  20-24 weeks  □2   24-28 weeks □3    28-34 weeks □4   34-37 
weeks □5    37-40 weeks  □6   > 40 weeks  □7      Unreported  □8           Other 
_______________________ 
 
10.i) Mean (range)______________________________________         Unreported  
□3 
 
10.ii) Median (range) ____________________________________        Unreported  
□3 
 
11) Pregnancy: 
Low Risk      □1  High Risk    □2  Unselected  □3  Unreported  □4 
 
11.i) State high risk conditions:      Unreported  □3 
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12) Were patients with the following conditions excluded/not included? 
12.i) Previous IUGR:    Yes □1  No  □2
 Unreported   □3 
12.ii) Insulin dependant diabetes mellitus:        Yes □1  No  □2
 Unreported   □3 
12.iii)   Chronic renal disease:       Yes □1  No  □2        Unreported   □3 
12.iv)   Systemic lupus erythematosus:  Yes □1  No  □2        Unreported   
□3 
12.v)    Antiphospholipid syndrome:          Yes □1  No  □2        
Unreported   □3 12.vi)   Chronic hypertension:  Yes □1  No  □2        
Unreported   □3 12.vii)   Pre-eclampsia:   Yes □1  No  □2        
Unreported   □3 
12.viii)  Foetal chromosomal/structural anomalies:  Yes □1  No  □2        
Unreported   □3 
 
13) Did all patients have singleton pregnancies?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
14) Were all patients primigravid?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
15) List other eligibility/ in-/exclusion criteria: 
 
 
 
 
 
16) Study population: (describe age (mean +/- SD or median/range), ethnicity, smoking, BMI 
etc.) 
 
 
 
   ----------/-------------            
   ----------/-------------            
 
         Not applicable  □3 
 
 
 
 
 
 
 
        Unreported  □3 
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17) Start of patient inclusion (year) :                        U    
Unreported □3  
18) End of patient inclusion (year) :              
Unreported □3 
 
19) Study Design:    
cohort  □1    case control  □2      RCT/CCT  □3        cross sectional  □4     before and 
after  □5         case series   □6  (no ______)      other  □7 
19.i) Data collection:  prospective □1      retrospective   □2      unreported  □3        
other  □4 
19.ii) Enrolment:    consecutive  □1       arbitary (random) □2      unreported  □3      
other  □4 
20) Numbers: 
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21) Completeness of Verification: 
(= E / C x 100 = %) 
> 90%  □1     81-90%  □2     < 81%  □3 
 
Index Test 
 
22) Description of technique:      
Adequate  □1   Inadequate  □2 
 
23) Timing of measurement (from delivery): 
< 7days □1  7-14 days  □2  14 -28 days □3  > 28 days  □4    Mixture  □5   
Unreported  □6 
 
23.i) Median gestational age at delivery   _____________________________ 
unreported  □3         
24) Measurement: 
SCANNING: 
24.i) Operator: 
 
B Reasons ________________ 
 
D Reasons ________________ 
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Single  □1   Multiple  □2       Unreported    □3 
24.ii) Operator experience__________________________________________ 
unreported  □3         
24.iii) Scanning Route: Transabdominal □1  Transvaginal  □2   Unreported  □3 
DOPPLER: 
24.iv) Method:   Continuous wave Doppler  □1  Pulsed wave Doppler  □2 Colour 
mapping  □3    
    Unreported   □4 
24.v) Measurement parameter:     Resistance index (RI)  □1   Systolic / diastolic 
ratio  □2 Diastolic / systolic ratio    □3   Unilateral Diastolic notch  □4   Bilateral 
diastolic notch  □5    Pulsatility index (PI) □6  Time averaged velocity (TAV)   □7   
Time averaged maximum velocity (TAMXV)  □8   Minimum velocity  □9   Unreported  
□10    
24.vi) Cut-off level for waveform ratio:   > 2 SD  □1   > 95th centile  □2  > 90th 
centile  □3    
> 80th centile □4     > 50th centile  □5  < 10th centile □6   < 5th centile  □7   
Unreported/NA  □8 
Other/Threshold data set: 
______________________________________________________ 
24.vii) Machine: _______________________________________     unreported  □3         
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24.viii) Probe: ________________________________________________      
unreported  □3         
24.ix) High pass filter: _______________________________________       
unreported  □3         
24.x) Pulse rePEition frequency: ______________________________        
unreported  □3         
24.xi) Size of sampling gate: ___________________________________       
unreported  □3         
24.xii) Site : _________________________________________________       
unreported  □3         
24.xiii) Angel of insonation: ____________________________________      
unreported  □3         
24.xiv) Number of consecutive waveforms: ________________________   
unreported  □3         
24.xv) Were both sides measured:    Yes □1    No  □2    Unreported  □3 
24.xvi) Other information: 
___________________________________________________________________ 
Reference Standard / Outcome 
25) Measured blind form diagnostic test:   Yes  □1    No  □2   Unclear  □3 
26) Measurement for FGR:   Birthweight  □1  Neonatal ponderal index  □2  
Skin fold thickness □3    MAC / OFC  □4    Other  □5  ______________________________ 
27) Threshold:   < 3rd centile  □1  < 5th centile  □2   < 10th centile  □3  < 25th 
centile □4     
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> 2SD  □5   Other □6 ________________________________________________      Unclear   
□7 
28) What data set was used to define threshold? 
___________________________________________________________          
unreported  □3         
29)Timing of measurement:  At delivery  □1   Within 24 hrs  □2   > 24 hrs  □3  
Mixture  □4   Unreported  □5     
                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Results 
  
318 
 
Appendix 17: Guide to quality assessment of included studies in review of uterine artery Doppler to predict small for gestational age 
fetuses. 
QUADAS question Applicability and criteria fulfilled when 
1. Representative spectrum of patients? 
(spectrum bias) 
Pregnant women, consecutively recruited and prospective design. 
2. Clearly described patient selection 
criteria? (selection bias)  
Information on chronic hypertension, diabetes mellitus, parity, singleton/multiple pregnancies, previous preeclampsia/ fetal 
growth restriction available. 
3. Reference standard correctly classifies 
target condition? 
SGA: birth weight < 10
th
 centile adjusted for gestational age and based on local population values and absolute birth weight 
threshold < 2500g. Severe FGR: birth weight < 5
th
 or < 3
rd
 centile or < 1750g. Neonatal ponderal index < 10
th
 centile, skin fold 
thickness, and mid-arm circumference/head circumference were also assessed.  
 
4. Time between tests short enough to be 
sure that target condition did not change? 
(disease progression bias) 
Not applicable 
5. Whole or random selection of study 
population received verification using a 
reference test? (partial verification bias) 
All patients or a random selection received verification with reference standard (even if reference standard not the same for all 
patients). 
6. Did patients receive the same 
reference test regardless of index test 
result? (differential verification bias) 
All patients received same reference test (this is likely because the index test is non-invasive).  
7. Reference test independent of index 
test? (incorporation bias) 
 
The results of the index test are not incorporated in the definition of SGA. 
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8. Execution of index test described in 
sufficient detail? 
Type of Doppler (e.g. color wave, pulsed, etc), site of measurement, measurement parameter and cut off level used, 
transvaginal or transabdominal route. 
9. Execution of reference test described 
in sufficient detail? 
Birthweight: timing of measurement, scales used, whether baby clothed or not. 
Neonatal ponderal index: description of birth weight and length measurement as above. 
Skin fold thickness: description of site of measurement, instrument used and timing of measurement. 
Mid-arm circumference/ head circumference: see skin fold thickness. 
 
10 Blind interpretation of index test 
results (review bias) 
Always fulfilled, reference test results not yet available when index test (Doppler) is performed (prediction). 
10 Blind interpretation of reference test 
results (review bias) 
Statement in text, such as “assessors were blind to Doppler results”.  
 
11. Same clinical data available when 
tests results were interpreted as would be 
available when test used in practice? 
Any information to the patient obtained by direct observation (age, symptoms, BMI) normally available when test is 
interpreted in practice and similar data were available when interpreting the test in the study or if data not available when 
interpreted and not available in practice. 
12. Uninterpretable/ intermediate test 
results reported? 
All test results including uninterpretable/ intermediate are reported. 
13. Were withdrawals from the study 
explained? 
 
Clear what happened to all patients in study e.g. flow diagram (follow-up). 
Additional  
14. Was there any preventative 
intervention? 
Patients after having uterine artery Doppler received any of the following: aspirin, low molecular weight heparin, vitamin C or 
E, antihypertensive medication, saline infusion, oxygen 
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Aardema MW, Lander M, Oosterhof H, De Wolf BT, Aarnoudse JG. Doppler 
ultrasound screening predicts recurrence of poor pregnancy outcome in subsequent 
pregnancies, but not the recurrence of PIH or preeclampsia. Hypertens.Pregnancy. 
2000;19:281-88. 
Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH. One-stage screening 
for pregnancy complications by color Doppler assessment of the uterine arteries at 23 
weeks' gestation. Obstet.Gynecol. 2000;96:559-64. 
Alkazaleh F, Chaddha V, Viero S, Malik A, Anastasiades C, Sroka H et al. Second-
trimester prediction of severe placental complications in women with combined 
elevations in alpha-fetoprotein and human chorionic gonadotrophin. 
Am.J.Obstet.Gynecol. 2006;194:821-27.  
Arenas J, Fernandez I, Rodriguez-Mon C, Dupla B, Diez E, Gonzalez-Garcia A. 
Doppler screening of the uterine arteries to predict complications during pregnancy. 
[Spanish]. Clinica e Investigacion en Ginecologia y Obstetricia 2003;30:178-84. 
Audibert F, Benchimol Y, Benattar C, Champagne C, Frydman R. Prediction of 
preeclampsia or intrauterine growth restriction by second trimester serum screening and 
uterine Doppler velocimetry. Fetal Diagn.Ther. 2005;20:48-53. 
Axt-Fliedner R, Schwarze A, Nelles I, Altgassen C, Friedrich M, Schmidt W et al. The 
value of uterine artery Doppler ultrasound in the prediction of severe complications in a 
risk population. Arch.Gynecol.Obstet. 2004;271:53-58. 
  
321 
 
Bassim S, Lange M, Salzer H. Uterine artery doppler and pregnancy complications in 
unselected women. Geburtshilfe und Frauenheilkunde 2006;66:59-62. 
Bower S, Schuchter K, Campbell S. Doppler ultrasound screening as part of routine 
antenatal scanning: prediction of pre-eclampsia and intrauterine growth retardation. 
BJOG. 1993;100:989-94. 
Caforio L, Testa AC, Mastromarino C, Carducci B, Ciampelli M, Mansueto D et al. 
Predictive value of uterine artery velocimetry at midgestation in low- and high-risk 
populations: a new perspective. Fetal Diagn.Ther. 1999;14:201-05. 
Carbillon L, Uzan M, Largilliere C, Perrot N, Tigaizin A, Paries J et al. Prospective 
evaluation of uterine artery flow velocity waveforms at 12-14 and 22-24 weeks of 
gestation in relation to pregnancy outcome and birth weight. Fetal Diagn.Ther. 
2004;19:381-84. 
Caruso A, De Carolis S, Ferrazzani S, Valesini G, Caforio L, Mancuso S. Pregnancy 
outcome in relation to uterine artery flow velocity waveforms and clinical 
characteristics in women with antiphospholipid syndrome. Obstet.Gynecol. 
1993;82:970-77. 
Caruso A, Caforio L, Testa AC, Ferrazzani S, Mastromarino C, Mancuso S. Chronic 
hypertension in pregnancy: color Doppler investigation of uterine arteries as a 
predictive test for superimposed preeclampsia and adverse perinatal outcome. 
J.Perinat.Med. 1996;24:141-53.  
  
322 
 
Coleman MA, McCowan LM, North RA. Mid-trimester uterine artery Doppler 
screening as a predictor of adverse pregnancy outcome in high-risk women. Ultrasound 
Obstet.Gynecol. 2000;15:7-12. 
Degani S, Leibovich Z, Shapiro I, Gonen R, Ohel G. Early second-trimester low 
umbilical coiling index predicts small-for-gestational-age fetuses. J.Ultrasound Med. 
2001;20:1183-88. 
Driul L, Springolo F, Pezzani I, Casarsa S, Plaino L, Ianni A et al. [Pathological 
monolateral Doppler velocimetry of the uterine artery and materno-fetal outcome]. 
Minerva Ginecol. 2002;54:397-402. 
Dugoff L, Lynch AM, Cioffi-Ragan D, Hobbins JC, Schultz LK, Malone FD et al. First 
trimester uterine artery Doppler abnormalities predict subsequent intrauterine growth 
restriction. Am.J.Obstet.Gynecol. 2005;193:1208-12. 
Ferrier C, North RA, Becker G, Cincotta R, Fairley K, Kincaid-Smith P. Uterine artery 
waveform as a predictor of pregnancy outcome in women with underlying renal disease. 
Clin.Nephrol. 1994;42:362-68. 
Frusca T, Soregaroli M, Danti L, Guandalini F, Lojacono A, Scalvi L et al. Uterine 
artery velocimetry as a screening test in patients with previous preeclampsia. 
Int.J.Gynaecol.Obstet. 1996;8:94-98. 
Frusca T, Soregaroli M, Valcamonico A, Guandalini F, Danti L. Doppler velocimetry of 
the uterine arteries in nulliparous women. Early Hum.Dev. 1997;48:177-85. 
  
323 
 
Geipel A, Ludwig M, Germer U, Katalinic A, Diedrich K, Gembruch U. Uterine artery 
Doppler velocimetry and the outcome of pregnancies resulting from ICSI. Hum.Reprod. 
2001;16:1397-402. 
Geipel A, Berg C, Germer U, Katalinic A, Krapp M, Smrcek J et al. Doppler assessment 
of the uterine circulation in the second trimester in twin pregnancies: prediction of pre-
eclampsia, fetal growth restriction and birth weight discordance. Ultrasound 
Obstet.Gynecol. 2002;20:541-45.  
Gomez O, Martinez JM, Figueras F, Del RM, Borobio V, Puerto B et al. Uterine artery 
Doppler at 11-14 weeks of gestation to screen for hypertensive disorders and associated 
complications in an unselected population. Ultrasound Obstet.Gynecol. 2005;26:490-94. 
Haddad B, Uzan M, Breart G, Uzan S. Uterine Doppler wave form and the prediction of 
the recurrence of pre-eclampsia and intra-uterine growth retardation in patients treated 
with low-dose aspirin. Eur.J.Obstet.Gynecol.Reprod.Biol. 1995;62:179-83.  
Hafner E, Metzenbauer M, Hofinger D, Stonek F, Schuchter K, Waldhor T et al. 
Comparison between three-dimensional placental volume at 12 weeks and uterine artery 
impedance/notching at 22 weeks in screening for pregnancy-induced hypertension, pre-
eclampsia and fetal growth restriction in a low-risk population. Ultrasound 
Obstet.Gynecol. 2006;27:652-57. 
Harrington K, Carpenter RG, Goldfrad C, Campbell S. Transvaginal Doppler ultrasound 
of the uteroplacental circulation in the early prediction of pre-eclampsia and intrauterine 
growth retardation. BJOG. 1997;104:674-81. 
  
324 
 
Harrington K, Cooper D, Lees C, Hecher K, Campbell S. Doppler ultrasound of the 
uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, 
placental abruption or delivery of a small-for-gestational-age baby. Ultrasound 
Obstet.Gynecol. 1996;7:182-88. 
Harrington K, Fayyad A, Thakur V, Aquilina J. The value of uterine artery Doppler in 
the prediction of uteroplacental complications in multiparous women. Ultrasound 
Obstet.Gynecol. 2004;23:50-55. 
  
Hershkovitz R, De SM, Kingdom J. Mid-trimester placentation assessment in high-risk 
pregnancies using maternal serum screening and uterine artery Doppler. 
Hypertens.Pregnancy. 2005;24:273-80. 
Jorn H, Dinkloh C, Ritter S, Fendel H, Rath W. Clinical value of mid-pregnancy uterine 
artery Doppler velocimetry in the prediction of pregnancy complications. [German]. 
Geburtshilfe und Frauenheilkunde. 2003;63:49-55. 
Konchak PS, Bernstein IM, Capeless EL. Uterine artery Doppler velocimetry in the 
detection of adverse obstetric outcomes in women with unexplained elevated maternal 
serum alpha-fetoprotein levels. Am.J.Obstet.Gynecol. 1995;173:1115-19. 
Kurdi W, Campbell S, Aquilina J, England P, Harrington K. The role of color Doppler 
imaging of the uterine arteries at 20 weeks' gestation in stratifying antenatal care. 
Ultrasound Obstet.Gynecol. 1998;12:339-45. 
  
325 
 
Kurdi W, Fayyad A, Thakur V, Harrington K. Delayed normalization of uterine artery 
Doppler waveforms is not a benign phenomenon. Eur.J.Obstet.Gynecol.Reprod.Biol. 
2004;117:20-23. 
Le Thi HD, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N, Andreu MR et al. 
The second trimester Doppler ultrasound examination is the best predictor of late 
pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid 
syndrome. Rheumatology.(Oxford) 2006;45:332-38. 
 
Liberati M, Rotmensch S, Zannolli P, Perrino S, Celentano C, Tiboni GM et al. Uterine 
artery Doppler velocimetry in pregnant women with lateral placentas. J.Perinat.Med. 
1997;25:133-38. 
Marchesoni D, Pezzani I, Springolo F, Ianni A, Casarsa S, Zavarise D et al. The use of 
uterine artery Doppler as a screening test for pre-eclampsia. Int.J.Gynaecol.Obstet. 
2003;15:15-20. 
Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH. Screening for pre-eclampsia 
and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. 
Ultrasound Obstet.Gynecol. 2001;18:583-86. 
Miyakoshi K, Tanaka M, Gabionza D, Ishimoto H, Miyazaki T, Yoshimura Y. 
Prediction of smallness for gestational age by maternal serum human chorionic 
gonadotropin levels and by uterine artery Doppler study. Fetal Diagn.Ther. 2001;16:42-
46. 
  
326 
 
Morris JM, Fay RA, Ellwood DA, Cook C-M, Devonald KJ. A randomized controlled 
trial of aspirin in patients with abnormal uterine artery blood flow. Obstet.Gynecol. 
1996;87:74-78. 
Nagtegaal MJ, van RS, McGavin S, Dekker G. Use of uterine Doppler in an Australian 
level II maternity hospital. Aust.N.Z.J.Obstet.Gynaecol. 2005;45:424-29. 
North RA, Ferrier C, Long D, Townend K, Kincaid-Smith P. Uterine artery Doppler 
flow velocity waveforms in the second trimester for the prediction of preeclampsia and 
fetal growth retardation. Obstet.Gynecol. 1994;83:378-86. 
Ohkuchi A, Minakami H, Sato I, Mori H, Nakano T, Tateno M. Predicting the risk of 
pre-eclampsia and a small-for-gestational-age infant by quantitative assessment of the 
diastolic notch in uterine artery flow velocity waveforms in unselected women. 
Ultrasound Obstet.Gynecol. 2000;16:171-78. 
Onalan R, Onalan G, Gunenc Z, Karabulut E. Combining 2nd-Trimester Maternal 
Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia 
and Isolated Intrauterine Growth Restriction. Gynecol.Obstet.Invest 2005;61:142-48. 
Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH. Multicenter screening 
for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 
23 weeks of gestation. Ultrasound Obstet.Gynecol. 2001;18:441-49. 
Park YW, Lim JC, Kim YH, Kwon HS. Uterine artery Doppler velocimetry during mid-
second trimester to predict complications of pregnancy based on unilateral or bilateral 
abnormalities. Yonsei Med.J. 2005;46:652-57. 
  
327 
 
Phupong V, Dejthevaporn T, Tanawattanacharoen S, Manotaya S, Tannirandorn Y, 
Charoenvidhya D. Predicting the risk of preeclampsia and small for gestational age  by 
uterine artery Doppler in low-risk women. Arch.Gynecol.Obstet. 2003;268:158-61. 
Prefumo F, Guven M, Ganapathy R, Thilaganathan B. The longitudinal variation in 
uterine artery blood flow pattern in relation to birth weight. Obstet.Gynecol. 
2004;103:764-68. 
Schwarze A, Nelles I, Krapp M, Friedrich M, Schmidt W, Diedrich K et al. Doppler 
ultrasound of the uterine artery in the prediction of severe complications during low-risk 
pregnancies. Arch.Gynecol.Obstet. 2005;271:46-52. 
Sekizuka N, Murakoshi T, Yoshizawa H. The uterine and spiral artery flow velocity 
waveforms in early pregnancy: A transvaginal color and pulsed Doppler study. 
J.Matern.Fetal.Invest. 1994;4:229-32. 
Soregaroli M, Valcamonico A, Scalvi L, Danti L, Frusca T. Late normalisation of 
uterine artery velocimetry in high risk pregnancy. Eur.J.Obstet.Gynecol.Reprod.Biol. 
2001;95:42-45. 
Soutif C, Prevost A, Andre M. [Value of the systematic uterine Doppler in the 
primiparous woman. A series of 315 cases]. J.Gynecol.Obstet.Biol.Reprod.(Paris) 
1996;25:819-23. 
Subtil D, Goeusse P, Houfflin-Debarge V, Puech F, Lequien P, Breart G et al. 
Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in 
nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 2). BJOG. 
2003;110:485-91. 
  
328 
 
Todros T, Ferrazzi E, Arduini D, Bastonero S, Bezzeccheri V, Biolcati M et al. 
Performance of Doppler ultrasonography as a screening test in low risk pregnancies: 
results of a multicentric study. J.Ultrasound Med. 1995;14:343-48. 
Uludag S, Madazli R, Benian A, Ocak V, Erez S. The relationship between maternal 
serum a-fetoprotein and uterine artery Doppler findings at 20-24 weeks' gestation for 
prediction of preeclampsia and intrauterine growth retardation. Marmara.Med.J. 
2002;15:167-74. 
Vainio M, Kujansuu E, Koivisto AM, Maenpaa J. Bilateral notching of uterine arteries 
at 12--14 weeks of gestation for prediction of hypertensive disorders of pregnancy. Acta 
Obstet.Gynecol.Scand. 2005;84:1062-67. 
Valensise H, Romanini C. Second-trimester uterine artery flow velocity waveform and 
oral glucose tolerance test as a means of predicting intrauterine growth retardation. 
Ultrasound Obstet.Gynecol. 1993;3:412-16. 
Valensise H, Bezzeccheri V, Rizzo G, Tranquilli AL, Garzetti GG, Romanini C. 
Doppler velocimetry of the uterine artery as a screening test for gestational 
hypertension. Ultrasound Obstet.Gynecol. 1993;3:18-22. 
Valensise H, Romanini C. Uterine Doppler in the identification of patients at risk for 
hypertension and IUGR. J.Perinat.Med. 1994;22 Suppl 1:69-72. 
Van den Elzen HJ, Cohen-Overbeek TE, Grobbee DE, Quartero RW, Wladimiroff JW. 
Early uterine artery Doppler velocimetry and the outcome of pregnancy in women aged 
35 years and older. Ultrasound Obstet.Gynecol. 1995;5:328-33. 
  
329 
 
Venkat-Raman N, Backos M, Teoh TG, Lo WT, Regan L. Uterine artery Doppler in 
predicting pregnancy outcome in women with antiphospholipid syndrome. 
Obstet.Gynecol. 2001;98:235-42. 
Zimmermann P, Eirio V, Koskinen J, Niemi K, Nyman R, Kujansuu E et al. Effect of 
low-dose aspirin treatment on vascular resistance in the uterine, uteroplacental, renal 
and umbilical arteries - A prospective longitudinal study on a high risk population with 
persistent notch in the uterine arteries. Eur.J.Ultrasound 1997;5:17-30. 
Yu CK, Papageorghiou AT, Boli A, Cacho AM, Nicolaides KH. Screening for pre-
eclampsia and fetal growth restriction in twin pregnancies at 23 weeks of gestation by 
transvaginal uterine artery Doppler. Ultrasound Obstet.Gynecol. 2002;20:535-40. 
  
330 
 
Appendix 19: Study characteristics of included studies on uterine artery Doppler and fetal growth restriction: low risk and 
unselected populations. 
 
Author  
(year)  
Country 
Gestation 
(weeks) 
N 
(%SGA) 
Details  
index test 
Index test (cut-off, centiles 
or absolute thresholds) 
Reference test  
(centiles or  
absolute thresholds (g)) 
Results 
(TP; FP; FN; 
TN) 
Population (study 
design)* 
Albaiges
 
(2000) UK 
22-25 1757 (8.9) 
for 
BW<10
th
 
 
1757 (2.9) 
for 
BW<3
rd
 
 
Unreported 
route, color + 
PW, crossover 
1) BilateraI notching or mean 
PI > 1.45 (95
th
) 
2) Bilateral notching only 
3) Mean PI > 1.45 only 
4) Mean PI > 1.45 + bilateral 
notching 
a) BW < 10
th
  
b) BW < 3
rd
 (local and 
gestational values) 
1a) 
32;96;111;1518 
1b) 
16;112;36;1593 
2a) 
19;58;124;1556 
2b) 
12;68;40;1637 
3a) 
30;60;113;1554 
3b) 
35;84;17;1621 
4a) 
17;21;126;1593 
4b) 
12;27;40;1678 
IN: singleton 
pregnancies, routine 
antenatal care 
Arenas
 
20 319 (8.2) TA, color + PW, 1) Mean RI ≥ 0.59 (75th) BW < 10th (local and 1) 12;77;14;216 IN: unselected women, 
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 (2003) Spain
 
crossover 
 
2) Mean RI ≥ 0.52 (50th) 
3) Mean RI ≥ 0.65 (90th) 
4) Mean RI ≥ 0.71 (95th) 
gestational values) 2) 16;159;10;134 
3) 5;32;21;261 
4) 3;16;23;277 
EX: multiple 
pregnancies, congenital 
defects 
Audibert
 
(2005) France 
18-26  2615 (8.8) Unreported 
route, type and 
site 
1) Bilateral notching 
2) Unilateral notching 
BW < 10
th
 (local 
values) 
1) 
30;85;200;2300 
2) 
52;267;178;2118 
IN: AFP and hCG 
testing at 14-18 weeks 
and ultrasound screening 
(USS).  
EX: women without 
USS 10-14 weeks for 
dating, women with 
raised NT, no Doppler at 
18-26 weeks delivery< 
24 weeks 
Bassim
 
(2006) 
20-24 490 (5.3) TA, unreported 
type, crossover 
1) Bilateral notching BW < 10th (local 
values) 
1) 8;28;18;436 IN: routine screening 
Bower
 
 (1993) UK 
18-22  2058 (3.5) 
for 
BW<3
rd
 
 
2058 (5.2) 
for 
BW<5
th 
 
2058 
TA, CW, 
crossover 
1) RI > 95
th
 centile either 
side +/- any notching 
a) BW < 10
th
 
b) BW < 5
th
 
c) BW < 3
rd
 
(local and gestational 
values) 
1a) 
84;245;141;1588 
1b) 
49;280;57;1672 
1c) 
34;295;39;1690 
IN: unselected women. 
EX: multiple 
pregnancies, outside 
gestational age, fetal 
anomalies 
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(10.9) 
for 
BW<10
th
 
Caforio
 
(1999) Italy 
i) 18-20 
ii) 22-
24 
a) 530 
(5.1) 
b) 530 
(10.9) 
Unreported 
route, color + 
pulsed, 
crossover 
1) RI > 90
th
 a) BW < 1750g 
b) BW < 2500g 
1ai) 
16;147;11;355 
1aii) 
14;127;11;378 
1bi) 
33;134;25;338 
1bii) 
31;98;32;369 
IN: healthy nulliparae.  
EX: congenital defects, 
chromosomal 
abnormalities, multiple 
pregnancies, infections, 
Rhesus isoimmunisation, 
non immune hydrops, 
PPROM, IUD, delivery 
< 26 weeks; 
Carbillon
 
(2004) France 
12-14  
and 22-
24  
243 (9.4) TA, unreported 
type, ascending 
branch 
1) No notching at 12-14 
weeks v uni- or bilateral 
notching 
2) Bilateral notching at 22-24 
weeks 
FGR no threshold 1) 19;120;4;100 
2) 6;15;17;205 
IN: routine ultrasound 
screening 
Driul
 
(2002) Italy 
24 830 (1.8) Unreported 
route, color, 
crossover 
1) RI ≥ 0.6 or unilateral 
notching 
FGR unreported 
threshold 
1) 8;103;7;722 Not reported   
Dugoff
 
(2005) UK 
10-14 1008 (1.2) TA, color + PW, 
crossover 
1) Mean RI ≥ 0.81(95th) 
2) Mean RI ≥ 0.78 (90th) 
3) Mean RI ≥ 0.70 (75th) 
BW < 10
th
 (local and 
gestational values) 
1) 2;49;10;947 
2) 4;102;8;894 
3) 8;248;4;748 
EX: structural or 
chromosomal anomalies, 
fetal genetic syndrome, 
IUD < 24 weeks, 
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congenital uterine 
malformation  
Frusca
 
(1997) Italy 
24 a) 419 
(7.1) 
b) 419 
(2.6) 
TA, color + PW, 
crossover 
1) RI > 0.58 a) BW < 10
th
 (local and 
gestational values) 
b) BW < 3
rd
  
1a) 13;23;17;366 
1b) 6;30;5;378 
IN: nulliparae without 
risk factors, EX: CH, 
DM, AID 
Geipel
 
(2001) 
Germany 
18-24 114 (8.8) 
 
 
Unreported 
route, color, 
crossover 
1) Bilateral notching + mean 
RI > 0.55 or unilateral 
notching + mean RI > 0.65 
or no notching + mean RI > 
0.7 
BW < 10
th
 (local 
values) 
1) 5;19;5;85 
 
IN: singleton 
pregnancies (control 
group of ICSI) 
Gomez
 
(2005) Spain 
11-14 999 (3.7) TVS, color + 
pulsed, 
cervicocorporeal 
junction 
1) Mean PI > 95
th
 a) BW < 5
th
 (local and 
gestational values) 
1a) 9;44;28;918 EX: fetal anomalies, 
women treated with 
aspirin, heparin or 
antihypertensive 
medication before 
enrolment 
Hafner
 
 (2006) 
Germany 
21-23 2489 (6.8) TA, color + PW, 
crossover 
1) Bilateral notching 
2) Mean PI ≥ 90th  
BW < 10
th 
(unreported 
dataset) 
1) 
37;189;131;2132 
2) 
34;218;134;2103 
IN: all singleton 
pregnancies 
Harrington
 
(1997) UK 
12-16  623 (19.9) TVS, 
unreported type 
and site 
1) Bilateral vs unilateral or 
no notching 
2) Bilateral or unilateral vs 
BW < 10
th
 (local and 
gestational values) 
1) 42;163;19;399 
2) 53;294;8;268 
IN: unselected singleton 
pregnancies 
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no notching 
Harrington
 
(1996) UK 
24 1204 
(10.8) 
TA, color + PW, 
crossover 
1) Any notching or mean RI 
> 95
th
 
2) Unilateral or bilateral 
notching 
3) Unilateral notching 
4) Bilateral notching 
BW < 10
th
 (local and 
gestational values) 
1) 42;68;89;1005 
2) 42;68;89;1005 
3) 
18;44;113;1029 
4) 
24;24;107;1049 
IN: unselected women. 
EX: multiple 
pregnancies, fetal 
anomalies, PE or FGR ≤ 
24 weeks 
Harrington
 
(2004) UK 
19-21 458 (5.2) TA, color + 
pulsed, 
crossover 
1) Bilateral notching + mean 
RI ≥ 0.55 (50th) or unilateral 
notching and mean RI ≥ 0.65 
(80
th
) 
BW < 5
th
 (local values) 1) 8;33;15;402 IN: unselected 
multiparae with 
singleton pregnancies 
EX: fetal anomalies 
Jorn
 
(2003) Germany 
18-24 602 (4.8) TA, color, 
ascending 
branch 
1) Mean RI > 0.61 BW < 5
th
 (local and 
gestational values) 
1) 22;46;7;527 Not reported 
Kurdi
 
(1998) UK 
19-21 946 (16.5) 
for 
BW<10
th
 
 
946 (6.0) 
for 
BW<5
th
 
TA, color + PW, 
crossover 
1) Bilateral notching + mean 
RI > 0.55(50
th
) or unilateral 
notching + mean RI > 0.65 
(90
th
), or no notching + mean 
RI > 0.70 (90
th
) 
2) Bilateral notching + mean 
RI > 0.55 (50
th
) 
a) BW < 10
th
  
b) BW < 5
th
  
(local and gestational 
values) 
1a) 
70;146;86;644 
1b) 
27;189;30;700 
 
2b) 21;96;36;793 
IN: unselected women 
EX: multiple 
pregnancies, fetal 
anomalies, women 
already on low dose 
aspirin 
Kurdi
 
(2004) UK 
19-21 
and 24-
26 
779 (13.2) 
for 
BW<10
th
 
TA, color + PW, 
crossover 
1) Bilateral notching + mean 
RI > 0.55 (50
th
) or unilateral 
notching + mean RI > 0.65 
a) BW < 10
th
  
b) BW < 3
rd
 (local and 
gestational values) 
1 or 2a) 
16;33;87;643 
1 or 2 b) 
sub-group analysis of 
cohort in Kurdi (1998) 
with normalization of 
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779 (4.2) 
for 
BW<3
rd
 
(90
th
), or no notching + mean 
RI > 0.70 (90
th
) 
2) Bilateral notching + mean 
RI >f0.55 (50
th
) 
29;45;4;701 
 
Doppler at 24-26 weeks 
Liberati
 
(1997) Israel 
22-24 481 (8.5) TA, color + PW, 
crossover 
1) Mean RI ≥ 90th 
2) Unilateral notching or 
mean RI ≥ 90th  
BW < 10
th
 (local 
values) 
1) 11;18;30;422 
2) 16;34;25;406 
EX: preterm delivery, 
multiple pregnancies, 
major fetal anomalies 
Marchesoni 
(2003) Italy 
24 900 (1.7) Unreported 
route and type, 
crossover 
1) Bilateral vs unilateral or 
no notching 
2) Bilateral or uni vs no 
notching 
BW < 3
rd
  1) 0;60;15;825 
2) 8;153;7;722 
IN: unselected women 
Martin
 
(2001)UK 
11-14 3045 (9.5) TA, color + PW, 
ascending 
branch 
1) Mean PI > 2.35 (95
th
) BW < 10
th
 (local and 
gestational values) 
1) 
34;121;256;2639 
IN: routine antenatal 
care 
Miyakoshi
 
(2001) Japan 
21-24 359 (11.4) Unreported 
route, color + 
PW, crossover 
1) Mean PI > 95
th
 +/- 
unilateral notching 
BW < 10
th
 (local and 
gestational values) 
1) 10;18;31;300 Not reported 
Morris
 
(1996) 
Australia 
18 a) 768 
(12.7) 
b) 768 
(4.6) 
c) 679 
(10.9) 
TA, color + PW, 
crossover 
1) S/D > 3.0 (90
th
) + any 
notching or S/D > 3.3 (2SD) 
a) BW < 10
th
 (local 
values) 
b) BW < 3
rd
  
c) PI < 10
th
 
1a) 21;54;77;616 
1b) 9;66;26;667 
1c) 15;46;59;559 
IN: all nulliparae (RCT) 
Nort 19-24 457 (6.6) TA, color + PW, 1) RI > 90
th
  BW < 10
th
 (local and 1) 15;41;15;386 IN: healthy nulliparae, 
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 (1994) 
Australia 
crossover 2) S/D > 90
th
  
3) RI > 0.53 
4) RI > 0.54 
5) RI > 0.55 
6) RI > 0.56 
7) RI > 0.57 
gestational values) 2) 14;47;16;380 
3) 17;86;13;342 
4) 16;74;14;354 
5) 16;60;14;368 
6) 16;45;14;383 
7) 14;38;16;390 
EX: renal disease, DM 
Ohkuchi
 
(2000) Japan 
16-23 288 (6.3) TA, color + PW, 
crossover 
1) RI > 70
th
  
2) S/D > 78
th
  
3) NDI > 0.14 
4) Any notching 
5) Bilateral notching 
BW < 10
th
 (local and 
gestational values) 
 
1) 10;102;8;168 
2) 9;69;9;201 
3) 6;21;12;249 
4) 6;53;12;217 
5) 3;25;15;245 
IN: unselected healthy 
women with singleton 
pregnancies 
Onala 
 (2005) Turkey 
19-21 406 (10.1) Unreported 
route, type and 
site 
1) Bilateral notching + mean 
RI > 0.55 or unilateral 
notching + mean RI > 0.65 
or no notching + mean RI > 
0.7 
BW < 5th (local 
values) 
1) 15;19;26;346 IN: fasting serum tHcy 
levels. EX: multiple 
pregnancies, history of 
PE, hypertension < 20 
weeks, altered renal 
function, DM, chronic 
disease, fetal anomalies, 
folic acid use > 12 wks, 
special folate diet, 
treatment with antifolate 
drugs, age >40 yrs 
Papageorghiou 
(2001) UK 
20-24 7851 (9.4) TVS, color + 
PW, level of 
Mean PI > 1.63 (95
th
) BW < 10
th 
(local and  
gestational values) 
1) 
121;280;619;6831 
IN: singleton 
pregnancies attending 
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internal cervical 
os 
for routine antenatal care 
Park
 
 (2005) Korea 
20-24 1090 (9.5) 
 
TA, color + PW, 
previously 
reported 
1) S/D > 2SD +/- any 
notching 
2) S/D > 2SD +/- bilateral 
notching only 
BW < 10th (local and  
gestational values) 
1) 38;227;66;759 
2) 18;51;86;935 
EX: multiple 
pregnancies, fetal 
anomalies, 
cardiovascular  and renal 
diseases, DM, FGR, 
PIH, preterm labour 
before performance of 
Doppler. 
Phupong
 
(2003) Thailand 
22-28 
(24.9 ± 
1.9) 
324 (1.9) TA, color + 
pulsed, 
crossover 
1) S/D + 2SD a/o bilateral 
notching 
BW < 10
th
 (gestational 
values) 
1) 4;56;2;262 IN: healthy nullparae 
and multiparae. EX: 
multiple pregnancies, 
renal and cardiovascular 
disease, DM, fetal 
anomalies 
Prefumo
 
(2004) UK 
i) 11-14 
ii) 18-
23 
662 (9.8) Unreported 
route, color, 
ascending 
branch 
1) Bilateral notching BW < 10
th
 (local, 
gestational and sex 
values) 
1i) 37;214;28;383 
1ii) 4;25;61;572 
EX:multiparae, fetal 
abnormalities, 
concurrent maternal 
disease and gestational 
diabetes 
Schwarze
 
(2005) 
Germany 
19-26 346 (10.1) TA, color, 
crossover 
1) Any RI > 0.58 
2) Both RI > 0.58 
3) Any RI > 0.7 
BW < 10
th
 1) 18;116;17;195 
2) 4;47;31;264 
3) 7;41;28;270 
EX: essential 
hypertension, DM, AID, 
history of PE, FGR, 
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4) Both RI > 0.7 
5) Any notching 
6) Bilateral notching 
4) 12;65;23;246 
5) 20;124;15;187 
6) 10;97;25;214 
IUD, placental abruption 
in previous pregnancies, 
multiple pregnancies, 
fetal abnormalities 
Sekizuka
 
(1994) Japan 
6-13 135 (7.4) TVS, color + 
pulsed, internal 
os 
1) Bilateral notching BW < 10
th
 (local and 
gestational values) 
1) 9;115;1;10 EX: threatened abortions 
and fibroids 
Soutif
 
(1996) France 
21 315 (10.4) Unreported 
route and site, 
color + PW 
1) S/D > 2.6 +/- any notching BW < 10
th
 (local 
values) 
1) 10;40;23;242 EX: nephropathy, CH, 
DM, systemic disorders, 
multiple pregnancies 
Subtil
 
(2003) France/ 
Belgium 
22-24 a) 1186 
(1.9) 
b) 1186 
(10.3) 
Unreported 
route and type, 
crossover 
1) RI ≥ 0.61 or any notching a) BW ≤ 3rd (local and 
gestational values) 
b) BW ≤ 10th  
1a) 
11;228;12;935 
1b) 
45;194;78;869 
Routine Doppler 
examination followed by 
a prescription for aspirin 
in case of abnormal 
Doppler findings versus 
placebo (RCT) 
Todros
 
 (1995) Italy 
a) 19-
24 
 
916 (4.6) Unreported 
route and site, 
CW + pulsed 
1a) S/D > 2.7 
 
BW < 10
th
 (local 
values) 
1a) 5;54;37;820 
 
IN: singleton 
pregnancies, no 
prepregnancy pathology, 
no obstetric risk, no 
chromosomal or 
structural anomalies 
Uludag
 
(2002) Turkey 
18-20  80 (11.3) TA, color + PW, 
unreported site 
1) Bilateral notching BW < 10
th
 (unreported 
data set) 
1) 6;11;3;60 IN: non-smokers, EX: 
DM, fetal anomalies, 
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multiple pregnancies 
Valensise
 
(1993) Italy 
24 192 (14.6) Unreported 
route and site, 
color 
1) RI > 0.58 (mean) BW < 10
th
 (gestational 
values 
1) 24;15;4;149 IN: low risk (n=104) 
primiparae, no current or 
previous relevant 
medical history. High 
risk (n=88) history of 
PIH, FGR, IUD. EX: 
FGR on ultrasound 
screening or 
oligohydramnios 
Valensise
 
(1993) Italy 
24 272 (7.7) TA, color + PW, 
crossover 
1) RI > 0.58 BW < 10
th
 (local 
values) 
1) 14;12;7;239 EX: history of 
hypertension, DM, SLE, 
pharmacological 
induction of ovulation, 
fetal or chromosomal 
abnormalities 
Zimmerman
 
(1997) Finland 
20-24 55 (7.2) Unreported 
route, PW, 
crossover 
1) Bilateral notching BW < 10
th
 (local 
values) 
1) 3;27;1;24 IN: low risk (n=29) or 
high risk (n=26; family 
or personal history of 
PE, CH or FGR or IUD) 
(RCT) 
* Studies are cohort studies unless otherwise stated (randomised controlled trial (RCT)).TP true positives; FP false positives; FN false negatives; TN true negatives; 
FPR false positive rate; BW birthweight;, PI pulsatility index; RI resistance index; a/o and/or; IN inclusion; EX exclusion; AFP alpha-fetoprotein; hCG human 
chorionic gonadotrophin; PE preeclampsia; PIH pregnancy induced hypertension; SGA small for gestational age; DM diabetes mellitus; AID auto immune disease; 
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APLS antiphospholipid syndrome; SLE systemic lupus erythematodes; IUD intra uterine demise; TTTS twin transfusion syndrome; MoM multiples of the median; PW 
pulsed waved; CW continuous waved, TA transabdominal, TVS transvaginal. 
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Appendix 20: Study characteristics of included studies on uterine artery Doppler and fetal growth restriction: high risk populations. 
 
Author  
(year) 
Country 
Gestation 
(weeks) 
N 
(% SGA) 
Details  
index test 
Index test (cut-off, centiles 
or absolute thresholds) 
Reference test  
(centiles or  
absolute thresholds (g)) 
Results 
(TP; FP; FN; TN) 
Population (study 
design)* 
Aardema
 
(2000) 
Netherlands 
21-22 94 (10.6) Unreported 
route, color 
+ PW, 
crossover 
1) PI ≥ 1.3 
2) Any notching 
BW < 10
th
 centile (local, 
gestational and sex 
values) 
1) 8;26;2;58 
2) 5;20;5;64 
IN: multiparae with history 
of hypertensive disorders 
in previous pregnancy, but 
no current pathology, 
singleton pregnancies 
Alkazaleh
 
(2006) 
Canada 
19-23 50 (52.0) Unreported 
route, color 
+ PW, 
crossover 
1) Mean PI > 1.45 or bilateral 
notching 
BW < 10
th 
(sex and 
gestational values) 
1) 21;7;5;17 IN: AFP > 2.0 MoM and 
hCG > 2.5 MoM 
Axt-
Fliedner
 
(2005) 
Germany 
19-26 52 (13.5) TA, color, 
crossover 
1) Any RI > 0.58 
2) Both RI > 0.58 
3) Any RI > 0.7 
4) Both RI > 0.7 
5) Any notching 
6) Bilateral notching 
BW < 10
th
  1) 7;24;0;21 
2) 5;9;2;36 
3) 3;4;4;41 
4) 2;1;5;44 
5) 5;22;2;23 
6) 5;10;2;36 
IN: high risk singleton 
pregnancies: history of PE, 
FGR, IUD, abruption 
Caforio
 
(1999) Italy 
a) 18-20 
b) 22-24 
i) 335 
(15.2) 
ii) 335 
Unreported 
route, color 
+ PW, 
1) RI > 90
th
 centile i) BW < 1750g 
ii) BW < 2500g 
1ai) 36;88;15;196 
1aii) 68;58;44;165 
1bi) 44;75;13;202 
IN: CH, DM, AID, SLE, 
renal disease; history of 
stillbirths, FGR, PE, 
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(33.4) crossover 1bii) 73;49;47;166 habitual abortion 
Caruso
 
(1993) Italy 
18-24 a) 28 
(10.7) 
b) 28 
(39.0) 
TA, color + 
PW, 
crossover 
1) RI > 90
th
  a) BW < 10
th
 (local 
values) 
b) BW < 1750g 
1a) 2;6;1;19 
1b) 9;0;2;17 
IN: APLS 
Caruso
 
(1996) Italy 
23-24 a) 42 (9.5) 
b) 42 
(42.0) 
TA, color, 
crossover 
1) Mean RI > 90
th
 a) BW < 10
th
 (local 
values) 
b) BW < 2500g 
1a) 4;11;0;27 
1b) 14;1;4;23 
IN: CH, singleton 
pregnancies. EX: AID, 
fetal anomalies, Rhesus 
isoimmunisation 
Coleman
 
(2000) New 
Zealand 
22-24 116 (26.7) TA, color, 
crossover 
1) Any RI > 0.58 
2) Both RI > 0.58 
3) Any RI ≥ 0.7 
4) Both RI ≥ 0.7 
5) Any notching 
6) Bilateral notching 
7) Any RI > 0.58 and any 
notching 
8) Any RI > 0.7 and any 
notching 
9) Both RI > 0.7 and any 
notching 
BW < 10
th
 (local values) 1) 26;52;5;33 
2) 14;18;17;67 
3) 17;23;14;62 
4) 8;4;23;81 
5) 19;26;12;59 
6) 11;9;20;76 
7) 19;26;12;59 
8) 15;16;16;69 
9) 8;3;23;82 
IN: essential and secondary 
hypertension, renal disease, 
SLE, APLS, previous PE 
or placental abruption. EX: 
multiple pregnancies, fetal 
abnormalities 
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Degani
 
(2001) Israel 
15 124 (31.5) TA, color + 
PW, 
unreported site 
1) Mean PI > 1.12 BW < 10
th
 (gestational 
values) 
1) 9;17;30;68 IN: singleton pregnancies, 
accurately dated, previous 
SGA infant, no 
chromosomal or structural 
anomalies 
Ferrier
 
(1994) 
Australia 
19-24 51 (11.8) TA, color, 
crossover 
 
1) RI > 90
th
 +/- notching on 
placental side or highest value 
if midline 
BW < 10
th
 (local and 
gestational values) 
1) 5;9;1;36 IN: renal disease other than 
diabetic nephropathy 
Frusca
 
(1996) Italy 
24 56 (23.2) TA, color + 
pulsed, 
crossover 
1) RI > 0.58 
2) Any notching 
3) Bilateral notching and RI > 
0.58 
BW < 10
th
  1) 11;13;2;30 
2) 11;10;2;33 
3) 6;2;7;41 
IN: previous history of PE, 
normal blood pressure after 
that pregnancy 
Geipel
 
(2002) 
Germany 
18-24 256 (17.6) Unreported 
route and 
type, 
crossover 
1) RI > 95
th
 (singleton ref) 
2) RI > 95
th
 (twin ref) 
3) RI > 95
th
 + any notching 
(twin ref) 
4) Any notching 
5) Bilateral notching 
BW < 10
th
 centile (twin 
reference ranges local 
population) 
1) 4;4;41;207 
2) 12;24;33;187 
3) 11;13;34;198 
4) 16;27;29;184 
5) 4;10;41;201 
IN: dichorionic twins EX: 
fetal malformation,  
PPROM, unclear 
chorionicity, unavailable 
outcome 
Geipel
 
(2001) 
Germany 
18-24 114 (14.0) 
 
 
Unreported 
route, color, 
crossover 
1) Bilateral notching + mean 
RI > 0.55 or unilateral 
notching + mean RI > 0.65 or 
no notching + mean RI > 0.7 
BW < 10
th
 (local values) 1) 7;20;9;78 
 
IN: ICSI patients, singleton 
pregnancies  
Geipel
 
(2001) 
18-24 32 (18.8) Unreported 
route, color, 
1) Bilateral notching only BW < 10
th
 (local values) 1) 4;4;2;22 
 
IN: ICSI patients, twin 
pregnancies 
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Germany crossover  
Geipel
 
(2001) 
Germany 
18-24 32 (21.8) Unreported 
route, color, 
crossover 
1) Bilateral notching only BW < 10
th
 (local values) 1) 3;5;4;20 
 
IN: twin pregnancies, 
(control group of (ICSI) 
Haddad
 
(1995) 
France 
First at 
mean 
23.8 
 
48 (18.7) Unreported 
route and 
site, CW 
1) D/S < 10
th
 unilateral 
2) D/S < 10
th
 unilateral +/- 
diastolic notching 
3) Unilateral diastolic 
notching 
BW < 10
th
 (local and 
gestational values) 
1) 7;15;2;24 
2) 8;18;1;21 
3) 7;11;2;28 
 
IN: aspirin treatment 
because of poor previous 
outcome, PE, eclampsia, 
HELLP, abruption, IUGR, 
IUD 
Harringto 
(2004) UK 
19-21 170 (10.2) TA, color + 
pw, crossover 
 
1) Bilateral notching + mean 
RI ≥ 0.55 (50th centile) or 
unilateral notching + mean RI 
≥ 0.65 (80th centile) 
BW < 5
th
 (local values) 1) 11;29;15;115 IN: CH, previous PE, GH, 
FGR, preterm labour, 
abruption, IUD, DM, renal 
disease, other medical 
diseases, EX: fetal 
anomalies 
Hershkovitz
 
(2005) UK 
24 88 (26.1) Unreported 
route, color 
+ PW, 
crossover 
1) PI (mean) > 95
th
 +/- any 
notching 
2) PI (mean) > 95
th
 +/- 
bilateral notching 
BW < 10
th
 centile (local, 
gestational and sex) 
1) 17;16;6;49 
2) 12;10;11;55 
IN: CH, history of severe 
PE, thrombophilia 
Konchak
 
(1995) 
USA 
17-22 a) 103 
(17.4) 
b) 103 
(13.5) 
TA, color + 
PW, 
crossover 
1) Unilateral notching 
2) RI ≥ 0.7 (95th centile) 
a) BW < 10
th
 centile 
(local values) 
b) BW < 2500g 
1a) 3;6;15;79 
1b) 4;5;10;84 
2a) 3;8;15;77 
2b) 5;6;9;83 
IN: AFP > 2.0 MoM twice 
or >2.5 MoM once. 
Singleton pregnancies, no 
fetal anomalies, normal 
amniotic fluid volume 
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Le Thi 
Huong
 
(2006) 
France 
2
nd
 
trimester 
100 (18.0) Unreported 
route and 
type, 
crossover 
Any notching BW < 10
th 
(gestational 
values) 
1) 3;15;12;70 IN: SLE, APLS 
Nagtegaal 
(2005) 
Australia 
18-22 a) 182 
(19.8) 
b) 182 
(12.1) 
Unreported 
route and site, 
color + PW 
1) Mean RI ≥ 0.58 + any/no 
notching or mean RI < 0.58 + 
bilateral notching 
a) BW < 10
th
 (local and 
gestational values) 
b) BW < 5
th
  
1a) 23;104;13;42 
1b) 14;113;8;47 
IN: previous PE, FGR, 
placental abruption, 
recurrent miscarriages, 
unexplained stillbirth, CH, 
IDDM, thrombophilia, 
positive family history of 
PE 
Soregaroli
 
(2001) Italy 
24 
 
282 (18.0) 
 
TA, color, 
crossover 
1) RI > 0.6 +/- bilateral 
notching 
BW < 10
th
 (local and 
gestational values) 
1) 40;45;10;187 
 
IN: high risk pregnancy: 
history of GH, PE, FGR, 
IUD; CH, AID, renal 
diseases EX: multiple 
pregnancies, fetal 
chromosomal anomalies, 
pregnancy complications 
<24 wks 
Vainio
 
(2005) 
Finland 
12-14 72 (5.6) TVS, color, 
uterocervical 
junction 
 
1) Bilateral notching BW < 10
th
 (local values) 1) 3;40;1;28 IN: high risk for PE, EX: 
GA <12 or >14 wks, 
asthma, allergy aspirin, 
peptic ulcer, prostaglandin 
inhibitors < 10 days of 
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investigation 
Valensise
 
(1994) Italy 
22 and 
24 
16 (43.7) Unreported 
route, CW, 
crossover 
1) RI > 0.58 (+2SD) + 
notching 
BW < 10
th
 (local and 
gestational) 
1) 7;1;0;8 IN: CH 
Van den 
Elzen
 
(1995) 
Netherlands 
a) 7-11 
b) 12-13 
c) 23-27 
 
a) 320 
(10.0) 
b) 341 
(9.4) 
c) 351 
(9.6) 
 
Unreported 
route, color, 
crossover 
1) PI > 25
th
  
a) 1.52; b)1.24; c) 0.96 
 
2) PI > 50
th
 
a) 1.78; b)1.41; c)1.09 
 
3) PI > 75
th
 
a) 2.07; b) 1.66; c)1.23 
BW < 10
th
 (local, sex 
and gestational values) 
1a) 22;218;10;70 
1b) 26;229;6;80 
1c) 26;238;9;78 
2a) 17;144;15;144 
2b) 18;153;14;156 
2c) 18;159;17;157 
3a) 13;67;19;221 
3b) 13;73;19;236 
3c) 13;75;22;241 
IN: age > 35 yrs at 20 
weeks, DBP < 85mmHg, 
no history of hypertension, 
cardiovascular disease or 
diabetes, viable singleton 
pregnancy < 11 weeks 
Venkat-
raman
 
(2001) UK 
a) 16-18 
b) 22-24 
a) 164 
(12.8) 
b) 163 
(13.5) 
Unreported 
route, color, 
crossover 
1) Any notching 
2) Bilateral notching 
BW < 10
th
 (local, sex 
and gestational values) 
1a) 16;62;5;81 
1b) 9;21;13;120 
2a) 12;25;9;118 
2b) 5;8;17;133 
IN: recurrent miscarriage 
and positive APL 
antibodies (no SLE or 
tromboembolic disease) 
Yu
 
(2002) UK 
22-24 a) 351 
(8.8) 
b) 351 
(23.6) 
c) 351 
(6.3) 
d) 351 
TVS, color + 
PW, level of 
internal os 
1) Mean PI > 1.5 (95
th
) 
2) Bilateral notching 
a) BW < 5
th
 both twins 
(local, gestational 
singleton reference) 
b) BW < 5
th
 one twin 
c) BW < 3
rd
 both twins 
d) BW < 3
rd
 one twin 
1a) 3;15;28;305 
1b) 5;13;78;255 
1c) 3;15;19;314 
1d) 4;14;59;274 
2a) 1;11;30;309 
2b) 5;7;78;261 
2c) 1;11;21;318 
IN: twin pregnancies, 2 
live fetuses, no fetal 
abnormality, no TTTS 
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(17.9) 2d) 5;7;58;281 
* Studies are cohort studies unless otherwise stated (randomised controlled trial (RCT)). TP true positives; FP false positives; FN false negatives; TN true negatives; 
FPR false positive rate; BW birthweight; DBP diastolic blood pressure, PI pulsatility index; RI resistance index; a/o and/or; IN inclusion; EX exclusion; AFP alpha-
fetoprotein; hCG human chorionic gonadotrophin; PE preeclampsia; PIH pregnancy induced hypertension; SGA small for gestational age;; DM diabetes mellitus; AID 
auto immune disease; APLS antiphospholipid syndrome; SLE systemic lupus erythematodes; IUD intra uterine demise; TTTS twin transfusion syndrome; MoM 
multiples of the median; PW pulsed waved; CW continuous waved, TA transabdominal, TVS transvaginal. 
  
348 
 
Appendix 21: Pooled and single estimates for uterine artery Doppler predicting small for gestational age fetuses: exclusion of studies 
that applied preventative treatment (sensitivity analysis). 
 
Doppler index No of studies No of women Sensitivity % (95% CI) Specificity % (95% CI) LR positive (95% CI) LR negative (95% CI) 
Low risk/ unselected: birth weight < 10th centile or < 2500g, 2nd trimester Doppler testing 
RI (0.58 or 90th)  9 3304 53 (42-64) 87 (79-94) 4.0 (1.6-6.3) 0.54 (0.41-0.68) 
RI (0.7 or 95th) 2 665 16 (10-23) 91 (86-97) 1.9 (0.5-3.3) 0.92 (0.81-1.0) 
PI 3 12097 18 (16-19) 95 (92-97) 3.4 (1.7-5.1) 0.87 (0.84-0.90) 
Bilateral notching 10 10174 21 (13-28) 93 (90-96) 3.0 (1.8-4.2) 0.85 (0.78-0.92) 
Unilateral notching 2 3819 17 (16-19) 93 (91-95) 2.4 (2.0-2.9) 0.89 (0.89-0.89) 
Any notching 4 2162 44 (32-57) 82 (72-92) 2.5 (1.4-3.5) 0.68 (0.56-0.80) 
RI or notching 4 3857 36 (33-40) 90 (83-97) 3.5 (2.0-4.9) 0.71 (0.66-0.76) 
RI and notching 1 946 45 (37-53) 82 (79-84) 2.4 (1.9-3.0) 0.68 0.58-0.77) 
PI or notching 2 2116 23 (19-27) 94 (93-95) 3.9 (3.0-4.7) 0.82 (0.77-0.87) 
PI and notching 1 1757 12 (7-18) 99 (98-99) 9.1 (5.0-16.7) 0.89 (0.85-0.93) 
S/D ratio 3 1661 34 (10-57) 88 (79-96) 2.7 (1.6-3.9) 0.76 (0.54-0.97) 
Notch index 1 288 33 (13-59) 92 (88-95) 4.3 (1.9-8.4) 0.72 (0.49-0.91) 
S/D or notching 1 1090 37 (27-47) 92 (88-95) 1.6 (1.2-2.1) 0.82 (0.70-0.94) 
High risk: birth weight < 10th centile or < 2500g, 2nd trimester Doppler testing 
RI (0.58 or 90
th
) 3 643 68 (58-78) 73 (71-75) 2.5 (2.4-2.6) 0.44 (0.31-0.56) 
RI (0.7 or 95
th
) 3 411 26 (18-33) 89 (97-92) 2.4 (1.6-3.3) 0.83 (0.75-0.91) 
PI 2 445 58 (25-91) 75 (72-78) 2.3 (1.0-3.6) 0.56 (0.12-1.0) 
Bilateral notching 2 279 17 (10-25) 92 (90-95) 2.2 (1.1-3.4) 0.90 (0.81-0.98) 
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Unilateral notching 1 103 17 (4-41) 93 (85-97) 2.4 (0.67-7.8) 0.90 (0.72-1.0) 
Any notching 5 522 51 (44-58) 77 (68-86) 2.2 (1.3-3.2) 0.63 (0.52-0.75) 
RI or notching 2 296 58 (48-67) 56 (17-95) 1.3 (0.14-2.5) 0.76 (0.20-1.3) 
RI and notching 2 272 35 (25-44) 94 (91-96) 5.4 (3.0-7.9) 0.70 (0.60-0.80) 
PI or notching 1 88 52 (31-73) 85 (74-92) 3.4 (1.7-6.4) 0.57 (0.38-0.81) 
D/S ratio 1 48 78 (40-97) 62 (45-77) 2.0 (1.1-2.7) 0.36 (0.10-0.94) 
D/S or notching 1 48 89 (52-100) 54 (37-70) 1.9 (1.1-2.2) 0.44 (0.31-0.56) 
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Appendix 22: Pooled and single estimates for uterine artery Doppler predicting 
small for gestational age fetuses in low risk populations: high quality studies 
(sensitivity analysis) 
Doppler index No of 
studies 
No of 
women 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
LR positive 
(95% CI) 
LR negative 
(95% CI) 
Birth weight < 10th centile or < 2500g/ second trimester Doppler testing 
RI (0.58 or 90th)  2 634 53 (43-62) 62 (60-65) 1.4 (1.1-1.7) 0.76 (0.60-0.91) 
RI (0.7 or 95th) 1 346 20 (8-37) 87 (83-90) 1.5 (0.72-2.9) 0.92 (0.75-1.0) 
Bilateral 
notching 
4 932 28 (21-34) 80 (63-97) 1.4 (0.13-2.7) 0.90 (0.69-1.1) 
Any notching 3 958 51 (42-60) 75 (65-86) 2.1 (1.1-3.0) 0.65 (0.50-0.80) 
RI or notching 1 2058 37 (31-44) 87 (85-88) 2.8 (2.3-3.4) 0.72 (0.65-0.79) 
RI and notching 1 946 45 (37-53) 82 (79-84) 2.4 (1.9-3.0) 0.68 (0.58-0.77) 
S/D ratio 1 288 50 (26-74) 74 (69-80) 2.0 (1.1-2.9) 0.67 (0.39-0.96) 
Notch index 1 288 33 (13-59) 92 (88-95) 4.3 (1.9-8.4) 0.72 (0.49-0.91) 
S/D or notching 1 768 21 (14-31) 92 (90-94) 2.7 (1.7-4.1) 0.86 (0.77-0.93) 
Birth weight < 5th centile, < 3rd centile or < 1750g/ second trimester Doppler testing 
RI or notching 1 2058 37 (31-44) 87 (85-88) 2.8 (2.3-3.4) 0.72 (0.65-0.79) 
RI and notching 2 1404 44 (36-51) 87 (76-96) 3.4 (0.86-5.8) 0.65 (0.53-0.76) 
S/D or notching 1 768 26 (12-43) 91 (89-93) 2.9 (1.5-4.9) 0.82 (0.64-0.95) 
Birth weight < 10th centile or < 2500g/ first trimester Doppler testing 
RI (>0.70 or 
95
th
) 
1 1008 67 (35-90) 75 (72-78) 2.7 (1.6-3.5) 0.44 (0.18-0.81) 
PI 1 3045 44 (36-51) 87 (76-96) 3.4 (0.86-5.8) 0.65 (0.53-0.76) 
Bilateral 
notching 
1 135 90 (56-100) 8 (4-14) 0.98 (0.68-1.1) 1.3 (0.21-6.0) 
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Appendix 23: Pooled and single estimates for uterine artery Doppler predicting 
small for gestational age fetuses in high risk populations: high quality studies 
(sensitivity analysis) 
Doppler index No of 
studies 
No of 
women 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
LR positive 
(95% CI) 
LR negative 
(95% CI) 
Birth weight < 10th centile or < 2500g/ second trimester Doppler testing 
RI (0.58 or 90th)  4 242 84 (77-91) 64 (49-79) 2.3 (1.4-3.3) 0.24 (0.12-0.37) 
RI (0.7 or 95th) 1 116 55 (36-73) 73 (62-82) 2.0 (1.2-3.1) 0.62 (0.41-0.88) 
Bilateral 
notching 
2 279 30 (21-39) 92 (89-96) 4.0 (1.96-6.0) 0.76 (0.66-0.85) 
Any notching 4 435 52 (26-78) 79 (73-85) 2.5 (1.5-3.5) 0.61 (0.31-0.92) 
RI or notching 2 333 80 (73-88) 81 (77-84) 4.1 (3.3-4.9) 0.24 (0.15-0.34) 
RI and notching 2 172 57 (46-67) 78 (73-83) 2.6 (1.8-3.4) 0.55 (0.42-0.69) 
PI or notching 1 50 81 (61-93) 71 (49-87) 2.8 (1.6-4.6) 0.27 (0.13-0.56) 
Birth weight < 5th centile, < 3rd centile or < 1750g/ second trimester Doppler testing 
PI 1 351 6 (2-14) 95 (92-97) 1.2 (0.47-3.2) 0.99 (0.92-1.0) 
Bilateral 
notching 
1 351 6 (2-14) 97 (95-99) 2.3 (0.79-6.7) 0.97 (0.91-1.0) 
RI and notching 1 170 42 (23-63) 80 (72-86) 2.1 (1.2-3.4) 0.72 (0.50-0.95) 
Birth weight < 10th centile or < 2500g/ first trimester Doppler testing 
Bilateral 
notching 
1 72 75 (18-99) 41 (29-54) 1.3 (0.50-1.7) 0.61 (0.11-1.8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
352 
 
Appendix 24: Search strategy for systematic review of umbilical artery Doppler to 
predict small for gestational age fetuses and compromise of fetal/neonatal wellbeing. 
Host: Ovid 
Date of search: March 2009 
Years covered by search: 1950-2009 
 
1. exp Pregnant Women/ 
2. exp Pregnancy/ 
3. pregnan$.mp. 
4. exp Prenatal Diagnosis/ 
5. exp Ultrasonography, Prenatal/ 
6. exp Ultrasonography, Doppler/ 
7. arterial doppler.mp. 
8. doppler velocimetry.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
9. doppler ultrason$.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
10. umbilical arter$.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
11. 1 or 2 or 3 
12. 4 or 5 or 6 
13. 7 or 8 or 9 or 10 
14. 11 and 12 
15. 13 and 14
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Appendix 25: Data extraction form for systematic review of umbilical artery 
Doppler to predict small for gestational age fetuses and compromise of 
fetal/neonatal wellbeing. 
 
Section A: Study Information 
 
1)Ref ID:  4)Publication year:  
2)Rev 
name: 
 5)First Author:  
3)Country:  6)Language:  
 
Section B: Data Retrieval for Umbilical Artery Doppler Study 
 
Population 
7) Healthcare Centre: 
Primary care □1  Secondary care  □2  Mixed □3    Other   □4        Unreported  □5 
 
8) Setting: 
 In-patient  □1  Out-patient  □2  Mixed  □3  Unreported  □4       Other  □5 
 
9) Number of participating centres: ____________________________________ 
 
10) Gestation at time of index test: 
<20 weeks   □1  20-24 weeks  □2   24-28 weeks □3    28-34 weeks □4   34-37 
weeks □5    37-40 weeks  □6   > 40 weeks  □7      Unreported  □8           Other 
_______________________ 
 
10.i) Mean (range)______________________________________         Unreported  
□3 
 
10.ii) Median (range) ____________________________________        Unreported  
□3 
 
11) Pregnancy: 
Low Risk      □1  High Risk    □2  Unselected  □3  Unreported  □4 
 
11.i) State high risk conditions:      Unreported  □3 
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12) Were patients with the following conditions excluded/not included? 
12.i) Previous IUGR:    Yes □1  No  □2
 Unreported   □3 
12.ii) Insulin dependent diabetes mellitus:        Yes □1  No  □2
 Unreported   □3 
12.iii)   Chronic renal disease:  Yes □1  No  □2        Unreported   □3 
12.iv)   Systemic lupus erythematosus:    Yes □1  No  □2        Unreported   
□3 
12.v)    Antiphospholipid syndrome:   Yes □1  No  □2        Unreported   
□3 12.vi)   Chronic hypertension:     Yes □1  No  □2        Unreported   
□3  
12.vii)   Pre-eclampsia:   Yes □1  No  □2        Unreported   □3 
12.viii)  Foetal chromosomal/structural anomalies:  Yes □1  No  □2        
Unreported   □3 
 
13) Did all patients have singleton pregnancies?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
14) Were all patients primigravid?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
15) List other eligibility/ in-/exclusion criteria: 
 
 
 
 
 
16) Study population: (describe age (mean +/- SD or median/range), ethnicity, smoking, BMI 
etc.) 
 
 
   ----------/-------------            
   ----------/-------------            
 
 
 
 
         Not applicable  □3 
 
 
 
 
 
 
           
         Unreported  □3 
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17) Start of patient inclusion (year) :                        U    
Unreported □3  
18) End of patient inclusion (year) :              
Unreported □3 
19) Study Design:    
cohort  □1    case control  □2      RCT/CCT  □3        cross sectional  □4     before and 
after  □5         case series   □6  (no ______)      other  □7 
19.i) Data collection:  prospective □1      retrospective   □2      unreported  □3        
other  □4 
19.ii) Enrolment:    consecutive  □1       arbitary (random) □2      unreported  □3      
other  □4 
20) Numbers: 
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21) Completeness of Verification: 
(= E / C x 100 = %) 
> 90%  □1     81-90%  □2     < 81%  □3 
Index Test 
 
22) Description of technique:      
Adequate  □1   Inadequate  □2 
 
23) Timing of measurement (from delivery): 
< 7days □1  7-14 days  □2  14 -28 days □3  > 28 days  □4    Mixture  □5   
Unreported  □6 
 
23.i) Median gestational age at delivery   _____________________________ 
unreported  □3         
24) Measurement: 
SCANNING: 
24.i) Operator: 
Single  □1   Multiple  □2       Unreported    □3 
 
B Reasons ________________ 
 
D Reasons ________________ 
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24.ii) Operator experience__________________________________________ 
unreported  □3         
24.iii) Scanning Route: Transabdominal □1  Transvaginal  □2   Unreported  □3 
DOPPLER: 
24.iv) Method:   Continuous wave Doppler  □1  Pulsed wave Doppler  □2 Colour 
mapping  □3     Unreported   □4 
24.v) Measurement parameter:     Resistance index (RI)  □1   Systolic / diastolic 
ratio  □2 Diastolic / systolic ratio    □3   Unilateral Diastolic notch  □4   Bilateral 
diastolic notch  □5    Pulsatility index (PI) □6  Reduced EDF  □7   
Absent EDF  □8   Reversed EDF  □9   Unreported  □10    
24.vi) Cut-off level for waveform ratio:   > 2 SD  □1   > 95th centile  □2  > 90th 
centile  □3    
> 80th centile □4     > 50th centile  □5  < 10th centile □6   < 5th centile  □7   
Unreported/NA  □8 
Other/Threshold data set: 
______________________________________________________ 
24.vii) Machine: ___________________________________________  unreported  
□3         
24.viii) Probe: 
_______________________________________________unreported  □3         
24.ix) High pass filter: ______________________________________  unreported  
□3         
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24.x) Pulse rePEition frequency: ______________________________  unreported 
□3         
24.xi) Size of sampling gate: 
___________________________________unreported  □3         
24.xii) Site : 
_________________________________________________unreported  □3         
24.xiii) Angel of insonation: __________________________________ unreported  
□3         
24.xiv) Number of consecutive waveforms: _____________________ unreported  
□3         
24.xv) Other information: 
___________________________________________________________________
__ 
Reference Standard / Outcome 
25) Measured blind form diagnostic test:   Yes  □1    No  □2   Unclear  □3 
26) Measurement for FGR:   Birthweight  □1  Neonatal ponderal index  □2  
Skin fold thickness □3    MAC / OFC  □4    Other  □5  
______________________________________ 
27) Threshold:   < 3rd centile  □1  < 5th centile  □2   < 10th centile  □3  < 25th 
centile □4     
> 2SD  □5   Other □6 ________________________________________________    Unclear   □7 
28) What data set was used to define threshold? 
____________________________________________________    unreported  □3         
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29)Timing of measurement:  At delivery  □1   Within 24 hrs  □2   > 24 hrs  □3  
Mixture  □4   Unreported  □5  
30) Marker of wellbeing e.g. Apgar score, perinatal mortality 
 
 
31) Threshold and data set (if applicable): 
 
 
32) Measured blind form diagnostic test:   Yes  □1    No  □2   Unclear  □3 
 
 
 
                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Results 
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Appendix 26: Guide to quality assessment of included studies in systematic review of umbilical artery Doppler to predict small for 
gestational age fetuses and compromise of fetal/neonatal wellbeing. 
Feature Item Applicability and criteria fulfilled when 
Population spectrum 1 Refers to severity of underlying target condition, demographic features and presence of differential 
diagnoses and/or co-morbidity. For study to be classified as adequate: Appropriate spectrum – 
pregnant women, either unselected or selected (high or low risk) in any health care setting. Ideally 
there was prospective, consecutive recruitment. 
Selection Criteria 2 Refers to inclusion/exclusion criteria. For an unselected population this would not be applicable. For 
a selected population high risk conditions must be explicitly documented. If the inclusion criteria for 
the categories were not explicitly described then the category was unclear. 
Appropriate Reference 
standard 
3 SGA: birth weight < 10
th
 centile adjusted for gestational age and based on local population values 
and absolute birth weight threshold < 2500g. Severe SGA: birth weight < 5
th
 or < 3
rd
 centile or < 
1750g. Neonatal ponderal index < 10
th
 centile, skin fold thickness, and mid-arm  
circumference/head circumference were also assessed. For reference standards for wellbeing: any 
test performed after birth e.g. cord pH, Apgar scores, perinatal death, admission to NICU, cerebral 
palsy  
Time period between tests 4 Time period needs to be short enough to ensure that target condition does not change. For this 
review this was always graded as N/A. 
Verification Bias 5 If >90% of patients or a random selection of patients received verification with reference standard 
then answer was yes, even if the reference standard was not the same for all patients.   If the number 
was <90% or a non-random selection then the answer was no. Unclear was utilised when the 
percentage could not be calculated or no information was given. 
Number of reference 
standards used 
6 This is N/A to this review: no invasive reference test. 
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Independent reference 
standard 
7 The results of the index test are not incorporated in the definition of fetal growth restriction/fetal 
wellbeing. For this review the answer will always be yes. 
Adequate description of 
index test 
8 Type of Doppler (e.g. color wave, pulsed, etc), site of measurement, measurement parameter and cut 
off level used, transvaginal or transabdominal route. 
Adequate description of 
reference standard 
9 Birth weight: timing of measurement, scales used, whether baby clothed or not. 
Neonatal ponderal index: description of birth weight and length measurement as above. 
Skin fold thickness: description of site of measurement, instrument used and timing of measurement. 
Mid-arm circumference/ head circumference: see skin fold thickness. 
Wellbeing measurements: timing of measurement, threshold used, adequate description of how 
measurement performed or details of outcome.If this information was not provided this was 
classified as unclear. 
Blinding of index test 10 For this review this answer will always be yes, as the reference standards can only be performed 
after delivery.  
Blinding of reference 
standard 
11 To confirm that blinding was present a statement in the text to the effect of “clinicians were 
blinded/unaware of the results of the Doppler test”. If there was a statement to the contrary the 
answer was no. If no statement existed the answer was unclear.  
Availability of clinical data 12 Clinical data refers to any information relating to the patient obtained by direct observation (e.g. age, 
sex, symptoms, BMI). If clinical data will be available when the test is interpreted in practice then 
this should be available when the test is evaluated.  
Intermediate results 13 If uninterpretable, failed or intermediate results are documented or no such events occurred then the 
answer is yes. If it was apparent that such results have occurred but are not reported then the answer 
was no. If not clear whether all results were reported then answer was unclear. 
Withdrawals from study 14 If clear what happened to all patients within the study e.g. flow diagram then answer was yes. If 
some did not receive both index and reference standard then answer was no.  
Intervention A If after receiving the index test patients received any medical or surgical intervention then the 
answer was yes, and the type of intervention recorded. If a statement existed that no intervention was 
given the answer was no. If no statement existed and no interventions were given then the answer 
was unclear. 
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umbilical artery Doppler to predict small for gestational age fetuses and 
compromise of fetal/neonatal wellbeing. 
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Appendix 28: Table of study characteristics of included studies for systematic review of umbilical artery Doppler to predict small for 
gestational age fetuses / compromise of fetal wellbeing. 
 
First 
Author 
(year) 
Population 
Maternal age (yrs) 
(country/study design) 
No of 
fetuses 
analyse
d 
Gestation
al age at 
test 
(weeks) 
Reference  
Standard 
 SGA 
Inciden
ce of 
SGA 
(%) 
Reference 
standard Fetal 
compromise 
 Details of Index 
test 
 
 
Anyaegbuna
m
 
(1990) 
 
High risk. 
INC: Patients with hypertension or suspected 
SGA 
Hypertension and SGA mean age 29+/-10. 
(USA) (Cohort, prospective) 
 
149 
 
Third 
trimester 
(32-40) 
 
BW<10th 
centile 
 
19.4% 
 
NA 
 
TA, pulsed, 
site not 
reported, SD≥3 
        
Arauz 
(2008) 
High risk 
INC: women with severe pre-eclampsia (one of 
systolic BP>160mmHg or diastolic>110mmHg 6 
hrs apart, proteinuria>2grms in 24 hrs or 3+ on 
dipstick twice 6 hrs apart without UTI, altered 
vision, epigastric pain, oliguria, pulmonary 
oedema, thromobocytopenia, abnormal hepatic 
function) 
EXC: multiple pregnancy, essential hypertension, 
43 27-33 
weeks 
(test to 
delivery 
interval 7 
days) 
BW<5
th
 
centile 
32.6% Admission to 
NICU, RDS, 
IVH, NEC, 
perinatal 
mortality 
Route not 
reported, 
pulsed and 
color, middle 
portion of cord, 
PI>95
th
 centile 
or AREDF 
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diabetes mellitus, autoimmune conditions, kidney 
disease, chromosomal and structural 
malformations. 
Mean maternal age 30 years (sd+/-5.34) normal 
Doppler 30+/-5.40 abnormal Doppler 
(Mexico) (Cohort, prospective) 
 
Arduini
 
(1987) 
 
High risk. 
INC: Singleton, suspected SGA with confirmed 
EDD, at risk of hypertension EXC: Patients 
receiving tocolytics 
Mean age not reported 
(Italy) (Cohort, prospective) 
 
75 
 
26-28 
weeks 
Test to 
delivery 
interval 
mean 8.3 
weeks +/-
2.1 (5-12) 
 
BW<10
th
 
centile 
(adjusted for 
ga/local/heig
ht 
/weight/parit
y/ sex) 
 
30.7% 
 
NA 
 
TA, pulsed, 
luminal centre, 
PI mean+1sd 
 
Arduini
 
(1991) 
 
Low risk. 
INC: 1000 patients with low risk pregnancies, 
singleton, certain gestational age. 
Mean age 28.71+/-4.76 
(Italy) (Cohort) 
 
1000 
 
Mean 
38.29+/-
1.57 
weeks. 
Test to 
delivery 
interval 
mean 
 
BW<10
th
 
centile 
 
6.4% 
 
Adverse perinatal 
outcome (one or 
more of cs for 
fetal distress, 
Apgar score <7 
at 5 mins, 
admission to 
NICU for 
 
Route not 
reported, 
continuous 
wave, site not 
reported, 
SD>3. 
  
387 
 
13.21+/-
7.93 days. 
asphyxia for 
>48hrs). 
 
Arduini
 
(1992) 
 
High risk.  
INC: Singleton, accurate EDD, AC<5
th
 centile or 
EFW<10
th
 centile, successful Doppler. EXC: No 
chromosomal or structural anomalies. 
Mean age 29.4+/-4.3 (18-36) 
(Italy) (Cohort) 
 
 
120 
 
Mean 
32.2+/-
3.0 (24-
36) 
weeks. 
First 
investigat
ion after 
diagnosis 
used for 
analysis. 
 
NA 
 
NA 
 
Adverse perinatal 
outcome (one or 
more of perinatal 
death, cs due to 
abnormal FHR, 
Apgar score <7 
at 5 mins, 
admission to 
NICU for 
asphyxia 
>48hrs). 
 
Route not 
reported, 
color+pulsed, 
site not 
reported, 
PI>95
th
 centile.  
 
Atkinson
 
(1994) 
 
Low  risk. 
INC: Singleton, low risk nullips enrolled on 
double blind trial of low dose (60mg) aspirin for 
PE prevention. EXC: Renal disease, collagen 
vascular disease, diabetes mellitus, multiple 
gestations, chronic hypertension. 
Mean age 19.9+/-2.7. 
(USA) (RCT, prospective, consecutive) 
 
 
490 
 
20-42 
weeks. 
 
BW<10
th
 
centile 
(ga/local) 
 
6.73% 
 
NA 
 
TA, continuous 
wave, site not 
reported, 
SD>90
th
 centile 
for ga. 
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   Baschat
 
(2000) 
High risk. 
INC: Ultrasonographic biometric results 
suggestive of IUGR, delivery >23+6 weeks. 
Mean age not reported. 
(USA) (Cohort, consecutive) 
302 Third 
trimester. 
Mean test 
to 
delivery 
interval 2 
weeks 
(1day-9 
weeks).  
BW<10
th
 
centile 
(local/ga) 
35.4% Admission to 
NICU, NEC, 
acidaemia 
(umbilical cord 
artery and vein 
pH<10
th
 centile).  
TA, method 
and site not 
reported, SD 
mean +2sd. 
 
Beattie 
(1989) 
 
Low risk. 
INC: 2097 ultrasonically dated singleton 
pregnancies attending hospital within 7 days of 
their 28
th
 gestational week.  
Mean age 26.3+/-5.5. 
(UK) (Cohort) 
 
2097 
 
28, 34 
and 38 
weeks. 
 
BW<5th 
centile  
 
4.14% 
 
NA  
 
TA, continuous 
wave, 
characteristic 
waveform, 
PI/RI/SD>90
th
 
centile. 
 
Bekedam
 
(1990) 
 
High risk. 
INC: Patients admitted for suspected IUGR who 
developed late heart rate decelerations, delivery 
by elective cs, BW<10
th
 centile, accurate 
gestation  EXC: fetal chromosomal and structural 
anomalies. 
Mean age normal Doppler 34; abnormal Doppler 
 
70 
 
Within 72 
hrs of 
delivery. 
Mean age 
at 
delivery 
normal 
 
NA 
 
NA 
 
Intra-uterine 
death, neonatal 
death, 
intubation>7days
, IVH, NEC. 
 
Route not 
reported, 
continuous 
wave, site not 
reported, 
AEDF or 
raised PI (cut-
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31 
(Netherlands) (Cohort, retrospective, 
consecutive) 
 
 
Doppler 
33 weeks; 
abnormal 
33.2 
weeks. 
off not 
reported.) 
 
Berkowitz
 
(1988) 
 
High risk. 
INC: Singleton, known risk factors or clinical 
suspicion of IUGR  
Mean age 26 +/-6.0 
(USA) (Cohort, prospective) 
 
  
 
168 
 
30-42 
weeks, 
mean 
31.6. 
 
BW<10
th
 
centile 
 
25.0% 
 
NA 
 
TA, continuous 
wave, site not 
reported, mean 
SD≥3 
 
Berkowit
 
(1988) 
 
High risk. 
INC: Singletons, known risk factors or 
EFW<10
th
 centile, accurate gestation.  
Mean age normal Doppler 26.5+/-6.1; abnormal 
27.1+/-5.5 
(USA)(Cohort, consecutive) 
 
 
 
129 
 
30-42 
weeks 
 
NA 
 
NA 
 
Apgar at 1 and 5 
mins <7, 
neonatal 
resuscitation, 
admission to 
NICU, RDS, 
neonatal death, 
perinatal 
morbidity. 
 
 
TA, continuous 
wave, site not 
reported, mean 
SD≥3 
Bilar
 
High risk. 213 Third NA NA Poor outcome TA, method 
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(2005) INC: Pregnant women delivered by cs (for 
preventive and urgent indications before labour) 
who had umbilical artery Doppler 7 days prior) 
Age not reported 
(Poland)  (Cohort) 
trimester. (Apgar at 5 
mins<4 and or 
umbilical artery 
pH≤7.20/BE≤11
mmol/l 
and site not 
reported, PI/SD 
mean+2sd, 
AREDF. 
 
Bo Hyun 
Yoon
 
(1992) 
 
High risk. 
INC: Singletons, delivery by cs within 16 hrs of 
ultrasound, intact membranes, not in labour  
EXC: structural and chromosomal abnormalities 
Mean age abnormal Doppler 28.9+/-3.6 years, 
normal Doppler 28.4+/- 3.5  years. 
(Korea)(Cohort) 
 
105 
 
Within 16 
hours of 
delivery 
 
NA 
 
NA 
 
Umbilical artery 
pH<7.20 
 
TA, pulsed, 
site not 
reported, 
SD>2sd above 
mean for 
ga/local 
population. 
 
Bo Hyun 
Yoon 
(1993) 
 
Low risk. 
INC: Singletons, known gestational age EXC: 
Doppler to delivery interval>7days, delivery of 
SGA infant, Doppler obtained during labour or 
therapy with ritodrine, multiple pregnancy, 
delivery outside institution, unavailability of 
follow-up, gestational age <26 weeks at delivery 
Mean age 29.6+/-3.2  
(Korea)(Cohort, prospective) 
 
328 
 
Third 
trimester 
(test to 
delivery 
interval 
≤7 days). 
 
NA 
 
NA 
 
Apgar 1 and 5 
mins<7, 
admission to 
NICU, perinatal 
death. 
 
 
TA, pulsed, 
free floating 
portion of cord, 
SD>2sd above 
mean ga/local 
population. 
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   Bo Hyun   
Yoon
 
(1994) 
 
High risk. 
INC: 72 consecutive patients with preeclampsia, 
singletons EXC: multiple pregnancy, congenital 
malformations 
Mean age normal Doppler 29.2+/-3.3; abnormal 
29.1+/-4.0 
(Korea) (Cohort, consecutive) 
 
72 
 
Within 7 
days of 
delivery. 
Mean ga 
at 
delivery 
normal 
Doppler 
38.1+/- 
2.7; 
abnormal 
32.3+/-
3.9 
weeks. 
 
NA 
 
NA 
 
Adverse perinatal 
outcome (fetal 
distress requiring 
cs, Apgar <7 at 5 
mins, significant 
neonatal 
morbidity or 
perinatal death) 
 
TA, pulsed, 
free loop of 
cord, PI>2sd 
above mean for 
ga/local 
population. 
        
Bracero 
(1989) 
High risk. 
INC: Women who had umbilical artery Doppler 
and quantitative placental examinations 
Mean age not reported 
(USA)(Cohort) 
47 Last test 
before 
delivery 
used for 
analysis. 
Mean ga 
at 
delivery 
NA NA 
 
Admission to 
NICU 
Route not 
reported, 
continuous 
wave, site not 
reported, 
SD≥3. 
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normal 
Doppler 
32+/-4.0, 
abnormal 
36+/-5.0 
 
Bracero
 
(1996) 
 
High risk. 
INC: Singletons, availability of mid-trimester 
glycosylated haemoglobin, test within 1 week of 
delivery.   
EXC: chromosomal and structural anomalies. 
Mean age 29.3+/-.4 
(USA) (Cohort, retrospective) 
 
207 
 
Within 1 
week of 
delivery 
 
BW 
mean<2sd 
for ga 
 
1.93% 
 
Hypocalcaemia, 
hypoglycaemia, 
hyperbilirubinae
mia, RDS. 
 
Route not 
reported cw+ 
pulsed, free 
loop of cord, 
SD≥3. 
 
    Brar
 
(1989) 
 
High risk. 
INC: High risk pregnancies (chronic 
hypertension, PIH, IUGR, SLE, post dates, 
diabetes, decreased fetal movements) 
Age not reported 
(USA) (Cohort) 
 
200 
 
Third 
trimester. 
Test 
within 7 
days of 
delivery. 
 
BW<10
th
 
centile, local 
values. 
 
10.5% 
 
Apgar score at 5 
mins <7. 
 
TA,pulsed, free 
loop of cord, 
SD>3. 
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Brar
 
(1989) 
High risk. 
INC: Premature uterine contractions ≥2 in 10 
mins at <36 completed weeks, cervical change 
and cervical dilatation<4cm. EXC: Ruptured 
membranes, known IUGR, medical 
complications of pregnancy or mature lung 
profile. 
Mean age 24.5+/-2.6 (18-32) 
(USA) (Cohort, consecutive) 
92 Mean 
32.7+/-
1.8 weeks 
(27-36) 
BW<10
th
 
centile 
(local/ga) 
3.26% Apgar at 1 and 5 
mins <7, 
neonatal death. 
TA, continuous 
wave, site not 
reported, 
SD>3.5. 
 
Bruinse
 
(1989) 
 
Unselected population. 
INC: Singleton, unselected women chosen at 
random. 
Age not reported 
(Netherlands) (Cohort, prospective, random) 
 
393 
 
28
th
 and 
34
th
 week. 
 
BW or PI 
<10
th
 centile 
(ga/local) 
 
22.6% 
 
NA 
 
 
Route not 
reported, 
pulsed, site not 
reported, 
PI>95
th
 centile 
(local). 
 
Bruner
 
(1993) 
 
High risk. 
INC: Women with various pregnancy 
complications 
Mean age abnormal Doppler 24.8+/-6.6 (16-40); 
normal Doppler 26.1+/-7.0 (14-41) 
(USA) (Cohort) 
 
92 
 
16 weeks, 
last test 
before 
delivery 
used in 
analysis. 
 
BW<10
th
 
cenitle 
(ga/local) 
 
25.0% 
 
NA 
 
TA, continuous 
wave, 
characteristic 
waveform, 
SD>95
th
 cenitle 
(ga/local). 
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Burke
 
(1990) 
High risk. 
INC: Singletons, suspected IUGR (AC<5
th
 
centile) 
Age not reported. 
(Ireland) (Cohort, prospective, consecutive) 
166 Not 
reported 
BW<5
th
 
centile 
(ga/local) 
57.8% NA Route not 
reported, 
continuous 
wave, site not 
reported, SD 
mean>2sd or 
AREDF. 
 
Carroll
 
(2000) 
 
High risk. 
INC: Singletons, intact membranes, 
oligohydramnios (AFI<5
th
 centile) EXC: 
congenital anomalies 
Mean age normal Doppler 26.1+/-7.0 (14-41); 
abnormal Doppler 24.8+/-6.6 (16-40) 
(USA) (Cohort, retrospective) 
 
86 
 
Mean 
normal 
Doppler 
35.0 
weeks, 
abnormal 
31.4 
weeks 
 
BW<10
th
 
centile 
 
 
36.8% 
 
Perinatal 
morbidity (SGA, 
preterm delivery, 
hyperbilirubinae
mia, blood 
transfusion, 
cardiovascular or 
pulmonary 
complications) or 
admission to 
NICU. 
 
TA, pulsed, 
free floating 
portion of cord, 
SD>95
th
 centile 
(ga/local). 
 
Chambers
 
(1989) 
 
High risk. 
INC: 145 patients in third trimester, high risk 
(suspected SGA, hypertensive disorder) 
Age not reported. 
 
145 
 
28-39 
weeks, 
mean 
35+/-3.2 
 
BW<10
th
 
centile 
(sex/parity) 
 
58.6% 
 
NA 
 
Route not 
reported, 
continuous 
wave, site not 
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(UK) (Cohort, prospective) reported, 
RI>2sd. 
 
Chan
 
(1996) 
 
High risk. 
INC: Severe IUGR (EFW<2sd), severe PE 
(diastolic BP>100mmHg), proteinuria 
(>300mg/24hrs or 2+ on dipstix), major 
congenital anomalies, clinically evident placental 
abruption. 
Mean age 28.7+/-5.0 
(Hong Kong) (Cohort, prospective) 
 
71 
 
Mean 
31.9+/-
5.1 
weeks, 
mean test 
to 
delivery 
interval 
1.2+/-1.6 
weeks 
 
BW 
ratio<0.75 
 
47.9% 
 
NEC, major 
perinatal 
morbidity or 
mortality 
 
TA, method 
not reported, 
site not 
reported, 
SD>90
th
 or 97
th
 
centile. 
 
Chang
 
(1993) 
 
High risk. 
INC: AC<10
th
 centile, anomaly scan performed, 
accurate dates, delivery>36 weeks. 
Mean age 28.6+/-4.9 
(UK) (Cohort, prospective) 
 
133 
 
Last scan 
median ga 
220 days 
(182-
270), 
median 
interval 
last scan 
to 
 
PI, 
subscapular 
thickness, 
MAC/HC<2s
d 
 
14.4% 
(PI) 
 
NA 
 
TA, 
color+pulsed, 
lumen away 
from insertion, 
PI mean>1.5sd 
(ROC analysis) 
    delivery     
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Chang
 
(1994) 
 
 
High risk. 
INC: AC<10
th
 centile, anomaly scan performed, 
accurate dates, delivery>36 weeks. 
Mean age 28.6+/-4.9 
(UK) (Cohort, prospective) 
 
 
104 
5 days (0-
14) 
 
Last scan 
median ga 
220 days 
(182-
270), 
median 
interval 
last scan 
to 
delivery 5 
days (0-
14) 
 
 
NA 
 
 
NA 
 
 
Adverse perinatal 
outcome (one or 
more of 
acidaemia at 
birth (pH<10
th
 
centile), fetal 
distress in labour, 
NICU admission) 
 
 
TA, 
color+pulsed, 
lumen away 
from insertion, 
PI mean>1.5sd  
(ROC analysis) 
 
Chanprapap
h
 
(2004) 
 
High risk. 
INC: Singleton, clinical suspicion of IUGR 
(SFH<3cm expected height), accurate dates, 
Doppler within 14 days of delivery 
Mean age 28.24+/-6.36 (16-45) 
(Thailand) (Cohort) 
 
212 
 
30-42 
weeks, 
test 
within 14 
days of 
delivery, 
mean ga 
at 
 
BW<10
th
 
centile 
(local/ga) 
 
50.9% 
 
NA 
 
TA, color, free 
floating portion 
of cord, SD≥3. 
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delivery 
37.66+/-
1.81 
weeks 
 
Chua 
(1996) 
 
Unselected population 
INC: Singleton, live fetus, cephalic, intact 
membranes, >37 weeks, admitted to labour ward. 
Age not reported. 
(Singapore) (Cohort, prospective) 
 
1092 
 
>37 
weeks 
 
NA 
 
NA 
 
Apgar at 1 or 5 
mins <7, need for 
assisted 
ventilation, 
admission to 
NICU. 
 
TA, continuous 
wave, site not 
reported, 
PI>1.2. 
 
Cosmi 
(2005) 
 
High risk 
INC: Singleton, ga established before 20 weeks, 
absence of maternal pathology, delivery before 
32 weeks, forward umbilical diastole, normal 
AFI≥5.0cm, absence of pulsation in umbilical 
vein, forward Ductus venosus flow, last Doppler 
within 24 hours of delivery 
EXC: structural anomalies 
Mean maternal age abnormal Doppler 32 (27-39), 
normal Doppler 31 (24-37) 
(Italy and USA) (Cohort, prospective) 
 
145 
 
24-30.4 
weeks. 
Test for 
analysis 
performe
d within 
24 hours 
of 
delivery. 
 
NA 
 
NA 
 
Neonatal death 
 
Route not 
reported, 
color+pusled, 
site abdominal 
origin of 
umbilical vein, 
REDF. 
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Craigo 
(1996) 
High risk. 
INC: Singleton, prenatal diagnosis of IUGR 
(EFW<10
th
 centile) 
EXC: Fetal abnormalities 
Age 11-42 years 
(USA) (Cohort, retrospective) 
59 Not 
reported 
NA NA Neonatal death, 
NEC, BPD, IVH 
Route, method 
and site not 
reported, 
elevated SD 
ratio, cut-off 
not reported. 
 
De 
Rochambeau 
(1988) 
 
High risk 
INC: Singleton, Ac<10
th
 centile. 
Age not reported. 
(France) (Cohort) 
 
117 
 
20-42 
weeks 
 
BW<10
th
 
centile 
BW<3
rd
 
centile 
 
69.2% 
49.6% 
 
Perinatal 
mortality 
 
Route not 
reported, 
continuous 
+pulsed wave, 
site not 
reported, 
RI>99
th
 centile 
(local). 
 
De 
Rochambeau 
(1992) 
 
High risk 
INC: Singleton, post dates, accurate dating prior 
to 17 weeks 
Age not reported. 
(France) (Cohort) 
 
80 
 
>40+3 
weeks, 
test 
performe
d every 2 
days and 
last 
before 
 
NA 
 
NA 
 
Umbilical artery 
pH<7.20 
 
Route not 
reported, 
continuous 
wave+pulsed, 
site not 
reported, 
RI≥0.54 
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delivery 
used for 
analysis 
 
Degani 
(1990) 
 
High risk 
INC: Singleton, accurate gestation, EFW<10
th
 
centile 
Age not reported. 
(Israel) (Cohort) 
 
49 
 
29-40 
weeks 
 
BW<10
th
 
centile 
(ga/parity/se
x) 
BW 
mean<2sd 
 
77.6% 
 
59.2% 
 
NA 
 
Route not 
reported 
color+pw, site 
not reported, 
PI>2sd. 
 
Degani 
(1992) 
 
High risk 
INC: Twin pregnancies >24 weeks 
Age not reported. 
(Israel) (Cohort, consecutive) 
 
242 
 
>24 
weeks 
 
BW<10
th
 
centile 
(ga/parity/se
x) 
Either twin 
 
24.8% 
 
NA 
 
Route not 
reported pulsed 
wave, site not 
reported, 
PI>2sd. 
 
Dempster 
(1989) 
 
High risk 
INC: High risk singletons (suspected SGA, 
hypertension, APH, diabetes, preterm labour) 
Age not reported. 
(UK) (Cohort) 
 
205 
 
Within 7 
days of 
delivery. 
Mean ga 
at 
delivery 
abnormal 
 
BW<10
th
 
centile 
(ga/parity/hei
ght/weight/se
x) 
 
 
40.0% 
 
 
 
NA 
 
TA, continuous 
wave, site not 
reported, 
SD>95
th
 centile 
(local). 
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Doppler 
36.7 (30-
40), 
normal 
38.2 (32-
41) 
 
Divon 
(1988) 
 
High risk 
INC: Singleton, suspected IUGR, accurate dates, 
intact membranes, delivery within 2 weeks of 
ultrasound 
Age not reported. 
(USA) (Cohort, prospective) 
 
127 
 
Within 2 
weeks of 
delivery. 
Mean ga 
at 
delivery 
39.2+/-
2.4 in 
IUGR, 
38.5+/-
2.5 non-
IUGR 
 
BW<10
th
 
centile 
(ga/local) 
 
35.4% 
 
 
 
NA 
 
Route not 
reported 
continuous 
wave, site not 
reported, 
SD>3. 
 
Divon 
(1989) 
 
High risk 
INC: Twins, third trimester, accurate gestation, 
intact membranes, delivery within 2 weeks of 
Doppler 
 
58 
 
Within 2 
weeks of 
delivery. 
Mean ga 
 
BW 
discordancy>
15% 
 
31.0% 
 
 
 
NA 
 
Route not 
reported 
continuous 
wave, site not 
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Age not reported. 
(USA) (Cohort, consecutive) 
at 
delivery 
37.4+/-
1.2 
weeks. 
reported, SD 
discordancy>1
5% 
 
Dubinsky 
(1997) 
 
High risk 
INC: Suspected SGA EXC: two foetuses with 
intrapartum complications resulting in poor 
outcomes 
Age not reported. 
(USA) (Cohort, prospective, consecutive) 
 
97 
 
Third 
trimester 
 
NA 
 
NA 
 
 
Poor neonatal 
outcome (CS for 
fetal distress, 
fetal death, IUD, 
IVH, cerebral 
infarction, 
admission to 
NICU>10 days, 
admission to 
NICU at term, 
preterm delivery) 
 
Route, method 
and site not 
reported, 
SD>4.0 (ROC 
analysis) 
 
Eronen 
(1993) 
 
High risk 
INC: PIH (BP>140/90 on more than 2 occasions 
>6 hrs apart), delivery prior to 34 weeks 
EXC: Fetal malformations 
Mean age abnormal Doppler 29.2+/-4.3; normal 
Doppler 28.2+/-4.3 
 
41 
 
24-34 
weeks 
 
NA 
 
NA 
 
 
 
RDS, NEC, BPD 
 
Route not 
reported, 
continuous and 
pulsed wave, 
free loops of 
cord, AREDF 
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(Sweden) (Cohort) (at three 
separate sites). 
 
Ezra 
(1997) 
 
High risk 
INC: Triplet and quadruplet pregnancies 
Age not reported 
(Canada) (Cohort, consecutive) 
 
73 
 
Within 2 
weeks of 
delivery. 
Mean ga 
at 
delivery 
33+/-2.8 
weeks 
(24-37) 
 
BW<5
th
 
centile 
(triplet 
growth 
curves) 
 
8.21% 
 
 
 
Neonatal death, 
stillbirth, 
perinatal death, 
admission to 
NICU 
 
TA, pulsed 
wave, site not 
reported, 
AEDF. 
 
Faber 
(1996) 
 
High risk 
INC: Threatened preterm labour (>3 contractions 
in 30 mins, maximum cervical dilatation 3cm, no 
other obstetric complications, Doppler performed 
within 48 hrs of admission and after 2 weeks of 
treatment with tocolysis+/-antibioitcs 
Age not reported 
(Germany) (Cohort, prospective) 
 
114 
 
24-34 
weeks, 
mean 
30.1 
weeks 
 
BW<10
th
 
centile 
 
70.2% 
 
 
 
Apgar at 5 mins 
≤7, umbilical 
artery pH<7.20 
 
Route, method 
and site not 
reported, 
PI>90
th
 centile. 
 
Farine 
(1998) 
 
High risk 
INC: Pregnant women with SLE, 45% treated 
 
56 
 
24-35 
weeks 
 
BW<10
th
 
centile 
 
28.6% 
 
 
Admission to 
NICU 
 
Route not 
reported colour 
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with aspirin, prednisolone, azathioprine. 
Median age abnormal Doppler 29 yrs (IQR 25-
29); normal Doppler 31 yrs (IQR 25-29) 
(Canada) (Cohort, retrospective) 
(ga/local)  and pulsed 
wave, site not 
reported, 
AREDF. 
  
Farmakides 
(1988) 
 
 
High risk 
INC: Women referred for non stress test 
(hypertension, diabetes, post dates, congenital 
anomaly, suspected IUGR) 
Age not reported 
(USA) (Cohort) 
 
140 
 
Third 
trimester 
 
NA 
 
NA 
 
Admission to 
NICU, assisted 
ventilation 
 
Route not 
reported, 
continuous 
wave, site not 
reported, 
SD>3. 
  
Ferchiou-
Cherif 
(1993) 
 
 
High risk 
INC: Singleton, high risk (hypertension, diabetes, 
history of IUD, hydramnios, oligohydramnios, 
suspected IUGR, placenta praevia) 
Age not reported 
(Tunisia) (Cohort) 
 
52 
 
30-41 
weeks, 
test for 
analysis 
within 5 
weeks of 
delivery 
 
BW<3
rd
 
centile 
 
30.8% 
 
Neonatal 
morbidity 
 
Route not 
reported, 
pulsed wave, 
site not 
reported, RI no 
cut-off 
reported. 
  
Figueras 
(2004) 
 
 
High risk 
INC: Singletons, feta size<5
th
 centile EXC: 
Neonates with a birth weight>10
th
 centile, 
congenital and structural anomalies 
 
108 
 
>26 
weeks. 
Test for 
analysis 
 
NA 
 
NA 
 
Adverse perinatal 
outcome 
[umbilical artery 
pH<7.10 or 
 
Route  and 
method not 
reported, free 
floating loop of 
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Median age 30.45 (3.25) 
(Spain) (Cohort, prospective) 
within 3 
days of 
delivery, 
median ga 
at 
delivery 
31.1 
(2.346) 
neonatal 
morbidity (severe 
IVH, HIE, 
retinopathy, 
seizures, NEC, 
RDS requiring 
ventilation, 
intubation, 
admission to 
NICU), perinatal 
mortality] 
cord. AREDF. 
        
Figueras 
(2008) 
High risk 
INC: 369 singleton fetuses identified as SGA on 
customised charts antenatally had umbilical artert 
Doppler performed  
EXC: multiple pregnancies, congenital 
anomalies, insufficient data for customised birth 
weight percentile 
Mean maternal age 30.3+/-5.3 years 
(Spain) (Cohort, retrospective, consecutive) 
 
 
365 >30 
weeks 
(test to 
delivery 
interval 
within 2 
weeks) 
NA NA Arterial cord 
pH<7.10, Apgar 
at 5 mins<7, 
admission to 
NICU, neonatal 
morbidity and 
perinatal death 
Route not 
reported, 
method and 
site not 
reported, 
PI>95
th
 centile 
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Fischer 
(1991) 
 
High risk 
INC: Women ≥287 days, accurate gestation, 
singleton pregnancy 
EXC: Hypertension, diabetes mellitus, renal 
disease, multiple gestations, suspected IUGR, 
fetal anomaly, substance abuse 
Mean age 24.3 (15-40) 
(USA) (Cohort) 
75 >41 
weeks, 
mean test 
to 
delivery 
interval 2 
days (all 
within 8 
days) 
BW<10
th
 
centile 
PI<10
th
 
centile 
(local/ga) 
5.33% 
13.9% 
Abnormal 
perinatal 
outcome (one of 
operative 
delivery due to 
non-reassuring 
FHR, umbilical 
artery pH<7.15 
and vein<7.2, 5 
minute Apgar<7, 
meconium below 
the cords, 
admission to 
NICU, BW<10
th
 
centile) 
TA, continuous 
wave, site not 
reported, 
SD≥2.40 (ROC 
analysis). 
  
Fong 
(1999) 
 
 
High risk 
INC: Singletons, >24 weeks, confirmed gestation, 
ultrasound EFW or AC <10
th
 centile 
EXC: Major congenital or chromosomal 
anomalies 
Mean age 30.3+/-5.6 
(Canada) (Cohort) 
 
293 
 
At study 
entry and 
36 weeks, 
mean 
32.6+/-
3.7. Mean 
test to 
delivery 
 
NA 
 
NA 
 
Adverse perinatal 
outcome – major 
(perinatal death, 
HIE, major IVH, 
PVLM, NEC), 
minor (CS for 
fetal distress, 
arterial cord 
 
TA, pulsed 
wave, middle 
of cord, PI>95
th
 
centile 
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interval 
2.4+/-2.6 
weeks. 
pH<7.1, Apgar at 
5 mins<7) 
  
Forouzan 
(1991) 
 
 
High risk 
INC: Prolonged pregnancies (≥41 weeks), no 
medical or obstetric problem, normal amniotic 
fluid volume and NST or CST 
EXC: Clinical or ultrasonic evidence of IUGR, 
oligohydramnios (MPD<2cm), positive NST or 
CST, abnormal BPS. 
Age not reported 
(USA) (Cohort) 
 
30 
 
>41 
weeks, 
test for 
analysis 
within 72 
hrs of 
delivery 
 
NA 
 
NA 
 
Poor outcome 
(abnormal fetal 
monitoring 
during labour, 
umbilical artery 
pH≤7.2, scalp 
pH≤7.2, 
intrapartum 
hypoxia 
requiring NICU 
admission) 
 
TA, color, site 
not reported, 
SD≥mean +1sd 
  
Gaziano 
(1988) 
 
 
High risk 
INC: Previous abnormal ultrasound, multiple 
gestations, suspected IUGR, abnormal MSAFP, 
history of suspected anomalies, other 
abnormalities 
Age range 15-45 years 
(USA) (Cohort) 
 
230 
 
15-44 
weeks, 
last test 
before 
delivery 
used for 
analysis 
 
BW≤10th 
centile 
 
10.4% 
 
NA 
 
Route not 
reported, 
pulsed wave, 
characteristic 
waveform, 
SD≥4/5. 
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Gaziano 
(1991) 
 
High risk 
INC: Multiple pregnancies 
Age not reported 
(USA) (Cohort) 
207 Abnormal 
Doppler 
mean 
27.7, 
normal 
28.6, last 
before 
delivery 
used for 
analysis 
BW<1500g 23.7% Apgar at 5 mins 
≤6, stillbirths. 
Route not 
reported, 
pulsed wave, 
midsegment of 
cord, SD no 
cut-off 
reported. 
  
Gaziano 
(1994) 
 
 
High risk 
INC: Multiple and singleton pregnancies, 
suspected SGA (EFW<10
th
 centile). 
EXC: Major chromosomal and structural 
anomalies 
Age not reported 
(USA) (Cohort, consecutive) 
 
90 
 
Test to 
delivery 
interval 
mean 5.2 
days; 
mean ga 
at 
delivery 
normal 
Doppler 
33.3+/-
2.9;abnor
mal 
 
BW<10
th
 
centile 
 
37.8% 
 
BW<10
th
 centile 
and need for 
admission to 
NICU 
 
Route not 
reported, 
pulsed wave, 
midsegment of 
cord, 
SD≥mean+2sd 
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32.4+/-
3.7 
  
Giles 
(1988) 
 
 
High risk 
INC: Twin pregnancies 
Age not reported 
(Australia) (Cohort) 
 
165 
 
28-32 
weeks 
 
BW<10
th
 
centile 
(either twin) 
 
49.1% 
 
Admission to 
NICU or need for 
ventilation either 
twin. 
 
Route not 
reported, 
continuous 
wave, site not 
reported, SD 
cut-off not 
reported. 
        
Ghosh 
(2008) 
 
 
 
 
 
 
 
Goffinet 
(1997) 
 
High risk 
INC: pregnancies suspected of FGR diagnosed by 
fetal biometry (EFW<2sd or decline of more than 
1 sd USS 2 weeks apart) EXC: multiple 
pregnancies, congenital malformations and 
chromosomal abnormalites, IUFD (n=6) were 
excluded 
Age not reported 
(Sweden) (Cohort, prospective) 
 
Low  risk 
INC: Singletons, routine consultation before 28 
weeks 
353 
 
 
 
 
 
 
 
 
1903 
Mean 
34.6+/-
3.2 weeks 
(test to 
delivery 
interval 
mean 
19.6+/-18 
days) 
 
 
 
 
BW<2sd 
 
 
 
 
 
 
 
 
BW<10
th
 
centile 
BW<3
rd
 
centile 
56.8% 
 
 
 
 
 
 
 
 
8.09% 
2.68% 
 
4.26% 
Admission to 
NICU 
 
 
 
 
 
 
 
 
Apgar at 1 and 5 
mins <7, 
resuscitation 
Route not 
reported, 
method and 
site not 
reported, 
PI>2sd or 
AREDF 
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EXC: Hypertension, diabetes, previous 
IUD/SGA/PIH/PE, fetal biometry<10
th
 centile, 
multiple pregnancy, abnormalities 
Mean age normal Doppler 27.9+/-5.2, abnormal 
mean 28.0+/-5.5 
(France) (Cohort) 
 
 
 
 
28-34 
weeks 
(local/ga) 
BW<2500g 
required  
 
Route, method 
and site not 
reported, 
RI>90
th
 centile 
ga. 
  
Gonzalez 
(1995) 
 
 
High risk 
INC: Suspected IUGR (EFW<10
th
 centile) 
Age range 18-37 years 
(Chile) (Cohort) 
 
74 
 
26-40 
weeks, 
test for 
analysis 
within 24 
hours of 
delivery 
 
NA 
 
NA 
 
Umbilical vein 
pH<7.16 and 
pO2<18% 
 
Route, method 
and site not 
reported, 
AREDF. 
        
  
Gonzalez 
(2007) 
 
 
High risk 
INC: Singleton, EFW<5
th
 centile 
EXC: Chromosomal and structural anomalies 
Mean age adverse outcome 26.7+/-7.0, normal 
outcome 25.9+/-6.8 
(USA) (Cohort, retrospective) 
 
151 
 
Last 
before 
delivery, 
mean ga 
at 
delivery 
abnormal 
 
NA 
 
NA 
 
Umbilical artery 
pH<7, RDS, 
PVL, IVH, 
perinatal 
mortality, NEC. 
Adverse outcome 
(one or more of 
 
Route, method 
and site not 
reported, 
AREDF. 
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outcome 
30.8+/-
3.6, 
normal 
outcome 
37.0+/-
2.5 
above) 
  
Gramellini 
(2001) 
 
 
High risk 
INC: Singletons, ultrasound dating prior to 20
th
 
week, AC<2.5
th
 centile, Doppler within 2 weeks 
of birth. 
EXC: Chromosomal and structural anomalies 
Age not reported 
(Italy) (Cohort) 
 
53 
 
24-35 
weeks, 
test for 
analysis 
within 2 
weeks of 
delivery 
 
BW<10
th
 
centile 
 
96.2% 
 
Admission to 
NICU, Apgar at 
5  mins<7, NEC, 
IVH, RDS, 
perinatal 
mortality 
 
Route not 
reported, color, 
intermediate 
section of cord, 
PI>95
th
 centile 
  
Gudmundsso
n 
(1988) 
 
 
High risk 
INC: Pregnancy complicated  by preeclampsia 
Mean age 28 +/-5.5 
(Sweden) (Cohort) 
 
58 
 
Mean ga 
at 
delivery 
258+/-19 
days, test 
to 
delivery 
interval 
 
BW≤mean -
2sd 
(local/ga) 
 
29.3% 
 
NA 
 
Route not 
reported, 
pulsed wave, 
characteristic 
waveform, PI 
mean>2sd for 
ga. 
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mean 6 
days (0-
19) 
  
Gudmundsso
n 
(1991) 
 
 
High risk 
INC: Singleton pregnancy, EFW≥15% below 
expected 
Mean age 27 years (17-42) 
(Sweden) (Cohort) 
 
139 
 
>32 
weeks, 
mean ga 
at 
delivery 
265+/-18 
days 
(203-
291); test 
to 
delivery 
interval 
mean 6 
days (0-
21) 
 
BW≤mean -
2sd 
(local/ga) 
 
51.8% 
 
Apgar at 1 and 5 
mins<7, 
umbilical artery 
pH≤ 7.10 
 
TA, pulsed 
wave, site not 
reported, PI 
mean >2sd for 
ga/ 
  
Guzman 
(1992) 
 
 
High risk 
INC: Women with SLE 
Mean age normal Doppler 27.9+/-4.4; abnormal 
27.2+/-5.4 
 
27 
 
Not 
reported 
 
BW≤10th 
centile 
(local/ga) 
 
25.9% 
 
Admission to 
NICU for >24 
hours, need for 
positive pressure 
 
Route not 
reported, 
continuous 
wave, site not 
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(USA) (Cohort, retrospective) ventilation, 
perinatal death. 
reported, SD 
mean>2sd <30 
weeks and >3.0 
after 30 weeks 
        
Hack 
(2008) 
Multiple pregnancies 
INC: 67 women with monochorionic twin 
pregnancies EXC: monoamniotic twin 
pregnancies, pregnancies complicated by TTTS, 
2 TOP due to HELLP and trisomy 21. 
Mean maternal age 31 years 
(Netherlands) (Cohort, retrospective) 
 
134 Median 
35.2 (20-
39+5), 
test to 
delivery 
interval 
median 3 
days (0-
17) 
BW<2000g 32.1% Stillbirth, 
neonatal 
morbidity and 
mortality 
Route, site and 
method not 
reported, 
PI>2sd+/-
AREDF either 
twin. 
 
Haddad 
(1988) 
 
 
High risk 
INC: Patients with hypertension (PIH, PE or 
chronic) 
Mean age PIH 24.8+/-4.2; PE 22.2+/-4.0; chronic 
30.7+/-3.1 
(UK) (Cohort) 
 
101 
 
Once 
weekly 
until 
delivery, 
first result 
used for 
analysis 
 
BW<10
th
 
centile 
(ga/sex/parit
y) 
 
25.7% 
 
NA 
 
Route not 
reported, 
continuous 
wave, 
characteristic 
waveform, 
RI>95
th
 centile 
  
Hastie 
 
High risk 
 
56 
 
36-39 
 
BW≤5th 
 
21.4% 
 
NA 
 
TA, continuous 
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(1989) 
 
INC: Consecutive unselected twin pregnancies 
Age not reported 
(UK) (Cohort, consecutive) 
weeks, 
test 
performe
d monthly 
centile either 
twin 
(ga/local) 
wave, 
characteristic 
waveform, 
SD>90
th
 centile 
for ga. 
  
Hastie 
(1990) 
 
 
High risk 
INC: 50 pregnancies with non-reactive CTG, >28 
weeks 
EXC: Major congenital anomalies, rhesus 
isoimmunisation, premature rupture of 
membranes 
Age not reported 
(UK) (Cohort) 
 
35 
 
>28 
weeks, 
mean 37 
(28-42) 
 
NA 
 
NA 
 
Adverse perinatal 
outcome 
[perinatal death, 
SGA (BW<10
th
 
centile), obstetric 
intervention for 
fetal distress] 
 
TA, method 
not reported, 
characteristic 
waveform, 
SD>90
th
 centile 
ga 
  
Hecher 
(1988) 
 
 
Population risk not reported 
INC: not reported 
EXC: not reported 
Age not reported 
(Germany) (Cohort, prospective and 
retrospective) 
 
188 
 
30-41 
weeks 
 
NA 
 
NA 
 
Adverse perinatal 
outcome [SGA 
(BW<10
th
 
centile) and/or 
operative 
delivery for 
suspected fetal 
hypoxia, 
admission to 
 
Route not 
reported, color 
and pulsed 
wave, site not 
reported, RI/PI 
mean+2sd 
(local values 
for third 
trimester) 
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NICU] 
  
Hitschold 
(1988) 
 
 
High risk 
INC: Ultrasound before 20 weeks, accurate dates, 
post dates pregnancies + 1-17 days post term. 
Age not reported 
(Germany) (Cohort) 
 
130 
 
281-297 
days, test 
for 
analysis 
within 10 
days of 
delivery 
 
NA 
 
NA 
 
Umbilical artery 
pH<7.20 or 
<7.10 
 
Route not 
reported, 
pulsed wave, 
site not 
reported, 
SD>2.3 or 
RI>95
th
 centile 
 
Hutter 
(1994) 
 
 
High risk 
INC: Not reported 
EXC: Not reported 
Age not reported 
(Germany) (Cohort) 
 
559 
 
Within 6 
days of 
delivery; 
41% 
delivered 
before 37 
weeks, 
49% 
before 33 
weeks. 
 
BW<10
th
 
centile 
(ga/local) 
 
17.9% 
 
NA 
 
Route not 
reported, 
continuous 
wave, site not 
reported, 
RI>90
th
 centile. 
  
Joern 
(1997) 
 
 
High risk 
INC: 130 multiple pregnancies (122 twins, 8 
triplets) 
 
261 
 
Mean 34 
weeks 
(26-42). 
 
BW<10
th
 
centile 
(local/ga) 
 
31.0% 
 
Adverse perinatal 
outcome 
(umbilical artery 
 
Route not 
reported, color 
and pulsed 
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EXC: Chromosomal and structural anomalies 
Mean age 29 yrs (19-40) 
(Germany) (Cohort) 
Mean test 
to 
delivery 
interval 
19 days. 
Any fetus pH<7.20, 5 min 
Apgar<8 or 
transfer to NICU) 
wave, site not 
reported, 
SD>3. 
  
Joern 
(2000) 
 
 
High risk 
INC: Twin pregnancies (68 monochorionic, 128 
dichorionic) 
Median age 30 (20-41) 
(Germany) (Cohort, prospective) 
 
412 
 
Third 
trimester, 
median 
35 weeks. 
Median 
test to 
delivery 
interval 9 
days (0-
15) 
 
BW<10
th
 
centile 
(local/ga) 
Either twin 
BW<1500g 
 
12.6% 
 
Umbilical artery 
pH≤7.15, 
admission to 
NICU, Apgar at 
5 mins<8, 
perinatal 
mortality. 
 
TA, method 
and site not 
reported, 
PI>95
th
 centile. 
  
Jorn 
(1993) 
 
 
High risk 
INC: Post-term, accurate gestation 
Age not reported 
(Germany) (Cohort) 
 
165 
 
>40 
weeks 
 
BW<10
th
 
centile 
(local/ga) 
 
7.23% 
 
NA 
 
TA, pulsed 
wave and 
color, site not 
reported, SD>3 
  
Jorn 
(1994) 
 
Unselected 
Age not reported 
 
120 
 
Third 
trimester 
 
BW<10
th
 
centile 
 
21.7% 
 
NA 
 
Doppler no 
details, no 
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 (Germany) (Cohort) threshold 
reported 
  
Karsdorp 
(1994) 
 
 
High risk 
INC: Singletons, confirmed ga, hypertension or 
suspected IUGR (EFW<5
th
 centile) 
EXC: Chromosomal or structural anomalies 
Mean maternal age normal Doppler 30.6 (95% CI 
29.8-31.4); abnormal Doppler 30.1 (29.2-31.0) 
(Netherlands, UK, Germany, Italy) (Cohort, 
prospective, consecutive) 
 
459 
 
Mean ga 
normal 
Doppler 
29.8 
(95% CI 
29.1-
30.4), 
abnormal 
Doppler 
30.1 
(29.2-
31.0) 
 
NA 
 
NA 
 
Perinatal 
mortality 
 
TA, method 
not reported, 
free loop of 
cord,  AREDF. 
  
Kay 
(1991) 
 
 
High  risk 
INC: Singletons, clinically suspected IUGR, 
accurate ga 
Age not reported 
(USA) (Cohort, retrospective) 
 
48 
 
Nearest to 
delivery, 
delivery 
range 26-
41 weeks 
 
BW<10
th
 
centile 
(local/ga) 
 
37.5% 
 
NA 
 
Route not 
reported, 
pulsed wave, 
free loop of 
cord, SD 
(average of 
standard 
values) 
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Kofinas 
(1990) 
 
 
High risk 
INC: 36 patients with chronic hypertension, 7 
chronic and PE, 25 PE 
Age not reported 
(USA) (Cohort) 
 
68 
 
Late 
second or 
third 
trimester, 
nearest to 
delivery 
used for 
analysis; 
mean ga 
at 
delivery 
abnormal 
Doppler 
33.5+/-
1.03, 
normal 
38.2+/-
0.24 
 
BW≤10th 
centile 
 
30.9% 
 
Apgar at 1 and 5 
mins <7, 
admission to 
NICU 
 
TA, continuous 
wave, 
characteristic 
waveform, 
SD>95
th
 centile 
(local values) 
  
Lakhkar 
(2006) 
 
 
High risk 
INC: 58 singleton pregnancies>30 weeks with 
severe PE (standard criteria) and or suspected 
IUGR (EFW<10
th
 centile) 
 
58 
 
Within 10 
days of 
delivery 
 
NA 
 
NA 
 
Major adverse 
perinatal 
outcome 
(perinatal deaths, 
 
TA, pulsed 
wave, free loop 
of cord, 
SD/RI/PI>2sd 
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EXC: Multiple gestations and congenital 
anomalies 
Mean age 27.3 years 
(India)  (Cohort, prospective) 
HIE, IVH, PVL, 
pulmonary 
haemorrhage, 
NEC). Minor 
adverse perinatal 
outcome (cs for 
fetal distress, 
Apgar at 5 
mins<7, 
admission to 
NICU) 
  
Le Thi 
Huong 
(2006) 
 
 
High risk 
INC: Women diagnosed with SLE and/or APS 
Age not reported 
(France) (Cohort, prospective, consecutive) 
 
100 
 
Second 
trimester 
 
NA 
 
NA 
 
Fetal or neonatal 
death; adverse 
perinatal 
outcome (fetal or 
neonatal death, 
PE, eclampsia or 
HELLP, 
premature birth, 
IUGR) 
 
Route and 
method not 
reported, 
placental end 
of cord, 
AREDF. 
  
Lombardi 
(1989) 
 
High risk 
INC: Women with subjective oligohydramnios, 
 
22 
 
Normal 
Doppler 
 
BW<10
th
 
centile 
 
45.4% 
 
NA 
 
Route not 
reported, 
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 intact membranes 
Mean age normal Doppler 25.6+/-5.2; abnormal 
26.8+/-5.7 
(USA) (Cohort, prospective) 
35.9+/-
2.4; 
abnormal 
34.0+/-
2.2; last 
before 
delivery 
used for 
analysis 
(ga/local) continuous 
wave, 
characteristic 
waveform, 
SD>95
th
 
centile. 
  
Lowery 
(1990) 
 
 
High risk 
INC: Singletons, women with risk factors for 
IUGR (smoking, short stature, low prepregnancy 
weight, previous low birth weight) 
EXC: Multiple pregnancies, fetal anomalies, 
failure to complete both studies 
Age not reported 
(USA) (Cohort, prospective) 
 
271 
 
24-40 
weeks 
(subgroup 
analysis 
based on 
test to 
delivery 
interval of 
2 weeks) 
 
BW<10
th
 
centile 
(local/ga) 
 
9.23% 
 
NA 
 
TA, continuous 
wave, 
characteristic 
waveform, 
SD>2sd 
  
Maria Fadda 
(2001) 
 
 
High risk 
INC: Pregnancies complicated by  IDDM, 
normotensive 
EXC: PIH 
 
67 
 
From 
second 
trimester; 
last 
 
BW<10
th
 
centile 
(local/ga) 
 
44.8% 
 
RDS, admission 
to NICU for >2 
days 
 
TA, color and 
pulsed wave, 
site not 
reported, 
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Age 
(Italy) (Cohort, prospective) 
before 
delivery 
used for 
analysis; 
mean ga 
at 
delivery 
normal 
Doppler 
38+/-1.9; 
abnormal 
Doppler 
36+/-1.2 
PI>95
th
 centile 
  
Maulik 
(1990) 
 
 
High risk 
INC: Singletons, women at high risk for adverse 
outcome 
Age not reported 
(USA) (Cohort, prospective, consecutive) 
 
350 
 
34-36 
weeks 
 
BW<10
th
 
centile 
 
12.3% 
 
Adverse perinatal 
outcome (one or 
more of BW,10
th
 
centile, Apgar at 
5 mins<7, 
umbilical artery 
pH at birth 
<7.20, thick 
meconium, fetal 
distress in labour, 
 
Route not 
reported, 
continuous 
wave, site not 
reported, 
SD>3. 
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neonatal 
complications 
needed 
admission to 
NICU) 
  
Maunu 
(2006) 
 
 
High risk. 
INC: Preterm birth (<37 weeks), VLBW<1500g. 
Mean age 30,2 (+/-5.2) years 
(Finland) (Cohort, prospective) 
 
67 
 
Mean 
28+2 
weeks 
(24-36) 
(last 
Doppler 
performe
d within 7 
days of 
delivery) 
 
NA 
 
NA 
 
MRI at term 
abnormal (e.g. 
IVH, 
ventriculomegaly
, ischaemic 
lesions) 
 
Route, method, 
site not 
reported, 
PI>95
th
 centile 
  
McCowan 
(1992) 
 
 
High risk 
INC: Singleton, 29 women admitted to the 
antenatal ward with suspected SGA (AC<5
th
 
centile) and at birth BW≤2sd below the mean, 
accurate gestation 
Age not reported 
(New Zealand) (Cohort) 
 
29 
 
Within 7 
days of 
delivery 
 
NA 
 
NA 
 
Adverse perinatal 
outcome [fetal 
distress and or 
acidosis at birth 
(umbilical artery 
pH<7.15 and 
base deficit>7) or 
 
TA, pulsed 
wave, mid 
section of cord, 
PI mean +2sd 
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perinatal death] 
 
McCowan 
(1992) 
 
 
High  risk 
INC: 29 women with hypertension 
Mean age 28 years (23-42) 
(New Zealand) (Cohort) 
 
29 
 
24 weeks 
or less 
 
BW mean -
2sd 
 
31.0% 
 
NA 
 
Route not 
reported, 
pulsed wave, 
mid section of 
cord, PI mean 
+2sd 
  
McCowan 
(2000) 
 
 
High risk 
INC: Singletons, suspected SGA (AC<10
th
 
centile), pregnancies taking part in one of two 
RCTs (aspirin study and fetal surveillance study 
for women with abnormal umbilical artery 
Dopplers), women included for anlaysis were 
those that gave birth to an SGA baby (BW<10
th
 
centile) 
EXC: Fetal chromosomal or structural anomalies 
Mean age abnormal Doppler 28.2+/-6.0; normal 
25.6+/-5.4 
(New Zealand) (Cohort, prospective) 
 
186 
 
24-36 
weeks 
 
PI<10
th
 
centile 
 
43.7% 
 
Admission to 
NICU>48 hrs, 
perinatal death, 
acidosis (cord 
srterial pH<7.15 
and 
BE>8mmol/l) 
 
TA, method 
not reported, 
mid section of 
cord, RI>95
th
 
centile 
  
Miller 
(1991) 
 
High risk 
INC: Singletons, 136 women at high risk for fetal 
 
136 
 
SGA 
254.7+/-
 
BW<10
th
 
centile 
 
33.8% 
 
NA 
 
Route not 
reported, 
  
423 
 
 growth abnormalities, delivery within 3 weeks of 
ultrasound, accurate gestation, intact membranes 
EXC: Fetal chromosomal and structural 
anomalies 
Age not reported 
(USA) (Cohort, prospective) 
23.2 days; 
non-SGA 
267.4+/-
14.0. Test 
to 
delivery 
interval 
SGA 
6.5+/-6.3 
days; non 
SGA 
7.0+/-6.0 
days. 
(local/ga) pulsed wave, 
free floating 
portion of cord, 
SD≥3.0 
  
Miyashita 
(2002) 
 
 
High risk 
INC: Singletons, 119 fetuses suspected IUGR 
(EFW<1,5sd) 
EXC: Structural and chromosomal anomalies 
Age not reported 
(Japan) (Cohort, prospective) 
 
119 
 
24-36 
weeks, 
test for 
analysis 
within 10 
days of 
delivery 
 
NA 
 
NA 
 
Adverse perinatal 
outcome 
(neoanatal death, 
infantile death, 
cerebral palsy 
and or 
developmental 
retardation) 
 
TA, pulsed 
wave, site not 
reported, 
RI≥1.0 
  
Moon 
 
Low risk 
 
96 
 
>30 
 
BW<10
th
 
 
25.0% 
 
NA 
 
Route not 
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(1999) 
 
INC: Singletons, >30 weeks, accurate gestation 
EXC: Multiple gestations 
Mean age 27 (14-42) 
(USA) (Cohort, retrospective) 
weeks centile 
(local/ga) 
reported, 
pulsed wave, 
free floating 
portion of cord, 
SD>3. 
  
Mulders 
(1987) 
 
 
Mixed risk 
INC: Singletons, 30 patients admitted with 
suspected IUGR or hypertension, 18 women with 
uncomplicated pregnancy, all accurate dates 
Age not reported 
(Netherlands) (Cohort) 
 
48 
 
Mean 
34+/- 2 
weeks 
 
BW<10
th
 
centile 
(local/ga) 
 
31.3% 
 
NA 
 
TA, continuous 
wave, site not 
reported, 
PI≥1.1 (ROC 
analysis) 
  
Mulders 
(1989) 
 
 
Mixed risk 
INC: Singletons, 99 gravid women (30 admitted 
due to complications) 
Age not reported 
(Netherlands) (Cohort) 
 
99 
 
Third 
trimester 
Last 
before 
delivery 
(1-28 
days) 
 
BW<10
th
 
centile 
(local/ga) 
 
34.3% 
 
Apgar at 1 and 5 
mins<7, 
umbilical artery 
pH≤7.15 
 
TA, continuous 
wave, site not 
reported, 
PI≥mean +1.64 
sd (95
th
 centile) 
  
Newnham 
(1990) 
 
 
Medium risk 
INC: Singleton, pregnant women attending 
antenatal clinic before 18 weeks  
 
516 
 
18,24,28 
and 34 
weeks 
 
BW<10
th
 
centile 
(local/ga/hei
 
9.88% 
 
Hypoxia 
(operative 
delivery for CTG 
 
TA, color and 
pulsed wave, 
site not 
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EXC: Chromosomal and structural anomalies 
Mean age 26.0 +/-5.1 
(Australia) (Cohort, prospective) 
ght/parity/se
x) 
abnormalities, 
uterine artery 
pH<7.20, 5 min 
Apgar<7) 
reported, 
SD>95
th
 centile 
 
Niknafs
 
(2001) 
 
 
Low risk 
INC: 219 women seen in routine antenatal clinic, 
accurate dates 
Mean age normal Doppler 25.8+/-7.0; abnormal 
25.9+/-6.4 
(Australia) (Cohort) 
 
 
219 
 
 
Not 
reported 
 
 
PI≤20th 
centile 
PI≤10th 
centile 
 
 
20.1% 
9.13% 
 
 
NA 
 
 
Route, method 
and site not 
reported, SD 
mean>3sd 
  
Nordstrom 
(1989) 
 
 
High risk 
INC: Singletons, 69 women at high risk 
(suspected IUGR, PIH,PE, APH, abdominal pain, 
IDDM or GDM, polyhydramnios, placenta 
praevia, threatened preterm labour, unstable lie, 
UTI, adenexal mass, maternal collagen disease), 
confirmed gestation 
Age not reported 
(UK) (Cohort) 
 
69 
 
28-42 
weeks, 
test for 
analysis 
last 
before 
delivery, 
median 
interval 2 
days 
 
NA 
 
NA 
 
Severe and 
moderate 
compromise 
(BW<10
th
 
centile, fetal 
distress during 
labour, Apgar at 
5 mins<7) 
 
TA, pulsed 
wave, site not 
reported, 
SD>95
th
 centile 
        
Odendaal High risk  Not BW<10
th
 26.3% Intrauterine death Route not 
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(2008) INC: Pregnant women with suspected poor fetal 
growth 
Mean age 29 years (13-46) 
(South Africa) (Cohort, retrospective, 
consecutive) 
reported centile 
(local/ga) 
reported, 
continuous 
wave, site not 
reported, 
RI>95
th
 
centile/AREDF 
  
Ogunyemi 
(1992) 
 
 
High risk 
INC: Patients in labour with a presumptive 
diagnosis of fetal distress based on abnormal fetal 
heart rate patterns, accurate gestation. 
Mean age normal Doppler 25.5+/-0.72; abnormal 
Doppler 25.6+/-1.4 
(USA) (Cohort, prospective, consecutive) 
 
102 
 
In labour, 
mean ga 
normal 
Doppler 
39.7+/-
0.24;abno
rmal 
37.9+/-
0.76; test 
for 
analysis 
within 10 
hrs of 
delivery 
(median 1 
hr) 
 
BW<10
th
 
centile 
(local/ga) 
 
5.88% 
 
Poor perinatal 
outcome [SGA, 
Apgar <7 at 1 
min, umbilical 
artery pH<7.12, 
presence of 
meconium below 
the cords, 
neonatal hospital 
stay>3 days, 
NICU admission, 
neonatal 
morbidity (RDS, 
hypoglycaemia, 
sepsis)] 
 
TA, continuous 
wave, 
characteristic 
waveform, 
SD≥3 after 30 
weeks 
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Ott 
(1990) 
 
High risk 
INC: Fetuses with suspected IUGR, completed 
studies, delivery within 21 days of last 
examination (11 twin  and 93 singleton) 
Age not reported 
(USA) (Cohort) 
104 Within 21 
days of 
delivery 
BW<10
th
 
centile 
(local/ga) 
27.9% NA Route not 
reported, 
pulsed wave, 
free floating 
portion of cord, 
SD≥3. 
 
Ott 
(2000) 
 
 
High risk 
INC: Singletons, delivered within 2 weeks of last 
examination, indications for ultrasound 
(wellbeing, PIH, preterm labour, IUGR, 
oligohydramnios, chronic hypertension, IDDM, 
bleeding, collagen vascular disease, 
polyhydramnios) 
Age not reported 
(USA) (Cohort, prospective) 
 
578 
 
Within 2 
weeks of 
delivery 
 
NA 
 
NA 
 
Neonatal 
morbidity (IVH, 
HIE, retinopathy, 
seizures, NEC, 
sepsis, preterm 
delivery) 
 
Route and 
method not 
reported, free 
floating portion 
of cord, 
SD>90
th
 centile 
  
Owen 
(1999) 
 
 
Low risk 
INC: Singletons, 313 women attending antenatal 
clinic, gestational age<85days, no risk factors for 
accelerated or restricted growth 
Age not reported 
(UK) (Cohort, prospective) 
 
257 
 
Last and 
penultima
te but one 
examinati
on (4 
weeks 
separation
 
Skinfold 
thickness 
<10
th
 centile, 
PI<25
th
 
centile 
MAC:OFC<-
1sd 
 
13.4% 
 
 
15.2% 
7.2% 
 
NA 
 
Route and 
method not 
reported, free 
floating portion 
of cord, PI 
(ROC analysis) 
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) 
  
Ozcan 
(1998) 
 
 
High risk 
INC: Singletons, EFW<5
th
 centile, Doppler 
within 2 weeks of delivery 
EXC: Chromosomal and structural anomalies, 
BW<5
th
 centile 
Age 
(USA) (Cohort) 
 
19 
 
Mean 
28.2 (27-
31.4); test 
for 
analysis 
within 2 
weeks of 
delivery 
median 2 
days (0-
14) 
 
NA 
 
NA 
 
Perinatal death 
(fetal demise or 
neonatal death 
within first 30 
days), Apgar at 5 
mins<7, NEC. 
 
TA, color and 
pulsed, 
insertion at 
fetal abdomen, 
AREDF. 
  
Ozden 
(1998) 
 
 
Unselected 
INC: Singletons, 99 randomly selected term 
pregnant women in labour 
Age not reported 
(Turkey) (RCT, prospective, random) 
 
99 
 
In labour 
 
NA 
 
NA 
 
Apgar at 1 and 5 
mins<7, 
umbilical artery 
pH<7.10, 
neonatal death 
 
Route not 
reported, 
pulsed wave, 
free floating 
portion of cord, 
SD>3 and or 
AREDF. 
  
Pattinson 
(1989) 
 
High risk 
INC: Patients with severe proteinuric 
 
46 
 
Within 3 
days of 
 
BW<10
th
 
centile 
 
36.9% 
 
Apgar at 1 and 5 
mins<6, NEC, 
 
Route not 
reported, 
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 hypertension (BP 160/110 mmHg and ≥2+ 
protein on dipstix) 
Median age normal Doppler 24 (17-41); 
abnormal Doppler 25 (20-41) 
(South Africa) (Cohort) 
delivery (local/ga) RDS, perinatal 
mortality 
pulsed wave, 
site not 
reported, 
SD≥6. 
  
Pattinson 
(1993) 
 
 
Low risk 
INC: Umbilical artery Doppler performed in 
women presenting for routine dating ultrasound 
Age not reported 
(South Africa) (Cohort) 
 
481 
 
16-24 
weeks 
 
BW<10
th
 
centile 
 
8.11% 
 
Perinatal death 
 
TA, continuous 
wave, 
characteristic 
waveform, 
AEDF 
  
Pattinson 
(1993) 
 
 
High risk 
INC: High risk pregnancies at risk of placental 
insufficiency 
Age not reported 
(South Africa) (Cohort) 
 
348 
 
>24 
weeks 
 
BW<10
th
 
centile 
(local/ga) 
 
55.5% 
 
Perinatal 
mortality (death 
of a baby with a 
birth 
weight>500g or 
>24 weeks 
gestation 
occurring within 
28 days of 
delivery) 
 
Route not 
reported, 
continuous 
wave, site not 
reported, 
RI>95
th
 centile 
  
Poulain 
 
High risk 
 
541 
 
28-34 
 
BW<10th 
 
20.1% 
 
Apgar at 1 and 5 
 
Route, method 
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(1994) 
 
INC: High risk pregnancy requiring ultrasound 
(IUGR, hypertension, history of obstetric 
hypertension, previous IUD or previous IUGR, 
beta-mimetic treatment or maternal diabetes) 
Age not reported 
(France) (Cohort, prospective) 
weeks, 
first 
Doppler 
performe
d used for 
analysis 
mean test 
to 
delivery 
interval 
6.6+/-3.2 
days 
centile 
(local/ga) 
BW<3
rd
 
centile 
 
10.1% 
mins<7, IUD. and site not 
reported, 
AEDF or 
RI>90
th
 centile. 
 
Puzey 
(1992) 
 
High risk 
INC: Patients in labour, no evidence of fetal 
distress before labour, >35 weeks, umbilical 
artery Doppler performed  if decelerations on 
CTG. 
Age not reported 
(South Africa) (Cohort) 
 
42 
 
Doppler 
performe
d in 
labour 
within 30 
mins of 
umbilical 
cord vein 
sample 
 
NA 
 
NA 
 
Umbilical vein 
pH<7.2 
 
Route not 
reported, 
continuous 
wave, site not 
reported, 
PI>2sd above 
mean (>1.15) 
 
   Rocca 
 
High risk 
 
113 
 
Third 
 
NA 
 
NA 
 
Apgar at 5 
 
TA, pulsed 
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(1995) INC: Singleton, 113 patients with PE 
Mean age 26.3+/-2.3 
(Egypt) (Cohort) 
trimester, 
weekly 
from 28 
weeks 
until 
delivery, 
last test 
performe
d used for 
analysis 
mins<7, perinatal 
death 
wave, site not 
reported, SD≥3 
 
Rochelson 
(1987) 
 
High risk 
INC: All women who delivered an SGA 
(BW<10
th
 centile) infant and had antenatal 
Doppler, accurate gestational age 
Age not reported 
(USA) (Cohort) 
 
54 
 
Third 
trimester 
 
NA 
 
NA 
 
Admission to 
NICU, positive 
pressure 
ventilation, 
perinatal 
mortality 
 
TA, continuous 
wave, site not 
reported, SD>3 
in third 
trimester, <30 
weeks SD 
mean>2sd 
 
Rochelson 
(1992) 
 
High  risk 
INC: 40 women with an ultrasound diagnosis of 
IUGR (poor growth by serial BPD/AC or 
EFW<10
th
 centile) 
Age not reported 
 
40 
 
27-42 
weeks; 
test for 
analysis 
performe
 
BW<10
th
 
centile 
(local/ga) 
 
65.0% 
 
NA 
 
TA, continuous 
wave, 
characteristic 
waveform, 
SD≥3 
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(USA) (Cohort) d within 3 
weeks of 
delivery 
  
Rognerud 
Jensen 
(1991) 
 
 
High risk 
INC: Confirmed ga, umbilical artery Doppler 
within 7 days of birth. High risk conditions 
include PE/hypertension, diabetes mellitus, poor 
obstetric history, suspected IUGR, abnormal fetal 
heart rate, decreased fetal movements, imminent 
preterm delivery) 
Age not reported 
(Norway) (Cohort) 
 
94 
 
30-42 
weeks, 
test for 
analysis 
within 7 
days of 
delivery, 
median ga 
at 
delivery 
normal 
Doppler 
38 (30-
42), 
abnormal 
35 (30-
40) 
 
BW<5
th
 
centile 
(local/ga/sex) 
 
29.8% 
 
Apgar at 1 and 5 
mins ≤7, 
admission to 
NICU, perinatal 
mortality. 
 
TA, pulsed 
wave, site not 
reported, SD>3 
after 30 weeks. 
 
Rognerud 
Jensen 
 
High risk 
INC: 50 women with twin pregnancies 
 
100 
 
28 weeks 
onwards; 
 
BW<5
th
 
centile 
 
25.0% 
 
Apgar at 1 min 
and 5 mins<7 
 
Route not 
reported, 
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(1992) Mean age 29.5 (18-39) 
(Norway) (Cohort, consecutive) 
test for 
analysis 
performe
d within 7 
days of 
delivery; 
mean ga 
at 
delivery 
37 weeks 
(30-40) 
(singleton 
values) 
pulsed wave, 
site not 
reported, 
RI≥80% 
 
Rudigoz 
(1991) 
 
High risk 
INC: 26 pregnancies with maternal hypertension 
(BP>130/90) 
Age not reported 
(France) (Cohort) 
 
28 
 
Not 
reported 
 
BW<10
th
 
centile 
(ga/local) 
 
46.4% 
 
NA 
 
Route, method, 
site not 
reported, RI no 
threshold 
 
Sarno 
(1989) 
 
Unselected 
INC: Singletons, ≥36 weeks, vertex presentation 
and latent phase of labour 
Mean age 26.0+/-5.3 
(USA) (Cohort) 
 
109 
 
≥36 
complete
d week; 
mean 
40.2+/-
2.0 
 
BW<10
th
 
centile 
 
1.83% 
 
Perinatal 
mortality, Apgar 
at 1 and 5 
mins<7 
 
TA, continuous 
wave, 
characteristic 
waveform, 
SD>3. 
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   Schulman 
(1989) 
 
Low risk 
INC: 255 women with routine prenatal care, 
monthly Doppler of uterine and umbilical arteries 
Mean age 28.4 years 
(USA) (Cohort) 
 
255 
 
>20 
weeks  
 
BW<15
th
 
centile 
(local/ga) 
 
9.02% 
 
NA 
 
Route not 
reported, 
continuous 
wave, 
characteristic 
waveform, 
SD>3 after 30 
weeks 
 
Sezik 
(2004) 
 
High risk 
INC: Singleton, 270 pre-eclamptic women 
EXC: Multiple gestations, glucose intolerance, 
preexisiting diabetes, major congenital 
malformations 
Mean age abnormal Doppler 29.8+/-1.2; normal 
Doppler 28.1+/-0.4 
(Turkey) (Cohort) 
 
270 
 
Abnormal 
Doppler 
31.5+/-
0.4; 
normal 
Doppler 
35.0+/-
0.2 
 
BW<10
th
 
centile 
BW<2500g 
BW<1500g 
 
44.1% 
24.8% 
24.8% 
 
Apgar at 1 and 5 
mins <4, RDS, 
ICH, seizures, 
neonatal 
mortality 
 
TA, continuous 
wave, free 
floating portion 
of cord, 
AREDF 
 
Sijmons 
(1989) 
 
Unselected 
INC: Singletons, random selection of hospital 
populations, confirmed ga 
Age not reported 
(Netherlands) (Cohort, prospective, consecutive) 
 
394 
 
28weeks+
/-6 days 
and 34 
weeks+/-
6 days 
 
BW<2.3
rd
 
centile 
BW<10
th
 
centile 
PI<3
rd
 centile 
 
3.3% 
22.6% 
4.26% 
10.2% 
 
NA 
 
TA, pulsed 
wave, 
characteristic 
waveform, 
PI>95
th
 centile 
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PI<10
th
 
centile 
(ga/local) 
 
Skodler 
(1989) 
 
High risk 
INC: Not reported 
EXC: Not reported 
Age not reported 
(Germany) (Cohort) 
 
163 
 
Third 
trimester 
 
BW<10
th
 
centile 
(local/ga) 
 
12.9% 
 
NA 
 
No details 
 
Soothill 
(1993) 
 
High risk 
INC: Singleton pregnancies booked for antenatal 
care and referred for fetal surveillance (suspected 
SGA, hypertension, post dates, reduced fetal 
movements, APH, pain) seen within one week of 
delivery, no clinical suspicion of ruptured 
membranes, delivery>32 weeks  
EXC: Fetal chromosomal and structural 
anomalies 
Mean age not reported 
(UK) (Cohort, prospective, consecutive) 
 
191 
 
Within 
one week 
of 
delivery 
 
NA 
 
NA 
 
Neonatal 
morbidity (one or 
more of fetal 
heart rate 
abnormalities in 
labour leading to 
cs, 5 min 
Apgar<7, 
umbilical venous 
pH<7.15, 
admission to 
NICU) 
 
Method not 
reported, 
continuous 
wave, site not 
reported, 
PI>97.5
th
 
centile 
 
Soregaroli 
 
High risk 
 
578 
 
Mean 
 
NA 
 
NA 
 
Apgar at 5 
 
Route not 
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(2002) INC: Singletons with a diagnosis of IUGR 
(AC<2sd), first ultrasound within 20 weeks and 
Doppler performed 
Age not reported 
(Italy) (Cohort, retrospective) 
31+/-4 
(19-38); 
test for 
analysis 
performe
d within 
48 hrs of 
delivery 
mins<7, 
admission to 
NICU, RDS, 
IVH, NEC, ROP, 
IUD, neonatal 
death, perinatal 
mortality (IUD 
and deaths up to 
28 days) 
reported, color, 
site not 
reported, 
PI>2sd or 
AREDF. 
 
Spinillo 
(2005) 
 
High risk 
INC: All pregnant women delivered at 
department of singleton fetus between 24 and 35 
weeks with a umbilical artery Doppler prior to 
delivery 
EXC: Congenital malformations and uncertain 
dates 
Mean age normal growth 30.5+/-5.4; abnormal 
growth 30.2+/-4.3 
(Italy) (Cohort, retrospective) 
 
316 
 
24-25 
weeks; 
test for 
analysis 
performe
d within 
7days of 
delivery 
 
NA 
 
NA 
 
Neonatal death, 
ICH. 
 
Route not 
reported, 
pulsed wave 
and color, site 
not reported, 
SD≥95th centile 
(local/ga) 
 
Strigini 
(1997) 
 
High risk 
INC: Singletons, suspected FGR, poor obstetric 
history, preterm labour, hypertension, diabetes, 
 
576 
 
25-41 
weeks; 
mean 
 
BW<10
th
 
centile 
 
17.9% 
 
Adverse perinatal 
outcome (fetal 
death or death 
 
TA, pulsed 
wave and 
color, free loop 
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reduced fetal movements, APH) 
EXC: Multiple pregnancies, chromosomal and 
structural anomalies 
Mean age not reported 
(Italy) (Cross-sectional, prospective) 
35.1 
weeks; 
test for 
analysis 
performe
d within 3 
weeks of 
delivery 
before discharge, 
5 min Apgar <7, 
CTG abnormality 
leading to 
emergency CS) 
of cord, 
SD>2sd 
 
Szalay 
(1991) 
 
Unselected 
INC: Singleton pregnancies 
EXC: Fetal chromosomal or structural anomalies 
Age not reported 
(Germany) (Cohort) 
 
810 
 
Third 
trimester 
 
BW<10
th
 
centile 
(local/ga) 
 
16.4% 
 
NA 
 
Route not 
reported, 
pulsed wave, 
site not 
reported, 
PI>95
th
 centile 
        
Tchirikov 
(2009) 
Mixed risk 
INC: 181 patients with singleton pregnancies, no 
fetal malformations 
Age not reported 
(Germany) (Cohort, prospective) 
 
181 17-41 
weeks 
(test to 
delivery 
interval 
compromi
sed group 
mean 
NA NA Adverse perinatal 
outcome (arterial 
cord pH, Apgar 
at 1 minute, birth 
weight, duration 
of gestation, need 
for respiratory 
support, 
TA, method 
and site not 
reported, PI 
(cut off not 
reported) 
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18.5 (9.5-
27.5) 
days, 
normal 
group 
79.91 
(72.2-
87.7 
days)) 
admission to 
NICU) 
 
Thiebaugeor
ges 
(2006) 
 
High risk 
INC: Singleton. Population based EPIPAGE 
cohort study, all births between 22-32 weeks in 9 
regions of France; sub-group born 24-32 weeks 
after a high risk pregnancy defined by antenatally 
suspected SGA (AC or FL<10
th
 centile) or 
maternal hypertension. 
EXC: Multiple pregnancies, congenital 
malformations 
Mean age 30.3+/-5.5 
(France) (Cohort) 
 
518 
 
24-32 
weeks; 
mean 
30.0+/-
1.7; test 
to 
delivery 
interval 
abnormal 
2.3 days 
(3.4), 
normal 
6.8 days 
(11.1) 
 
NA 
 
NA 
 
Perinatal 
mortlaity 
 
No details 
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To 
(2005) 
 
High risk 
INC: Singletons, accurate gestation, suspected 
IUGR (decreased SFH, decreased LV, maternal 
smoking, PIH or other antenatal disorders) 
EXC: Fetal chromosomal or structural anomalies 
Mean age normal Doppler 27.7+/-5.5; abnormal 
Doppler 27.75+/-3.9 
(Hong Kong) (Cohort, prospective, consecutive) 
 
187 
 
>34 
weeks; 
test for 
analysis 
performe
d within 2 
weeks of 
delivery 
 
NA 
 
NA 
 
Apgar at  1 
min≤4, at 5 mins 
≤7 
 
Route and 
method not 
reported, free 
loop of cord 
 
Todros 
(1995) 
 
Low risk 
INC: Singletons, no pre-pregnancy pathologic 
condition, no obstetrical risk  
EXC: Fetal chromosomal or structural anomalies 
Age: 57%<30 yrs, 38% 30-39 yrs, 5% >40 yrs 
(Italy) (Cohort) 
 
916 
 
19-24 and 
26-31 
weeks 
 
BW<10
th
 
centile 
(local/ga) 
 
4.6% 
 
Abnormal 
perinatal 
outcome  
(perinatal death 
or admission to 
NICU) 
 
TA, continuous 
and pulsed 
wave, site not 
reported, SD 
(ROC analysis) 
 
Todros 
(1996) 
 
High risk 
INC: Singletons with an ultrasound diagnosis of 
SGA (AC<10
th
 or weekly increase of AC<5mm) 
or PIH. 
EXC: Fetal chromosomal or structural anomalies 
Age not reported 
(Italy) (Cohort, prospective) 
 
265 
 
At 
diagnosis, 
then 
every 2-3 
weeks 
 
NA 
 
NA 
 
Outcome 1 (IUD 
or early neonatal 
death) 
Outcome 2 
(death or Apgar 
<7 at 5 mins or 
need for 
 
Route not 
reported, 
continuous 
wave, free 
floating portion 
of cord, 
PI>50
th
, 60
th
, 
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admission to 
NICU) Outcome 
3 (As outcome 2 
or BW<10
th
 
centile) Outcome 
4 (BW<10
th
 
centile and any 
of outcome 2) 
70
th
, 80
th
, 90
th
, 
95
th
 centile, 
AREDF 
 
Torres 
(1995) 
 
High risk 
INC: Singletons, hypertension (40 PE, 16 chronic 
with superimposed PE) 
(Spain) (Cohort, prospective) 
 
172 
 
Fortnightl
y from 28 
weeks; 
last 
before 
delivery 
used for 
analysis 
 
BW<10
th
 
centile 
(local/ga) 
 
27.9% 
 
Fetal death 
 
Route not 
reported, 
pulsed wave, 
site not 
reported, 
RI>2sd or 
AEDF 
 
Trudinger 
(1991) 
 
High risk 
INC: Singleton, delivered after 26 weeks, all with 
obstetric risk factors indicating increased risk of 
fetal compromise 
Mean age 27.4+/-5.2 
(Australia) (Cohort, prospective) 
 
2178 
 
12.1-43.6 
weeks; 
test to 
delivery 
interval 
mean 
 
BW<10
th
 
centile 
BW<5
th
 
centile 
 
27.0% 
17.9% 
 
Apgar at 1 and 5 
mins≤6, 
admission to 
NICU 
 
Route not 
reported, 
continuous 
wave, site not 
reported, 
SD>95
th
 centile 
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12.5 
days+/-
16.5 
 
Tyrrell 
(1989) 
 
Mixed risk 
INC: All women admitted to antenatal ward 
before elective cs with umbilical artery Doppler 
performed within 4 hours of delivery 
Age not reported 
(UK) (Cohort, prospective) 
 
116 
 
27-42 
weeks; 
test 
performe
d within 4 
hours of 
delivery 
 
NA 
 
NA 
 
Hypoxia 
(umbilical cord 
artery pO2<2.5
th
 
centile) 
Acidosis 
(umbilical artery 
pH<7.25) 
 
Route not 
reported, 
continuous 
wave, site not 
reported, 
SD>4.5 
 
Van Asselt 
(1998) 
 
High risk 
INC: Singletons, referred for Doppler because of 
PE 
(Sweden) (Cohort) 
 
108 
 
Last test 
before 
delivery; 
median 
interval 
3.5 days 
(0-25); ga 
at 
delivery 
severe PE 
median 
37 (27-
 
BW mean – 
2sd 
 
16.7% 
 
Admission to 
NICU 
 
Route not 
reported, 
pulsed wave, 
free floating 
protion of cord, 
PI>2sd 
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42), mild 
39 (27-
42) 
 
Vergani 
(2003) 
 
High risk 
INC: Antenatally suspected FGR (AC<10
th
 
centile), accurate dating, ga>34 weeks at delivery 
EXC: Fetal chromosomal or structural anomalies, 
Doppler more than 2 weeks before delivery 
Mean age adverse outcome 32.5+/-4.5; good 
outcome 31.9+/04.8 
(Italy) (Cohort, prospective, consecutive) 
 
447 
 
Within 2 
weeks of 
delivery 
 
NA 
 
NA 
 
Admission to 
NICU for reason 
other than low 
birth weight 
alone 
 
TA, pulsed 
wave, mid 
section of cord, 
PI>95
th
 centile 
 
Vintzileos 
(1991) 
 
Population risk not reported 
INC: Singletons, consecutive, 25-37 weeks, 
accurate dates. All delivered by cs prior to onset 
of labour, umbilical artery Doppler and BPS 
performed within 3 hrs of delivery 
EXC: Congenital anomalies, medication during 
testing 
Mean age 31.9+/-3.1 weeks 
(USA) (Cohort, prospective, consecutive) 
 
62 
 
Within 3 
hrs of 
delivery 
 
NA 
 
NA 
 
Umbilical artery 
pH<7.20 
 
Route not 
reported, 
continuous 
wave, site not 
reported, SD>3 
or AEDF 
 
Weiner 
 
High risk 
 
139 
 
Test 
 
NA 
 
NA 
 
Abnormal 
 
TA, pulsed 
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(1993) INC: 142 post term gravid women, all>287 days 
EXC: Women with complicated pregnancies. 
Mean age 27.3+/-5.6 (16-39) 
(Israel) (Cohort, prospective) 
performe
d every 3 
days until 
delivery; 
mean ga 
at 
delivery 
41.8+/-
0.64 (41-
43) 
outcome (5 min 
Apgar score<7, 
admission to 
NICU, cs 
because of felal 
distress, BW<5
th
 
centile) 
wave, site not 
reported, 
RI>95
th
 centile 
 
Weiner 
(1996) 
 
High risk 
INC: Singletons, 98 pregnant women with 
suspected SGA according to EFW and BW<10
th
 
centile 
EXC: Fetal chromsosomal and structural 
anomalies 
Mean age 29.7+/-5.2 
(USA) (Cohort) 
 
81 
 
Mean 
32.7+/05.
1 (26-
38.5) 
 
NA 
 
NA 
 
Apgar at 5 
mins<7, 
admission to 
NICU, perinatal 
death 
 
TA, continuous 
wave, site not 
reported, RI 
(no threshold) 
 
Wong 
(2003) 
 
High risk 
INC: Women with pre-existing diabetes (types 1 
and 2) 
EXC: Gestational diabetes, fetal chromosomal or 
 
104 
 
28, 32, 36 
and 38 
weeks 
 
BW<10
th
 
centile 
(local/ga) 
 
8.65% 
 
Adverse outcome 
(one or more of 
SGA, cs for 
abnormal CTG, 
 
Route, method 
and site not 
reported, 
PI>95th 
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structural anomalies 
Age not reported 
(Australia) (Cohort, retrospective) 
arterial cord 
pH<7.2, 1 min 
Apgar<3, 5 min 
Apgar<7, HIE, 
stillbirth or 
perinatal death) 
 
Worrell 
(1991) 
 
High risk 
INC: Singletons, ultrasound predicted 
weight<10
th
 centile or a referral for a patient 
clinically at risk of IUGR, accurate dates 
Age not reported 
(USA) (Cohort) 
 
43 
 
Third 
trimester 
 
BW<10
th
 
centile and  
BW<2500g 
(local/ga) 
 
20.9% 
 
NA 
 
Route and 
method not 
reported, free 
loop of cord, 
RI≥0.67 
        
Yildirim 
(2008) 
High risk 
INC: 310 singleton pregnancies, EFW<10th 
centile suspected on ultrasound EXC: multiple 
pregnancies, chromosomal and structural 
anomalies 
Abnormal Doppler mean maternal age 28.1 
(27.2-29.1) years, normal Doppler 28.4 (27.6-
29.3) years 
(Turkey) (Cohort, retrospective) 
 
310 Normal 
Doppler 
test to 
delivery 
interval 
14.1 
(11.2-
17.06) 
days, 
abnormal 
NA NA Apgar at 5 
mins<7, neonatal 
mortality and 
morbidity, 
perinatal 
mortality, 
admission to 
NICU, 
intubation, NEC. 
TA, method 
not reported, 
free loop of 
cord, AREDF 
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Doppler 
7.5 (5.8-
9.2) days 
 
Zhou 
(1991) 
 
Population risk not reported 
INC: Not reported 
EXC: Not reported 
Age not reported 
(China) (Cohort) 
 
123 
 
37-42 
weeks 
 
BW<2500g 
 
4.01% 
 
Apgar at 5 mins 
≤7, admission to 
NICU, adverse 
perinatal 
outcome 
 
Route not 
reported, 
pulsed wave, 
site not 
reported, SD≥3 
 
Zimmerman 
(1995) 
 
High risk 
INC: At least 287 days ga, confirmed gestation 
EXC: Maternal disease, premature rupture of 
membranes>24 hours, fetal malpresentation, 
IUGR 
Age not reported 
(Finland) (Cross-sectional, prospective) 
 
123 
 
Within 2 
days of 
delivery, 
median ga 
at 
delivery 
41.8 (41-
42.9) 
 
NA 
 
NA 
 
Asphyxia (Apgar 
at 1 min or 5 
mins≤7 or 
umbilical artery 
pH≤7.15 or 
admission to 
NICU with signs 
of asphyxia 
encephalopathy) 
 
Route not 
reported, 
pulsed wave 
and color, site 
not reported, 
RI≥0.62 (ROC 
analysis) 
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BP blood pressure; UTI urinary tract infection; Hrs hour; INC inclusion; EXC exclusion; PE preeclampsia; RCT randomised controlled trial; PIH pregnancy induced 
hypertension; HELLP haemolysis elevated liver enzymes low platelets; FGR fetal growth restriction; SGA small for gestational age; IUGR intrauterine growth 
restriction; APS antiphospholipid syndrome; SLE systemic lupus erythematous; BW birth weight; PI ponderal index; UK United Kingdom; USA United States of 
America; NA not applicable; USS ultrasound scan; ga gestational age; sd standard deviation, % percent; NICU neonatal intensive care unit; TA transabdominal; PI 
pulsatility index; RI resistance index; SD systolic/diastolic ratio; AREDF absent reversed end diastolic flow; AEDF absent end diastolic flow; REDF reversed end 
diastolic flow; AC abdominal circumference; BPD/AC biparietal diameter/abdominal circumference; EFW estimated fetal weight; CS caesarean section; FHR fetal 
heart rate; EDD estimated date of delivery; BE base excess; IVH intraventricular haemorrhage; NEC necrotising enterocolitis; RDS respiratory distress syndrome; 
BPD bronchopulmonary dysplasia; HIE hypoxic ischaemic encephalopathy; PVL (M) peri-ventricular leukomalacia; ICH intracranial haemorrhage; ROP retinopathy 
of prematurity; VLBW very low birth weight;  CTG cardiotocogram; CST contraction stress test; NST non-stress test; mins minutes; cw continuous wave; BP blood 
pressure; GDM gestational diabetes; IDDM insulin dependent diabetes mellitus; UTI urinary tract infection; APH antepartum haemorrhage; IUD intrauterine death; 
SFH symphiseal fundal height; MAC/HC mid-arm circumference/head circumference ratio; AFI amniotic fluid index; MPD maximum pool depth; LV liquor volume; 
BPS biophysical profile; MSAFP maternal serum alpha feto-protein; ROC receiver operating characteristic; IQR interquartile range, TTS twin to twin transfusion 
syndrome 
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Appendix 29: Search strategy for systematic review of the accuracy of middle 
cerebral artery Doppler to predict small for gestational age fetuses and compromise 
of fetal/neonatal wellbeing. 
Host: Ovid 
Date of search: May 2009 
Years covered by search: 1950-2009 
 
1. MEDLINE (inception until May 2009) -1574 citations 
1. (“Pregnant woman”[MeSH] OR “Pregnancy”[MeSH] OR pregnan*) 
2. (“Prenatal Diagnosis[MeSH] OR “Ultrasonography/Prenatal”[MeSH} OR 
“Ultrasonography/Doppler”[MeSH]) 
3. {(arterial Doppler.mp) OR (Doppler velocimetry.mp) OR (Doppler 
ultrasound.mp) OR (MCA.mp) OR (Middle cerebral artery[MeSH])} 
4. (1 AND 2) 
5. (4 AND 3) 
6. Limit 5 to animals 
7. (5 NOT 6) 
 
2. Medline search adapted for EMBASE (inception until May 2009) - 407 
citations 
 
3. Cochrane library (2009:2) – 85 reviews, 169 clinical trials, 89 DARE 
1. Pregnant women 
2. Prenatal diagnosis 
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3. Ultrasonography prenatal 
4. Ultrasonography Doppler 
5. Arterial Doppler 
6. Doppler velocimetry 
7. Doppler ultrasound 
8. MCA 
9. Middle cerebral artery 
10. (2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9) 
11. (1 AND 10) 
 
4. MEDION – 0 citations 
 
5. Grey literature – 0 citations 
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Appendix 30: Data extraction form for systematic review of the accuracy of middle 
cerebral artery Doppler to predict small for gestational age fetuses and compromise 
of fetal/neonatal wellbeing. 
 
Section A: Study Information 
 
1)Ref ID:  4)Publication year:  
2)Rev 
name: 
 5)First Author:  
3)Country:  6)Language:  
 
Section B: Data Retrieval for Middle Cerebral Artery Doppler Study 
 
Population 
7) Healthcare Centre: 
Primary care □1  Secondary care  □2  Mixed □3    Other   □4        Unreported  □5 
 
8) Setting: 
 In-patient  □1  Out-patient  □2  Mixed  □3  Unreported  □4       Other  □5  
 
9) Number of participating centres: ____________________________________ 
 
10) Gestation at time of index test: 
<20 weeks   □1  20-24 weeks  □2   24-28 weeks □3    28-34 weeks □4   34-37 
weeks □5    37-40 weeks  □6   > 40 weeks  □7      Unreported  □8           Other  
10.i) Mean (range)______________________________________         Unreported  
□3 
 
10.ii) Median (range) ____________________________________        Unreported  
□3 
 
11) Pregnancy: 
Low Risk      □1  High Risk    □2  Unselected  □3  Unreported  □4 
 
11.i) State high risk conditions:      Unreported  □3 
            
           
           
  
450 
 
12) Were patients with the following conditions excluded/not included? 
12.i) Previous IUGR:   Yes □1  No  □2 Unreported   
□3 
12.ii) Insulin dependent diabetes mellitus:      Yes □1 No  □2 Unreported   
□3 
12.iii)   Chronic renal disease:  Yes □1  No  □2        Unreported   
□3 
12.iv)   Systemic lupus erythematosus:  Yes □1  No  □2        Unreported   
□3 
12.v)    Antiphospholipid syndrome:   Yes □1  No  □2        Unreported   
□3 12.vi)   Chronic hypertension:   Yes □1  No  □2        
Unreported   □3 12.vii)   Pre-eclampsia:   Yes □1  No  
□2        Unreported   □3 
12.viii)  Foetal chromosomal/structural anomalies:  Yes □1  No  □2        
Unreported   □3 
 
13) Did all patients have singleton pregnancies?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
14) Were all patients primigravid?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
15) List other eligibility/ in-/exclusion criteria: 
 
 
 
 
 
16) Study population: (describe age (mean +/- SD or median/range), ethnicity, smoking, BMI 
etc.) 
   ----------/-------------            
   ----------/-------------            
 
         Not applicable  □3 
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17) Start of patient inclusion (year) :                        U    
Unreported □3  
18) End of patient inclusion (year) :              
Unreported □3 
19) Study Design:    
cohort  □1    case control  □2      RCT/CCT  □3        cross sectional  □4     before and 
after  □5         case series   □6  (no ______)      other  □7 
19.i) Data collection:  prospective □1      retrospective   □2      unreported  □3        
other  □4 
19.ii) Enrolment:    consecutive  □1       arbitary (random) □2      unreported  □3        
other  □4 
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20) Numbers: 
 
21) Completeness of Verification: 
(= E / C x 100 = %) 
> 90%  □1     81-90%  □2     < 81%  □3 
 
Index Test 
 
22) Description of technique:      
Adequate  □1   Inadequate  □2 
 
23) Timing of measurement (from delivery): 
< 7days □1  7-14 days  □2  14 -28 days □3  > 28 days  □4    Mixture  □5   
Unreported  □6 
 
23.i) Median gestational age at delivery   ________________________unreported  
□3         
24) Measurement: 
SCANNING: 
24.i) Operator: 
 
B Reasons ________________ 
 
D Reasons ________________ 
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Single  □1   Multiple  □2       Unreported    □3 
24.ii) Operator experience__________________________________________ 
unreported  □3         
24.iii) Scanning Route: Transabdominal □1  Transvaginal  □2   Unreported  □3 
DOPPLER: 
24.iv) Method:   Continuous wave Doppler  □1  Pulsed wave Doppler  □2 Colour 
mapping  □3       Unreported   □4 
24.v) Measurement parameter:     Resistance index (RI)  □1   Systolic / diastolic 
ratio  □2 Pulsatility index (PI) □3  Cerebroplacental ratio  □4  Unreported  □5    
24.vi) Cut-off level for waveform ratio:   > 2 SD  □1   > 95th centile  □2  > 90th 
centile  □3    
> 80th centile □4     > 50th centile  □5  < 10th centile □6   < 5th centile  □7   
Unreported/NA  □8 
Other/Threshold data set: 
______________________________________________________ 
24.vii) Machine: _______________________________________________     
unreported  □3         
24.viii) Probe: _______________________________________________ 
unreported  □3         
24.ix) High pass filter: ______________________________________   unreported  
□3         
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24.x) Pulse repetition frequency: ____________________________    unreported  
□3         
24.xi) Size of sampling gate: __________________________________unreported  
□3         
24.xii) Site : ________________________________________________ unreported  
□3         
24.xiii) Angel of insonation: ___________________________________ 
unreported  □3         
24.xiv) Number of consecutive waveforms: ______________________unreported  
□3         
24.xvi) Other information:  
Maximal output 
power_____________________________________________________ 
Sample volume 
___________________________________________________________ 
Spatial peak temporal intensity 
______________________________________________ 
Reference Standard / Outcome 
25) Measured blind form diagnostic test:   Yes  □1    No  □2   Unclear  □3 
26) Measurement for FGR:   Birthweight  □1  Neonatal ponderal index  □2  
Skin fold thickness □3    MAC / OFC  □4    Other  □5  
______________________________________ 
27) Threshold:   < 3rd centile  □1  < 5th centile  □2   < 10th centile  □3  < 25th 
centile □4     
> 2SD  □5   Other □6 ______________________________________________     Unclear   □7 
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28) What data set was used to define threshold? 
___________________________________________________________          
unreported  □3         
29)Timing of measurement:  At delivery  □1   Within 24 hrs  □2   > 24 hrs  □3  
Mixture  □4   Unreported  □5     
30) Marker of wellbeing e.g. Apgar score, perinatal mortality 
 
31) Threshold and data set (if applicable): 
 
32) Measured blind form diagnostic test:   Yes  □1    No  □2   Unclear  □3 
 
 
 
 
Appendix 31: Reference list of included studies in systematic review of accuracy of 
middle cerebral artery Doppler to predict small for gestational age fetuses and 
compromise of fetal/neonatal wellbeing. 
                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Results 
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Appendix 32: Table of study characteristics of included studies for systematic review of middle cerbral artery Doppler to predict 
small for gestational age fetuses / compromise of fetal wellbeing. 
 
First 
Author 
(year) 
Population 
Age 
(country/study design) 
No of 
fetuses 
analys
ed 
Gestatio
nal age 
at test 
(weeks) 
Reference  
Standard 
 SGA 
Inciden
ce of 
SGA 
(%) 
Reference 
standard 
Fetal 
compromise 
Details 
Index test 
 
 
Alatas
 
(1996) 
 
High and low risk populations. 
INC: Previous perinatal death, poor obstetric history, IDDM, 
previous premature birth, hypertension, recurrent spontaneous 
abortion, CAH 
High risk mean age 28.2 (17-41), low risk 25.0 (18-34) 
(Turkey) (cohort) 
 
237 
 
>24. 
Mean test 
to 
delivery 
interval 
high risk 
5.5 days 
(0-12); 
low risk 
7.1 days 
(0-14) 
 
BW<10th 
centile 
 
High 
risk 
25% 
Low 
risk 
14.8% 
 
Apgar score at 
1 min<7, 5 
min<7, cord 
pH<7.2, 
admission to 
NICU 
 
TA, 
pulsed+col
or, site not 
reported 
PI<2sd 
 
Arduini
 
(1992) 
 
High risk. 
INC: singleton, accurate gestation, AC<5th or EFW<10th, no 
structural or chromosomal anomalies 
 
120 
 
Mean 
32.2+/-
3.0 
 
NA 
 
NA 
 
Adverse 
perinatal 
outcome 
 
TA, 
pulsed+col
or, site not 
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Mean age 29.4+/-4.3 weeks 
(Italy) (cohort) 
(perinatal 
death, cs due 
to abnormal 
FHR, Apgar 
score at 5 
mins<7, 
admission to 
NICU for 
asphyxia>48h
rs) 
reported, 
PI<5th 
centile 
 
Arias
 
(1994) 
 
High risk. 
INC: Suspected IUGR, PE, preterm labour, chronic hypertension, 
APS. 
Mean age control 31+/-3.8 yrs; study 29.5+/-5.7 yrs. 
(USA) (Case-control, prospective) 
 
81 
 
24-38 
weeks, 
Doppler 
within 2 
weeks of 
delivery 
 
BW<10th 
centile with 
evidence of 
FGR (decreased 
subcutaneous 
fat, 
hypoglycaemia, 
hyperbilirubinae
mia, 
hypocalcaemia, 
hyperviscosity) 
 
23.4% 
 
NA 
 
TA, 
method 
not 
reported, 
Circle of 
Willis, RI-
cut-off not 
reported. 
 
Cavero
 
 
High risk. 
 
83 
 
Control 
 
BW<10th 
 
49.4% 
 
Apgar 1 
 
TA, 
  
463 
 
(1996)  INC: Cases-Antenatally suspected IUGR (AC<2sd), controls 
matched for maternal age, parity, height, weight, edd. 
Mean age controls 28.3+/-4.5 yrs; cases 27.6+/-6.8 yrs 
(Spain) (Case control, prospective) 
 
mean 247 
days+/-
23.8; 
cases 
247.2 
days+/-
24.6 
centile min<7, 
neonatal 
resuscitation 
required, 
admission to 
NICU. 
method 
and site 
not 
reported, 
parameter 
and cut-off 
not 
reported. 
 
Chandra
n
 
(1993) 
 
High risk. 
INC: PE, AC<3rd centile, abnormal umbilical artery Doppler, 
singleton, delivery by prelabour cs. 
EXC: fetal chromosomal and structural anomalies 
Mean age not reported 
(Malaysia) (Cohort, prospective) 
 
 
27 
 
24-39 
weeks 
(test for 
analysis 
performe
d within 
24 hrs of 
delivery)  
 
BW<3rd centile 
 
70.4% 
 
Cord pH<7.12 
BE>12.0mmo
l/l; cord 
pO2<8.9mmH
g; IVH, NEC, 
HMD; 
adverse 
outcome. 
 
TA, 
method 
not 
reported, 
level of 
BPD, 
PI<2sd 
        
Del Ri
 
(2008) 
High risk 
INC: 51 singleton fetuses with IUGR (EFW<10th centile) and either 
an umbilical artery pulsatility index>95th centile or a 
cerebroplacental ratio<5th centile (MCA/UA<5th centile)  
EXC: no structural or chromosomal abnormalities 
Median maternal age in abnormal Doppler 32 (22-40) normal 28 (22-
51 24-36 
weeks 
(test for 
analysis 
within  
48 hours 
NA NA APO= any of 
stillbirth, 
neonatal 
mortality, 
BPD, RDS, 
grade 3/4 
Route not 
reported, 
color+puls
ed, site not 
reported, 
vasodilatat
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37) years. 
(Spain) (Cohort, prospective) 
 
 
of 
delivery) 
IVH, NEC, 
sepsis and 
stay in 
NICU>14 
days 
 
ion 
        
   Dubiel
 
(1997) 
High risk. 
INC: suspected IUGR, PIH, post term, diabetes, decreased fetal 
movements, increased resistance in umbilical artery. 
Mean age not reported. 
(Sweden) (Cohort) 
50 31-42 
Median 
38 (test 
for 
analysis 
performe
d within 
7 days of 
delivery) 
NA NA Apgar at 1 or 
5 mins<7 
Route not 
reported, 
color 
+pulsed, 
site not 
reported, 
PI <mean -
2sd. 
 
Dubiel 
(2000) 
 
High risk. 
INC: singletons with PIH.  
Mean age not reported 
(Sweden) (Cohort) 
 
102 
 
27-41 
Median 
36 (test 
for 
analysis 
performe
d within 
 
BW<5th centile 
(local values) 
 
55.6% 
 
Apgar at 5 
mins<7; cord 
artery 
pH<7.15, cord 
vein pH<7.20; 
admission to 
NICU, need 
 
TA, 
color+puls
ed, site not 
reported, 
PI<mean -
2sd. 
  
465 
 
1-2 days 
of 
delivery) 
for 
ventilation, 
Perinatal 
mortality  
 
Ebrashy
 
(2005) 
 
High risk 
INC: Viable singleton pregnancy, no other obstetric or other 
morbidity, PE diagnosed according to ISSHP criteria, no medication 
except for iron and delivered by elective cs not in labour and not for 
fetal distress. EXC: fetal chromosomal and structural anomalies. 
Mean age 24.8+/-6.1 years 
(Egypt) (Case control, prospective) 
 
 
 
50 
 
Mean 
36.9+/-
2.5 
 
NA 
 
NA 
 
Cord pH<7.20 
 
TA, 
color+puls
ed, Cirlce 
of Willis, 
RI<0.69 
        
 
Fong
 
(1999) 
 
High risk. 
INC: singleton, >24weeks, EFW<10th EXC: congenital or 
chromosomal abnormality 
Mean age 32.6+/_3.7 years 
(Canada) 
(Cohort, prospective, consecutive) 
  
 
293 
 
Mean 
32.6+/-
3.7 (test 
for 
analysis 
within 2 
weeks of 
delivery) 
 
NA 
 
NA 
 
Adverse 
perinatal 
outcome 
(perinatal 
death, HIE, 
IVH, PVL, 
NEC, arterial 
cord pH<7.1, 
 
TA, 
pulsed+col
or, Circle 
of Willis, 
PI<5th 
centile 
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Apgar 5 
mins<7, cs for 
fetal distress) 
 
Gramelli
ni
 
(1992) 
 
Unselected population 
INC: singletons  
Age not reported 
(Italy)(Case control, retrospective) 
 
 
 
90 
 
30-41 
 
BW<10
th
 
centile, local 
values 
 
50% 
 
NA 
 
TA, 
Method 
not 
reported, 
level of 
thalamus, 
PI cut-off 
not 
reported. 
Gramelli
ni
 
(2001) 
High risk. 
INC: Ultrasound dated pregnancy <20 weeks, AC<2.5
th
 centile, 
Doppler within 2 weeks of birth and a non-stress test within 2 hrs of 
delivery, singleton. 
EXC: chromosomal or structural anomalies 
Age not reported 
(Italy) (cohort, retrospective) 
53 24-35 
(test for 
analysis 
performe
d within 
2 weeks 
of 
delivery) 
NA NA Neonatal 
resuscitation 
required, 
perinatal 
mortality. 
Route not 
reported, 
color, site 
not 
reported, 
PI<5
th
 
centile. 
 
Hata
 
(1999) 
 
High risk. 
INC: singletons, EFW<10
th
 centile EXC: structural and 
 
54 
 
Within 2-
3 weeks 
 
NA 
 
NA 
 
Apgar at 5 
mins<7, 
 
TA, 
color+puls
  
467 
 
chromosomal abnormalities 
Mean age abnormal Doppler 29.4+/-5.1 years, normal Doppler 
28.4+/-4.9 years. 
(Japan)(cohort) 
of 
delivery 
umbilical 
artery 
pH<7.15, 
admission to 
NICU. 
ed, level of 
greater 
wings of 
sphenoid, 
PI cut-off 
not 
reported. 
        
Hernand
ez-
Andrade
 
(2008) 
High risk 
INC: 56 fetuses with IUGR (EFW<10th centile and an abnormal PI 
mean<2sd in umbilical artery). 
Median maternal age 32 (20-39) years 
(Spain) (Cohort) 
 
56 Median 
29 (26-
32) 
weeks 
NA NA Apgar at 5 
mins<7, 
umbilical 
artery 
pH<7.20, 
IUD, NND, 
PND, adverse 
perinatal 
outcome 
TA, 
color+puls
ed, origin 
from 
Circle of 
Willis, PI 
mean<2sd. 
 
Hershko
vitz
 
(2000) 
 
High risk. 
INC: singletons, EFW<5
th
 centile EXC: structural and chromosomal 
abnormalities 
Mean age abnormal Doppler 28.8+/-9.7 years, normal Doppler 
26.27+/-6.7 years. 
(UK)(case control, retrospective) 
 
47 
 
Median 
gestation 
abnormal 
Doppler 
37(35-
40), 
 
NA 
 
NA 
 
Apgar 5 
mins<7, 
admission to 
NICU. 
 
 
TA, 
color+puls
ed, site not 
reported, 
PI<5th 
centile. 
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normal 
Doppler 
38(35-
40). 
    
   Joern
 
(1993) 
 
High risk. 
INC: post term, EDD from LMP and first trimester ultrasound. 
Age not reported 
(Germany) (Cohort) 
 
59 
 
>40 
weeks 
 
BW<10
th
 centile 
local values. 
 
10.1% 
 
 
NA 
 
TA, 
color+puls
ed, site not 
reported, 
PI<1.0. 
        
 
Joern  
(1997) 
 
High risk. 
INC: twins and triplets EXC: structural and chromosomal anomalies. 
Mean age 29 (19-40) 
(Germany)(cohort) 
 
261 
 
Mean 34 
(26-41), 
(test for 
analysis 
performe
d within 
mean of 
19 days 
of 
delivery) 
 
BW<10
th
 centile 
local values. 
 
31% 
 
 
Adverse 
outcome (any 
of umbilical 
artery 
pH<7,20, 
Apgar at 5 
mins<8, 
admission to 
NICU) 
 
 
Route not 
reported, 
color, site 
not 
reported, 
PI<1.3. 
 
Lakhkar
 
 
High risk. 
 
58 
 
>30 
 
NA 
 
NA 
 
Minor adverse 
outcome (cs 
 
TA, 
  
469 
 
(2006) INC: singletons, PE, EFW<10
th
 centile. EXC: chromosomal and 
structural anomalies. 
Mean age 27.3 years. 
(India) (cohort, prospective) 
weeks 
(test for 
analysis 
performe
d within 
10 days 
of 
delivery) 
for fetal 
distress or 
Apgar at 5 
mins<7 or 
admission to 
NICU) Major 
(perinatal 
death, HIE, 
IVH, PVL, 
pulmonary 
haemorrhage, 
NEC) 
 
pulsed, 
level of 
wings of 
greater 
sphenoid, 
PI<5
th
 
centile. 
 
    Luzi
 
(1996) 
 
High risk. 
INC: delay in rate of fetal growth>25
th
 centile. 
Age not reported 
(Italy) (case control) 
 
37 
 
28-term  
 
BW<10
th
 
centile, local 
values. 
 
8.1% 
 
NA 
 
TA, 
method 
and site 
not 
reported, 
PI< 1 sd. 
        
 
Mari
 
(1992) 
 
High risk. 
INC: Suspected SGA (HC and AC mean -2sd) 
Age not reported. 
(USA) (case-control) 
 
33 
 
Mean 
31+/-4.3 
weeks 
(20-37) 
 
NA 
 
NA 
 
Adverse 
perinatal 
outcome 
(admission to 
NICU>12 
hours or 
 
TA, 
color+puls
ed, site not 
reported, 
PI mean -
2sd. 
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perinatal 
death) 
 
Mari
 
(2007) 
 
High risk. 
INC: Singleton, EFW<3rd centile, Umbilical Artery PI>95th, all 
delivered<33 weeks 
EXC: chromosomal and structural anomalies. 
Age not reported 
(Italy) (cohort, prospective) 
 
30 
 
Median 
27+2 
weeks 
(23-
32+4) 
(test for 
analysis 
performe
d within 
8 days of 
delivery) 
 
NA 
 
NA 
 
Perinatal 
mortality; 
perinatal 
morbidity 
(IVH grade 3 
or 4, BPD) 
 
TA, 
color+puls
ed, site not 
reported, 
PSV mean 
+2sd or PI 
mean -2sd. 
 
Maunu
 
(2007) 
 
High risk. 
INC: Preterm birth (<37 weeks), VLBW<1500g. 
Mean age 30,2 (+/-5.2) years 
(Finland) (Cohort, prospective) 
 
63 
 
Mean 
28+2 
weeks 
(24-36) 
(last 
Doppler 
performe
d within 
7 days of 
 
NA 
 
NA 
 
MRI at term 
abnormal (e.g. 
IVH, 
ventriculomeg
aly, ischaemic 
lesions) 
 
Route, 
method 
and site 
not 
reported, 
PI<5
th
 
centile. 
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delivery) 
 
 
Meyberg
 
(2000) 
 
 
Unselected. 
INC: Not reported. 
Age not reported. 
(Germany) (Cohort) 
 
 
144 
 
 
28-40 
 
 
BW<10
th
 centile 
BW<5
th
 centile 
(local values) 
 
 
27.1% 
13.9% 
 
 
Adverse 
outcome 
(umbilical 
artery pH<7.2 
and/or Apgar 
at 1 min<7) 
 
 
Route and 
site not 
reported, 
pulsed+col
or, 
SD<10
th
 
centile. 
 
Meyberg
 
(2001) 
 
High risk. 
INC: Abnormal umbilical artery and fetal aorta Doppler. 
Age not reported 
(Germany) (case control) 
 
96 
 
28-40 
 
BW<10
th
 centile 
(local values) 
 
74.0% 
 
Adverse 
outcome 
(umbilical 
artery pH<7.2 
and/or Apgar 
at 1 min<7) 
 
Route and 
site not 
reported, 
pulsed+col
or, 
SD<10
th
 
centile. 
 
Mimica
 
(1995) 
 
High risk. 
INC: singletons, suspected SGA., absent end –diastolic flow of 
umbilical artery 
Age not reported. 
(Croatia) (Cohort) 
 
21 
 
Not 
reported 
 
NA 
 
NA 
 
Apgar 5 
mins<7, 
perinatal 
death. 
 
TA, 
pulsed, site 
not 
reported, 
RI<5
th
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centile. 
 
Miyashit
a
 
(2002) 
 
High risk. 
INC: singletons, EFW<1.5sd EXC: structural and chromosomal 
anomalies. 
Age not reported. 
(Japan) (Cohort, prospective) 
 
119 
 
24-36 
(test for 
analysis 
within 10 
days of 
delivery) 
 
NA 
 
NA 
 
Adverse 
outcome 
(neonatal 
death, 
infantile 
death, 
cerebral palsy 
and or 
developmenta
l retardation) 
 
 
TA, 
pulsed, site 
not 
reported, 
RI<4.0sd. 
 
Ozcan
 
(1998) 
High risk. 
INC: EFW<5th centile, Doppler within 2 weeks of delivery EXC: 
chromosomal and structural anomalies, birth weight>5th centile. 
Age not reported. 
(USA) (cohort) 
19 Mean 
28.2 
weeks 
(27-31.4) 
(test for 
analysis 
performe
d within 
a median 
of 2 days 
(0-14)) 
NA NA Perinatal 
death, Apgar 
5 mins<7, 
NEC. 
TA, 
color+puls
ed, Circle 
of Willis, 
PSV mean 
+2sd or PI 
mean -2sd. 
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Ozeren
 
(1999) 
 
High risk. 
INC: singletons, PE EXC: structural and chromosomal anomalies 
Mean age 27.6+/-5.2 years 
(Turkey) (case control) 
 
62 
 
Mean 
35.8+/-
2.6 
weeks. 
 
BW<10
th
 centile 
(local values) 
 
40.3% 
 
Perinatal 
deaths, 
NICU≥7 days 
or neonatal 
death, Apgar 
<7 at 5 mins. 
Combined as 
adverse 
outcome. 
 
TA, 
method 
not 
reported, 
level of 
thalamus, 
PI<2sd. 
        
Spinillo
 
(2009) 
High risk 
INC: 184 singleton pregnancies at 24-35 weeks complicated by FGR 
(AC<10th centile) and abnormal uterine artery Doppler 
measurements (PI>95th centile or AREDF), ga confirmed by 
ultrasound scan  
EXC: fetal chromosomal and structural anomalies 
Age not reported 
(Italy) (Cohort, prospective) 
 
184 Median 
28.9 (23-
34) 
weeks 
(test for 
analysis 
performe
d within 
48 hrs of 
delivery) 
NA NA Adverse 
perinatal 
outcome: fetal 
and neonatal 
death, severe 
neonatal brain 
damage 
(grade 3 or 4 
ICH or cystic 
leukomalacia)
. Severe 
neonatal 
complicatins: 
Route, 
method 
and site 
not 
reported, 
PI<10
th
 
centile. 
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brain damage, 
ROP, broncho 
pulmonary 
dysplasia, 
NEC) 
 
 
Strigini
 
(1997) 
 
High risk. 
INC: Singleton, suspected FGR, poor obstetric history, preterm 
labour, hypertension, diabetes, reduced fetal movements, APH 
EXC: structural and chromosomal anomalies 
Age not reported. 
(Italy) 
 
576 
 
Mean 
35.1 (25-
41) 
weeks 
(test for 
analysis 
performe
d within 
3 weeks 
of 
delivery) 
 
BW<10
th
 centile 
(local values) 
 
17.9% 
 
Adverse 
perinatal 
outcome (fetal 
death or death 
before 
discharge, 5 
min Apgar<7, 
CTG 
abnormality 
leading to 
emergency cs) 
 
 
TA, 
color+puls
ed, level of 
BPD, PI 
mean 
<1.5sd. 
        
Tchiriko
v
 
(2009) 
Mixed risk 
INC: 181 patients with singleton pregnancies, confirmed ga. 
EXC: fetal malformations 
Age not reported 
 17-41 
weeks 
NA NA Adverse 
perinatal 
outcome 
TA, 
method 
and site 
not 
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(Germany) (Cohort, prospective) 
 
reported, 
PI<5
th
 
centile 
Hrs hour; INC inclusion; EXC exclusion; CAH congenital adrenal hyperplasia; PE preeclampsia; PIH pregnancy induced hypertension; FGR fetal growth restriction; 
APS antiphospholipid syndrome; BW birth weight; UK United Kingdom; USA United States of America; NA not applicable; SGA small for gestational age; IUGR 
intrauterine growth restriction; USS ultrasound scan; ISSHP International Society for the Study of Hypertension in Pregnancy; ga gestational age; sd standard 
deviation, % percent; NICU neonatal intensive care unit; TA transabdominal; PI pulsatility index; RI resistance index; PSV peak systolic velocity; SD systolic/diastolic 
ratio; AC abdominal circumference; EFW estimated fetal weight; CS caesarean section; FHR fetal heart rate; EDD estimated date of delivery; BE base excess; IVH 
intraventricular haemorrhage; NEC necrotising enterocolitis; HMD hyaline membrane disease; BPD biparietal diameter; HIE hypoxic ischaemic encephalopathy; PVL 
peri-ventricular leukomalacia; LMP last menstrual period; CTG cardiotocogram; mins minutes; APO adverse perinatal outcome; MCA middle cerebral artery; UA 
umbilical artery; RDS respiratory distress syndrome; IUD intrauterine death; NND neonatal death; PND perinatal death; AREDF absent reversed end-diastolic flow; 
ICH intracranial haemorrhage; ROP retinopathy of prematurity
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Appendix 33: Forest plot of positive and negative likelihood ratios for middle cerebral artery Doppler to predict compromise of fetal 
wellbeing (Apgar scores). Single studies are represented by a filled box, pooled results by an open diamond and subgroup analysis by 
a filled diamond. 
2 studies c High risk, test within 7 days of delivery, PI<2sd
4 studies a High risk, test within 2 weeks of delivery, PI<2sd
3 studies c High risk, singletons only, any PI
6 studies a High risk PI<2sd
9 studies a High risk              Any index parameter
Meta-analysis
Ozeren 1999        High risk    PI<2sd
Ozcan 1998        High risk    PI<2sd
Ozcan 1998        High risk     PSV+2sd
Mimica 1995       High risk      RI<5th centile
Hershkovitz 2000 High risk    PI<5th centile
Author Year Population Index Test  Positive Likelihood Ratio (95% CI) Negative Likelihood Ratio (95% CI)
No of studies
Apgar at 1 minute <7
Sub-group analysis
2.16 (1.47, 3.16)
2.02 (0.75, 5.44)
1.47 (0.85, 2.55)
1.76(0.98, 3.16)
1.65 (1.07, 2.52)
1.40 (0.71, 2.74)
0.68 (0.24, 1.90)
1.52 (0.92, 2.50)
1.04 (0.61, 1.77)
2.27 (0.93, 5.58)
Hata 1999 High risk PI
Dubiel 2000 High risk PI<2sd
Dubiel 1997 High risk PI<2sd
Alatas 1996 High risk PI<2sd
Apgar at 5 minutes <7
1.21 (0.23, 6.40)
2.02 (1.17, 3.50)
2.29 (1.35, 3.89)
11.50 (3.80, 34.78)
2 studies a High risk, singletons only, PI<2sd
2 studies a High risk PI<2sd
3 studies a Any risk PI<2sd
Meta-analysis
Sub-group analysis
3.14 (1.00, 9.89)
3.14 (1.00, 9.89)
3.47 (1.68, 7.15)
Dubiel 1997 High risk PI<2sd
Cavero 1996 Mixed risk Not reported
Alatas 1996 High risk PI<2sd
2.29 (1.35, 3.89)
4.79 (2.04, 11.26)
6.00 (1.30, 27.62)
Positive Likelihood Ratio
0.61 (0.38, 0.97)
0.56 (0.37, 0.85)
0.57 (0.33, 1.02)
0.56 (0.32, 0.96)
0.59 (0.37, 0.92)
0.82 (0.51, 1.29)
1.88 (0.52, 6.81)
0.25 (0.02, 3.65)
0.87 (0.13, 6.50)
0.37 (0.03, 4.15)
0.92 (0.41, 2.08)
0.64 (0.40, 1.03)
0.26 (0.04, 1.59)
0.35 (0.11, 1.10)
0.58 (0.17, 1.99)
0.58 (0.17, 1.99)
0.65 (0.41, 1.03)
0.26 (0.04, 1.59)
0.56 (0.34, 0.92)
0.79 (0.63, 1.00)
Negative Likelihood Ratio
0.1 0.2 0.5 1 2 5 10 100
Hernandez  2008 High risk    PI<2sd 1.30 (1.03, 1.64) 0.20 (0.01, 3.10)
0.01 0.1 0.2 0.5 1 2 5 10 100
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Appendix 34: Forest plot of positive and negative likelihood ratios for middle cerebral artery Doppler to predict compromise of fetal 
wellbeing (cord blood gas analysis/need for neonatal resuscitation). Single studies are represented by a filled box, pooled results by 
an open diamond and subgroup analysis by a filled diamond. 
Author  Year Population Index Test  Reference standard Positive Likelihood Ratio (95% CI)                      Negative Likelihood Ratio (95% CI)
No of studies
1.98 (0.88, 4.49)
2.32 (1.15, 4.65)
1.42 (0.99, 2.04)
2.93 (1.62, 5.29)
3.60 (1.49, 8.69)
1.92 (1.77, 3.13)
1.27 (0.79, 2.06)
2.36 (0.78, 7.15)
1.22 (0.74, 2.00)
1.21 (0.61, 2.38)
2.29 (0.74, 7.11)
1.98 (0.83, 4.73)
1.75 (0.98, 3.14)
Positive Likelihood Ratio
2 studies b High risk, any PI within 2 weeks of delivery, any reference parameter
Sub-group analysis
3 studies b Any risk Any index parameter Any reference parameter
Meta-analysis
Gramellini 2001 High risk PI<5th centile Resuscitation required
Dubiel 2000 High risk PI<2sd Ventilation required
Cavero 1996 Mixed risk Index not reported Resuscitation required
Neonatal resuscitation required
Chandran 1993 High risk, singletons only, PI<2sd within 24 hours of delivery
Cord Blood Gas Analysis – hypoxaemia (cord PO2<8.9mmHg)
2 studies c High risk, PI<2sd within 7 days of delivery, any reference
3 studies b High risk, PI<2sd within 2 weeks of delivery, any reference
3 studies c High risk , singletons only, any index or reference parameter
2 studies c High risk Any index Cord pH artery<7.15
3 studies b High risk Any index Cord pH artery<7.2
4 studies a High risk PI<2sd Any reference parameter
Sub-group analysis
6 studies a High risk Any index or reference parameter
Meta-analysis
1.20 (0.56, 2.56)
1.60 (0.88, 2.91)
1.24 (0.61, 2.52)
1.33 (0.83, 2.11)
1.75 (0.50, 6.18)
15.75 (3.60, 68.94)
0.87 (0.08, 9.96)Hata 1999 High risk PI Cord pH artery<7.15
Ebrashy 2005 High risk RI<0.69 Cord pH<7.20
Dubiel 2000 High risk PI<2sd Cord pH vein<7.20
Dubiel 2000 High risk PI<2sd Cord pH artery<7.15
Chandran 1993 High risk PI<2sd Cord pH<7.12/BE>12mmol/l
Alatas 1996 Low risk PI<2sd Cord pH<7.2
Alatas 1996 High risk PI<2sd Cord pH<7.2
Cord Blood Gas Analysis - acidosis
0.55 (0.39, 0.78)
0.61 (0.47, 0.78)
0.40 (0.11, 1.50)
0.56 (0.39, 0.81)
0.68 (0.47, 0.98)
0.08 (0.01, 1.31)
0.84 (0.55, 1.29)
0.70 (0.44, 1.11)
0.85 (0.56, 1.30)
0.93 (0.64, 1.33)
0.66 (0.40, 1.10)
0.45 (0.21, 0.99)
0.61 (0.38, 0.98)
1.05 (0.46, 2.38)
0.89 (0.56, 1.41)
0.76 (0.50, 1.16)
0.90 (0.60, 1.34)
0.37 (0.03, 5.20)
0.88 (0.58, 1.31)
0.52 (0.29, 0.91)
Negative Likelihood Ratio
0.01 0.1 0.2 0.5 1 2 5 10 100
1.26 (0.98, 1.62)Hernandez 2008 High risk PI<2sd Cord pH artery<7.15 0.31 (0.04, 2.12)
0.01 0.1 0.2 0.5 1 2 5 10
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Appendix 35: Forest plot of positive and negative likelihood ratios for middle cerebral artery Doppler to predict compromise of fetal 
wellbeing (admission to neonatal intensive care/neonatal complications). Single studies are represented by a filled box, pooled results 
by an open diamond and subgroup analysis by a filled diamond. 
 
Author  Year Population Index Test  Reference standard Positive Likelihood Ratio (95% CI)                      Negative Likelihood Ratio (95% CI)
No of studies
Negative Likelihood RatioPositive Likelihood Ratio
Chandran 1993 High risk PI<2sd HMD
Chandran 1993 High risk PI<2sd IVH
Other Neonatal Complications
Ozeren 1999 High risk PI<2sd NICU>7 days and/or
Neonatal death
Maunu 2007 High risk PI<5th centile Abnormal MRI brain
1.32 (0.68, 2.57)
1.04 (0.34, 3.15)
0.92 (0.54, 1.59)
1.24 (0.70, 2.20)
2 studies c High risk PI<2sd
Meta-analysis
1.30 (0.92, 1.85)
Ozcan 1998 High risk PI<2sd
Ozcan 1998 High risk PSV+2sd
Chandran 1993 High risk PI<2sd
Necrotising Enterocolitis
1.29 (0.78, 2.12)
1.07 (0.58, 1.98)
1.33 (0.83, 2.11)
2 studies c High risk, singletons only, PI any
2 studies c High risk PI<2sd within 2 weeks of delivery
4 studies a High risk Any index parameter
Sub- group analysis
5 studies a Any risk Any index parameter
Meta-analysis
2.60 (1.52, 4.45)
4.66 (1.83, 11.86)
3.24 (1.97, 5.32)
4.00 (2.13, 7.51)
Hershkovitz 2000 High risk PI<5th centile
Hata 1999 High risk PI
Dubiel 2000 High risk PI<2sd
Cavero 1996 Mixed risk Not reported
Alatas 1996 Low risk PI<2sd
Alatas 1996 High risk PI<2sd
Admission to NICU
3.17 (1.82, 5.51)
2.28 (1.00, 5.17)
5.27 (1.73, 16.11)
17.41 (2.40, 126.30)
2.36 (0.72, 7.82)
2.79 (0.67, 11.58)
0.2 0.5 1 2 5 10 100 1000
Hernandez  2008 High risk PI<2sd Intrauterine death
Hernandez 2008 High risk PI<2sd Neonatal death
0.98 ( 0.54, 1.75)
1.3 (1.03, 1.65) 0.20 (0.01, 3.10)
1.08 (0.19, 6.35)
1.20 (0.37, 3.93)
0.51 (0.04, 6.79)
0.40 (0.08, 1.99)
0.43 (0.06, 3.11)
0.86 (0.21, 3.54)
0.37 (0.03, 5.20)
0.53 (0.30, 0.91)
0.66 (0.54, 0.81)
0.60 (0.42, 0.84)
0.61 (0.50, 0.75)
0.14 (0.01, 1.95)
0.67 (0.41, 1.11)
0.61 (0.48, 0.77)
0.64 (0.49, 0.82)
0.78 (0.44, 1.37)
0.82 (0.55, 1.24)
0.99 (0.71, 1.38)
0.85 (0.57, 1.27)
0.01 0.1 0.2 0.5 1 2 5 10
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Appendix 36: Forest plot of positive and negative likelihood ratios for middle cerebral artery Doppler to predict perinatal morbidity 
and mortality. Single studies are represented by a filled box, pooled results by an open diamond and subgroup analysis by a filled 
diamond. 
 
Author  Year       Population   Index Test       Positive Likelihood Ratio (95% CI)                      Negative Likelihood Ratio (95% CI)
No of studies
2 studies c High risk PI<2sd within 2 weeks of delivery
5 studies a High risk Any index parameter within 2 weeks of delivery
4 studies a High risk , singletons only, any index parameter
2 studies b High risk PSV+2sd within 2 weeks of delivery
4 studies a High risk Pi<2sd
Sub-group analysis
8 studies a High risk Any index parameter
Meta-analysis
Perinatal Mortality
Positive Likelihood Ratio
0.74 (0.36, 1.51)
0.42 (0.19, 0.91)
0.34 (0.09, 1.26)
0.17 (0.04, 0.80)
0.69 (0.40, 1.19)
0.51 (0.29, 0.89)
0.92 (0.53, 1.58)
1.40 (0.36, 5.43)
0.19 (0.01, 2.91)
0.89 (0.19, 4.26)
0.16 (0.02, 1.06)
0.41 (0.03, 5.68)
0.59 (0.25, 1.40)
0.42 (0.18, 0.95)
0.11 (0.01, 1.82)
Negative Likelihood Ratio
1.34 (0.80, 2.26)
1.45 (1.07, 1.96)
1.49 (1.16, 1.90)
1.84 (1.27, 2.68)
1.32 (0.92, 1.88)
1.36 (1.10, 1.67)
Ozereb 1999 High risk PI<2sd
Ozcan 1998 High risk PI<2sd
Ozcan 1998 High risk PSV+2sd
Mimica 1995 High risk RI<5th centile
Mari 2007 High risk PSV+2sd
1.16 (0.50, 2.69)
0.84 (0.38, 1.85)
1.62 (0.98, 2.68)
1.04 (0.64, 1.67)
2.16 (1.23, 3.78)
Gramellini 2001 High risk PI<5th centile 1.26 (0.83, 1.90)
Dubiel 2000 High risk PI<2sd 2.09 (1.02, 4.29)
Mari 2007 High risk PSV+2sd
Mari  2007 High risk PI<2sd
Perinatal Morbidity
5.09 (0.77, 33.60)
1.57 (0.92, 2.68)
0.2 0.5 1 2 5 10 100
Del Rio   2008 High risk Not reported 1.20 (0.90, 1.61) 0.42 (0.06, 2.85)
Hernandez 2008 High risk PI<2sd 1.24 (0.96, 1.60) 0.34 (0.05, 2.35)
0.01 0.1 0.2 0.5 1 2 5 10
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Appendix 37: Summary receiver operating characteristic curves for middle cerebral 
artery Doppler to predict apgar at 5 mins<7, acidosis at cord pH, admission to 
neonatal intensive care unit (NICU) and perinatal mortality produced using the 
bivariate method.  
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Appendix 38: Search strategy for systematic review of ductus venosus Doppler to 
predict small for gestational age fetuses and compromise of fetal/neonatal wellbeing. 
 Host: Ovid 
 Date of search: May 2009 
 Years covered by search: 1950-2009 
 
1. MEDLINE (inception until May 2009) -614 citations 
8. (“Pregnant woman”[MeSH] OR “Pregnancy”[MeSH] OR pregnan*) 
9. (“Prenatal Diagnosis[MeSH] OR “Ultrasonography/Prenatal”[MeSH} OR 
“Ultrasonography/Doppler”[MeSH]) 
10. {(venous Doppler.mp) OR (Doppler velocimetry.mp) OR (Doppler 
ultrasound.mp) OR (DV.mp) OR (Ductus venosus[MeSH])} 
11. (1 AND 2) 
12. (4 AND 3) 
13. Limit 5 to animals 
14. (5 NOT 6) 
 
2. Medline search adapted for EMBASE (inception until May 2009) - 456 
citations 
 
3. Cochrane library (2009:2) – 82 reviews, 173 clinical trials, 15 technology 
assessments, 75 economic evaluations 
12. Pregnant women 
13. Prenatal diagnosis 
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14. Ultrasonography prenatal 
15. Ultrasonography Doppler 
16. Venous Doppler 
17. Doppler velocimetry 
18. Doppler ultrasound 
19. DV 
20. Ductus venosus 
21. (2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9) 
22. (1 AND 10) 
 
4. MEDION – 0 citations 
 
5. Grey literature – 0 citations 
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Appendix 39: Data extraction form for systematic review of ductus venosus Doppler 
to predict small for gestational age fetuses and compromise of fetal/neonatal 
wellbeing. 
Section A: Study Information 
 
1)Ref ID:  4)Publication year:  
2)Rev 
name: 
 5)First Author:  
3)Country:  6)Language:  
 
Section B: Data Retrieval for Ductus venosus Doppler Study 
 
Population 
7) Healthcare Centre: 
Primary care □1  Secondary care  □2  Mixed □3    Other   □4        Unreported  □5 
 
8) Setting: 
 In-patient  □1  Out-patient  □2  Mixed  □3  Unreported  □4       Other  □5 
________________ 
 
9) Number of participating centres: ____________________________________ 
 
10) Gestation at time of index test: 
<20 weeks   □1  20-24 weeks  □2   24-28 weeks □3    28-34 weeks □4   34-37 
weeks □5    37-40 weeks  □6   > 40 weeks  □7      Unreported  □8           Other 
_______________________ 
 
10.i) Mean (range)______________________________________         Unreported  
□3 
 
10.ii) Median (range) ____________________________________        Unreported  
□3 
 
11) Pregnancy: 
Low Risk      □1  High Risk    □2  Unselected  □3  Unreported  □4 
 
11.i) State high risk conditions:     Unreported  □3 
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12) Were patients with the following conditions excluded/not included? 
12.i) Previous IUGR:    Yes □1  No  □2
 Unreported   □3 
12.ii) Insulin dependant diabetes mellitus:        Yes □1  No  □2
 Unreported   □3 
12.iii)   Chronic renal disease:     Yes □1  No  □2        Unreported   □3 
12.iv)   Systemic lupus erythematosus: Yes □1  No  □2        Unreported   
□3 
12.v)    Antiphospholipid syndrome: Yes □1  No  □2        Unreported   □3  
12.vi)   Chronic hypertension:   Yes □1  No  □2        Unreported   □3  
12.vii)   Pre-eclampsia:      Yes □1  No  □2        Unreported   □3 
12.viii)  Foetal chromosomal/structural anomalies:  Yes □1  No  □2        
Unreported   □3 
 
13) Did all patients have singleton pregnancies?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
14) Were all patients primigravid?: 
Yes □1  No  □2       Unreported                                       Unreported   □3 
15) List other eligibility/ in-/exclusion criteria: 
 
 
 
 
16) Study population: (describe age (mean +/- SD or median/range), ethnicity, smoking, BMI 
etc.) 
 
 
   ----------/-------------            
   ----------/-------------            
 
 
         Not applicable  □3 
 
 
 
 
 
Unreported  □3 
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17) Start of patient inclusion (year) :                        U    
Unreported □3  
18) End of patient inclusion (year) :              
Unreported □3 
19) Study Design:    
cohort  □1    case control  □2      RCT/CCT  □3        cross sectional  □4     before and 
after  □5         case series   □6  (no ______)      other  □7 
19.i) Data collection:  prospective □1      retrospective   □2      unreported  □3        
other  □4 
19.ii) Enrolment:    consecutive  □1       arbitary (random) □2      unreported  □3        
other  □4 
20) Numbers: 
 
 
 
 
B Reasons ________________ 
 
D Reasons ________________ 
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21) Completeness of Verification: 
(= E / C x 100 = %) 
> 90%  □1     81-90%  □2     < 81%  □3 
 
Index Test 
 
22) Description of technique:      
Adequate  □1   Inadequate  □2 
 
23) Timing of measurement (from delivery): 
< 7days □1  7-14 days  □2  14 -28 days □3  > 28 days  □4    Mixture  □5   
Unreported  □6 
 
23.i) Median gestational age at delivery   _____________________________ 
unreported  □3         
24) Measurement: 
SCANNING: 
24.i) Operator: 
Single  □1   Multiple  □2       Unreported    □3 
24.ii) Operator experience__________________________________________ 
unreported  □3         
24.iii) Scanning Route: Transabdominal □1  Transvaginal  □2   Unreported  □3 
DOPPLER: 
24.iv) Method:   Continuous wave Doppler  □1  Pulsed wave Doppler  □2 Colour 
mapping  □3       Unreported   □4 
24.v) Measurement parameter:     Resistance index (RI)  □1   Systolic / diastolic 
ratio  □2 Diastolic / systolic ratio    □3   Unilateral Diastolic notch  □4   Bilateral 
diastolic notch  □5    Pulsatility index (PI) □6  Reduced EDF  □7   
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Absent EDF  □8   Reversed EDF  □9   Peak velocity  □10   Time-averaged maximal 
velocity  □11   Minimum velocity  □12   Unreported  □13    
24.vi) Cut-off level for waveform ratio:   > 2 SD  □1   > 95th centile  □2  > 90th 
centile  □3    
> 80th centile □4     > 50th centile  □5  < 10th centile □6   < 5th centile  □7   
Unreported/NA  □8 
Other/Threshold data set: 
______________________________________________________ 
24.vii) Machine: _______________________________________________     
unreported  □3         
24.viii) Probe: _______________________________________________ 
unreported  □3         
24.ix) High pass filter: _______________________________________  
unreported  □3         
24.x) Pulse rePEition frequency: ______________________________   
unreported  □3         
24.xi) Size of sampling gate: __________________________________ 
unreported  □3         
24.xii) Site : _______________________________________________    
unreported  □3         
24.xiii) Angel of insonation: _______________________________unreported  □3         
24.xiv) Number of consecutive waveforms: __________________unreported  □3         
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24.xv) Other information: 
___________________________________________________________________ 
Reference Standard / Outcome 
25) Measured blind form diagnostic test:   Yes  □1    No  □2   Unclear  □3 
26) Measurement for FGR:   Birthweight  □1  Neonatal ponderal index  □2  
Skin fold thickness □3    MAC / OFC  □4    Other  □5   
27) Threshold:   < 3rd centile  □1  < 5th centile  □2   < 10th centile  □3  < 25th 
centile □4     
> 2SD  □5   Other □6 ________________________________________________    Unclear   □7 
28) What data set was used to define threshold? 
_____________________________________________________     unreported  □3         
29)Timing of measurement:  At delivery  □1   Within 24 hrs  □2   > 24 hrs  □3  
Mixture  □4   Unreported  □5  
30) Marker of wellbeing e.g. Apgar score, perinatal mortality 
31) Threshold and data set (if applicable): 
32) Measured blind form diagnostic test:   Yes  □1    No  □2   Unclear  □3 
 
 
 
 
                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Results 
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Appendix 40: References of included papers for systematic review of ductus venosus 
Doppler to predict small for gestational age fetuses and compromise of 
fetal/neonatal wellbeing. 
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Appendix 41:  Study characteristics of included studies for ductus venosus Doppler to predict compromise of fetal/neonatal 
wellbeing. 
 
First 
Author 
(year) 
Population 
Age 
(country/study design) 
No of 
women 
analyse
d 
Gestationa
l age at test 
(weeks) 
Reference  
Standard 
 SGA 
Incidence 
of SGA 
(%) 
Reference 
standard Fetal 
compromise 
 Details of Index 
test 
 
 
Alves 
(2008) 
 
High risk populations 
INC: 103 newborns with AREDF of  the 
umbilical artery, singleton, no fetal anomalies, no 
premature rupture of membranes, fetal wellbeing 
tests performed on day of delivery 
EXC: Fetal chromosomal and structural 
anomalies 
Mean maternal age 30.08+/-6.7 (16-45) 
(Brazil) (Cohort, prospective) 
 
103 
 
On day of 
delivery 
 
BW<10
th
 
centile 
(sex, ga) 
 
74.8% 
 
Hyaline 
membrane 
disease, 
pneumothorax, 
pulmonary 
haemorrhage, 
BPD, arterial 
canal persistence, 
septicaemia, 
NEC, ROP, 
thrombocytopeni
a, 
hypoglycaemia, 
hyperglycaemia, 
intracranial 
 
Route not 
reported, 
pulsed and 
colour, origin 
from umbilical 
vein, a wave 
absent or 
reversed. 
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haemorrhage, 
death 
 
Baschat 
(2003) 
High risk populations. 
INC: Singleton, delivery prior to 37 weeks, birth 
weight<10th centile, umbilical artery PI 
mean>2sd 
EXC: Fetal chromosomal and structural 
anomalies 
Mean maternal age 28 +/-5.5. 
 (Germany and USA) (cohort) 
224 Within 48 
hours of 
delivery 
NA NA Acidaemia 
pH<5th 
percentile for 
gestational age; 
birth asphyxia 
pH<7.0 and/or 
BE>-13, 
stillbirths, 
neonatal deaths, 
perinatal deaths. 
Route not 
reported, 
pulsed, at inlet, 
a wave absent 
or reversed. 
 
Baschat 
(2004) 
 
High risk populations. 
INC: Singleton, EFW<10th centile, umbilical 
artery PI>2sd, normal anatomy and karyotype, 
absence of active labour prior to caesarean 
section. 
EXC: No structural or chromosomal anomalies 
Mean maternal age 28+/-5.5. 
(Germany, USA, Turkey) (cohort, prospective) 
 
122 
 
Within 48 
hours of 
delivery 
 
NA 
 
NA 
 
Umbilical artery 
pH<7.20; 
umbilical artery 
pH<7.00 and/or 
BE<-13mmol/l 
 
 
Route and 
method not 
reported, inlet, 
PI, S/A or 
RAV 
mean>2SD. 
 
Baschat 
 
High risk populations. 
 
328 
 
23-41 
 
NA 
 
NA 
 
Umbilical artery 
 
Route not 
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(2006) INC: Singleton, normal anatomy, AC<5th, 
elevated umbilical PI, delivery at a viable 
gestational age. EXC: Fetal infection, 
chorioamnionitis, fetal anomalies, abnormal fetal 
karyotype 
Mean maternal age 29 (14-45). 
 (Germany) (cohort, prospective) 
weeks, test 
within 3 
days of 
delivery 
pH<7.20, Apgar 
at 5 minutes <7, 
stillbirth, 
neonatal death, 
perinatal 
mortality 
reported, 
pulsed and 
color, site not 
reported, PI 
cut-off not 
reported, 
absence or 
reversal or 
atrial systolic 
velocity. 
 
Bilardo 
(2004) 
 
High risk populations. 
INC: Singleton, IUGR before 33 weeks 
(AC<5th)+/-PIH 
Mean maternal age not reported 
(Germany and Holland) (cohort) 
 
 
70 
 
Test within 
24 hours of 
delivery 
 
NA 
 
NA 
 
Adverse perinatal 
outcome 
(antenatal death, 
NND, major 
neonatal 
complications 
before discharge 
(ICH>grade 2, 
BPD) 
 
Route, method 
and site not 
reported, 
PIV>/=2sd or 
absent or 
reversed 
diastolic flow. 
 
Carvalho 
(2005) 
 
High risk populations. 
INC: Live born, singleton, no chromosomal or 
structural anomalies, at least 26 weeks of age on 
 
47 
 
>26 weeks 
(test for 
analysis 
 
NA 
 
NA 
 
Acidaemia: 
Umbilical artery 
pH<7.2 in the 
 
TA, colour and 
pulsed wave, 
narrowest 
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entry, all had Doppler studies within 24 hours of 
delivery and cord blood gasometry immediately 
after birth. EXC: Placental abruption before or at 
delivery, GA for caesarean section, 
Mean maternal age 28.9 years (16-44) 
(Brazil) (Cross-sectional, prospective, 
consecutive) 
 
performed 
within 24 
hrs of 
delivery)  
absence of 
uterine 
contractions and 
<7.15 with 
contractions. Had 
to be mixed or 
metabolic 
acidosis (BE<-10 
and 
pCO2>60mmHg 
in the absence of 
labour and BE<-
11 and pCO2>65 
in labour) 
 
isthmic 
portion, S/A or 
S-A/S or PIV, 
thresholds 
determined by 
ROC analysis. 
   Cosmi 
(2005) 
High risk populations. 
INC: Gestational age established before 20 
weeks, normal fetal anatomy, absence of maternal 
pathology, delivery before 32 weeks, forward 
umbilical diastole, normal AFI>/=5cm, absence 
of pulsation in umbilical vein, forward DV flow, 
last Doppler within 24 hours of delivery.  
Mean maternal age abnormal Doppler 32 (27-39), 
normal Doppler 31(24-37) 
145 24-30.4 
weeks (test 
for analysis 
performed 
within 24 
hours of 
delivery) 
NA NA Neonatal death Route not 
reported, 
colour and 
pulsed, origin 
from umbilical 
vein, absent or 
reversed flow 
at late diastole. 
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(Italy and USA) (Cohort, prospective) 
 
Del Rio 
(2008) 
 
High risk populations 
INC: gestational age confirmed by sonography in 
first trimester, absence of structural 
malformations or chromosomal abnormalities, 
estimated birth weight <10th centile, 
cerebroplacental ratio<5th centile, last Doppler 
examination performed within 48 hrs before 
delivery, delivery between 24 and 36 weeks 
gestation, singleton pregnancy. 
Median age normal Doppler 32 (22-40); abnormal 
Doppler 28 (22-37) 
(Spain) (Cohort, prospective) 
 
51 
 
Within 
48hrs of 
delivery 
 
NA 
 
NA 
 
Adverse perinatal 
outcome:  any of 
stillbirth, 
neonatal 
mortality, BPD, 
RDS, Grade 
III/IV IVH, NEC, 
sepsis and NICU 
stay longer than 
14 days 
 
 
TA, colour and 
pulsed, site not 
reported, 
absent or 
reversed a 
wave 
 
Figueras 
(2003) 
 
High risk populations. 
INC: Singleton, no congenital abnormalities 
EXC: BW>10th centile. 
Mean age not reported 
(Spain) (Cohort, consecutive) 
 
68 
 
>26 weeks 
(test for 
analysis 
performed 
within 3 
days of 
delivery) 
 
NA 
 
NA 
 
Admission to 
NICU, umbilical 
artery pH<7.10, 
neonatal 
morbidity (IVH, 
HIE, retinopathy, 
seizures, NEC, 
sepsis), 
intubation.  
 
Route, method 
and site not 
reported, 
PI>95
th
 centile. 
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Figueras 
(2004) 
 
High risk populations. 
INC: Singleton, no congenital abnormalities 
EXC: BW>10th centile. 
Median maternal age 30.34 (SD 3.25) years 
(Spain) (Cohort, consecutive) 
 
 
 
108 
 
>26 weeks 
(test for 
analysis 
performed 
within 3 
days of 
delivery) 
 
NA 
 
NA 
 
Adverse perinatal 
outcome 
[admission to 
NICU, umbilical 
artery pH<7.10, 
neonatal 
morbidity (IVH, 
HIE, retinopathy, 
seizures, NEC, 
sepsis), 
intubation]. 
 
Route, method 
and isthmic  
portion, 
PI>95
th
 centile. 
 
Gramellini 
(2001) 
 
High risk populations. 
INC: Pregnancy dated by USS prior to 20 weeks, 
singleton fetus normal anatomy and karyotype, 
Doppler within 2 weeks of birth. EXC: 
chromosomal or structural anomalies 
Maternal age not reported 
(Italy) (Cohort, retrospective) 
 
 
53 
 
24-35 
weeks (test 
for analysis 
performed 
within 2 
weeks of 
delivery) 
 
NA 
 
NA 
 
Neonatal 
resuscitation 
required, 
perinatal 
mortality. 
 
Route not 
reported, 
colour, site not 
reported, 
S/A>5
th
 centile. 
 
   
Hofstaetter 
(1996) 
 
High risk populations. 
INC: Women with high risk pregnancy referred 
to ultrasound unit for Doppler.  
 
87 
 
Abnormal 
Doppler 
mean 
 
BW mean 
<2SD 
 
49.4% 
 
Apgars, 
umbilical artery 
pH, admission to 
 
Route not 
reported, 
colour and 
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Maternal age not reported 
(Sweden and Germany)(Cohort) 
 
 
gestation 
35 (27-39); 
normal 36 
(27-40); 
test for 
analysis 
median 
interval to 
delivery 1 
day (0-12) 
 
NICU. pulsed, distal 
smallest 
portion, 
S/A>95
th
 
centile.  
Hung 
(2006) 
High risk populations. 
INC: Suspected IUGR and one or more of EH, 
secondary hypertension, CRD, SLE, PE, 
eclampsia, DM. 
Median maternal age 31 (23-36) 
(Taiwan) (Case-control, retrospective) 
97 20-40 
weeks (test 
for analysis 
performed 
within 1 
week of 
delivery) 
NA NA Umbilical artery 
pH<7.12 
Route not 
reported, 
colour and 
pulsed, isthmic 
portion, 
PIV>95
th
 
centile. 
 
   Maiz 
   (2008) 
 
Low risk populations 
INC: singleton, screening clinic for trisomy 21 
Median maternal age 32 (16-49) 
(UK) (Cohort, prospective) 
 
 
10490 
 
11-13+6 
weeks 
 
NA 
 
NA 
 
Adverse perinatal 
outcome : 
miscarriage 
before 24 weeks, 
fetal death after 
 
TA, colour and 
pulsed, above 
umbilical 
sinus, reversed 
a wave 
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24 weeks, 
abnormal fetal 
karyotype, fetal 
defects 
 
Maiz 
(2009) 
 
 
 
 
Manogura 
(2008) 
High risk population 
INC: diamniotic twin pregnancies 11-13 weeks, 
accurate gestation and determination of 
chorionicity. 
Median maternal age 33 (29-36) 
(UK) (Cohort, prospective) 
 
High risk populations 
INC: accurate assessment of gestational age 
before 20 weeks, singleton, normal fetal anatomy, 
fetal AC<5th centile, elevated umbilical artery 
Doppler, delivery of a live birth at 24-36+6 
weeks, last Doppler within 1 week of delivery 
EXC: Fetal chromosomal and structural 
anomalies 
Maternal age not reported 
(USA, Germany, UK) (Cohort, prospective) 
516 
dichorio
nic 
179 
monoch
orionic 
 
404 
11-13+6 
weeks 
 
 
 
 
Doppler 
within 1 
week of 
delivery 
NA 
 
 
 
 
 
NA 
NA 
 
 
 
 
 
NA 
Death of one 
twin 
 
 
 
 
 
NEC 
TA, colour and 
pulsed, above 
umbilical 
sinus, reversed 
a wave 
 
 
Route, method 
and site not 
reported. 
Abnormal 
ductus venosus 
or absent or 
reversed a 
wave 
 
Muller 
 
High risk populations. 
 
33 
 
Mean 
 
NA 
 
NA 
 
Intubation, NEC, 
 
Route not 
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(2002) INC: Singletons, AREDF umbilical artery.  EXC: 
structural and chromosomal abnormalities 
Mean maternal age not reported.  
(Germany)(Cohort, prospective) 
gestational 
age 28.5+/-
3.4 weeks. 
Within 24 
hours of 
delivery 
IVH. reported, 
colour  and 
pulsed, 
smallest distal 
portion, absent 
or reversed 
flow. 
 
Ozcan 
(1998) 
 
High risk populations 
INC: Gestational age established before 20 
weeks, normal fetal anatomy, EFW<5th centile on 
USS between 26-32 weeks, Doppler waveform 
estimations within 2 weeks of delivery. 
Mean maternal age not reported. 
(USA)(Cohort) 
 
18 
 
Median 
gestation 
28.2 (27-
31.4) 
weeks. 
Median 
interval 2 
days (0-
14). 
 
NA 
 
NA 
 
Fetal demise or 
NND in first 30 
days, 5 min 
Apgar<7mins, 
stay in 
NICU>60days, 
IVH, PVL. 
 
Route not 
reported, color  
and pulsed, 
origin of 
umbilical vein, 
absent or 
reversed a 
wave. 
    
   Schwarze 
(2005) 
 
High risk populations. 
INC: Fetuses with suspected IUGR on USS and 
AREDF in umbilical artery EXC: multiple 
pregnancies. 
Maternal age not reported 
(Germany) (Cohort, retrospective) 
 
74 
 
Within 48 
hours of 
delivery; 
mean 
gestational 
age at 
 
BW<3
rd
 
centile 
local 
values. 
 
51.5% 
 
Stillbirths, NND, 
perinatal death, 
acidaemia, 
asphyxia 
 
TA, colour, 
inlet, absent or 
reversed a 
wave. 
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delivery 
28+6 
(24+1-
33+5) 
 
Turan 
(2007) 
 
High risk populations. 
INC: Singleton, no chromosomal or structural 
anomalies, elevated umbilical artery PI, delivery 
at viable gestational age (all delivered by pre-
labour CS) EXC: Fetal infection, 
chorioamnionitis. 
Median maternal age 30 (16-41) 
(UK)(Cohort, prospective) 
 
56 
 
Median 
gestation 
age at 
delivery 
30+6 weeks 
(test for 
analysis 
performed 
on day of 
delivery) 
 
NA 
 
NA 
 
 
Umbilical artery 
pH<7.20. 
 
 
Route not 
reported, 
pulsed and 
colour, site not 
reported, 
PI>2sd or 
absent or 
reversed a 
wave. 
       
Hrs hour; INC inclusion; EXC exclusion; PE preeclampsia; PIH pregnancy induced hypertension; IUGR intrauterine growth restriction; BW birth weight; UK United 
Kingdom; USA United States of America; NA not applicable; SGA small for gestational age; USS ultrasound scan; ga gestational age; sd standard deviation, % 
percent; NICU neonatal intensive care unit; TA transabdominal; PI pulsatility index; RI resistance index; PIV pulsatility index for vein s; S/A ventricular/atrial systolic 
ratio; S-A/S ventricular – atrial systole/ventricular systole; AREDF absent reversed end diastolic flow; DV ductus vensosus;  AC abdominal circumference; EFW 
estimated fetal weight; CS caesarean section; BE base excess; IVH intraventricular haemorrhage; NEC necrotising enterocolitis; HIE hypoxic ischaemic 
encephalopathy; PVL peri-ventricular leukomalacia; NND neonatal death; GA general anaesthetic; mmHg millimetres of mercury; ROC receiver operating 
characteristic curve; EH essential hypertension ; CRD chronic renal disease; SLE systemic lupus erythematus, AFI amniotic fluid index, BPD bronochopulmonary 
dysplasia, RDS respiratory distress syndrome, ROP retinopathy of prematurity. 
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Appendix 42: Search strategy for electronic database identification of systematic 
reviews of effectiveness for interventions for fetal growth restriction and 
compromise of fetal wellbeing.  
Host: Ovid 
Date of search: July 2009 
Years covered by search: 1950-2009 
Medline: 3228  
Embase: 4172 
British Nursing Index: 4 
Cohrane library: 989 
Web of Science: 959 
1. exp Infant, Small for Gestational Age/ 
2. exp Fetal Growth Retardation/ 
3. exp Infant, Low Birth Weight/ 
4. exp Placental Insufficiency/ 
5. exp Asphyxia Neonatorum/ 
6. exp Fetal Hypoxia/ 
7. exp Fetal Distress/ 
8. small for gestational age.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word] 
9. sga.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word] 
10. small for date$.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
11. small for gestation$.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
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12. fetal growth restriction.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word] 
13. fetal growth retardation.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word] 
14. fgr.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word] 
15. intrauterine growth retardation.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
16. intrauterine growth restriction.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
17. iugr.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word] 
18. low birth weight.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
19. low birthweight.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
20. lbw.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word] 
21. fetal wellbeing.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
22. fetal compromise.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
23. fetal distress.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word] 
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24. fetal hypoxia.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word] 
25. neonatal wellbeing.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
26. neonatal asphyxia.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
27. neonatal distress.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
28. birth asphyxia.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
29. 6 or 4 or 1 or 3 or 7 or 2 or 5 
30. 11 or 21 or 26 or 17 or 22 or 18 or 23 or 16 or 13 or 27 or 25 or 28 or 9 or 12 or 14 
or 15 or 20 or 8 or 24 or 10 or 19 
31. 30 or 29 
32. limit 31 to animals 
33. 31 not 32 
Then combined with Haynes et al filters
165-167
 for (prognosis or therapy) sensitive and 
reviews (sensitive) 
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Appendix 43: Quality assessment checklist for methodological quality of included 
systematic reviews of effectiveness. 
Assessed by : __________________       Date Assessed:________ Paper No :_______ 
 Quality 
Item 
Code  
   1         2          3             4 
Did the review ask a clearly structured and 
focused question?  
(utilises PICOS) 
1 Yes □  No  □  Unclear □ NA □ 
Were selection criteria clearly described? 
(inclusion/exclusion related to 
question/PICOS) 
2 Yes □  No  □  Unclear □ NA □ 
Were all relevant studies identified?  
(consider whether search was adequate in 
the sources and search strategy) 
3 Yes □  No  □  Unclear □ NA □ 
Were the included studies synthesised? 
(consider whether results of each study are 
clearly displayed, whether the pooling of 
results was appropriate/heterogeneity) 
4 Yes □  No  □  Unclear □ NA □ 
Was the validity of the included studies 
assessed? 
(was there quality assessment – was this 
planned? which tools? How many 
assessors?) 
5 Yes □  No  □  Unclear □ NA □ 
Were there sufficient details about the 
individual included studies presented? 
(how are the results summarised and 
presented? How meaningful/precise are the 
results?) 
6 Yes □  No  □  Unclear □ NA □ 
 
PICOS – population, intervention, comparator, outcome, study design 
Adapted from Oxman AD, Cook DJ, Guyatt GH. User's guide to the medical literature 
VI. How to use an overview. JAMA 1994; 272(17):1367-1371. 
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Appendix 44: References of included papers for systematic reviews of reviews of 
effectiveness for interventions for fetal growth restriction and compromise of fetal 
wellbeing.  
 
 Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy 
for mild to moderate hypertension during pregnancy. Cochrane Database of 
Systematic Reviews (1), 2007 Article Number: CD002252 Date of Publication: 
2007 2007;(1). 
 
 Anotayanonth S, Subhedar N, V, Neilson JP, Harigopal S. Betamimetics for 
inhibiting preterm labour. Cochrane Database of Systematic Reviews: Reviews 2004 
Issue 4 John Wiley & Sons , Ltd Chichester, CD004352 2004. 
 
 Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, PARIS Collaborative 
Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of 
individual patient data. Lancet 2007; 369(9575):1791-1798. 
 
 Brown HC, Smith HJ. Giving women their own case notes to carry during 
pregnancy. Cochrane Database of Systematic Reviews: Reviews 2004 Issue 2 John 
Wiley & Sons, Ltd Chichester, CD002856 pub2 2004. 
 
Charles DH, Ness AR, Campbell D, Smith GD, Whitley E, Hall MH. Folic acid 
supplements in pregnancy and birth outcome: re-analysis of a large randomised 
controlled trial and update of Cochrane review. Paediatric and Perinatal 
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Epidemiology 2005; 19(2):112-124. 
 
Churchill D, Duley L. Interventionist versus expectant care for severe pre-eclampsia 
before term. Cochrane Database of Systematic Reviews 2002;(3):CD003106. 
 
 Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm 
birth after threatened preterm labour. Cochrane Database of Systematic Reviews: 
Reviews 1998 Issue 1 John Wiley & Sons , Ltd Chichester, CD 1998. 
 
 Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm 
birth in threatened preterm labour. Cochrane Database of Systematic Reviews: 
Reviews 2002 Issue 4 John Wiley & Sons , Ltd Chichester, CD0 2002. 
 
 Dodd JM, Crowther CA, Dare MR, Middleton P. Oral betamimetics for 
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 Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of 
progesterone for preventing preterm birth in women considered to be at risk of 
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 Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for 
women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database 
of Systematic Reviews: Reviews 2009 Issue 1 John Wiley & Sons 2009. 
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 Drakeley AJ, Roberts D, Alfirevic Z. Cervical stitch (cerclage) for preventing 
pregnancy loss in women. Cochrane Database of Systematic Reviews 2003; (1): 
CD003253.  
 
 Duckitt K, Thornton S. Nitric oxide donors for the treatment of preterm labour. 
Cochrane Database of Systematic Reviews: Reviews 2002 Issue 3 John Wiley & 
Sons , Ltd Chichester, CD002860 2002. 
 
 Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for 
preventing pre-eclampsia and its complicationsCochrane Database of Systematic 
Reviews 2004;(1):CD004659. 
 
 Duley L, Henderson-Smart DJ, Meher S. Altered dietary salt for preventing pre-
eclampsia, and its complications. Cochrane Database of Systematic Reviews: 
Reviews 2005 Issue 4 John Wiley & Sons , Ltd Chichester. 
 
 Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other 
anticonvulsants for women with pre-eclampsia. Cochrane Database of Systematic 
Reviews: Reviews 2003 Issue 2 John Wiley & Sons , Ltd Chichester. 
 
 Duley L, Williams J, Henderson-Smart DJ. Plasma volume expansion for treatment 
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John Wiley & Sons, Ltd Chichester, CD001805. 
 
 Duley L, Henderson-Smart DJ. Reduced salt intake compared to normal dietary salt, 
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 Flenady V, King JF. Antibiotics for prelabour rupture of membranes at or near term. 
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Appendix 45: Study characteristics of included studies in review of systematic reviews of effectiveness of interventions for prevention of 
fetal growth restriction and compromise of wellbeing.  
   
Author and year Population Intervention Comparator Outcomes No of 
inc 
RCTs 
   
Abalos 2007 Pregnant women with mild 
to moderate hypertension 
Antihypertensives Placebo or none Death, SGA, PTL, Apgars, NICU 
admission, RDS, impaired long 
term growth and development in 
infancy and childhood and 
maternal outcomes 
4
6 
   
Anotayanonth 2004 Pregnant women in 
spontaneous preterm labour 
Betamimetics Placebo or none Maternal and perinatal 1
7 
   
Askie 2007 Women at risk of PE, GH, 
IUGR based on previous 
pregnancy history, pre-
existing medical condition 
or obstetric risk factors in 
current pregnancy 
One or more 
antiplatelet agents 
Placebo or none PE, IUD, death before discharge, 
PTL, SGA, maternal death, APH, 
abruption, maternal morbidity, 
PPH, NICU, ventilation, neonatal 
bleeding 
6
3 
   
Brown 2004 Pregnant women  Carrying own case 
notes 
Usual care Maternal and perinatal 3    
Charles 2005 Pregnant women Folic acid  Placebo Birth weight, PTL, APH, PE, 
stillbirths and neonatal deaths 
6    
Churchill 2002 Women with early onset Early elective delivery Expectant management Maternal and perinatal 2    
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pre-eclmapsia 
Crowther 1998 Pregnant women with at 
least one episode of 
threatened preterm labour 
that settled without delivery 
Magnesium 
maintenance therapy 
any route 
Placebo or no treatment  Preterm birth, perinatal mortality, 
neurological disability 
3    
Crowther 2002 Women in threatened PTL Magnesium sulphate 
IV or oral 
Placebo or no treatment  Preterm birth, IVH or PVL,  death, 
apgars 
2
3 
   
Dodd 2006 Pregnant women at risk of 
preterm birth 
Progesterone any route Placebo Perinatal mortality, preterm birth, 
neurodevelopmental, birth weight, 
apgar 
1
1 
   
Dodd 2006 Women with at least one 
episode of threatened 
preterm labour 
Oral betamimetics Placebo or none Maternal and fetal 1
1 
   
Doyle 2009 Women at risk of preterm 
birth 
Magnesium sulphate 
IV, IM or oral 
Placebo or none Perinatal mortality, neurological, 
IVH, apgar 
5    
Drakeley 2003 Women with confirmed or 
suspected cervical 
incomPEence or women 
who present as an 
emergency with potential 
cervical incomPEence 
Cervical cerclage No intervention Maternal and perinatal 6    
Duckitt 2002 Pregnant women assessed as 
being in preterm labour and 
suitable for tocolysis 
Nitric oxide donors Placebo or none Maternal and perinatal 5    
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Duley 2004 Women at risk of PE Antiplatelets Placebo or none Death, PE, bleeding, maternal 
morbidity, perinatal mortality and 
morbidity 
5
9 
   
Duley 2005 Women who had normal or 
high blood pressure without 
proteinuria in pregnancy 
Altered dietary salt 
intake 
Normal salt intake  PE, death, morbidity, APH, 
abruption, side effects, PTL, SGA, 
Apgars. 
2    
Duley 2003 Women with PE Anticonvulsants Placebo or none Maternal and neonatal mortality 
and morbidity 
6    
Duley 1999 Women with hypertension 
in pregnancy, with or 
without proteinuria 
Plasma volume 
expansion 
No expansion  Maternal and neonatal mortality 
and morbidity 
3    
Duley 1999 Pregnant women Dietary advice to alter 
salt intake 
No alteration Maternal and neonatal mortality 
and morbidity 
2    
Flenady 2002 Women with PROM > 36 
weeks 
Antibiotics Placebo or none Fetal and maternal mortality and 
morbidity 
2    
Garner 2003 Pregnant women living in 
endemic malaria areas 
Antimalarial drugs None Fetal and maternal mortality and 
morbidity 
1
7 
   
Grant 2001 Women at high risk of 
delivering a small or 
immature baby 
Elective caesarean 
section 
Expectant management Fetal and maternal mortality and 
morbidity 
6    
Gulmezoglu 2006 Pregnant women at or 
beyond term  
Induction of labour Expectant management Maternal and perinatal mortality 
and morbidity 
1
9 
   
Haider 2006 Pregnant women Multiple 
micronutrients (three 
Placebo or none  PTL, SGA, LBW, PROM, PE, 
miscarriage, perinatal mortality 
9    
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or more) and morbidity. 
Hatem 2008 Pregnant women low and 
mixed risk 
Midwifery led models 
of care 
Other models Fetal and maternal mortality and 
morbidity 
1
1 
   
Hodnett 2003 Pregnant women at risk of 
preterm labour or IUGR 
Standardised or 
individualised 
programs of additional 
social support 
Routine care FGR, neonatal morbidity and 
mortality 
1
8 
   
Hofmeyr 1996 Healthy pregnant women Abdominal 
decompression 
antenatally or during 
labour 
None or dummy 
decompression 
PE, FGR, perinatal morbidity and 
mortality 
3    
Hofmeyr 1996 Women with PE, fetal 
compromise 
Antenatal abdominal 
decompression 
None or dummy 
decompression 
Perinatal morbidity and mortality 3    
Hofmeyr 2000 Pregnant women Calcium Placebo Perinatal morbidity and mortality 
plus long term outcomes 
1
2 
   
Hofmeyr 2006 Pregnant women with fetal 
distress 
Operative 
management 
Conservative management Maternal and perinatal 1    
Honest 2009 Asymptomatic low risk 
women with singleton 
gestation and low-risk 
women symptomatic for 
threatened preterm labour 
with singleton pregnancy 
Home uterine activity 
monitoring 
None Maternal and perinatal 3    
  Periodontal treatment None Maternal and perinatal 1    
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Kenyon 2003 Women with preterm (<37 
weeks) rupture of 
membranes 
Any antibiotic  placebo Maternal and fetal outcomes 2
2 
   
King 2002 Women assessed as being in 
PTL 
Cyclo-oxygenase 
inhibitors 
Placebo or none PTL, gestational age at delivery, 
birth weight 
1
3 
   
King 2005 Women in preterm labour 
with intact membranes 
Antibiotics Placebo or none Maternal, perinatal or paediatric 
benefit 
1
1 
   
Kramer 2003 Pregnant women Advice to increase 
dietary energy and 
protein intakes, energy 
and or protein 
supplementation or 
low energy diet 
Usual diet Pregnancy outcome 2
3 
   
Lumley 2004 Pregnant smokers Smoking cessation No intervention PTL, LBW, perinatal morbidity 
and mortality 
7
2 
   
Magee 2003 Women with mild to 
moderate hypertension 
Oral beta-blockers Placebo or none Maternal, perinatal mortality or 
morbidity 
2
9 
   
Mahomed 2007 Pregnant women Zinc No treatment Maternal, perinatal mortality or 
morbidity 
1
7 
   
Mahomed 1999 Pregnant women at risk of 
vitamin D deficiency 
Vitamin D No treatment LBW, perinatal mortality 2    
Makrides 2001 Normal or high risk 
pregnancies 
Oral magnesium prior 
to 25th week 
No treatment Neonatal mortality, maternal 
morbidity 
7    
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Makrides 2006 Pregnant women Marine oil or other 
prostaglandin 
precursors 
Placebo or none PE, PTL, LBW 6    
McDonald 2007 Pregnant women with 
bacterial vaginosis 
Antibiotic treatment Placebo or none  PTL, LBW 1
5 
   
Meher 2006 Women at risk of PE Exercise or increased 
physical activity 
Maintenance or normal 
activity 
Maternal and perinatal 2    
Meher 2006 Pregnant women with 
normal or high blood 
pressure 
Progestogen  None or placebo Maternal and perinatal 2    
Meher 2005 Women with hypertension    Bed rest    Normal activity Maternal and perinatal 4    
Meher 2006 Pregnant women Garlic Placebo or none Maternal, perinatal mortality or 
morbidity 
1    
Meher 2007 Pregnant women Nitric oxide Placebo or none Maternal, perinatal mortality or 
morbidity 
6    
Naik 2004 Pregnant women after 
threatened PTL 
Maintenance with 
calcium channel 
blockers 
No treatment Maternal, perinatal mortality or 
morbidity 
1    
Papatsonis 2005 Women in PTL Oxytocin receptor 
antagonists  
Placebo or no treatment  Perinatal mortality, neonatal 
morbidity 
2    
Papatsonis 2009 Pregnant women with at 
least one episode of 
threatened preterm labour 
that settled without delivery 
Oxytocin antagonists 
administered as 
maintenance therapy 
Placebo or none PTL, perinatal or neonatal outcome 1    
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Pena-Rosas 2006 Pregnant women Iron and iron plus folic 
acid 
Placebo or none LBW 4
9 
   
Rahimi 2009 Women at risk of PE Vitamin C and vitamin 
E 
Placebo Gestational hypertension, PE, PTL, 
SGA and LBW 
7    
Raynes-Greenow 
2004 
Pregnant women with 
ureaplasma in the vagina  
Antibiotics Placebo or none Perinatal mortality, neonatal 
morbidity 
1    
Roberts 2006 Pregnant women expected 
to deliver preterm 
Steroids Placebo or none Maternal and perinatal 2
1 
   
Rumbold 2008 Pregnant women any risk Antioxidants Placebo or none Maternal and perinatal 1
0 
   
Rumbold 2005 Pregnant women Vitamin c Placebo or none Maternal and perinatal 7    
Rumbold 2005 Pregnant women Vitamin e Placebo or none Maternal and perinatal 4    
Say 2003 Suspected impaired fetal 
growth 
Maternal oxygen 
therapy 
Placebo or none Fetal growth, perinatal mortality, 
neonatal morbidity, adverse effects 
3    
Say 1996 Suspected impaired fetal 
growth 
Bed rest in hospital Ambulatory management Fetal and neonatal outcome 1    
Say 2001 Suspected impaired fetal 
growth 
Betamimetic Placebo or none Perinatal mortality, neonatal 
morbidity 
2    
Say 1996 Suspected impaired fetal 
growth 
Calcium channel 
blockers 
Placebo or none Neonatal morbidity and mortality 1    
Say 2003 Suspected impaired fetal 
growth 
Hormones Placebo or none Perinatal death, neonatal 
morbidity, fetal growth, adverse 
effects 
0    
Say 2003 Suspected impaired fetal Nutrient Placebo or none Fetal growth, perinatal mortality, 4    
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growth administration neonatal morbidity, adverse effects 
Say 1996 Suspected impaired fetal 
growth 
Plasma volume 
expansion 
None    Fetal growth, pregnancy duration, 
neonatal condition, maternal 
complications 
0    
Say 1996 Suspected impaired fetal 
growth or placental 
insufficiency 
Transcutaneous 
electrostiumlation 
Dummy or no treatment Fetal growth, perinatal mortality, 
neonatal morbidity, adverse effects 
0    
Shah 2009 Pregnant women Multimicronutrients  Placebo LBW<2500g, SGA, 1
3 
   
Smaill 2007 Pregnant women 
asymptomatic bacteriuria 
Any antibiotics None LBW 1
4 
   
Su 2007 Preterm labour Progestational agents Placebo or none LBW 4    
Thaver 2006 Pregnant women Vitamin B6 None LBW 5    
Thinkamrop 2002 Women in second or third 
trimester before pregnancy 
or delivery 
Prophylactic 
antibiotics  
Placebo or none Maternal and perinatal 6    
Whitworth 2008 Pregnant women at high 
risk of PTL 
Oral betamimetics Placebo Perinatal mortality, neonatal 
morbidity 
1    
RCT randomised controlled trial; PE pre-eclampsia; GH gestational hypertension; IUGR intra-uterine growth restriction; PTL preterm labour; SGA 
small for gestational age; NICU neonatal intensive care unit; RDS respiratory distress syndrome; IUD intra-uterine death; APH ante-partum 
haemorrhage; PPH post-partum haemorrhage; IV intravenous; PVL periventricular leukomalacia; LBW low birth weight; IVH intraventricular 
haemorrhage; IM intramuscular; PROM preterm rupture of membranes; FGR fetal growth restriction 
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Appendix 46: Table of effectiveness data for outcomes relating to fetal growth restriction 
Intervention 
Number of 
included 
trials 
Number of 
participants Population Outcome 
Relative 
risk 
95% 
confidence 
intervals 
Z p 
value 
Abdominal decompression 
       
Abdominal decompression 1 253 Normal pregnancy LBW 0.69 0.27-1.77 0.44 
 
2 304 Suspected FGR and/or PE LBW 0.5 0.40-0.63 
<0.00
001 
Antibiotics     
       
Inhibiting preterm labour with intact 
membranes 
5 6628 
Suspected preterm labour 
with intact membranes 20-
36 weeks 
BW<2500g 1.04 0.95-1.13 0.38 
Preterm rupture of membranes  2 4876 
Preterm rupture of 
membranes 
BW<2500g 1 0.96-1.04 0.96 
Bacterial vaginosis 4 3151 General population LBW 1 0.80-1.24 0.99 
 
1 80 High risk LBW 0.41 0.17-0.95 0.037 
Ureaplasma 1 825 Women with ureaplasma BW<2500g 0.7 0.46-1.07 0.1 
Prophylactic antibiotics to prevent 
infectious morbidity and mortality 
2 555 Unselected LBW 0.83 0.30-2.32 0.87 
 
1 229 Unselected SGA 1.29 0.45-3.77 0.65 
 
1 253 High risk LBW 0.48 0.27-0.84 0.01 
Asymptomatic bacteriuria 7 1502 Asymptomatic bacteriuria BW<2500g 0.66 0.49-0.89 0.0059 
Antihypertensives 
       
Antihypertensive drug therapy for mild to 
moderate hypertension during pregnancy 
19 2437 
Mild to moderate 
hypertension 
SGA 1.04 0.84-1.27 0.74 
 
9 1116 
 
BW<10th 1.1 0.86-1.42 0.45 
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centile 
 
3 287 
 
BW<5th 
centile 
3.04 1.25-7.40 0.014 
Oral beta-blockers for mild to moderate 
hypertension during pregnancy 
7 485 
Mild to moderate 
hypertension 
SGA 1.36 1.02-1.82 0.035 
Antioxidants    
       
Antioxidants (vitamin C and E) 3 3582 At risk of PE LBW 1.13 1.00-1.27 
 
 
5 5621 
 
SGA 1.04 0.94-1.15 
 
Antioxidants for preventing pre-eclampsia 5 5271 At risk of PE 
BW<10th 
centile 
0.83 0.62-1.11 0.21 
 
1 2784 
 
BW<5th 
centile 
1.13 0.98-1.32 0.1 
 
1 1853 
 
BW<3rd 
centile 
0.64 0.38-1.08 0.092 
Antiplatelets 
       
Antiplatelets agents for preventing pre-
eclampsia and its complications 
36 23638 All pregnant women SGA 0.90 0.83-0.98 0.02 
 
23 19399 At moderate risk of PE SGA 0.91 0.83-0.99 0.04 
 
13 4239 At high risk of PE SGA 0.89 0.74-1.08 0.02 
 
16 8945 
 
BW<10th 
centile 
0.92 0.82-1.04 0.2 
 
5 1962 
 
BW<5th 
centile 
0.97 0.78-1.21 0.8 
 
8 13002 
 
BW<3rd 
centile 
0.92 0.81-1.06 0.2 
 
6 7512 
 
BW<2500g 0.93 0.83-1.05 0.2 
Antiplatelet agents for prevention of pre-
eclampsia: a meta-analysis of individual 
patient data 
20 21426 At risk of PE SGA 0.9 0.81-1.01 
 
Bed rest    
       
Bed rest with or without hospitalisation for 
hypertension during pregnancy 
1 218 At risk of PE SGA 0.98 0.51-1.91 0.96 
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Betamimetics 
       
Prophylactic oral betamimetics for 
preventing preterm labour in singleton 
pregnancies 
1 64 At risk of PTL BW<2500g 1.60 0.53-4.89 0.43 
Betamimetics for suspected impaired fetal 
growth 
1 98 
Suspected impaired fetal 
growth 
LBW 1.17 0.75-1.83 0.49 
Calcium 
       
Calcium supplementation during 
pregnancy for preventing hypertensive 
disorders and related problems 
8 14359 Pregnant women BW<2500g 0.84 0.68-1.03 0.097 
 
3 13091 
 
SGA 1.1 0.88-1.37 0.39 
Calcium channel blockers 
       
Maintenance therapy with calcium channel 
blockers for preventing preterm birth after 
threatened preterm labour 
1 74 
Pregnant women after 
threatened PTL 
SGA 1.5 0.27-8.46 0.65 
Delivery 
       
Interventionist versus expectant care for 
severe pre-eclampsia before term 
1 95 
Women with severe PE 
before term 
SGA 0.36 0.14-0.90 0.029 
Energy and protein intake 
       
Nutritional advice during pregnancy 1 404 Pregnant women SGA 0.97 0.45-2.11 0.94 
Balanced protein/energy supplementation 6 3396 Pregnant women SGA 0.68 0.56-0.84 
0.0002
6 
High protein supplementation 1 505 Pregnant women SGA 1.58 1.03-2.41 0.036 
Isocaloric balanced protein 
supplementation 
1 782 Pregnant women SGA 1.35 1.12-1.61 0.0013 
Exercise 
       
Exercise or other physical activity for 
preventing pre-eclampsia and its 
complications 
1 16 At risk of PE SGA 3 0.14-64.26 0.48 
Fish oils 
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Marine oil, and other prostaglandin 
precursor, supplementation for pregnancy 
uncomplicated by pre-eclampsia or 
intrauterine growth restriction 
1 1374 All pregnant women SGA 1.13 0.96-1.34 0.15 
 
1 1111 Low/moderate risk SGA 1.12 0.93-1.35 0.23 
 
1 263 High risk SGA 1.17 0.81-1.69 0.4 
 
5 2302 All pregnant women BW<2500g 1 0.88-1.12 0.94 
 
2 1413 Low/moderate risk BW<2500g 0.99 0.87-1.13 0.91 
 
3 789 High risk BW<2500g 1.03 0.80-1.33 0.8 
Folic acid and iron 
       
Folic acid supplementation 6 NA NA LBW 0.81 0.63-1.04 0.11 
Effects and safety of preventive oral iron 
or iron and folic acid supplementation for 
women during pregnancy 
9 6275 
Pregnant women with iron 
deficiency anaemia 
BW<2500g 0.79 0.61-1.03 0.08 
 
5 2687 
 
VLBW 
<1500g 
0.73 0.31-1.74 0.48 
 
4 2511 
 
BW<10th 
centile 
0.87 0.58-1.30 0.48 
Home uterine monitoring 
       
Home uterine monitoring 1 133 
Asymptomatic women at 
risk of preterm labour 
BW<2500g 1.11 0.56-2.18 
 
 
1 279 
 
BW<2500g 0.47 0.28-0.78 
 
 
1 133 
 
BW<1500g 0.69 0.20-2.33 
 
Magnesium supplementation 
       
Orally administered magnesium prior to 25 
weeks 
4 1954 High and low risk women BW<2500g 0.67 0.46-0.96 0.031 
 
1 568 
 
BW<1500g 0.52 0.13-2.07 0.35 
 
3 1741 
 
BW<10th 
centile 
0.7 0.53-0.93 0.014 
Malaria 
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Drugs for preventing malaria in pregnant 
women 
2 1438 Women of all parity LBW 1.06 0.83-1.34 0.66 
Midwifery-led care 
       
Midwife-led versus other models of care 
for childbearing women 
5 8009 Pregnant women BW<2500g 0.99 0.83-1.17 0.87 
Multiple micronutrient supplementation 
       
Multiple micronutrient supplementation 
for women during pregnancy 
2 2826 Pregnant women SGA 0.92 0.86-0.99 0.036 
 
5 5110 Pregnant women LBW 0.83 0.76-0.91 
0.0000
91 
Prenatal multimicronutrient 
supplementation 
4 6097 Pregnant women BW<2500g 0.81 0.73-0.91 
 
 
3 5140 Pregnant women 
SGA<10th 
centile or 2sd 
0.85 0.71-1.02 
 
Nitric oxide donors 
       
Nitric oxide for preventing pre-eclampsia 
and its complications 
2 108 Pregnant women SGA 0.78 0.36-1.70 0.62 
Nutrient supplementation 
       
Maternal nutrient supplementation for 
suspected impaired fetal growth (calf 
blood extract) 
1 31 
Women with suspected 
impaired fetal growth 
BW<5th 
centile 
0.54 0.20-1.47 0.22 
Periodontal care 
       
Periodontal therapy to prevent preterm 
birth 
1 351 Pregnant women BW<2500g 0.16 0.02-1.33 
 
Plasma volume expansion 
       
Plasma volume expansion for treatment of 
pre-eclampsia 
1 10 
Women with hypertension 
during pregnancy 
BW<2500g 1.57 0.77-3.22 0.22 
Prenatal care 
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Support during pregnancy for women at 
increased risk of low birth weight babies 
13 10235 
Pregnant women at risk of 
preterm or growth 
restricted babies 
BW<2500g 0.98 0.89-1.08 0.69 
 
3 2428 
 
BW<1500g 0.72 0.47-1.09 0.12 
 
2 3523 
 
SGA 1.05 0.88-1.26 0.58 
Progesterone 
       
Prenatal administration of progesterone for 
preventing preterm birth in women 
considered to be at risk of preterm birth 
2 501 
Pregnant women at risk of 
preterm birth 
BW<2500g 0.64 0.49-0.83 
0.0006
8 
Progesterone for preventing pre-eclampsia 
and its complications 
1 168 
Pregnant women with 
normal blood pressure or 
high blood pressure 
without proteinuria 
SGA 0.83 0.19-3.57 0.8 
Salt 
       
Altered dietary salt for preventing pre-
eclampsia and its complications (low 
versus normal salt intake) 
1 242 
Pregnant women with 
normal blood pressure or 
high blood pressure 
without proteinuria 
SGA 1.5 0.73-3.07 0.27 
Reduced salt intake compared to normal 
dietary salt, or high intake, in pregnancy 
(low versus normal salt intake) 
1 361 Normal pregnant women BW<2500g 0.84 0.42-1.67 0.62 
Smoking cessation 
       
Interventions for promoting smoking 
cessation during pregnancy 
16 9916 Pregnant women BW<2500g 0.83 0.73-0.95 0.0079 
 
4 5496 
 
BW<1500g 1.16 0.69-1.96 0.57 
Steroids 
       
Antenatal corticosteroids for accelerating 
fetal lung maturation for women at risk of 
preterm birth 
3 378 
Women expected to 
deliver preterm 
SGA 0.96 0.63-1.44 
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Vitamins 
       
Vitamin C supplementation in pregnancy 2 383 All pregnant women 
BW<10th 
centile 
0.72 0.49-1.04 0.079 
Vitamin D supplementation in pregnancy 1 128 
Pregnant women at risk of 
vitamin D deficiency 
BW<2500g 0.5 0.20-1.26 0.14 
Vitamin E supplementation in pregnancy 2 383 All pregnant women 
BW<10th 
centile 
0.72 0.49-1.04 0.079 
Zinc 
       
Zinc supplementation for improving 
pregnancy outcome and infant outcome 
5 3469 Normal pregnant women SGA 1.04 0.96-1.13 0.3 
  11 4860   LBW 1.03 0.94-1.13 0.51 
 
NA not available 
     BW birth weight; LBW low birth weight; VLBW very low birth weight; SGA small for gestational age; FGR 
fetal growth restriction; PE pre-eclampsia; PTL preterm labour 
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Appendix 47: Table of effectiveness data for outcome of perinatal mortality  
Intervention 
Number of 
included 
trials 
Number of 
participants Population 
Relative 
risk 
95% 
confidence 
intervals Z p value 
Abdominal decompression 
  
 
   Abdominal decompression  2 709 Normal pregnancy 2.47 0.77-7.92 0.13 
 3 367 
Suspected FGR and/or 
PE 0.39 0.22-0.71 0.0021 
Antibiotics     
  
 
   
Inhibiting preterm labour with intact membranes 
9 7208 
Suspected preterm labour 
with intact membranes 
20-36 weeks 
1.22 0.88-1.70 0.24 
Prelabour rupture of membranes at or near term 
2 838 
Spontaneous rupture of 
membranes >36 weeks 
0.98 0.14-6.89 0.98 
Preterm rupture of membranes  
13 6411 
Preterm rupture of 
membranes 0.9 0.74-1.10 0.32 
Bacterial vaginosis 3 2666 General population 0.96 0.53-1.73 0.89 
Prophylactic antibiotics to prevent infectious morbidity and 
mortality 1 229 
Unselected 
0.19 0.00-1.76 0.14 
 
1 253 High risk 0.71 0.20-2.58 0.37 
Anticonvulsants 
  
 
   
Magnesium sulphate and other anticonvulsants for women 
with pre-eclampsia 
2 9259 
Women with PE 
0.98 0.88-1.10 0.78 
Antihypertensives 
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Antihypertensive drug therapy for mild to moderate 
hypertension during pregnancy 
20 2382 
Mild to moderate 
hypertension 
0.96 0.60-1.54 0.87 
Oral beta-blockers for mild to moderate hypertension during 
pregnancy 13 1429 
Mild to moderate 
hypertension 1.01 0.46-2.22 0.97 
Antiplatelets 
  
 
   Antiplatelets agents for preventing pre-eclampsia and its 
complications 23 28655 
At moderate risk of PE 
0.92 0.80-1.07 0.3 
 
17 4443 At high risk of PE 0.69 0.53-0.90 0.006 
Antiplatelet agents for prevention of pre-eclampsia: a meta-
analysis of individual patient data 
23 30672 
At risk of PE 
0.91 0.81-1.03 
 Bed rest    
  
 
   Bed rest with or without hospitalisation for hypertension 
during pregnancy 2 145 
At risk of PE 
1.07 0.52-2.19 0.86 
Betamimetics 
  
 
   
Betamimetics for inhibiting preterm labour 
11 1332 
Pregnant women in 
spontaneous PTL 0.84 0.46-1.55 0.58 
Oral betamimetics for maintenance therapy after threatened 
preterm labour 
6 681 
Women with at least one 
episode of threatened 
PTL 2.41 0.86-6.74 0.093 
Prophylactic oral betamimetics for preventing preterm 
labour in singleton pregnancies 
1 64 
At risk of PTL 
4.74 0.50-45.00 0.18 
Betamimetics for suspected impaired fetal growth 
1 98 
Suspected impaired fetal 
growth 0.24 0.01-4.96 0.36 
Calcium 
  
 
   
Calcium supplementation during pregnancy for preventing 
hypertensive disorders and related problems 
10 15141 
Pregnant women 
0.89 0.73-1.09 0.25 
Calcium channel blockers 
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Calcium channel blockers for potential impaired fetal 
growth 
1 100 
Women at high risk or 
with suspected impaired 
fetal growth 
0.33 0.00-3.78 0.32 
Case notes 
  
 
   Giving women their own case notes to carry during 
pregnancy 1 212 
Pregnant women 
1.04 0.15-7.24 0.97 
Cervical cerclage 
  
 
   
Cervical stitich for preventing pregnancy loss in women 
4 2059 
Women with confirmed 
or suspected 
incomPEence 
0.8 0.48-1.36 0.41 
Cyclo-oxygenase inhibitors 
  
 
   
Cyclo-oxygenase inhibitors for treating preterm labour 
3 106 
Women in PTL 
0.8 0.25-2.58 0.71 
Delivery 
  
 
   
Elective caesarean section versus expectant management for 
delivery of the small baby 
5 122 
Women in labour with 
suspected small baby-
breech 0.30 0.08-1.18 0.041 
Induction of labour for improving birth outcomes for women 
at or beyond term 
2 584 
Pregnant women at or 
beyond term- 37-40 
weeks 0.32 0.03-3.09 0.33 
 
10 5643 41 weeks 0.25 0.05-1.18 0.081 
 
2 296 42 weeks 0.41 0.06-2.73 0.36 
Interventionist versus expectant care for severe pre-
eclampsia before term 1 38 
Women with severe PE 
before term 0.45 0.04-4.55 0.5 
Operative versus conservative management for fetal distress 
in labour 
1 350 
Pregnant women with 
evidence of fetal distress 
1.18 0.56-2.48 0.66 
Folic acid and iron 
  
 
   Folic acid supplementation 2 NA NA 1.18 0.74-1.91 0.47 
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Effects and safety of preventive oral iron or iron and folic 
acid supplementation for women during pregnancy 
3 5036 
Pregnant women with 
iron deficiency anaemia 
0.93 0.67-1.29 0.66 
Magnesium sulphate  
  
 
   
Magnesium sulphate for preventing preterm birth in 
threatened preterm labour 
7 727 
Women though to be in 
preterm labour 
2.82 1.20-6.62 0.017 
Magnesium maintenance therapy for preventing preterm 
birth after threatened preterm birth 
1 50 
Pregnant women with at 
least one episode of 
threatened PTL 
5 0.25-99.16 0.29 
Magnesium sulphate for women at risk of preterm birth for 
neuroprotection of the fetus 5 6145 
Women at risk of PTL 
1.04 0.92-1.17 0.57 
Malaria 
  
 
   
Drugs for preventing malaria in pregnant women 
4 2890 
Women of all parity 
1.02 0.73-1.43 0.9 
Midwifery-led care 
  
 
   Midwife-led versus other models of care for childbearing 
women 9 11604 
Pregnant women 
1.01 0.67-1.53 0.95 
Multiple micronutrient supplementation 
  
 
   Multiple micronutrient supplementation for women during 
pregnancy 7 11956 
Pregnant women 
1.05 0.90-1.23 0.65 
Nitric oxide donors 
  
 
   Nitric oxide for preventing pre-eclampsia and its 
complications 2 114 
Pregnant women 
0.25 0.03-2.34 0.23 
Nutrient supplementation 
  
 
   
Maternal nutrient supplementation for suspected impaired 
fetal growth (calf blood extract) 
1 31 
Women with suspected 
impaired fetal growth 
0.19 0.01-3.63 0.27 
Oxygen 
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Maternal oxygen administration for suspected impaired fetal 
growth 
3 94 
Women with suspected 
impaired fetal growth 
0.5 0.32-0.81 0.0041 
Oxytocin receptor antagonists 
  
 
   
Oxytocin receptor antagonists for inhibiting preterm labour 
1 583 
Women in PTL 
2.25 0.79-6.40 0.13 
Maintenance therapy with oxytocin antagonists for 
inhibiting preterm birth after threatened preterm labour 
1 512 
Pregnant women with at 
least one episode of 
threatened PTL 
0.77 0.21-2.83 0.69 
Plasma volume expansion 
  
 
   
Plasma volume expansion for treatment of pre-eclampsia 
1 32 
Women with 
hypertension during 
pregnancy 3.5 0.18-67.45 0.41 
Prenatal care 
  
 
   
Support during pregnancy for women at increased risk of 
low birth weight babies 
11 9507 
Pregnant women at risk 
of preterm or growth 
restricted babies 
1.15 0.89-1.51 0.29 
Progesterone 
  
 
   Prenatal administration of progesterone for preventing 
preterm birth in women considered to be at risk of preterm 
birth 3 1114 
Pregnant women at risk 
of preterm birth 
0.65 0.38-1.11 0.11 
Progesterone for preventing pre-eclampsia and its 
complications 
2 296 
Pregnant women with 
normal blood pressure or 
high blood pressure 
without proteinuria 0.72 0.21-2.51 0.61 
Salt 
  
 
   
Altered dietary salt for preventing pre-eclampsia and its 
complications (low versus normal salt intake) 
2 409 
Pregnant women with 
normal blood pressure or 
high blood pressure 
without proteinuria 1.92 0.18-21.03 0.59 
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Reduced salt intake compared to normal dietary salt, or high 
intake, in pregnancy (low versus normal salt intake) 
2 409 
Normal pregnant women 
1.92 0.18-21.03 0.59 
Smoking cessation 
  
 
   Interventions for promoting smoking cessation during 
pregnancy 3 4335 
Pregnant women 
1.13 0.72-1.77 0.59 
Steroids 
  
 
   
Antenatal corticosteroids for accelerating fetal lung 
maturation for women at risk of preterm birth 
13 3627 
Women expected to 
deliver preterm 
0.77 0.67-0.89 0.00035 
Vitamins 
  
 
   Vitamin C supplementation in pregnancy 2 238 All pregnant women 1.16 0.61-2.18 0.65 
Vitamin E supplementation in pregnancy 1 56 All pregnant women 1.29 0.67-2.48 0.45 
Zinc 
  
 
   
Zinc supplementation for improving pregnancy outcome and 
infant outcome 
1 1555 
Normal pregnant women 
1.03 0.71-1.51 0.87 
 
NA not available 
    FGR fetal growth restriction; PE pre-eclampsia; PTL preterm labour; PPROM preterm prelabour rupture of membranes 
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Appendix 48: Search strategy for cost data related to outcome for economic 
evaluation 
 
 
((("small-for-gestational-age") OR (small-for-gestational-age) OR (lbw) OR (small for 
gestational age) OR (sga) OR (small for date*) OR (small for gestation*) OR (fgr) OR 
(iugr) OR (intrauterine growth retard*) OR (intrauterine growth restrict*) OR (fetal 
growth retard*) OR (fetal growth restrict*) OR (growth restrict*) OR (growth retard*) 
OR ("Placental Insufficiency"[MeSH]) OR ("Fetal Growth Retardation"[MeSH]) OR 
("Infant, Low Birth Weight"[MeSH]) OR (low birth weight) OR (low birthweight))) 
AND (economic* OR cost OR costs OR cost-effectiveness OR cost analysis OR 
resource*) 
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